Blood	O
collection	O
for	O
RNA	O
studies	O
is	O
a	O
new	O
direction	O
.	O

Genetic	O
studies	O
of	O
longitudinal	O
phenotypes	O
hold	O
promise	O
for	O
elucidating	O
disease	O
mechanisms	O
and	O
risk	O
,	O
development	O
of	O
therapeutic	O
strategies	O
,	O
and	O
refining	O
selection	O
criteria	O
for	O
clinical	O
trials	O
.	O

Genome	O
-	O
wide	O
array	O
data	O
have	O
been	O
publicly	O
released	O
and	O
updated	O
,	O
and	O
several	O
neuroimaging	O
GWAS	O
have	O
recently	O
been	O
reported	O
examining	O
baseline	O
magnetic	O
resonance	O
imaging	O
measures	O
as	O
quantitative	O
phenotypes	O
.	O

Other	O
preliminary	O
investigations	O
include	O
copy	O
number	O
variation	O
in	O
mild	O
cognitive	O
impairment	O
and	O
Alzheimer	O
's	O
disease	O
and	O
GWAS	O
of	O
baseline	O
cerebrospinal	O
fluid	O
biomarkers	O
and	O
longitudinal	O
changes	O
on	O
magnetic	O
resonance	O
imaging	O
.	O

The	O
role	O
of	O
the	O
Alzheimer	O
's	O
Disease	O
Neuroimaging	O
Initiative	O
Genetics	O
Core	O
is	O
to	O
facilitate	O
the	O
investigation	O
of	O
genetic	O
influences	O
on	O
disease	O
onset	O
and	O
trajectory	O
as	O
reflected	O
in	O
structural	O
,	O
functional	O
,	O
and	O
molecular	O
imaging	O
changes	O
;	O
fluid	O
biomarkers	O
;	O
and	O
cognitive	O
status	O
.	O

Major	O
goals	O
include	O
(	O
1	O
)	O
blood	O
sample	O
processing	O
,	O
genotyping	O
,	O
and	O
dissemination	O
,	O
(	O
2	O
)	O
genome	O
-	O
wide	O
association	O
studies	O
(	O
GWAS	O
)	O
of	O
longitudinal	O
phenotypic	O
data	O
,	O
and	O
(	O
3	O
)	O
providing	O
a	O
central	O
resource	O
,	O
point	O
of	O
contact	O
and	O
planning	O
group	O
for	O
genetics	O
within	O
the	O
Alzheimer	O
's	O
Disease	O
Neuroimaging	O
Initiative	O
.	O

Alzheimer	O
's	O
Disease	O
Neuroimaging	O
Initiative	O
biomarkers	O
as	O
quantitative	O
phenotypes	O
:	O
Genetics	O
core	O
aims	O
,	O
progress	O
,	O
and	O
plans	O
.	O

While	O
confirmation	O
is	O
required	O
,	O
this	O
study	O
suggests	O
that	O
microRNA	O
mutations	O
can	O
contribute	O
to	O
schizophrenia	O
.	O

One	O
ultra	O
-	O
rare	O
variant	O
was	O
identified	O
in	O
a	O
control	O
sample	O
(	O
with	O
a	O
history	O
of	O
depression	O
)	O
(	O
8	O
/	O
193	O
versus	O
1	O
/	O
191	O
,	O
p	O
=	O
0.02	O
by	O
one	O
-	O
sided	O
Fisher	O
's	O
exact	O
test	O
,	O
odds	O
ratio	O
=	O
8.2	O
)	O
.	O

These	O
variants	O
were	O
not	O
found	O
in	O
an	O
additional	O
7,197	O
control	O
X	O
-	O
chromosomes	O
.	O

CONCLUSIONS	O
:	O
Functional	O
analyses	O
of	O
ectopically	O
expressed	O
copies	O
of	O
the	O
variant	O
miRNA	O
precursors	O
demonstrate	O
loss	O
of	O
function	O
,	O
gain	O
of	O
function	O
or	O
altered	O
expression	O
levels	O
.	O

In	O
addition	O
,	O
components	O
required	O
for	O
miRNA	O
processing	O
and/or	O
function	O
have	O
also	O
been	O
implicated	O
in	O
X	O
-	O
linked	O
mental	O
retardation	O
,	O
neurological	O
and	O
neoplastic	O
diseases	O
,	O
pointing	O
to	O
the	O
wide	O
ranging	O
involvement	O
of	O
miRNAs	O
in	O
disease	O
.	O

METHODS	O
AND	O
FINDINGS	O
:	O
To	O
explore	O
the	O
role	O
of	O
miRNAs	O
in	O
schizophrenia	O
,	O
59	O
microRNA	O
genes	O
on	O
the	O
X	O
-	O
chromosome	O
were	O
amplified	O
and	O
sequenced	O
in	O
males	O
with	O
(	O
193	O
)	O
and	O
without	O
(	O
191	O
)	O
schizophrenia	O
spectrum	O
disorders	O
to	O
test	O
the	O
hypothesis	O
that	O
ultra	O
-	O
rare	O
mutations	O
in	O
microRNA	O
collectively	O
contribute	O
to	O
the	O
risk	O
of	O
schizophrenia	O
.	O

Here	O
we	O
provide	O
the	O
first	O
association	O
of	O
microRNA	O
gene	O
dysfunction	O
with	O
schizophrenia	O
.	O

Eight	O
ultra	O
-	O
rare	O
variants	O
in	O
the	O
precursor	O
or	O
mature	O
miRNA	O
were	O
identified	O
in	O
eight	O
distinct	O
miRNA	O
genes	O
in	O
4	O
%	O
of	O
analyzed	O
males	O
with	O
schizophrenia	O
.	O

Evidence	O
for	O
X	O
-	O
chromosomal	O
schizophrenia	O
associated	O
with	O
microRNA	O
alterations	O
.	O

BACKGROUND	O
:	O
Schizophrenia	O
is	O
a	O
severe	O
disabling	O
brain	O
disease	O
affecting	O
about	O
1	O
%	O
of	O
the	O
population	O
.	O

Individual	O
microRNAs	O
(	O
miRNAs	O
)	O
affect	O
moderate	O
downregulation	O
of	O
gene	O
expression	O
.	O

Specifically	O
,	O
we	O
highlight	O
the	O
importance	O
of	O
unbiased	O
association	O
studies	O
and	O
follow	O
-	O
up	O
functional	O
experiments	O
for	O
providing	O
a	O
clearer	O
picture	O
of	O
the	O
extent	O
to	O
which	O
microRNA	O
target	O
site	O
variations	O
are	O
relevant	O
in	O
various	O
human	B
diseases	O
.	O

We	O
therefore	O
suggest	O
a	O
set	O
of	O
concrete	O
recommendations	O
to	O
guide	O
future	O
investigations	O
.	O

However	O
,	O
careful	O
assessment	O
of	O
these	O
studies	O
indicates	O
that	O
very	O
few	O
provide	O
a	O
combination	O
of	O
rigorous	O
genetic	O
and	O
functional	O
evidence	O
.	O

Several	O
studies	O
have	O
identified	O
genetic	O
variants	O
in	O
miRNA	O
target	O
sites	O
that	O
are	O
claimed	O
to	O
be	O
associated	O
with	O
disorders	O
ranging	O
from	O
Parkinson	O
's	O
disease	O
to	O
cancer	O
.	O

They	O
have	O
been	O
implicated	O
in	O
a	O
broad	O
range	O
of	O
biological	O
processes	O
,	O
and	O
miRNA	O
-	O
related	O
genetic	O
alterations	O
probably	O
underlie	O
more	O
human	B
diseases	O
than	O
currently	O
appreciated	O
.	O

MicroRNAs	O
(	O
miRNAs	O
)	O
are	O
important	O
regulators	O
of	O
eukaryotic	O
gene	O
expression	O
.	O

MicroRNA	O
target	O
site	O
polymorphisms	O
and	O
human	B
disease	O
.	O

Human	B
traumatic	O
brain	O
injury	O
alters	O
plasma	O
microRNA	O
levels	O
.	O

Circulating	O
microRNAs	O
(	O
miRNAs	O
)	O
present	O
in	O
the	O
serum	O
/	O
plasma	O
are	O
characteristically	O
altered	O
in	O
many	O
pathological	O
conditions	O
,	O
and	O
have	O
been	O
employed	O
as	O
diagnostic	O
markers	O
for	O
specific	O
diseases	O
.	O

We	O
examined	O
if	O
plasma	O
miRNA	O
levels	O
are	O
altered	O
in	O
patients	B
with	O
traumatic	O
brain	O
injury	O
(	O
TBI	O
)	O
relative	O
to	O
matched	O
healthy	O
volunteers	O
,	O
and	O
explored	O
their	O
potential	O
for	O
use	O
as	O
diagnostic	O
TBI	O
biomarkers	O
.	O

The	O
plasma	O
miRNA	O
profiles	O
from	O
severe	O
TBI	O
patients	B
(	O
Glasgow	O
Coma	O
Scale	O
[	O
GCS	O
]	O
score	O
≤8	O
)	O
and	O
age-	O
,	O
gender-	O
,	O
and	O
race	O
-	O
matched	O
healthy	O
volunteers	O
were	O
compared	O
by	O
microarray	O
analysis	O
.	O

Of	O
the	O
108	O
miRNAs	O
identified	O
in	O
healthy	O
volunteer	O
plasma	O
,	O
52	O
were	O
altered	O
after	O
severe	O
TBI	O
,	O
including	O
33	O
with	O
decreased	O
and	O
19	O
with	O
increased	O
relative	O
abundance	O
.	O

An	O
additional	O
8	O
miRNAs	O
were	O
detected	O
only	O
in	O
the	O
TBI	O
plasma	O
.	O

We	O
used	O
quantitative	O
RT	O
-	O
PCR	O
to	O
determine	O
if	O
plasma	O
miRNAs	O
could	O
identify	O
TBI	O
patients	B
within	O
the	O
first	O
24	O
h	O
post	O
-	O
injury	O
.	O

Receiver	O
operating	O
characteristic	O
curve	O
analysis	O
indicated	O
that	O
miR-16	O
,	O
miR-92a	O
,	O
and	O
miR-765	O
were	O
good	O
markers	O
of	O
severe	O
TBI	O
(	O
0.89	O
,	O
0.82	O
,	O
and	O
0.86	O
AUC	O
values	O
,	O
respectively	O
)	O
.	O

Multiple	O
logistic	O
regression	O
analysis	O
revealed	O
that	O
combining	O
these	O
miRNAs	O
markedly	O
increased	O
diagnostic	O
accuracy	O
(	O
100	O
%	O
specificity	O
and	O
100	O
%	O
sensitivity	O
)	O
,	O
compared	O
to	O
either	O
healthy	O
volunteers	O
or	O
orthopedic	O
injury	O
patients	B
.	O

In	O
mild	O
TBI	O
patients	B
(	O
GCS	O
score	O
>	O
12	O
)	O
,	O
miR-765	O
levels	O
were	O
unchanged	O
,	O
while	O
the	O
plasma	O
levels	O
of	O
miR-92a	O
and	O
miR-16	O
were	O
significantly	O
increased	O
within	O
the	O
first	O
24	O
h	O
of	O
injury	O
compared	O
to	O
healthy	O
volunteers	O
,	O
and	O
had	O
AUC	O
values	O
of	O
0.78	O
and	O
0.82	O
,	O
respectively	O
.	O

Plasma	O
-	O
derived	O
miRNA	O
biomarkers	O
,	O
used	O
in	O
combination	O
with	O
established	O
clinical	O
practices	O
such	O
as	O
imaging	O
,	O
neurocognitive	O
,	O
and	O
motor	O
examinations	O
,	O
have	O
the	O
potential	O
to	O
improve	O
TBI	O
patient	B
classification	O
and	O
possibly	O
management	O
.	O

Our	O
results	O
demonstrate	O
that	O
circulating	O
miRNA	O
levels	O
are	O
altered	O
after	O
TBI	O
,	O
providing	O
a	O
rich	O
new	O
source	O
of	O
potential	O
molecular	O
biomarkers	O
.	O

MicroRNA-205	O
inhibits	O
tumor	O
cell	O
migration	O
through	O
down	O
-	O
regulating	O
the	O
expression	O
of	O
the	O
LDL	O
receptor	O
-	O
related	O
protein	O
1	O
.	O
Low	O
-	O
density	O
lipoprotein	O
receptor	O
-	O
related	O
protein	O
1	O
(	O
LRP1	O
)	O
is	O
a	O
multifunctional	O
endocytic	O
receptor	O
that	O
plays	O
critical	O
roles	O
in	O
the	O
pathogenesis	O
of	O
several	O
human	B
diseases	O
including	O
tumor	O
metastasis	O
and	O
Alzheimer	O
's	O
disease	O
.	O

In	O
human	B
cell	O
lines	O
,	O
we	O
found	O
that	O
miR-205	O
down	O
-	O
regulates	O
the	O
expression	O
of	O
LRP1	O
by	O
targeting	O
sequences	O
in	O
the	O
3'UTR	O
of	O
LRP1	O
mRNA	O
.	O

However	O
,	O
mechanisms	O
that	O
regulate	O
LRP1	O
expression	O
under	O
physiological	O
and	O
pathophysiological	O
conditions	O
are	O
not	O
unclear	O
.	O

The	O
ectopic	O
expression	O
of	O
miR-205	O
also	O
significantly	O
mitigated	O
migration	O
of	O
both	O
U87	O
and	O
SK	O
-	O
LU-1	O
cells	O
.	O

This	O
effect	O
was	O
abolished	O
by	O
deleting	O
the	O
miR-205	O
seed	O
site	O
in	O
the	O
3'UTR	O
of	O
LRP1	O
.	O

These	O
results	O
,	O
for	O
the	O
first	O
time	O
,	O
demonstrate	O
that	O
expression	O
of	O
human	B
LRP1	O
is	O
regulated	O
in	O
part	O
by	O
a	O
specific	O
miRNA	O
,	O
leading	O
to	O
decreased	O
tumor	O
cell	O
migration	O
.	O

The	O
present	O
review	O
examines	O
the	O
various	O
miRNAs	O
that	O
have	O
been	O
identified	O
as	O
being	O
potentially	O
involved	O
in	O
T2D	O
,	O
focusing	O
on	O
the	O
insulin	O
-	O
sensitive	O
organs	O
:	O
white	O
adipose	O
tissue	O
,	O
liver	O
,	O
skeletal	O
muscle	O
and	O
the	O
insulin	O
-	O
producing	O
pancreatic	O
β	O
-	O
cells	O
.	O

miRNAs	O
are	O
involved	O
in	O
a	O
large	O
number	O
of	O
biological	O
functions	O
such	O
as	O
development	O
,	O
metabolism	O
,	O
immunity	O
and	O
diseases	O
such	O
as	O
cancer	O
,	O
cardiovascular	O
diseases	O
and	O
diabetes	O
.	O

miRNAs	O
are	O
small	O
22	O
-	O
25-nt	O
-	O
long	O
untranslated	O
RNAs	O
that	O
negatively	O
regulate	O
the	O
translation	O
of	O
mRNAs	O
.	O

Although	O
T2D	O
seems	O
to	O
be	O
strongly	O
linked	O
to	O
environmental	O
factors	O
such	O
as	O
nutrition	O
and	O
lifestyle	O
,	O
studies	O
have	O
shown	O
that	O
genetic	O
factors	O
,	O
such	O
as	O
polymorphisms	O
associated	O
with	O
metabolic	O
genes	O
,	O
imprinting	O
,	O
fetal	O
programming	O
and	O
miRNA	O
(	O
microRNA	O
)	O
expression	O
,	O
could	O
also	O
contribute	O
to	O
the	O
development	O
of	O
this	O
disease	O
.	O

The	O
aetiology	O
and	O
molecular	O
mechanisms	O
of	O
T2D	O
are	O
not	O
fully	O
understood	O
,	O
but	O
compelling	O
evidence	O
points	O
to	O
a	O
link	O
between	O
T2D	O
,	O
obesity	O
,	O
dyslipidaemia	O
and	O
insulin	O
resistance	O
.	O

Improper	O
treatment	O
of	O
TD2	O
can	O
lead	O
to	O
severe	O
complications	O
such	O
as	O
heart	O
disease	O
,	O
stroke	O
,	O
kidney	O
failure	O
,	O
blindness	O
and	O
nerve	O
damage	O
.	O

T2D	O
is	O
a	O
progressive	O
metabolic	O
disorder	O
characterized	O
by	O
reduced	O
insulin	O
sensitivity	O
,	O
insulin	O
resistance	O
and	O
pancreatic	O
β	O
-	O
cell	O
dysfunction	O
.	O

The	O
involvement	O
of	O
microRNAs	O
in	O
Type	O
2	O
diabetes	O
.	O

T2D	O
(	O
Type	O
2	O
diabetes	O
mellitus	O
)	O
is	O
a	O
major	O
health	O
issue	O
that	O
has	O
reached	O
epidemic	O
status	O
worldwide	O
.	O

Loss	O
of	O
microRNA	O
cluster	O
miR-29a	O
/	O
b-1	O
in	O
sporadic	O
Alzheimer	O
's	O
disease	O
correlates	O
with	O
increased	O
BACE1	O
/	O
beta	O
-	O
secretase	O
expression	O
.	O

Although	O
the	O
role	O
of	O
APP	O
and	O
PSEN	O
genes	O
in	O
genetic	O
Alzheimer	O
's	O
disease	O
(	O
AD	O
)	O
cases	O
is	O
well	O
established	O
,	O
fairly	O
little	O
is	O
known	O
about	O
the	O
molecular	O
mechanisms	O
affecting	O
Abeta	O
generation	O
in	O
sporadic	O
AD	O
.	O
Deficiency	O
in	O
Abeta	O
clearance	O
is	O
certainly	O
a	O
possibility	O
,	O
but	O
increased	O
expression	O
of	O
proteins	O
like	O
APP	O
or	O
BACE1	O
/	O
beta	O
-	O
secretase	O
may	O
also	O
be	O
associated	O
with	O
the	O
disease	O
.	O

We	O
therefore	O
investigated	O
changes	O
in	O
microRNA	O
(	O
miRNA	O
)	O
expression	O
profiles	O
of	O
sporadic	O
AD	O
patients	B
and	O
found	O
that	O
several	O
miRNAs	O
potentially	O
involved	O
in	O
the	O
regulation	O
of	O
APP	O
and	O
BACE1	O
expression	O
appeared	O
to	O
be	O
decreased	O
in	O
diseased	O
brain	O
.	O

We	O
show	O
here	O
that	O
miR-29a	O
,	O
-29b-1	O
,	O
and	O
-9	O
can	O
regulate	O
BACE1	O
expression	O
in	O
vitro	O
.	O

The	O
miR-29a	O
/	O
b-1	O
cluster	O
was	O
significantly	O
(	O
and	O
AD	O
-	O
dementia	O
-	O
specific	O
)	O
decreased	O
in	O
AD	O
patients	B
displaying	O
abnormally	O
high	O
BACE1	O
protein	O
.	O

Similar	O
correlations	O
between	O
expression	O
of	O
this	O
cluster	O
and	O
BACE1	O
were	O
found	O
during	O
brain	O
development	O
and	O
in	O
primary	O
neuronal	O
cultures	O
.	O

Finally	O
,	O
we	O
provide	O
evidence	O
for	O
a	O
potential	O
causal	O
relationship	O
between	O
miR-29a	O
/	O
b-1	O
expression	O
and	O
Abeta	O
generation	O
in	O
a	O
cell	O
culture	O
model	O
.	O

We	O
propose	O
that	O
loss	O
of	O
specific	O
miRNAs	O
can	O
contribute	O
to	O
increased	O
BACE1	O
and	O
Abeta	O
levels	O
in	O
sporadic	O
AD	O
.	O

Taken	O
together	O
,	O
our	O
findings	O
indicate	O
that	O
miR-15b	O
regulates	O
cell	O
cycle	O
progression	O
in	O
glioma	O
cells	O
by	O
targeting	O
cell	O
cycle	O
-	O
related	O
molecules	O
.	O

Over	O
-	O
expression	O
of	O
miR-15b	O
resulted	O
in	O
cell	O
cycle	O
arrest	O
at	O
G0	O
/	O
G1	O
phase	O
while	O
suppression	O
of	O
miR-15b	O
expression	O
resulted	O
in	O
a	O
decrease	O
of	O
cell	O
populations	O
in	O
G0	O
/	O
G1	O
and	O
a	O
corresponding	O
increase	O
of	O
cell	O
populations	O
in	O
S	O
phase	O
.	O

We	O
further	O
showed	O
that	O
CCNE1	O
(	O
encoding	O
cyclin	O
E1	O
)	O
is	O
one	O
of	O
the	O
downstream	O
targets	O
of	O
miR-15b	O
.	O

We	O
have	O
recently	O
compared	O
the	O
miRNA	O
expression	O
profiles	O
between	O
normal	O
brain	O
and	O
glioma	O
tissues	O
from	O
Chinese	O
patients	B
by	O
miRNA	O
microarray	O
and	O
identified	O
a	O
panel	O
of	O
differentially	O
expressed	O
miRNAs	O
.	O

Here	O
,	O
we	O
studied	O
the	O
function	O
of	O
one	O
miRNA	O
,	O
miR-15b	O
,	O
in	O
glioma	O
carcinogenesis	O
and	O
elucidated	O
its	O
downstream	O
targets	O
.	O

MicroRNAs	O
(	O
miRNAs	O
)	O
are	O
non	O
-	O
protein	O
-	O
coding	O
RNAs	O
that	O
function	O
as	O
post	O
-	O
transcriptional	O
gene	O
regulators	O
.	O

Recent	O
evidence	O
has	O
shown	O
that	O
miRNA	O
plays	O
a	O
pivotal	O
role	O
in	O
the	O
development	O
of	O
many	O
cancers	O
including	O
glioma	O
,	O
a	O
lethal	O
brain	O
cancer	O
.	O

MicroRNA-15b	O
regulates	O
cell	O
cycle	O
progression	O
by	O
targeting	O
cyclins	O
in	O
glioma	O
cells	O
.	O

Our	O
work	O
places	O
apl-1	O
in	O
a	O
developmental	O
timing	O
pathway	O
and	O
may	O
provide	O
new	O
insights	O
into	O
the	O
time	O
-	O
dependent	O
progression	O
of	O
AD	O
.	O

Moreover	O
,	O
the	O
levels	O
of	O
the	O
apl-1	O
transcription	O
are	O
modulated	O
by	O
the	O
activity	O
of	O
let-7	O
family	O
microRNAs	O
.	O

apl-1	O
expression	O
is	O
upregulated	O
during	O
the	O
last	O
larval	O
stage	O
in	O
hypodermal	O
seam	O
cells	O
which	O
is	O
transcriptionally	O
regulated	O
by	O
hbl-1	O
,	O
lin-41	O
and	O
lin-42	O
.	O

On	O
the	O
other	O
hand	O
,	O
the	O
pathogenesis	O
of	O
amyloid	O
plaque	O
deposition	O
in	O
AD	O
is	O
thought	O
to	O
be	O
the	O
result	O
of	O
age	O
-	O
related	O
changes	O
with	O
unknown	O
mechanisms	O
.	O

Here	O
we	O
show	O
that	O
the	O
Caenorhabditis	B
elegans	I
homolog	O
of	O
APP	O
,	O
APP	O
-	O
like-1	O
(	O
apl-1	O
)	O
,	O
functions	O
with	O
and	O
is	O
under	O
the	O
control	O
of	O
molecules	O
regulating	O
developmental	O
progression	O
.	O

In	O
C.	B
elegans	I
,	O
the	O
timing	O
of	O
cell	O
fate	O
determination	O
is	O
controlled	O
by	O
the	O
heterochronic	O
genes	O
,	O
including	O
let-7	O
microRNAs	O
.	O

C.	B
elegans	I
apl-1	O
shows	O
significant	O
genetic	O
interactions	O
with	O
let-7	O
family	O
microRNAs	O
and	O
let-7-targeted	O
heterochronic	O
genes	O
,	O
hbl-1	O
,	O
lin-41	O
and	O
lin-42	O
.	O

The	O
expression	O
of	O
the	O
Alzheimer	O
's	O
amyloid	O
precursor	O
protein	O
-	O
like	O
gene	O
is	O
regulated	O
by	O
developmental	O
timing	O
microRNAs	O
and	O
their	O
targets	O
in	O
Caenorhabditis	B
elegans	I
.	O

Alzheimer	O
's	O
disease	O
(	O
AD	O
)	O
is	O
a	O
neurodegenerative	O
disorder	O
characterized	O
by	O
the	O
accumulation	O
of	O
dense	O
plaques	O
in	O
the	O
brain	O
,	O
resulting	O
in	O
progressive	O
dementia	O
.	O

A	O
major	O
plaque	O
component	O
is	O
the	O
beta	O
-	O
amyloid	O
peptide	O
,	O
which	O
is	O
a	O
cleavage	O
product	O
of	O
the	O
amyloid	O
precursor	O
protein	O
(	O
APP	O
)	O
.	O

Studies	O
of	O
dominant	O
inheritable	O
familial	O
AD	O
support	O
the	O
hypothesis	O
that	O
APP	O
is	O
critical	O
for	O
AD	O
development	O
.	O

We	O
will	O
describe	O
the	O
evidence	O
that	O
disruption	O
to	O
the	O
REST	O
regulon	O
brought	O
about	O
by	O
a	O
loss	O
of	O
interaction	O
between	O
REST	O
and	O
mutHtt	O
may	O
be	O
a	O
key	O
contributory	O
factor	O
in	O
the	O
widespread	O
dysregulation	O
of	O
gene	O
expression	O
in	O
HD	O
.	O

Transcriptional	O
dysregulation	O
of	O
coding	O
and	O
non	O
-	O
coding	O
genes	O
in	O
cellular	O
models	O
of	O
Huntington	O
's	O
disease	O
.	O

HD	O
(	O
Huntington	O
's	O
disease	O
)	O
is	O
a	O
late	O
onset	O
heritable	O
neurodegenerative	O
disorder	O
that	O
is	O
characterized	O
by	O
neuronal	O
dysfunction	O
and	O
death	O
,	O
particularly	O
in	O
the	O
cerebral	O
cortex	O
and	O
medium	O
spiny	O
neurons	O
of	O
the	O
striatum	O
.	O

This	O
is	O
followed	O
by	O
progressive	O
chorea	O
,	O
dementia	O
and	O
emotional	O
dysfunction	O
,	O
eventually	O
resulting	O
in	O
death	O
.	O

HD	O
is	O
caused	O
by	O
an	O
expanded	O
CAG	O
repeat	O
in	O
the	O
first	O
exon	O
of	O
the	O
HD	O
gene	O
that	O
results	O
in	O
an	O
abnormally	O
elongated	O
polyQ	O
(	O
polyglutamine	O
)	O
tract	O
in	O
its	O
protein	O
product	O
,	O
Htt	O
(	O
Huntingtin	O
)	O
.	O

Wild	O
-	O
type	O
Htt	O
is	O
largely	O
cytoplasmic	O
;	O
however	O
,	O
in	O
HD	O
,	O
proteolytic	O
N	O
-	O
terminal	O
fragments	O
of	O
Htt	O
form	O
insoluble	O
deposits	O
in	O
both	O
the	O
cytoplasm	O
and	O
nucleus	O
,	O
provoking	O
the	O
idea	O
that	O
mutHtt	O
(	O
mutant	O
Htt	O
)	O
causes	O
transcriptional	O
dysfunction	O
.	O

While	O
a	O
number	O
of	O
specific	O
transcription	O
factors	O
and	O
co	O
-	O
factors	O
have	O
been	O
proposed	O
as	O
mediators	O
of	O
mutHtt	O
toxicity	O
,	O
the	O
causal	O
relationship	O
between	O
these	O
Htt	O
/	O
transcription	O
factor	O
interactions	O
and	O
HD	O
pathology	O
remains	O
unknown	O
.	O

Previous	O
work	O
has	O
highlighted	O
REST	O
[	O
RE1	O
(	O
repressor	O
element	O
1	O
)	O
-silencing	O
transcription	O
factor	O
]	O
as	O
one	O
such	O
transcription	O
factor	O
.	O

Recent	O
evidence	O
has	O
also	O
shown	O
that	O
REST	O
regulates	O
transcription	O
of	O
regulatory	O
miRNAs	O
(	O
microRNAs	O
)	O
,	O
many	O
of	O
which	O
are	O
known	O
to	O
regulate	O
neuronal	O
gene	O
expression	O
and	O
are	O
dysregulated	O
in	O
HD	O
.	O
Thus	O
repression	O
of	O
miRNAs	O
constitutes	O
a	O
second	O
,	O
indirect	O
mechanism	O
by	O
which	O
REST	O
can	O
alter	O
the	O
neuronal	O
transcriptome	O
in	O
HD	O
.	O

Many	O
of	O
its	O
direct	O
target	O
genes	O
are	O
known	O
or	O
suspected	O
to	O
have	O
a	O
role	O
in	O
HD	O
pathogenesis	O
,	O
including	O
BDNF	O
(	O
brain	O
-	O
derived	O
neurotrophic	O
factor	O
)	O
.	O

REST	O
is	O
a	O
master	O
regulator	O
of	O
neuronal	O
genes	O
,	O
repressing	O
their	O
expression	O
.	O

An	O
understanding	O
of	O
how	O
microRNAs	O
influence	O
the	O
body	O
's	O
response	O
to	O
certain	O
drugs	O
and	O
how	O
these	O
affect	O
the	O
expression	O
of	O
microRNAs	O
,	O
will	O
be	O
of	O
key	O
importance	O
in	O
developing	O
drugs	O
with	O
greater	O
safety	O
and	O
efficacy	O
.	O

MicroRNAs	O
(	O
miRNAs	O
)	O
are	O
short	O
non	O
-	O
coding	O
RNAs	O
involved	O
in	O
post	O
-	O
transcriptional	O
regulation	O
of	O
gene	O
expression	O
.	O

Since	O
the	O
discovery	O
of	O
the	O
first	O
miRNA	O
gene	O
lin-4	O
in	O
C.	B
elegans	I
,	O
over	O
500	O
miRNAs	O
have	O
been	O
identified	O
in	O
humans	B
and	O
the	O
list	O
is	O
growing	O
.	O

Their	O
biological	O
importance	O
,	O
initially	O
demonstrated	O
in	O
cancer	O
,	O
was	O
also	O
more	O
recently	O
discovered	O
in	O
many	O
other	O
pathologies	O
like	O
Alzheimer	O
's	O
disease	O
,	O
Parkinson	O
's	O
disease	O
,	O
viral	O
infections	O
,	O
diabetes	O
,	O
and	O
myopathies	O
.	O

In	O
the	O
present	O
review	O
we	O
will	O
summarize	O
miRNA	O
profiling	O
studies	O
in	O
human	B
diseases	O
and	O
discuss	O
the	O
newly	O
discovered	O
link	O
between	O
microRNAs	O
and	O
drug	O
response	O
.	O

MicroRNAs	O
in	O
diseases	O
and	O
drug	O
response	O
.	O

Role	O
of	O
epigenetic	O
effectors	O
in	O
maintenance	O
of	O
the	O
long	O
-	O
term	O
persistent	O
bystander	O
effect	O
in	O
spleen	O
in	O
vivo	O
.	O

These	O
cancers	O
are	O
thought	O
to	O
be	O
linked	O
to	O
indirect	O
radiation	O
-	O
induced	O
bystander	O
effect	O
.	O

Radiation	O
therapy	O
is	O
a	O
primary	O
treatment	O
modality	O
for	O
brain	O
tumors	O
,	O
yet	O
it	O
has	O
been	O
linked	O
to	O
the	O
increased	O
incidence	O
of	O
secondary	O
,	O
post	O
-	O
radiation	O
therapy	O
cancers	O
.	O

Recent	O
evidence	O
suggests	O
that	O
bystander	O
effect	O
may	O
be	O
epigenetic	O
in	O
nature	O
;	O
however	O
,	O
characterization	O
of	O
epigenetic	O
mechanisms	O
involved	O
in	O
bystander	O
effect	O
generation	O
and	O
its	O
long	O
-	O
term	O
persistence	O
has	O
yet	O
to	O
be	O
defined	O
.	O

Bystander	O
effect	O
occurs	O
when	O
irradiated	O
cells	O
communicate	O
damage	O
to	O
nearby	O
,	O
non	O
-	O
irradiated	O
'	O
bystander	O
'	O
cells	O
,	O
ultimately	O
contributing	O
to	O
genome	O
destabilization	O
in	O
the	O
non	O
-	O
exposed	O
cells	O
.	O

We	O
found	O
that	O
localized	O
cranial	O
radiation	O
exposure	O
led	O
to	O
the	O
induction	O
of	O
bystander	O
effect	O
in	O
lead	O
-	O
shielded	O
,	O
distant	O
spleen	O
tissue	O
.	O

To	O
investigate	O
the	O
possibility	O
that	O
localized	O
X	O
-	O
ray	O
irradiation	O
induces	O
persistent	O
bystander	O
effects	O
in	O
distant	O
tissue	O
,	O
we	O
monitored	O
the	O
induction	O
of	O
epigenetic	O
changes	O
(	O
i.e.	O
alterations	O
in	O
DNA	O
methylation	O
,	O
histone	O
methylation	O
and	O
microRNA	O
(	O
miRNA	O
)	O
expression	O
)	O
in	O
the	O
rat	B
spleen	O
tissue	O
24	O
h	O
and	O
7	O
months	O
after	O
localized	O
cranial	O
exposure	O
to	O
20	O
Gy	O
of	O
X	O
-	O
rays	O
.	O

Further	O
,	O
irradiation	O
significantly	O
altered	O
expression	O
of	O
miR-194	O
,	O
a	O
miRNA	O
putatively	O
targeting	O
both	O
DNA	O
methyltransferase-3a	O
and	O
MeCP2	O
.	O

Specifically	O
,	O
this	O
exposure	O
caused	O
the	O
profound	O
epigenetic	O
dysregulation	O
in	O
the	O
bystander	O
spleen	O
tissue	O
that	O
manifested	O
as	O
a	O
significant	O
loss	O
of	O
global	O
DNA	O
methylation	O
,	O
alterations	O
in	O
methylation	O
of	O
long	O
interspersed	O
nucleotide	O
element-1	O
(	O
LINE-1	O
)	O
retrotransposable	O
elements	O
and	O
down	O
-	O
regulation	O
of	O
DNA	O
methyltransferases	O
and	O
methyl	O
-	O
binding	O
protein	O
methyl	O
CpG	O
binding	O
protein	O
2	O
(	O
MeCP2	O
)	O
.	O

This	O
study	O
is	O
the	O
first	O
to	O
report	O
conclusive	O
evidence	O
of	O
the	O
long	O
-	O
term	O
persistence	O
of	O
bystander	O
effects	O
in	O
radiation	O
carcinogenesis	O
target	O
organ	O
(	O
spleen	O
)	O
upon	O
localized	O
distant	O
exposure	O
using	O
the	O
doses	O
comparable	O
with	O
those	O
used	O
for	O
clinical	O
brain	O
tumor	O
treatments	O
.	O

Extensive	O
modulation	O
of	O
a	O
set	O
of	O
microRNAs	O
in	O
primary	O
glioblastoma	O
.	O

MicroRNAs	O
(	O
miRNAs	O
)	O
are	O
short	O
non	O
-	O
coding	O
RNA	O
molecules	O
playing	O
regulatory	O
roles	O
in	O
animals	O
and	O
plants	O
by	O
repressing	O
translation	O
or	O
cleaving	O
RNA	O
transcripts	O
.	O

The	O
specific	O
modulation	O
of	O
several	O
microRNAs	O
has	O
been	O
recently	O
associated	O
to	O
some	O
forms	O
of	O
human	B
cancer	O
,	O
suggesting	O
that	O
these	O
short	O
molecules	O
may	O
represent	O
a	O
new	O
class	O
of	O
genes	O
involved	O
in	O
oncogenesis	O
.	O

In	O
our	O
study	O
,	O
we	O
examined	O
by	O
microarray	O
the	O
global	O
expression	O
levels	O
of	O
245	O
microRNAs	O
in	O
glioblastoma	O
multiforme	O
,	O
the	O
most	O
frequent	O
and	O
malignant	O
of	O
primary	O
brain	O
tumors	O
.	O

The	O
analysis	O
of	O
both	O
glioblastoma	O
tissues	O
and	O
glioblastoma	O
cell	O
lines	O
allowed	O
us	O
to	O
identify	O
a	O
group	O
of	O
microRNAs	O
whose	O
expression	O
is	O
significantly	O
altered	O
in	O
this	O
tumor	O
.	O

The	O
most	O
interesting	O
results	O
came	O
from	O
miR-221	O
,	O
strongly	O
up	O
-	O
regulated	O
in	O
glioblastoma	O
and	O
from	O
a	O
set	O
of	O
brain	O
-	O
enriched	O
miRNAs	O
,	O
miR-128	O
,	O
miR-181a	O
,	O
miR-181b	O
,	O
and	O
miR-181c	O
,	O
which	O
are	O
down	O
-	O
regulated	O
in	O
glioblastoma	O
.	O

Pharmacologic	O
and	O
genetic	O
inhibition	O
of	O
p53	O
corroborated	O
the	O
hypothesis	O
that	O
pre	O
-	O
miR-630	O
(	O
but	O
not	O
pre	O
-	O
miR-181a	O
)	O
blocks	O
the	O
upstream	O
signaling	O
pathways	O
that	O
are	O
ignited	O
by	O
DNA	O
damage	O
and	O
converge	O
on	O
p53	O
activation	O
.	O

Pre	O
-	O
miR-630	O
arrested	O
A549	O
cells	O
in	O
the	O
G0-G1	O
phase	O
of	O
the	O
cell	O
cycle	O
,	O
correlating	O
with	O
increased	O
levels	O
of	O
the	O
cell	O
cycle	O
inhibitor	O
p27	O
(	O
Kip1	O
)	O
as	O
well	O
as	O
with	O
reduced	O
proliferation	O
rates	O
and	O
resulting	O
in	O
greatly	O
diminished	O
sensitivity	O
of	O
A549	O
cells	O
to	O
the	O
late	O
S	O
-	O
G2-M	O
cell	O
cycle	O
arrest	O
mediated	O
by	O
CDDP	O
.	O

Altogether	O
,	O
these	O
results	O
identify	O
miR-181a	O
and	O
miR-630	O
as	O
novel	O
modulators	O
of	O
the	O
CDDP	O
response	O
in	O
NSCLC	O
.	O

The	O
corresponding	O
synthetic	O
miRNA	O
precursors	O
(	O
pre	O
-	O
miRNAs	O
)	O
per	O
se	O
were	O
not	O
lethal	O
when	O
transfected	O
into	O
A549	O
cells	O
yet	O
affected	O
cell	O
death	O
induction	O
by	O
CDDP	O
,	O
C2-ceramide	O
,	O
cadmium	O
,	O
etoposide	O
,	O
and	O
mitoxantrone	O
in	O
an	O
inducer	O
-	O
specific	O
fashion	O
.	O

Whereas	O
synthetic	O
miRNA	O
inhibitors	O
(	O
anti	O
-	O
miRNAs	O
)	O
targeting	O
miR-181a	O
and	O
miR-630	O
failed	O
to	O
modulate	O
the	O
response	O
of	O
A549	O
to	O
CDDP	O
,	O
pre	O
-	O
miR-181a	O
and	O
pre	O
-	O
miR-630	O
enhanced	O
and	O
reduced	O
CDDP	O
-	O
triggered	O
cell	O
death	O
,	O
respectively	O
.	O

Pre	O
-	O
miR-181a	O
and	O
pre	O
-	O
miR-630	O
consistently	O
modulated	O
mitochondrial	O
/	O
postmitochondrial	O
steps	O
of	O
the	O
intrinsic	O
pathway	O
of	O
apoptosis	O
,	O
including	O
Bax	O
oligomerization	O
,	O
mitochondrial	O
transmembrane	O
potential	O
dissipation	O
,	O
and	O
the	O
proteolytic	O
maturation	O
of	O
caspase-9	O
and	O
caspase-3	O
.	O

In	O
addition	O
,	O
pre	O
-	O
miR-630	O
blocked	O
early	O
manifestations	O
of	O
the	O
DNA	O
damage	O
response	O
,	O
including	O
the	O
phosphorylation	O
of	O
the	O
ataxia	O
-	O
telangiectasia	O
mutated	O
(	O
ATM	O
)	O
kinase	O
and	O
of	O
two	O
ATM	O
substrates	O
,	O
histone	O
H2AX	O
and	O
p53	O
.	O

miR-181a	O
and	O
miR-630	O
regulate	O
cisplatin	O
-	O
induced	O
cancer	O
cell	O
death	O
.	O

MicroRNAs	O
(	O
miRNA	O
)	O
are	O
noncoding	O
RNAs	O
that	O
regulate	O
multiple	O
cellular	O
processes	O
,	O
including	O
proliferation	O
and	O
apoptosis	O
.	O

We	O
used	O
microarray	O
technology	O
to	O
identify	O
miRNAs	O
that	O
were	O
upregulated	O
by	O
non	O
-	O
small	O
cell	O
lung	O
cancer	O
(	O
NSCLC	O
)	O
A549	O
cells	O
in	O
response	O
to	O
cisplatin	O
(	O
CDDP	O
)	O
.	O

Although	O
microRNAs	O
are	O
being	O
extensively	O
studied	O
for	O
their	O
involvement	O
in	O
cancer	O
and	O
development	O
,	O
little	O
is	O
known	O
about	O
their	O
roles	O
in	O
Alzheimer	O
's	O
disease	O
(	O
AD	O
)	O
.	O

Joint	O
genome	O
-	O
wide	O
profiling	O
of	O
miRNA	O
and	O
mRNA	O
expression	O
in	O
Alzheimer	O
's	O
disease	O
cortex	O
reveals	O
altered	O
miRNA	O
regulation	O
.	O

These	O
data	O
provided	O
the	O
unique	O
opportunity	O
to	O
study	O
the	O
relationship	O
between	O
miRNA	O
and	O
mRNA	O
expression	O
in	O
normal	O
and	O
AD	O
brains	O
.	O

In	O
this	O
study	O
,	O
we	O
used	O
microarrays	O
for	O
the	O
first	O
joint	O
profiling	O
and	O
analysis	O
of	O
miRNAs	O
and	O
mRNAs	O
expression	O
in	O
brain	O
cortex	O
from	O
AD	O
and	O
age	O
-	O
matched	O
control	O
subjects	O
.	O

Comparative	O
analysis	O
with	O
independent	O
cancer	O
datasets	O
showed	O
that	O
such	O
miRNA	O
-	O
mRNA	O
expression	O
correlations	O
are	O
not	O
static	O
,	O
but	O
rather	O
context	O
-	O
dependent	O
.	O

Using	O
a	O
non	O
-	O
parametric	O
analysis	O
,	O
we	O
showed	O
that	O
the	O
levels	O
of	O
many	O
miRNAs	O
can	O
be	O
either	O
positively	O
or	O
negatively	O
correlated	O
with	O
those	O
of	O
their	O
target	O
mRNAs	O
.	O

Our	O
results	O
demonstrate	O
a	O
robust	O
relationship	O
between	O
the	O
levels	O
of	O
miRNAs	O
and	O
those	O
of	O
their	O
targets	O
in	O
the	O
brain	O
.	O

Subsequently	O
,	O
we	O
identified	O
a	O
large	O
set	O
of	O
miRNA	O
-	O
mRNA	O
associations	O
that	O
are	O
changed	O
in	O
AD	O
versus	O
control	O
,	O
highlighting	O
AD	O
-	O
specific	O
changes	O
in	O
the	O
miRNA	O
regulatory	O
system	O
.	O

This	O
has	O
implications	O
in	O
the	O
study	O
of	O
the	O
molecular	O
pathology	O
of	O
AD	O
,	O
as	O
well	O
as	O
miRNA	O
biology	O
in	O
general	O
.	O

In	O
this	O
review	O
,	O
we	O
focus	O
on	O
studies	O
addressing	O
the	O
role	O
of	O
various	O
microRNAs	O
in	O
heart	O
,	O
muscle	O
,	O
liver	O
,	O
pancreas	O
,	O
central	O
nervous	O
system	O
,	O
and	O
hematopoiesis	O
.	O

Large	O
numbers	O
and	O
quantities	O
of	O
different	O
,	O
small	O
RNA	O
molecules	O
are	O
present	O
in	O
the	O
cytoplasm	O
of	O
animal	O
and	O
plant	O
cells	O
.	O

MicroRNAs	O
in	O
organogenesis	O
and	O
disease	O
.	O

Since	O
their	O
discovery	O
in	O
the	O
1990s	O
a	O
multitude	O
of	O
basic	O
information	O
has	O
accumulated	O
,	O
which	O
has	O
identified	O
their	O
function	O
in	O
post	O
-	O
transcriptional	O
control	O
,	O
either	O
via	O
degradation	O
or	O
translational	O
inhibition	O
of	O
target	O
mRNAs	O
.	O

One	O
subclass	O
of	O
these	O
molecules	O
is	O
represented	O
by	O
the	O
noncoding	O
microRNAs	O
.	O

MicroRNA	O
expression	O
profiles	O
are	O
highly	O
dynamic	O
during	O
embryonic	O
development	O
and	O
in	O
adulthood	O
.	O

This	O
function	O
is	O
in	O
most	O
of	O
the	O
cases	O
a	O
finetuning	O
of	O
gene	O
expression	O
,	O
working	O
in	O
parallel	O
with	O
transcriptional	O
regulatory	O
processes	O
.	O

Evidence	O
from	O
gain-	O
and	O
loss	O
-	O
of	O
function	O
studies	O
indicates	O
roles	O
for	O
microRNAs	O
in	O
pathophysiologic	O
states	O
including	O
cardiac	O
hypertrophy	O
,	O
muscle	O
dystrophy	O
,	O
hepatitis	O
infection	O
,	O
diabetes	O
,	O
Parkinson	O
syndrome	O
,	O
hematological	O
malignancies	O
and	O
other	O
types	O
of	O
cancer	O
.	O

Misexpression	O
of	O
microRNAs	O
can	O
perturb	O
embryogenesis	O
,	O
organogenesis	O
,	O
tissue	O
homeostasis	O
and	O
the	O
cell	O
cycle	O
.	O

BACKGROUND	O
:	O
The	O
aberrant	O
expression	O
of	O
microRNAs	O
(	O
miRNAs	O
)	O
is	O
associated	O
with	O
a	O
variety	O
of	O
diseases	O
including	O
cancers	O
.	O

In	O
the	O
present	O
study	O
,	O
the	O
miRNA	O
expression	O
profile	O
was	O
examined	O
in	O
astrocytoma	O
,	O
a	O
malignant	O
and	O
prevalent	O
intracranial	O
tumour	O
in	O
adults	O
.	O

METHODS	O
:	O
We	O
screened	O
the	O
expression	O
profile	O
of	O
200	O
miRNAs	O
in	O
a	O
training	O
sample	O
set	O
consisting	O
of	O
84	O
astrocytoma	O
samples	O
and	O
20	O
normal	O
adjacent	O
tissue	O
(	O
NAT	O
)	O
samples	O
using	O
the	O
method	O
of	O
stem	O
-	O
loop	O
quantitative	O
RT	O
-	O
PCR	O
.	O

The	O
significantly	O
altered	O
miRNAs	O
were	O
validated	O
in	O
another	O
independent	O
sample	O
set	O
consisting	O
of	O
40	O
astrocytoma	O
samples	O
and	O
40	O
NAT	O
samples	O
.	O

The	O
correlation	O
of	O
the	O
miRNA	O
levels	O
with	O
survival	O
in	O
astrocytoma	O
samples	O
was	O
estimated	O
by	O
performing	O
Kaplan	O
-	O
Meier	O
survival	O
analysis	O
and	O
univariate	O
/	O
multivariate	O
Cox	O
proportional	O
hazard	O
regression	O
analysis	O
.	O

RESULTS	O
:	O
After	O
a	O
two	O
-	O
phase	O
selection	O
and	O
validation	O
process	O
,	O
seven	O
miRNAs	O
were	O
found	O
to	O
have	O
a	O
significantly	O
different	O
expression	O
profile	O
in	O
astrocytoma	O
samples	O
upon	O
comparison	O
to	O
the	O
NAT	O
samples	O
.	O

Unsupervised	O
clustering	O
analysis	O
further	O
revealed	O
the	O
great	O
potential	O
of	O
the	O
7-miRNA	O
profile	O
to	O
differentiate	O
between	O
tumours	O
and	O
normal	O
brain	O
tissues	O
.	O

The	O
down	O
-	O
regulation	O
of	O
hsa	O
-	O
miR-137	O
in	O
astrocytomas	O
was	O
shown	O
to	O
be	O
associated	O
with	O
advanced	O
clinical	O
stages	O
of	O
this	O
disease	O
.	O

The	O
use	O
of	O
hsa	O
-	O
miR-21	O
,	O
hsa	O
-	O
miR-181b	O
and	O
hsa	O
-	O
miR-106a	O
as	O
prognostic	O
indicators	O
of	O
astrocytoma	O
.	O

Using	O
Kaplan	O
-	O
Meier	O
survival	O
analysis	O
we	O
showed	O
that	O
low	O
expression	O
of	O
hsa	O
-	O
miR-181b	O
or	O
hsa	O
-	O
miR-106a	O
,	O
or	O
high	O
expression	O
of	O
hsa	O
-	O
miR-21	O
was	O
significantly	O
associated	O
with	O
poor	O
patient	B
survival	O
.	O

CONCLUSIONS	O
:	O
Our	O
results	O
suggest	O
a	O
great	O
potential	O
for	O
the	O
use	O
of	O
miRNA	O
profiling	O
as	O
a	O
powerful	O
diagnostic	O
and	O
prognostic	O
marker	O
in	O
defining	O
the	O
signature	O
of	O
astrocytomas	O
and	O
in	O
predicting	O
the	O
post	O
-	O
surgical	O
outcome	O
.	O

Moreover	O
,	O
Cox	O
proportional	O
hazard	O
regression	O
analysis	O
revealed	O
that	O
this	O
prognostic	O
impact	O
was	O
independent	O
of	O
other	O
clinicopathological	O
factors	O
.	O

Phosphodiesterase-4D	O
knock	O
-	O
out	O
and	O
RNA	O
interference	O
-	O
mediated	O
knock	O
-	O
down	O
enhance	O
memory	O
and	O
increase	O
hippocampal	O
neurogenesis	O
via	O
increased	O
cAMP	O
signaling	O
.	O

Phosphodiesterase-4	O
(	O
PDE4	O
)	O
plays	O
an	O
important	O
role	O
in	O
mediating	O
memory	O
via	O
the	O
control	O
of	O
intracellular	O
cAMP	O
signaling	O
;	O
inhibition	O
of	O
PDE4	O
enhances	O
memory	O
.	O

However	O
,	O
development	O
of	O
PDE4	O
inhibitors	O
as	O
memory	O
enhancers	O
has	O
been	O
hampered	O
by	O
their	O
major	O
side	O
effect	O
of	O
emesis	O
.	O

PDE4	O
has	O
four	O
subtypes	O
(	O
PDE4A	O
-	O
D	O
)	O
consisting	O
of	O
25	O
splice	O
variants	O
.	O

Mice	B
deficient	O
in	O
PDE4D	O
displayed	O
memory	O
enhancement	O
in	O
radial	O
arm	O
maze	O
,	O
water	O
maze	O
,	O
and	O
object	O
recognition	O
tests	O
.	O

These	O
effects	O
were	O
mimicked	O
by	O
repeated	O
treatment	O
with	O
rolipram	O
in	O
wild	O
-	O
type	O
mice	B
.	O

In	O
addition	O
,	O
similarly	O
as	O
rolipram	O
-	O
treated	O
wild	O
-	O
type	O
mice	B
,	O
PDE4D	O
-	O
deficient	O
mice	B
also	O
displayed	O
increased	O
hippocampal	O
neurogenesis	O
and	O
phosphorylated	O
cAMP	O
response	O
element	O
-	O
binding	O
protein	O
(	O
pCREB	O
)	O
.	O

Furthermore	O
,	O
microinfusion	O
of	O
lentiviral	O
vectors	O
that	O
contained	O
microRNAs	O
(	O
miRNAs	O
)	O
targeting	O
long	O
-	O
form	O
PDE4D	O
isoforms	O
into	O
bilateral	O
dentate	O
gyri	O
of	O
the	O
mouse	B
hippocampus	O
downregulated	O
PDE4D4	O
and	O
PDE4D5	O
,	O
enhanced	O
memory	O
,	O
and	O
increased	O
hippocampal	O
neurogenesis	O
and	O
pCREB	O
.	O

Finally	O
,	O
while	O
rolipram	O
and	O
PDE4D	O
deficiency	O
shortened	O
α2	O
adrenergic	O
receptor	O
-	O
mediated	O
anesthesia	O
,	O
a	O
surrogate	O
measure	O
of	O
emesis	O
,	O
miRNA	O
-	O
mediated	O
PDE4D	O
knock	O
-	O
down	O
in	O
the	O
hippocampus	O
did	O
not	O
.	O

The	O
present	O
results	O
suggest	O
that	O
PDE4D	O
,	O
in	O
particular	O
long	O
-	O
form	O
PDE4D	O
,	O
plays	O
a	O
critical	O
role	O
in	O
the	O
mediation	O
of	O
memory	O
and	O
hippocampal	O
neurogenesis	O
,	O
which	O
are	O
mediated	O
by	O
cAMP	O
/	O
CREB	O
signaling	O
;	O
reduced	O
expression	O
of	O
PDE4D	O
,	O
or	O
at	O
least	O
PDE4D4	O
and	O
PDE4D5	O
,	O
in	O
the	O
hippocampus	O
enhances	O
memory	O
but	O
appears	O
not	O
to	O
cause	O
emesis	O
.	O

These	O
novel	O
findings	O
will	O
aid	O
in	O
the	O
development	O
of	O
PDE4	O
subtype-	O
or	O
variant	O
-	O
selective	O
inhibitors	O
for	O
treatment	O
of	O
disorders	O
involving	O
impaired	O
cognition	O
,	O
including	O
Alzheimer	O
's	O
disease	O
.	O

MicroRNAs	O
(	O
miRNAs	O
)	O
are	O
known	O
to	O
influence	O
many	O
important	O
cellular	O
processes	O
,	O
including	O
proliferation	O
,	O
apoptosis	O
,	O
neurogenesis	O
,	O
angiogenesis	O
,	O
and	O
morphogenesis	O
,	O
all	O
processes	O
that	O
are	O
involved	O
in	O
TBI	O
pathophysiology	O
.	O

Multiple	O
cellular	O
,	O
molecular	O
,	O
and	O
biochemical	O
changes	O
contribute	O
to	O
outcome	O
after	O
traumatic	O
brain	O
injury	O
(	O
TBI	O
)	O
.	O

In	O
the	O
present	O
study	O
,	O
we	O
used	O
a	O
microarray	O
platform	O
to	O
examine	O
changes	O
in	O
the	O
hippocampal	O
expression	O
levels	O
of	O
444	O
verified	O
rodent	O
miRNAs	O
at	O
3	O
and	O
24	O
hr	O
after	O
controlled	O
cortical	O
impact	O
injury	O
.	O

However	O
,	O
it	O
has	O
not	O
yet	O
been	O
determined	O
whether	O
miRNA	O
expression	O
is	O
altered	O
after	O
TBI	O
.	O

We	O
extended	O
the	O
microarray	O
findings	O
using	O
quantitative	O
polymerase	O
chain	O
reaction	O
analysis	O
for	O
a	O
subset	O
of	O
the	O
miRNAs	O
with	O
altered	O
expression	O
levels	O
(	O
miR-107	O
,	O
-130a	O
,	O
-223	O
,	O
-292	O
-	O
5p	O
,	O
-433	O
-	O
3p	O
,	O
-451	O
,	O
-541	O
,	O
and	O
-711	O
)	O
.	O

Our	O
analysis	O
found	O
50	O
miRNAs	O
exhibited	O
decreased	O
expression	O
levels	O
and	O
35	O
miRNAs	O
exhibited	O
increased	O
expression	O
levels	O
in	O
the	O
hippocampus	O
after	O
injury	O
.	O

Our	O
results	O
indicate	O
that	O
multiple	O
protein	O
targets	O
and	O
biological	O
processes	O
involved	O
in	O
TBI	O
pathophysiology	O
may	O
be	O
regulated	O
by	O
miRNAs	O
.	O

Bioinformatic	O
analysis	O
of	O
the	O
predicted	O
targets	O
for	O
this	O
panel	O
of	O
miRNAs	O
revealed	O
an	O
overrepresentation	O
of	O
proteins	O
involved	O
in	O
several	O
biological	O
processes	O
and	O
functions	O
known	O
to	O
be	O
initiated	O
after	O
injury	O
,	O
including	O
signal	O
transduction	O
,	O
transcriptional	O
regulation	O
,	O
proliferation	O
,	O
and	O
differentiation	O
.	O

Traumatic	O
brain	O
injury	O
alters	O
expression	O
of	O
hippocampal	O
microRNAs	O
:	O
potential	O
regulators	O
of	O
multiple	O
pathophysiological	O
processes	O
.	O

Potent	O
,	O
allele	O
selective	O
inhibition	O
of	O
HTT	O
by	O
mismatched	O
RNAs	O
provides	O
a	O
new	O
option	O
for	O
developing	O
HD	O
therapeutics	O
.	O

Switching	O
the	O
RNAi	O
mechanism	O
toward	O
that	O
used	O
by	O
miRNAs	O
by	O
introducing	O
one	O
or	O
more	O
mismatched	O
bases	O
into	O
these	O
duplex	O
RNAs	O
leads	O
to	O
potent	O
(	O
<	O
10	O
nM	O
)	O
and	O
highly	O
selective	O
(	O
>	O
30-fold	O
relative	O
to	O
wild	O
-	O
type	O
HTT	O
)	O
inhibition	O
of	O
mutant	O
HTT	O
expression	O
in	O
patient	B
-	O
derived	O
cells	O
.	O

We	O
observe	O
that	O
fully	O
complementary	O
duplex	O
RNAs	O
targeting	O
the	O
expanded	O
CAG	O
repeat	O
within	O
HTT	O
mRNA	O
block	O
expression	O
of	O
both	O
alleles	O
.	O

An	O
ideal	O
silencing	O
agent	O
would	O
block	O
expression	O
of	O
mutant	O
HTT	O
while	O
leaving	O
expression	O
of	O
wild	O
-	O
type	O
HTT	O
intact	O
.	O

Inhibiting	O
expression	O
of	O
huntingtin	O
(	O
HTT	O
)	O
protein	O
is	O
a	O
promising	O
strategy	O
for	O
treating	O
Huntington	O
's	O
disease	O
(	O
HD	O
)	O
,	O
but	O
indiscriminant	O
inhibition	O
of	O
both	O
wild	O
-	O
type	O
and	O
mutant	O
alleles	O
may	O
lead	O
to	O
toxicity	O
.	O

Allele	O
-	O
selective	O
inhibition	O
of	O
huntingtin	O
expression	O
by	O
switching	O
to	O
an	O
miRNA	O
-	O
like	O
RNAi	O
mechanism	O
.	O

Thus	O
we	O
have	O
identified	O
a	O
miRNA	O
expression	O
signature	O
that	O
can	O
predict	O
GBM	O
patient	B
survival	O
.	O

Cox	O
multivariate	O
analysis	O
with	O
patient	B
age	O
as	O
a	O
covariate	O
on	O
the	O
entire	O
patient	B
set	O
identified	O
risk	O
score	O
based	O
on	O
the	O
10	O
miRNA	O
expression	O
signature	O
to	O
be	O
an	O
independent	O
predictor	O
of	O
patient	B
survival	O
(	O
HR	O
=	O
1.120	O
;	O
95	O
%	O
CI	O
=	O
1.04	O
-	O
1.20	O
;	O
p	O
=	O
0.003	O
)	O
.	O

These	O
findings	O
may	O
have	O
implications	O
in	O
the	O
understanding	O
of	O
gliomagenesis	O
,	O
development	O
of	O
targeted	O
therapy	O
and	O
selection	O
of	O
high	O
risk	O
cancer	O
patients	B
for	O
adjuvant	O
therapy	O
.	O

GBM	O
patients	B
with	O
high	O
risk	O
scores	O
had	O
overall	O
poor	O
survival	O
compared	O
to	O
the	O
patients	B
with	O
low	O
risk	O
scores	O
.	O

Overall	O
survival	O
among	O
the	O
entire	O
patient	B
set	O
was	O
35.0	O
%	O
at	O
2	O
years	O
,	O
21.5	O
%	O
at	O
3	O
years	O
,	O
18.5	O
%	O
at	O
4	O
years	O
and	O
11.8	O
%	O
at	O
5	O
years	O
in	O
the	O
low	O
risk	O
group	O
,	O
versus	O
11.0	O
%	O
,	O
5.5	O
%	O
,	O
0.0	O
and	O
0.0	O
%	O
respectively	O
in	O
the	O
high	O
risk	O
group	O
(	O
HR	O
=	O
2.0	O
;	O
95	O
%	O
CI	O
=	O
1.4	O
-	O
2.8	O
;	O
p<0.0001	O
)	O
.	O

To	O
identify	O
a	O
microRNA	O
(	O
miRNA	O
)	O
expression	O
signature	O
that	O
can	O
predict	O
GBM	O
patient	B
survival	O
,	O
we	O
analyzed	O
the	O
miRNA	O
expression	O
data	O
of	O
GBM	O
patients	B
(	O
n	O
=	O
222	O
)	O
derived	O
from	O
The	O
Cancer	O
Genome	O
Atlas	O
(	O
TCGA	O
)	O
dataset	O
.	O

We	O
divided	O
the	O
patients	B
randomly	O
into	O
training	O
and	O
testing	O
sets	O
with	O
equal	O
number	O
in	O
each	O
group	O
.	O

A	O
Ten	O
-	O
microRNA	O
Expression	O
Signature	O
Predicts	O
Survival	O
in	O
Glioblastoma	O
.	O

Glioblastoma	O
(	O
GBM	O
)	O
is	O
the	O
most	O
common	O
and	O
aggressive	O
primary	O
brain	O
tumor	O
with	O
very	O
poor	O
patient	B
median	O
survival	O
.	O

Of	O
these	O
10	O
miRNAs	O
,	O
7	O
were	O
found	O
to	O
be	O
risky	O
miRNAs	O
and	O
3	O
were	O
found	O
to	O
be	O
protective	O
.	O

This	O
signature	O
was	O
independently	O
validated	O
in	O
the	O
testing	O
set	O
(	O
HR	O
=	O
1.7	O
;	O
95	O
%	O
CI	O
=	O
1.1	O
-	O
2.8	O
;	O
p	O
=	O
0.002	O
)	O
.	O

We	O
identified	O
10	O
significant	O
miRNAs	O
using	O
Cox	O
regression	O
analysis	O
on	O
the	O
training	O
set	O
and	O
formulated	O
a	O
risk	O
score	O
based	O
on	O
the	O
expression	O
signature	O
of	O
these	O
miRNAs	O
that	O
segregated	O
the	O
patients	B
into	O
high	O
and	O
low	O
risk	O
groups	O
with	O
significantly	O
different	O
survival	O
times	O
(	O
hazard	O
ratio	O
[	O
HR	O
]	O
=	O
2.4	O
;	O
95	O
%	O
CI	O
=	O
1.4	O
-	O
3.8	O
;	O
p<0.0001	O
)	O
.	O

Microarray	O
analysis	O
showed	O
differential	O
expression	O
of	O
multiple	O
miRNAs	O
in	O
HIVE	O
compared	O
to	O
control	O
brains	O
.	O

Target	O
prediction	O
and	O
gene	O
ontology	O
enrichment	O
analysis	O
disclosed	O
targeting	O
of	O
several	O
gene	O
families	O
/	O
biological	O
processes	O
by	O
differentially	O
expressed	O
miRNAs	O
(	O
DEMs	O
)	O
,	O
with	O
cell	O
death	O
-	O
related	O
genes	O
,	O
including	O
caspase-6	O
,	O
showing	O
a	O
bias	O
toward	O
down	O
-	O
regulated	O
DEMs	O
.	O

Consistent	O
with	O
the	O
miRNA	O
data	O
,	O
HIVE	O
brains	O
exhibited	O
higher	O
levels	O
of	O
caspase-6	O
transcripts	O
compared	O
with	O
control	O
patients	B
.	O

Immunohistochemical	O
analysis	O
showed	O
localization	O
of	O
the	O
cleaved	O
form	O
of	O
caspase-6	O
in	O
astrocytes	O
in	O
HIVE	O
brain	O
sections	O
.	O

Exposure	O
of	O
cultured	O
human	B
primary	O
astrocytes	O
to	O
HIV	O
viral	O
protein	O
R	O
(	O
Vpr	O
)	O
induced	O
p53	O
up	O
-	O
regulation	O
,	O
loss	O
of	O
mitochondrial	O
membrane	O
potential	O
,	O
and	O
caspase-6	O
activation	O
followed	O
by	O
cell	O
injury	O
.	O

Transgenic	B
mice	I
,	O
expressing	O
Vpr	O
in	O
microglial	O
cells	O
,	O
demonstrated	O
astrocyte	O
apoptosis	O
in	O
brain	O
,	O
which	O
was	O
associated	O
with	O
caspase-6	O
activation	O
and	O
neurobehavioral	O
abnormalities	O
.	O

Overall	O
,	O
these	O
data	O
point	O
to	O
previously	O
unrecognized	O
alterations	O
in	O
miRNA	O
profile	O
in	O
the	O
brain	O
during	O
HIV	O
infection	O
,	O
which	O
contribute	O
to	O
cell	O
death	O
through	O
dysregulation	O
of	O
cell	O
death	O
machinery	O
.	O

MicroRNA	O
profiling	O
reveals	O
new	O
aspects	O
of	O
HIV	O
neurodegeneration	O
:	O
caspase-6	O
regulates	O
astrocyte	O
survival	O
.	O

MicroRNAs	O
(	O
miRNAs	O
)	O
are	O
small	O
noncoding	O
RNA	O
molecules	O
,	O
which	O
are	O
known	O
to	O
regulate	O
gene	O
expression	O
in	O
physiological	O
and	O
pathological	O
conditions	O
.	O

miRNA	O
profiling	O
was	O
performed	O
using	O
brain	O
tissue	O
from	O
patients	B
with	O
HIV	O
encephalitis	O
(	O
HIVE	O
)	O
,	O
a	O
neuroinflammatory	O
/	O
degenerative	O
disorder	O
caused	O
by	O
HIV	O
infection	O
of	O
the	O
brain	O
.	O

Language	O
brain	O
dominance	O
in	O
patients	B
with	O
refractory	O
temporal	O
lobe	O
epilepsy	O
:	O
a	O
comparative	O
study	O
between	O
functional	O
magnetic	O
resonance	O
imaging	O
and	O
dichotic	O
listening	O
test	O
.	O

PURPOSE	O
:	O
To	O
identify	O
brain	O
dominance	O
for	O
language	O
functions	O
with	O
DLT	O
and	O
correlate	O
these	O
results	O
with	O
those	O
obtained	O
from	O
fMRI	O
in	O
patients	B
suffering	O
from	O
intractable	O
temporal	O
lobe	O
epilepsy	O
.	O

METHOD	O
:	O
This	O
study	O
reports	O
on	O
13	O
patients	B
who	O
underwent	O
pre	O
-	O
surgical	O
epileptic	O
evaluation	O
between	O
April	O
and	O
October	O
2004	O
at	O
the	O
Epilepsy	O
Surgery	O
Program	O
,	O
Hospital	O
Sao	O
Lucas	O
,	O
PUCRS	O
.	O

In	O
DLT	O
,	O
dominance	O
was	O
assessed	O
through	O
a	O
consonant	O
-	O
vowel	O
task	O
,	O
whereas	O
in	O
fMRI	O
patients	B
performed	O
a	O
verb	O
generation	O
task	O
.	O

These	O
findings	O
indicate	O
that	O
DLT	O
(	O
a	O
non	O
-	O
invasive	O
procedure	O
)	O
could	O
be	O
a	O
useful	O
tool	O
to	O
evaluate	O
language	O
brain	O
dominance	O
in	O
pre	O
-	O
surgical	O
epileptic	O
patients	B
as	O
it	O
is	O
cheaper	O
to	O
perform	O
than	O
fMRI	O
.	O

CONCLUSION	O
:	O
DLT	O
was	O
found	O
to	O
significantly	O
correlate	O
with	O
fMRI	O
.	O

RESULTS	O
:	O
Our	O
results	O
identified	O
a	O
correlation	O
between	O
the	O
fMRI	O
lateralization	O
index	O
and	O
the	O
DLT	O
ear	O
predominance	O
index	O
and	O
reply	O
difference	O
index	O
(	O
r=0.6	O
,	O
p=0.02	O
;	O
Pearson	O
Correlation	O
Coefficient	O
)	O
,	O
showing	O
positive	O
correlation	O
between	O
results	O
obtained	O
from	O
fMRI	O
and	O
DLT	O
.	O

Our	O
method	O
significantly	O
decreased	O
the	O
duration	O
of	O
hospital	O
admission	O
for	O
monitoring	O
and	O
minimal	O
complications	O
occurred	O
only	O
in	O
8	O
%	O
of	O
patients	B
.	O

CONCLUSIONS	O
:	O
In	O
conclusion	O
,	O
our	O
method	O
for	O
short	O
VEEG	O
monitoring	O
has	O
a	O
high	O
yield	O
for	O
diagnosis	O
,	O
minimal	O
complications	O
and	O
is	O
cost	O
effective	O
.	O

These	O
qualities	O
,	O
together	O
with	O
good	O
surgery	O
results	O
validate	O
our	O
method	O
for	O
the	O
investigation	O
and	O
treatment	O
of	O
refractory	O
seizure	O
cases	O
.	O

RESULTS	O
:	O
Our	O
monitoring	O
answered	O
the	O
study	O
question	O
in	O
88	O
%	O
of	O
the	O
patients	B
.	O

We	O
prospectively	O
assessed	O
the	O
yield	O
and	O
safety	O
of	O
the	O
telemetry	O
investigation	O
as	O
well	O
as	O
epilepsy	O
surgery	O
outcomes	O
.	O

Our	O
results	O
changed	O
the	O
management	O
in	O
74	O
%	O
of	O
cases	O
and	O
potentially	O
improved	O
quality	O
of	O
life	O
by	O
decreasing	O
the	O
AEDs	O
consumption	O
and	O
number	O
of	O
seizures	O
per	O
month	O
.	O

The	O
question	O
was	O
not	O
answered	O
in	O
12	O
%	O
of	O
cases	O
due	O
to	O
the	O
lack	O
of	O
recorded	O
events	O
.	O

Over	O
all	O
,	O
22	O
%	O
received	O
epilepsy	O
surgery	O
and	O
became	O
either	O
seizure	O
free	O
or	O
their	O
seizures	O
became	O
non	O
-	O
disabling	O
.	O

Safety	O
and	O
yield	O
of	O
early	O
cessation	O
of	O
AEDs	O
in	O
video	O
-	O
EEG	O
telemetry	O
and	O
outcomes	O
.	O

METHODS	O
:	O
This	O
is	O
a	O
prospective	O
study	O
performed	O
to	O
asses	O
the	O
safety	O
and	O
yield	O
of	O
early	O
discontinuation	O
of	O
antiepileptic	O
drugs	O
(	O
AEDs	O
)	O
in	O
the	O
telemetry	O
unit	O
.	O

BACKGROUND	O
:	O
Video	O
-	O
electroencephalography	O
(	O
VEEG	O
)	O
telemetry	O
is	O
the	O
simultaneous	O
recording	O
of	O
ictal	O
and	O
interictal	O
EEG	O
pattern	O
and	O
paroxysmal	O
behavior	O
to	O
investigate	O
the	O
nature	O
of	O
paroxysmal	O
events	O
.	O

In	O
most	O
cases	O
AEDs	O
(	O
except	O
Phenobarbital	O
)	O
were	O
discontinued	O
in	O
24h	O
.	O

Over	O
a	O
2.5-year	O
period	O
,	O
50	O
patients	B
that	O
met	O
the	O
indications	O
for	O
VEEG	O
monitoring	O
were	O
admitted	O
by	O
an	O
epileptologist	O
to	O
neuro	O
-	O
observation	O
units	O
with	O
continuous	O
monitoring	O
,	O
nursing	O
coverage	O
and	O
EEG	O
technicians	O
support	O
during	O
working	O
hours	O
and	O
on	O
-	O
call	O
thereafter	O
.	O

The	O
molecular	O
mechanisms	O
that	O
contribute	O
to	O
gliomagenesis	O
have	O
become	O
increasingly	O
clear	O
in	O
recent	O
years	O
,	O
yet	O
much	O
remains	O
to	O
be	O
learned	O
.	O

Gliomas	O
are	O
the	O
most	O
common	O
form	O
of	O
primary	O
brain	O
tumors	O
and	O
are	O
associated	O
with	O
a	O
poor	O
clinical	O
outcome	O
.	O

microRNAs	O
in	O
gliomas	O
:	O
small	O
regulators	O
of	O
a	O
big	O
problem	O
.	O

This	O
is	O
a	O
rapidly	O
evolving	O
field	O
and	O
it	O
is	O
likely	O
that	O
we	O
have	O
only	O
begun	O
to	O
appreciate	O
the	O
involvement	O
of	O
microRNAs	O
in	O
relation	O
to	O
glioma	O
formation	O
,	O
and	O
the	O
therapeutic	O
potential	O
of	O
microRNAs	O
to	O
improve	O
outcome	O
for	O
glioma	O
patients	B
.	O

Here	O
we	O
review	O
the	O
current	O
state	O
of	O
knowledge	O
related	O
to	O
the	O
role	O
of	O
microRNAs	O
in	O
glial	O
tumor	O
development	O
.	O

It	O
is	O
now	O
evident	O
that	O
microRNAs	O
regulate	O
a	O
wide	O
variety	O
of	O
tumorigenic	O
processes	O
including	O
cellular	O
proliferation	O
,	O
differentiation	O
,	O
angiogenesis	O
,	O
invasion	O
,	O
and	O
apoptosis	O
.	O

This	O
is	O
particularly	O
true	O
for	O
the	O
role	O
of	O
microRNAs	O
in	O
gliomagenesis	O
,	O
as	O
an	O
appreciation	O
for	O
the	O
significance	O
of	O
aberrant	O
miRNA	O
expression	O
in	O
human	B
cancer	O
has	O
only	O
emerged	O
in	O
the	O
last	O
5	O
years	O
.	O

Altered	O
microRNA	O
expression	O
following	O
traumatic	O
spinal	O
cord	O
injury	O
.	O

MicroRNAs	O
(	O
miRNAs	O
)	O
are	O
a	O
novel	O
class	O
of	O
small	O
non	O
-	O
coding	O
RNAs	O
that	O
negatively	O
regulate	O
gene	O
expression	O
at	O
the	O
posttranscriptional	O
level	O
by	O
binding	O
to	O
the	O
3	O
'	O
untranslated	O
region	O
of	O
target	O
mRNAs	O
leading	O
to	O
their	O
translational	O
inhibition	O
or	O
sometimes	O
degradation	O
.	O

We	O
uncovered	O
a	O
previously	O
unknown	O
alteration	O
in	O
temporal	O
expression	O
of	O
a	O
large	O
set	O
of	O
miRNAs	O
following	O
a	O
contusive	O
spinal	O
cord	O
injury	O
(	O
SCI	O
)	O
in	O
adult	O
rats	B
using	O
microarray	O
analysis	O
.	O

These	O
altered	O
miRNAs	O
can	O
be	O
classified	O
into	O
3	O
categories	O
:	O
(	O
1	O
)	O
up	O
-	O
regulation	O
,	O
(	O
2	O
)	O
down	O
-	O
regulation	O
and	O
(	O
3	O
)	O
an	O
early	O
up	O
-	O
regulation	O
at	O
4	O
h	O
followed	O
by	O
down	O
-	O
regulation	O
at	O
1	O
and	O
7	O
days	O
post	O
-	O
SCI	O
.	O

The	O
bioinformatics	O
analysis	O
indicates	O
that	O
the	O
potential	O
targets	O
for	O
miRNAs	O
altered	O
after	O
SCI	O
include	O
genes	O
encoding	O
components	O
that	O
are	O
involved	O
in	O
the	O
inflammation	O
,	O
oxidation	O
,	O
and	O
apoptosis	O
that	O
are	O
known	O
to	O
play	O
important	O
roles	O
in	O
the	O
pathogenesis	O
of	O
SCI	O
.	O

These	O
findings	O
suggest	O
that	O
abnormal	O
expression	O
of	O
miRNAs	O
may	O
contribute	O
to	O
the	O
pathogenesis	O
of	O
SCI	O
and	O
are	O
potential	O
targets	O
for	O
therapeutic	O
interventions	O
following	O
SCI	O
.	O

Demyelinating	O
process	O
may	O
be	O
the	O
feature	O
of	O
nervous	O
impairment	O
in	O
systemic	O
lupus	O
erythematosus	O
,	O
Behcet	O
's	O
disease	O
(	O
BD	O
)	O
,	O
Sjoegren	O
's	O
syndrome	O
(	O
SS	O
)	O
,	O
systemic	O
sclerosis	O
(	O
SSc	O
)	O
or	O
very	O
rarely	O
other	O
systemic	O
autoimmune	O
diseases	O
.	O

An	O
acute	O
isolated	O
neurological	O
syndrome	O
,	O
as	O
the	O
most	O
common	O
symptom	O
of	O
MS	O
can	O
sometimes	O
be	O
the	O
only	O
feature	O
or	O
even	O
first	O
manifestation	O
of	O
nervous	O
impairment	O
in	O
connective	O
tissue	O
disease	O
,	O
hence	O
presenting	O
the	O
diagnostic	O
problem	O
.	O

Although	O
the	O
white	O
matter	O
abnormalities	O
seen	O
by	O
magnetic	O
resonance	O
imaging	O
may	O
be	O
similar	O
in	O
non	O
-	O
MS	O
autoimmune	O
demyelination	O
and	O
MS	O
,	O
it	O
is	O
the	O
most	O
important	O
diagnostic	O
tool	O
in	O
the	O
differential	O
diagnosis	O
of	O
the	O
mentioned	O
conditions	O
.	O

Investigating	O
the	O
presence	O
of	O
various	O
autoantibodies	O
potentially	O
involved	O
in	O
the	O
pathogenesis	O
of	O
demyelinating	O
lesions	O
as	O
well	O
as	O
cerebrospinal	O
fluid	O
(	O
CSF	O
)	O
analysis	O
can	O
be	O
helpful	O
.	O

Non	O
-	O
MS	O
autoimmune	O
demyelination	O
.	O

Connective	O
tissue	O
diseases	O
can	O
be	O
characterised	O
by	O
central	O
nervous	O
system	O
(	O
CNS	O
)	O
involvement	O
,	O
in	O
some	O
patients	B
manifested	O
by	O
demyelination	O
areas	O
in	O
the	O
white	O
matter	O
of	O
the	O
brain	O
and	O
spinal	O
cord	O
,	O
which	O
are	O
difficult	O
to	O
differentiate	O
from	O
multiple	O
sclerosis	O
(	O
MS	O
)	O
and	O
other	O
demyelinating	O
processes	O
,	O
such	O
as	O
transverse	O
myelitis	O
and	O
optic	O
neuritis	O
.	O

Targeting	O
miRNAs	O
in	O
Alzheimer	O
's	O
disease	O
.	O

These	O
findings	O
identify	O
specific	O
microRNAs	O
as	O
attenuators	O
of	O
growth	O
factor	O
signaling	O
and	O
oncogenesis	O
.	O

In	O
line	O
with	O
roles	O
as	O
suppressors	O
of	O
EGF	O
receptor	O
(	O
EGFR	O
)	O
signaling	O
,	O
we	O
report	O
that	O
the	O
abundance	O
of	O
this	O
early	O
subset	O
of	O
microRNAs	O
is	O
decreased	O
in	O
breast	O
and	O
in	O
brain	O
tumors	O
driven	O
by	O
the	O
EGFR	O
or	O
the	O
closely	O
related	O
HER2	O
.	O

This	O
step	O
permitted	O
rapid	O
induction	O
of	O
oncogenic	O
transcription	O
factors	O
,	O
such	O
as	O
c	O
-	O
FOS	O
,	O
encoded	O
by	O
immediate	O
early	O
genes	O
.	O

EGF	O
decreases	O
the	O
abundance	O
of	O
microRNAs	O
that	O
restrain	O
oncogenic	O
transcription	O
factors	O
.	O

The	O
earliest	O
event	O
involved	O
a	O
decrease	O
in	O
the	O
abundance	O
of	O
a	O
subset	O
of	O
23	O
microRNAs	O
.	O

Using	O
genome	O
-	O
wide	O
approaches	O
,	O
we	O
showed	O
that	O
EGF	O
stimulation	O
initiates	O
a	O
coordinated	O
transcriptional	O
program	O
of	O
microRNAs	O
and	O
transcription	O
factors	O
.	O

MicroRNAs	O
,	O
which	O
attenuate	O
gene	O
expression	O
by	O
binding	O
complementary	O
regions	O
in	O
messenger	O
RNAs	O
,	O
are	O
broadly	O
implicated	O
in	O
cancer	O
.	O

Epidermal	O
growth	O
factor	O
(	O
EGF	O
)	O
stimulates	O
cells	O
by	O
launching	O
gene	O
expression	O
programs	O
that	O
are	O
frequently	O
deregulated	O
in	O
cancer	O
.	O

To	O
determine	O
the	O
role	O
of	O
possible	O
pathogenic	O
cofactors	O
such	O
as	O
geographic	O
,	O
ethnic	B
,	O
genetic	O
,	O
and	O
cultural	O
features	O
,	O
further	O
pertinent	O
surveys	O
are	O
required	O
in	O
subtropical	O
northwestern	O
Argentina	O
.	O

Considering	O
the	O
HAM	O
/	O
TSP	O
cluster	O
described	O
here	O
plus	O
previously	O
reported	O
isolated	O
cases	O
in	O
neighboring	O
Salta	O
Province	O
,	O
we	O
speculate	O
that	O
the	O
Puna	O
Jujeña	O
region	O
and	O
regions	O
in	O
that	O
vicinity	O
would	O
be	O
a	O
microepidemic	O
focus	O
of	O
disease	O
.	O

Therefore	O
,	O
the	O
long	O
-	O
term	O
presence	O
of	O
virus	O
in	O
Jujuy	O
natives	O
may	O
be	O
taken	O
for	O
granted	O
.	O

In	O
contrast	O
to	O
the	O
Andean	O
region	O
of	O
Bolivia	O
,	O
where	O
high	O
HTLV	O
-	O
I	O
seroprevalence	O
is	O
in	O
part	O
attributable	O
to	O
Japanese	O
immigrants	O
,	O
the	O
Jujuy	O
population	O
mainly	O
consists	O
of	O
aborigines	O
,	O
mestizos	O
,	O
and	O
European	O
descendants	O
.	O

No	O
history	O
of	O
risk	O
factors	O
was	O
disclosed	O
,	O
except	O
for	O
a	O
single	O
transfusion	O
in	O
1	O
patient	B
.	O

Most	O
patients	B
(	O
9	O
/	O
11	O
)	O
were	O
born	O
in	O
Cochinoca	O
Department	O
,	O
located	O
in	O
an	O
Andes	O
highland	O
area	O
called	O
Puna	O
Jujeña	O
,	O
situated	O
at	O
more	O
that	O
3400	O
m	O
above	O
sea	O
level	O
.	O

Accordingly	O
,	O
a	O
clinically	O
diagnosed	O
and	O
serologically	O
confirmed	O
cluster	O
of	O
cases	O
in	O
1	O
man	B
and	O
10	O
women	B
,	O
including	O
2	O
sisters	O
,	O
is	O
described	O
here	O
.	O

Compared	O
with	O
other	O
regions	O
in	O
Argentina	O
,	O
greater	O
human	B
T	O
-	O
cell	O
lymphotropic	O
virus	O
type	O
I	O
(	O
HTLV	O
-	O
I	O
)	O
seroprevalence	O
has	O
been	O
reported	O
in	O
Jujuy	O
Province	O
,	O
where	O
it	O
reaches	O
2.32	O
%	O
in	O
the	O
general	O
population	O
,	O
so	O
that	O
a	O
search	O
for	O
HTLV	O
-	O
I	O
-	O
associated	O
myelopathy	O
/	O
tropical	O
spastic	O
paraparesis	O
(	O
HAM	O
/	O
TSP	O
)	O
cases	O
deserved	O
to	O
be	O
carried	O
out	O
.	O

A	O
cluster	O
of	O
human	B
T	O
-	O
cell	O
lymphotropic	O
virus	O
type	O
I	O
-	O
associated	O
myelopathy	O
/	O
tropical	O
spastic	O
paraparesis	O
in	O
Jujuy	O
,	O
Argentina	O
.	O

Atrial	O
fibrillation	O
(	O
AF	O
)	O
is	O
an	O
emerging	O
clinical	O
problem	O
with	O
multifaceted	O
issues	O
:	O
current	O
and	O
expected	O
prevalence	O
,	O
significant	O
morbidity	O
,	O
potentially	O
fatal	O
outcome	O
(	O
e.g.	O
,	O
stroke	O
)	O
and	O
gaps	O
in	O
therapeutic	O
approaches	O
.	O

Targeting	O
the	O
arrhythmogenic	O
substrate	O
in	O
atrial	O
fibrillation	O
:	O
focus	O
on	O
structural	O
remodeling	O
.	O

Although	O
a	O
number	O
of	O
drugs	O
have	O
just	O
come	O
out	O
of	O
the	O
pipeline	O
with	O
promising	O
results	O
(	O
e.g.	O
,	O
dronedarone	O
)	O
,	O
the	O
question	O
arises	O
whether	O
channel	O
-	O
targeted	O
drugs	O
represent	O
the	O
only	O
viable	O
approach	O
.	O

Current	O
anti	O
-	O
arrhythmic	O
strategies	O
not	O
only	O
fail	O
to	O
guarantee	O
effective	O
rhythm	O
control	O
,	O
but	O
also	O
cause	O
""""	O
on	O
target	O
""""	O
(	O
i.e.	O
,	O
pro	O
-	O
arrhythmia	O
,	O
namely	O
torsade	O
de	O
pointes	O
)	O
and	O
""""	O
off	O
target	O
""""	O
(	O
i.e.	O
,	O
extra	O
-	O
cardiac	O
toxicities	O
)	O
side	O
effects	O
.	O

Fascinating	O
and	O
innovative	O
strategies	O
have	O
been	O
proposed	O
(	O
e.g.	O
,	O
miRNAs	O
modulation	O
)	O
,	O
but	O
the	O
actual	O
benefit	O
is	O
debated	O
.	O

This	O
review	O
will	O
provide	O
mechanistic	O
insights	O
into	O
structural	O
remodeling	O
and	O
highlight	O
emerging	O
upstream	O
strategies	O
in	O
AF	O
management	O
.	O

A	O
body	O
of	O
evidence	O
has	O
emerged	O
supporting	O
structural	O
remodeling	O
as	O
the	O
main	O
arrhythmogenic	O
substrate	O
perpetuating	O
AF	O
.	O
Fibrosis	O
,	O
inflammation	O
and	O
oxidative	O
stress	O
appear	O
strongly	O
interconnected	O
in	O
the	O
pathogenesis	O
of	O
remodeling	O
-	O
induced	O
abnormalities	O
.	O

Moreover	O
,	O
insights	O
into	O
extracellular	O
matrix	O
network	O
strongly	O
suggested	O
an	O
active	O
cross	O
-	O
talk	O
within	O
the	O
cardiac	O
microenvironment	O
,	O
which	O
should	O
be	O
further	O
investigated	O
as	O
promising	O
""""	O
anti	O
-	O
remodeling	O
""""	O
approach	O
.	O

Therefore	O
,	O
pharmacological	O
modulation	O
of	O
non	O
-	O
ionic	O
targets	O
(	O
the	O
so	O
called	O
""""	O
upstream	O
""""	O
therapy	O
)	O
has	O
gained	O
interest	O
as	O
a	O
preventive	O
strategy	O
in	O
AF	O
.	O

At	O
the	O
present	O
state	O
of	O
knowledge	O
,	O
renin	O
-	O
angiotensin	O
-	O
aldosterone	O
system	O
blockers	O
and	O
statins	O
offer	O
evidence	O
for	O
potential	O
clinical	O
exploitation	O
,	O
while	O
several	O
remodeling	O
-	O
targeted	O
therapies	O
have	O
been	O
tested	O
only	O
experimentally	O
or	O
failed	O
when	O
studied	O
for	O
human	B
validation	O
.	O

Epigenetics	O
are	O
defined	O
,	O
in	O
broad	O
-	O
terms	O
,	O
as	O
alterations	O
in	O
gene	O
expression	O
without	O
changes	O
in	O
DNA	O
sequence	O
.	O

Epigenetic	O
changes	O
in	O
gliomas	O
.	O

In	O
this	O
review	O
,	O
we	O
will	O
first	O
describe	O
briefly	O
histone	O
modifications	O
,	O
DNA	O
methylation	O
and	O
miRNAs	O
and	O
the	O
functions	O
of	O
these	O
epigenetic	O
marks	O
during	O
different	O
cellular	O
processes	O
involving	O
DNA	O
metabolism	O
.	O

While	O
histone	O
modifications	O
and	O
DNA	O
methylation	O
are	O
two	O
classical	O
means	O
to	O
regulate	O
gene	O
expression	O
,	O
miRNA	O
has	O
also	O
recently	O
been	O
documented	O
to	O
govern	O
gene	O
expression	O
in	O
normal	O
as	O
well	O
as	O
cancer	O
cells	O
.	O

We	O
expect	O
that	O
novel	O
therapies	O
will	O
be	O
developed	O
to	O
counter	O
epigenetic	O
changes	O
in	O
this	O
deadly	O
disease	O
.	O

We	O
will	O
then	O
highlight	O
some	O
epigenetic	O
changes	O
in	O
glioblastomas	O
,	O
a	O
malignant	O
form	O
of	O
brain	O
tumor	O
,	O
and	O
potential	O
application	O
of	O
epigenetic	O
means	O
for	O
diagnosis	O
,	O
prognosis	O
,	O
and	O
treatment	O
of	O
gliomas	O
.	O

Human	B
brains	O
retain	O
discrete	O
populations	O
of	O
micro	O
RNA	O
(	O
miRNA	O
)	O
species	O
that	O
support	O
homeostatic	O
brain	O
gene	O
expression	O
functions	O
;	O
however	O
,	O
specific	O
miRNA	O
abundance	O
is	O
significantly	O
altered	O
in	O
neurological	O
disorders	O
such	O
as	O
Alzheimer	O
disease	O
(	O
AD	O
)	O
when	O
compared	O
with	O
age	O
-	O
matched	O
controls	O
.	O

An	O
NF	O
-	O
kappaB	O
-	O
sensitive	O
micro	O
RNA-146a	O
-	O
mediated	O
inflammatory	O
circuit	O
in	O
Alzheimer	O
disease	O
and	O
in	O
stressed	O
human	B
brain	O
cells	O
.	O

Up	O
-	O
regulation	O
of	O
miRNA-146a	O
coupled	O
to	O
down	O
-	O
regulation	O
of	O
CFH	O
was	O
observed	O
in	O
AD	O
brain	O
and	O
in	O
interleukin-1beta	O
,	O
Abeta42	O
,	O
and/or	O
oxidatively	O
stressed	O
human	B
neural	O
(	O
HN	O
)	O
cells	O
in	O
primary	O
culture	O
.	O

Here	O
we	O
provide	O
evidence	O
in	O
AD	O
brains	O
of	O
a	O
specific	O
up	O
-	O
regulation	O
of	O
an	O
NF	O
-	O
kappaB	O
-	O
sensitive	O
miRNA-146a	O
highly	O
complementary	O
to	O
the	O
3'-untranslated	O
region	O
of	O
complement	O
factor	O
H	O
(	O
CFH	O
)	O
,	O
an	O
important	O
repressor	O
of	O
the	O
inflammatory	O
response	O
of	O
the	O
brain	O
.	O

Treatment	O
of	O
stressed	O
HN	O
cells	O
with	O
the	O
NF	O
-	O
kappaB	O
inhibitor	O
pyrollidine	O
dithiocarbamate	O
or	O
the	O
resveratrol	O
analog	O
CAY10512	O
abrogated	O
this	O
response	O
.	O

Transfection	O
of	O
HN	O
cells	O
using	O
an	O
NF	O
-	O
kappaB	O
-	O
containing	O
pre	O
-	O
miRNA-146a	O
promoter	O
-	O
luciferase	O
reporter	O
construct	O
in	O
stressed	O
HN	O
cells	O
showed	O
significant	O
up	O
-	O
regulation	O
of	O
luciferase	O
activity	O
that	O
paralleled	O
decreases	O
in	O
CFH	O
gene	O
expression	O
.	O

Incubation	O
of	O
an	O
antisense	O
oligonucleotide	O
to	O
miRNA-146a	O
(	O
anti	O
-	O
miRNA-146a	O
;	O
AM-146a	O
)	O
was	O
found	O
to	O
restore	O
CFH	O
expression	O
levels	O
.	O

These	O
data	O
indicate	O
that	O
NF	O
-	O
kappaB	O
-	O
sensitive	O
miRNA-146a	O
-	O
mediated	O
modulation	O
of	O
CFH	O
gene	O
expression	O
may	O
in	O
part	O
regulate	O
an	O
inflammatory	O
response	O
in	O
AD	O
brain	O
and	O
in	O
stressed	O
HN	O
cell	O
models	O
of	O
AD	O
and	O
illustrate	O
the	O
potential	O
for	O
anti	O
-	O
miRNAs	O
as	O
an	O
effective	O
therapeutic	O
strategy	O
against	O
pathogenic	O
inflammatory	O
signaling	O
.	O

The	O
prevalence	O
of	O
neurodegenerative	O
disorders	O
is	O
rising	O
steadily	O
as	O
human	B
life	O
expectancy	O
increases	O
.	O

However	O
,	O
limited	O
knowledge	O
of	O
the	O
molecular	O
basis	O
of	O
disease	O
pathogenesis	O
is	O
a	O
major	O
hurdle	O
in	O
the	O
identification	O
of	O
drug	O
targets	O
and	O
development	O
of	O
therapeutic	O
strategies	O
for	O
these	O
largely	O
incurable	O
disorders	O
.	O

MicroRNAs	O
:	O
novel	O
therapeutic	O
targets	O
in	O
neurodegenerative	O
diseases	O
.	O

Our	O
bioinformatic	O
analysis	O
suggests	O
novel	O
miRNA	O
-	O
target	O
interactions	O
that	O
could	O
potentially	O
influence	O
neurodegeneration	O
.	O

The	O
recent	O
development	O
of	O
molecules	O
that	O
alter	O
miRNA	O
expression	O
promises	O
valuable	O
tools	O
that	O
will	O
enhance	O
the	O
therapeutic	O
potential	O
of	O
miRNAs	O
.	O

Recently	O
,	O
differential	O
expression	O
of	O
endogenous	O
regulatory	O
small	O
RNAs	O
,	O
known	O
as	O
'	O
microRNAs	O
'	O
(	O
miRNAs	O
)	O
,	O
in	O
patients	B
of	O
Alzheimer	O
's	O
disease	O
,	O
Parkinson	O
's	O
disease	O
and	O
models	O
of	O
ataxia	O
suggest	O
that	O
they	O
might	O
have	O
key	O
regulatory	O
roles	O
in	O
neurodegeneration	O
.	O

miRNAs	O
that	O
can	O
target	O
known	O
mediators	O
of	O
neurodegeneration	O
offer	O
potential	O
therapeutic	O
targets	O
.	O

The	O
miR-146a	O
expression	O
was	O
confirmed	O
to	O
be	O
present	O
in	O
reactive	O
astrocytes	O
.	O

In	O
human	B
TLE	O
with	O
hippocampal	O
sclerosis	O
,	O
increased	O
astroglial	O
expression	O
of	O
miR-146a	O
was	O
observed	O
mainly	O
in	O
regions	O
where	O
neuronal	O
cell	O
loss	O
and	O
reactive	O
gliosis	O
occurred	O
.	O

The	O
increased	O
and	O
persistent	O
expression	O
of	O
miR-146a	O
in	O
reactive	O
astrocytes	O
supports	O
the	O
possible	O
involvement	O
of	O
miRNAs	O
in	O
the	O
modulation	O
of	O
the	O
astroglial	O
inflammatory	O
response	O
occurring	O
in	O
TLE	O
and	O
provides	O
a	O
target	O
for	O
future	O
studies	O
aimed	O
at	O
developing	O
strategies	O
against	O
pro	O
-	O
epileptogenic	O
inflammatory	O
signalling	O
.	O

Increasing	O
evidence	O
supports	O
the	O
involvement	O
of	O
inflammatory	O
and	O
immune	O
processes	O
in	O
temporal	O
lobe	O
epilepsy	O
(	O
TLE	O
)	O
.	O

Expression	O
pattern	O
of	O
miR-146a	O
,	O
an	O
inflammation	O
-	O
associated	O
microRNA	O
,	O
in	O
experimental	O
and	O
human	B
temporal	O
lobe	O
epilepsy	O
.	O

We	O
investigated	O
the	O
expression	O
and	O
cellular	O
distribution	O
of	O
miRNA-146a	O
(	O
miR-146a	O
)	O
in	O
a	O
rat	B
model	O
of	O
TLE	O
as	O
well	O
as	O
in	O
human	B
TLE	O
.	O

MicroRNAs	O
(	O
miRNA	O
)	O
represent	O
small	O
regulatory	O
RNA	O
molecules	O
that	O
have	O
been	O
shown	O
to	O
act	O
as	O
negative	O
regulators	O
of	O
gene	O
expression	O
controlling	O
different	O
biological	O
processes	O
,	O
including	O
immune	O
-	O
system	O
homeostasis	O
and	O
function	O
.	O

Prominent	O
upregulation	O
of	O
miR-146a	O
activation	O
was	O
evident	O
at	O
1	O
week	O
after	O
SE	O
and	O
persisted	O
in	O
the	O
chronic	O
phase	O
.	O

miR-146a	O
analysis	O
in	O
rat	B
hippocampus	O
was	O
performed	O
by	O
polymerase	O
chain	O
reaction	O
and	O
immunocytochemistry	O
at	O
1	O
week	O
and	O
3	O
-	O
4	O
months	O
after	O
induction	O
of	O
status	O
epilepticus	O
(	O
SE	O
)	O
.	O

Regeneration	O
of	O
neuromuscular	O
synapses	O
:	O
action	O
of	O
microRNA-206	O
.	O

DESIGN	O
:	O
:	O
Cross	O
-	O
sectional	O
study	O
.	O

OBJECTIVE	O
:	O
:	O
To	O
compare	O
presentation	O
of	O
Alzheimer	O
disease	O
(	O
AD	O
)	O
at	O
the	O
time	O
of	O
initial	O
evaluation	O
at	O
a	O
university	O
specialty	O
clinic	O
across	O
three	O
ethnoracial	O
groups	O
in	O
order	O
to	O
understand	O
similarities	O
and	O
differences	O
in	O
the	O
demographic	O
,	O
clinical	O
,	O
cognitive	O
,	O
psychiatric	O
,	O
and	O
biologic	O
features	O
.	O

Ethnoracial	O
differences	O
in	O
the	O
clinical	O
characteristics	O
of	O
Alzheimer	O
's	O
disease	O
at	O
initial	O
presentation	O
at	O
an	O
urban	O
Alzheimer	O
's	O
disease	O
center	O
.	O

The	O
apolipoprotein	O
E-4	O
genotype	O
was	O
not	O
associated	O
with	O
AD	O
in	O
the	O
Latino	O
cohort	O
.	O

Greater	O
severity	O
of	O
symptoms	O
was	O
not	O
accounted	O
for	O
by	O
a	O
difference	O
in	O
lag	O
time	O
between	O
onset	O
of	O
symptoms	O
and	O
initial	O
evaluation	O
.	O

There	O
was	O
more	O
depression	O
in	O
the	O
Latinos	O
compared	O
with	O
African	O
Americans	O
and	O
WNHs	O
.	O

In	O
particular	O
,	O
the	O
largely	O
immigrant	O
Puerto	O
Rican	O
Latino	O
group	O
had	O
an	O
earlier	O
age	O
of	O
onset	O
of	O
AD	O
,	O
more	O
cognitive	O
impairment	O
,	O
and	O
greater	O
severity	O
of	O
cognitive	O
impairment	O
at	O
the	O
time	O
of	O
initial	O
evaluation	O
in	O
the	O
setting	O
of	O
low	O
average	O
education	O
and	O
socioeconomic	O
status	O
.	O

RESULTS	O
:	O
:	O
Differences	O
among	O
ethnoracial	O
groups	O
were	O
found	O
for	O
nearly	O
all	O
variables	O
of	O
interest	O
.	O

MEASUREMENTS	O
:	O
:	O
Demographic	O
variables	O
and	O
age	O
of	O
onset	O
of	O
AD	O
,	O
as	O
well	O
as	O
cognitive	O
,	O
functional	O
,	O
and	O
mood	O
impairments	O
at	O
the	O
time	O
of	O
initial	O
presentation	O
and	O
frequencies	O
of	O
apolipoprotein	O
E	O
genotypes	O
,	O
were	O
compared	O
across	O
groups	O
.	O

PARTICIPANTS	O
:	O
:	O
A	O
total	O
of	O
1,341	O
self	O
-	O
identified	O
African	O
American	O
,	O
Latino	O
(	O
primarily	O
of	O
Caribbean	O
origin	O
)	O
,	O
and	O
white	O
non	O
-	O
Hispanic	O
(	O
""""	O
WNH	O
""""	O
)	O
subjects	O
were	O
recruited	O
from	O
primary	O
care	O
sites	O
or	O
by	O
referral	O
by	O
primary	O
care	O
physicians	O
.	O

Important	O
potential	O
confounds	O
need	O
to	O
be	O
considered	O
and	O
future	O
research	O
comparing	O
immigrant	O
and	O
nonimmigrant	O
Latino	O
groups	O
will	O
be	O
necessary	O
to	O
elucidate	O
the	O
highly	O
significant	O
differences	O
reported	O
.	O

CONCLUSIONS	O
:	O
:	O
Minority	O
groups	O
in	O
Philadelphia	O
,	O
especially	O
Latinos	O
,	O
exhibit	O
a	O
more	O
severe	O
profile	O
of	O
AD	O
at	O
the	O
time	O
of	O
presentation	O
than	O
WNHs	O
.	O

These	O
tumors	O
arise	O
in	O
the	O
cerebellum	O
and	O
may	O
attribute	O
their	O
origins	O
to	O
deregulated	O
proliferation	O
of	O
neural	O
progenitor	O
cells	O
during	O
development	O
.	O

However	O
,	O
only	O
a	O
few	O
studies	O
to	O
date	O
have	O
focused	O
on	O
the	O
role	O
of	O
miRNAs	O
in	O
medulloblastoma	O
,	O
the	O
most	O
common	O
malignant	O
pediatric	O
brain	O
tumor	O
.	O

MiRNA	O
expression	O
profiling	O
of	O
both	O
mouse	B
and	O
human	B
medulloblastomas	O
has	O
led	O
to	O
the	O
identification	O
of	O
signatures	O
correlating	O
with	O
the	O
molecular	O
subgroups	O
of	O
medulloblastoma	O
,	O
tumor	O
diagnosis	O
and	O
response	O
to	O
treatment	O
,	O
as	O
well	O
as	O
novel	O
targets	O
of	O
potential	O
clinical	O
relevance	O
.	O

Understanding	O
the	O
interplay	O
between	O
normal	O
brain	O
development	O
and	O
medulloblastoma	O
pathogenesis	O
is	O
necessary	O
in	O
order	O
for	O
more	O
efficient	O
,	O
less	O
toxic	O
targeted	O
therapies	O
to	O
be	O
developed	O
and	O
implemented	O
.	O

Normal	O
and	O
oncogenic	O
roles	O
for	O
microRNAs	O
in	O
the	O
developing	O
brain	O
.	O

Emerging	O
evidence	O
indicates	O
that	O
miRNAs	O
are	O
key	O
players	O
in	O
mammalian	O
development	O
that	O
,	O
when	O
altered	O
,	O
contribute	O
to	O
tumorigenesis	O
.	O

MicroRNAS	O
(	O
miRNAs	O
)	O
are	O
small	O
endogenous	O
non	O
-	O
coding	O
RNAs	O
that	O
play	O
important	O
roles	O
in	O
many	O
different	O
biological	O
processes	O
including	O
proliferation	O
,	O
differentiation	O
and	O
apoptosis	O
through	O
silencing	O
of	O
target	O
genes	O
.	O

This	O
review	O
summarizes	O
the	O
recent	O
miRNA	O
literature	O
in	O
both	O
medulloblastoma	O
and	O
normal	O
brain	O
development	O
.	O

A	O
miRNA	O
signature	O
of	O
prion	O
induced	O
neurodegeneration	O
.	O

Compelling	O
evidence	O
links	O
miRNAs	O
to	O
the	O
control	O
of	O
neuronal	O
development	O
and	O
differentiation	O
,	O
however	O
,	O
little	O
is	O
known	O
about	O
their	O
role	O
in	O
neurodegeneration	O
.	O

MicroRNAs	O
(	O
miRNAs	O
)	O
are	O
small	O
,	O
non	O
-	O
coding	O
RNA	O
molecules	O
which	O
are	O
emerging	O
as	O
key	O
regulators	O
of	O
numerous	O
cellular	O
processes	O
.	O

We	O
determined	O
15	O
miRNAs	O
were	O
de	O
-	O
regulated	O
during	O
the	O
disease	O
processes	O
;	O
miR-342	O
-	O
3p	O
,	O
miR-320	O
,	O
let-7b	O
,	O
miR-328	O
,	O
miR-128	O
,	O
miR-139	O
-	O
5p	O
and	O
miR-146a	O
were	O
over	O
2.5	O
fold	O
up	O
-	O
regulated	O
and	O
miR-338	O
-	O
3p	O
and	O
miR-337	O
-	O
3p	O
over	O
2.5	O
fold	O
down	O
-	O
regulated	O
.	O

We	O
used	O
microarrays	O
and	O
RT	O
-	O
PCR	O
to	O
profile	O
miRNA	O
expression	O
changes	O
in	O
the	O
brains	O
of	O
mice	B
infected	O
with	O
mouse	B
-	O
adapted	O
scrapie	O
.	O

De	O
-	O
regulation	O
of	O
a	O
unique	O
subset	O
of	O
miRNAs	O
suggests	O
a	O
conserved	O
,	O
disease	O
-	O
specific	O
pattern	O
of	O
differentially	O
expressed	O
miRNAs	O
is	O
associated	O
with	O
prion	O
-	O
induced	O
neurodegeneration	O
.	O

Only	O
one	O
of	O
these	O
miRNAs	O
,	O
miR-128	O
,	O
has	O
previously	O
been	O
shown	O
to	O
be	O
de	O
-	O
regulated	O
in	O
neurodegenerative	O
disease	O
.	O

Computational	O
analysis	O
predicted	O
numerous	O
potential	O
gene	O
targets	O
of	O
these	O
miRNAs	O
,	O
including	O
119	O
genes	O
previously	O
determined	O
to	O
be	O
also	O
de	O
-	O
regulated	O
in	O
mouse	B
scrapie	O
.	O

We	O
used	O
a	O
co	O
-	O
ordinated	O
approach	O
to	O
integrate	O
miRNA	O
and	O
mRNA	O
profiling	O
,	O
bioinformatic	O
predictions	O
and	O
biochemical	O
validation	O
to	O
determine	O
miRNA	O
regulated	O
processes	O
and	O
genes	O
potentially	O
involved	O
in	O
disease	O
progression	O
.	O

In	O
particular	O
,	O
a	O
correlation	O
between	O
miRNA	O
expression	O
and	O
putative	O
gene	O
targets	O
involved	O
in	O
intracellular	O
protein	O
-	O
degradation	O
pathways	O
and	O
signaling	O
pathways	O
related	O
to	O
cell	O
death	O
,	O
synapse	O
function	O
and	O
neurogenesis	O
was	O
identified	O
.	O

Type	O
III	O
RNase	O
Dicer	O
is	O
responsible	O
for	O
the	O
maturation	O
and	O
function	O
of	O
microRNA	O
(	O
miRNA	O
)	O
molecules	O
in	O
the	O
cell	O
.	O

Genetic	O
ablation	O
of	O
Dicer	O
in	O
adult	O
forebrain	O
neurons	O
results	O
in	O
abnormal	O
tau	O
hyperphosphorylation	O
and	O
neurodegeneration	O
.	O

Although	O
neuronal	O
loss	O
is	O
observed	O
in	O
the	O
hippocampus	O
,	O
cellular	O
shrinkage	O
is	O
predominant	O
in	O
the	O
cortex	O
.	O

Here	O
we	O
show	O
that	O
the	O
absence	O
of	O
Dicer	O
in	O
the	O
adult	O
forebrain	O
is	O
accompanied	O
by	O
a	O
mixed	O
neurodegenerative	O
phenotype	O
.	O

However	O
,	O
the	O
underlying	O
mechanisms	O
involved	O
in	O
neuronal	O
death	O
,	O
particularly	O
in	O
the	O
adult	O
brain	O
,	O
remain	O
poorly	O
defined	O
.	O

It	O
is	O
now	O
well	O
-	O
documented	O
that	O
Dicer	O
and	O
the	O
fine	O
-	O
tuning	O
of	O
the	O
miRNA	O
gene	O
network	O
are	O
important	O
for	O
neuronal	O
integrity	O
.	O

We	O
further	O
demonstrate	O
that	O
miRNAs	O
belonging	O
to	O
the	O
miR-15	O
family	O
are	O
potent	O
regulators	O
of	O
ERK1	O
expression	O
in	O
mouse	B
neuronal	O
cells	O
and	O
co	O
-	O
expressed	O
with	O
ERK1	O
/	O
2	O
in	O
vivo	O
.	O

Finally	O
,	O
we	O
show	O
that	O
miR-15a	O
is	O
specifically	O
downregulated	O
in	O
Alzheimer	O
's	O
disease	O
brain	O
.	O

Interestingly	O
,	O
neuronal	O
degeneration	O
coincides	O
with	O
the	O
hyperphosphorylation	O
of	O
endogenous	O
tau	O
at	O
several	O
epitopes	O
previously	O
associated	O
with	O
neurofibrillary	O
pathology	O
.	O

Transcriptome	O
analysis	O
of	O
enzymes	O
involved	O
in	O
tau	O
phosphorylation	O
identified	O
ERK1	O
as	O
one	O
of	O
the	O
candidate	O
kinases	O
responsible	O
for	O
this	O
event	O
in	O
vivo	O
.	O

In	O
summary	O
,	O
these	O
results	O
support	O
the	O
hypothesis	O
that	O
changes	O
in	O
the	O
miRNA	O
network	O
may	O
contribute	O
to	O
a	O
neurodegenerative	O
phenotype	O
by	O
affecting	O
tau	O
phosphorylation	O
.	O

MiR-21	O
can	O
be	O
induced	O
in	O
neurons	O
by	O
prolonged	O
N	O
-	O
methyl	O
-	O
D	O
-	O
aspartic	O
acid	O
receptor	O
stimulation	O
,	O
an	O
excitotoxic	O
process	O
active	O
in	O
HIV	O
and	O
other	O
neurodegenerative	O
diseases	O
.	O

Introduction	O
of	O
miR-21	O
into	O
human	B
neurons	O
leads	O
to	O
pathological	O
functional	O
defects	O
.	O

Furthermore	O
,	O
we	O
show	O
that	O
miR-21	O
specifically	O
targets	O
the	O
mRNA	O
of	O
myocyte	O
enhancer	O
factor	O
2C	O
(	O
MEF2C	O
)	O
,	O
a	O
transcription	O
factor	O
crucial	O
for	O
neuronal	O
function	O
,	O
and	O
reduces	O
its	O
expression	O
.	O

MEF2C	O
is	O
dramatically	O
downregulated	O
in	O
neurons	O
of	O
HIV	O
-	O
associated	O
dementia	O
patients	B
as	O
well	O
as	O
monkeys	O
with	O
SIVE	O
.	O

Together	O
,	O
this	O
study	O
elucidates	O
a	O
novel	O
role	O
for	O
miR-21	O
in	O
the	O
brain	O
,	O
not	O
only	O
as	O
a	O
potential	O
signature	O
of	O
neurological	O
disease	O
but	O
also	O
as	O
a	O
crucial	O
effector	O
of	O
HIV	O
induced	O
neuronal	O
dysfunction	O
and	O
neurodegeneration	O
.	O

MicroRNAs	O
(	O
miRNAs	O
)	O
play	O
important	O
roles	O
in	O
regulating	O
a	O
plethora	O
of	O
physiological	O
and	O
pathophysiogical	O
processes	O
including	O
neurodegeneration	O
.	O

MicroRNA-21	O
dysregulates	O
the	O
expression	O
of	O
MEF2C	O
in	O
neurons	O
in	O
monkey	O
and	O
human	B
SIV	O
/	O
HIV	O
neurological	O
disease	O
.	O

In	O
situ	O
hybridization	O
of	O
the	O
diseased	O
brain	O
sections	O
revealed	O
induction	O
of	O
miR-21	O
in	O
neurons	O
.	O

In	O
both	O
HIV	O
associated	O
dementia	O
in	O
humans	B
and	O
its	O
monkey	O
model	O
SIV	O
encephalitis	O
we	O
find	O
miR-21	O
,	O
a	O
miRNA	O
largely	O
known	O
for	O
its	O
link	O
to	O
oncogenesis	O
,	O
to	O
be	O
significantly	O
upregulated	O
in	O
the	O
brain	O
.	O

However	O
,	O
by	O
examining	O
pairs	O
in	O
which	O
the	O
significance	O
of	O
the	O
correlation	O
coefficients	O
is	O
modestly	O
relaxed	O
,	O
negative	O
correlations	O
do	O
tend	O
to	O
predict	O
targets	O
and	O
positive	O
correlations	O
tend	O
to	O
predict	O
physically	O
proximate	O
pairs	O
.	O

A	O
subset	O
of	O
high	O
correlation	O
pairs	O
were	O
experimentally	O
validated	O
by	O
over	O
-	O
expressing	O
or	O
suppressing	O
a	O
miRNA	O
and	O
measuring	O
the	O
correlated	O
mRNAs	O
.	O

Most	O
of	O
these	O
highest	O
correlation	O
pairs	O
do	O
not	O
contain	O
sufficiently	O
complementary	O
sequences	O
to	O
predict	O
a	O
target	O
relationship	O
;	O
nor	O
do	O
they	O
lie	O
in	O
physical	O
proximity	O
to	O
each	O
other	O
.	O

From	O
these	O
data	O
sets	O
,	O
we	O
inferred	O
and	O
validated	O
a	O
tumor	O
suppression	O
pathway	O
linked	O
to	O
miR-181c	O
.	O

CONCLUSIONS	O
/	O
SIGNIFICANCE	O
:	O
Sufficient	O
information	O
exists	O
within	O
a	O
set	O
of	O
tumor	O
samples	O
to	O
detect	O
endogenous	O
correlations	O
between	O
miRNA	O
and	O
mRNA	O
levels	O
.	O

Based	O
on	O
the	O
validations	O
the	O
causal	O
arrow	O
for	O
these	O
correlations	O
is	O
likely	O
to	O
be	O
directed	O
from	O
the	O
miRNAs	O
to	O
the	O
mRNAs	O
.	O

METHODOLOGY	O
/	O
PRINCIPAL	O
FINDINGS	O
:	O
RNA	O
was	O
extracted	O
from	O
12	O
human	B
primary	O
brain	O
tumor	O
biopsies	O
.	O

These	O
samples	O
were	O
used	O
to	O
determine	O
genome	O
-	O
wide	O
mRNA	O
expression	O
levels	O
by	O
microarray	O
analysis	O
and	O
a	O
miRNA	O
profile	O
by	O
real	O
-	O
time	O
reverse	O
transcription	O
PCR	O
.	O

Correlation	O
coefficients	O
were	O
determined	O
for	O
all	O
possible	O
mRNA	O
-	O
miRNA	O
pairs	O
and	O
the	O
distribution	O
of	O
these	O
correlations	O
compared	O
to	O
the	O
random	O
distribution	O
.	O

An	O
excess	O
of	O
high	O
positive	O
and	O
negative	O
correlation	O
pairs	O
were	O
observed	O
at	O
the	O
tails	O
of	O
these	O
distributions	O
.	O

BACKGROUND	O
:	O
microRNAs	O
(	O
miRNAs	O
)	O
are	O
approximately	O
21	O
nucleotide	O
non	O
-	O
coding	O
transcripts	O
capable	O
of	O
regulating	O
gene	O
expression	O
.	O

Detection	O
of	O
a	O
microRNA	O
signal	O
in	O
an	O
in	O
vivo	O
expression	O
set	O
of	O
mRNAs	O
.	O

As	O
a	O
result	O
,	O
translation	O
of	O
the	O
target	O
mRNA	O
is	O
inhibited	O
and	O
the	O
mRNA	O
may	O
be	O
destabilized	O
.	O

The	O
most	O
widely	O
studied	O
mechanism	O
of	O
regulation	O
involves	O
binding	O
of	O
a	O
miRNA	O
to	O
the	O
target	O
mRNA	O
.	O

We	O
asked	O
whether	O
endogenous	O
fluctuations	O
in	O
a	O
set	O
of	O
mRNA	O
and	O
miRNA	O
profiles	O
contain	O
correlated	O
changes	O
that	O
are	O
statistically	O
distinguishable	O
from	O
the	O
many	O
other	O
fluctuations	O
in	O
the	O
data	O
set	O
.	O

The	O
inhibitory	O
effects	O
of	O
miRNAs	O
have	O
been	O
linked	O
to	O
diverse	O
cellular	O
processes	O
including	O
malignant	O
proliferation	O
,	O
apoptosis	O
,	O
development	O
,	O
differentiation	O
,	O
and	O
metabolic	O
processes	O
.	O

METHODOLOGY	O
/	O
PRINCIPAL	O
FINDINGS	O
:	O
In	O
a	O
screening	O
of	O
MB	O
cell	O
lines	O
,	O
the	O
miRNA	O
miR-199b-5p	O
was	O
seen	O
to	O
be	O
a	O
regulator	O
of	O
the	O
Notch	O
pathway	O
through	O
its	O
targeting	O
of	O
the	O
transcription	O
factor	O
HES1	O
.	O
Down	O
-	O
regulation	O
of	O
HES1	O
expression	O
by	O
miR-199b-5p	O
negatively	O
regulates	O
the	O
proliferation	O
rate	O
and	O
anchorage	O
-	O
independent	O
growth	O
of	O
MB	O
cells	O
.	O

MiR-199b-5p	O
over	O
-	O
expression	O
blocks	O
expression	O
of	O
several	O
cancer	O
stem	O
-	O
cell	O
genes	O
,	O
impairs	O
the	O
engrafting	O
potential	O
of	O
MB	O
cells	O
in	O
the	O
cerebellum	O
of	O
athymic	O
/	O
nude	B
mice	I
,	O
and	O
of	O
particular	O
interest	O
,	O
decreases	O
the	O
MB	O
stem	O
-	O
cell	O
-	O
like	O
(	O
CD133	O
+	O
)	O
subpopulation	O
of	O
cells	O
.	O

In	O
our	O
analysis	O
of	O
61	O
patients	B
with	O
MB	O
,	O
the	O
expression	O
of	O
miR-199b-5p	O
in	O
the	O
non	O
-	O
metastatic	O
cases	O
was	O
significantly	O
higher	O
than	O
in	O
the	O
metastatic	O
cases	O
(	O
P	O
=	O
0.001	O
)	O
.	O

Correlation	O
with	O
survival	O
for	O
these	O
patients	B
with	O
high	O
levels	O
of	O
miR-199b	O
expression	O
showed	O
a	O
positive	O
trend	O
to	O
better	O
overall	O
survival	O
than	O
for	O
the	O
low	O
-	O
expressing	O
patients	B
.	O

Here	O
we	O
have	O
investigated	O
medulloblastoma	O
tumors	O
(	O
MBs	O
)	O
,	O
which	O
arise	O
from	O
an	O
early	O
impairment	O
of	O
developmental	O
processes	O
in	O
the	O
cerebellum	O
,	O
where	O
Notch	O
signaling	O
is	O
involved	O
in	O
many	O
cell	O
-	O
fate	O
-	O
determining	O
stages	O
.	O

MBs	O
occur	O
bimodally	O
,	O
with	O
the	O
peak	O
incidence	O
seen	O
between	O
3	O
-	O
4	O
years	O
and	O
8	O
-	O
9	O
years	O
of	O
age	O
,	O
although	O
it	O
can	O
also	O
occur	O
in	O
adults	O
.	O

Notch	O
regulates	O
a	O
subset	O
of	O
the	O
MB	O
cells	O
that	O
have	O
stem	O
-	O
cell	O
-	O
like	O
properties	O
and	O
can	O
promote	O
tumor	O
growth	O
.	O

On	O
the	O
basis	O
of	O
this	O
evidence	O
,	O
we	O
hypothesized	O
that	O
miRNAs	O
targeting	O
the	O
Notch	O
pathway	O
can	O
regulated	O
these	O
phenomena	O
,	O
and	O
can	O
be	O
used	O
in	O
anti	O
-	O
cancer	O
therapies	O
.	O

BACKGROUND	O
:	O
Through	O
negative	O
regulation	O
of	O
gene	O
expression	O
,	O
microRNAs	O
(	O
miRNAs	O
)	O
can	O
function	O
in	O
cancers	O
as	O
oncosuppressors	O
,	O
and	O
they	O
can	O
show	O
altered	O
expression	O
in	O
various	O
tumor	O
types	O
.	O

MicroRNA-199b-5p	O
impairs	O
cancer	O
stem	O
cells	O
through	O
negative	O
regulation	O
of	O
HES1	O
in	O
medulloblastoma	O
.	O

To	O
date	O
,	O
this	O
is	O
the	O
first	O
report	O
that	O
expression	O
of	O
a	O
miRNA	O
can	O
deplete	O
the	O
tumor	O
stem	O
cells	O
,	O
indicating	O
an	O
interesting	O
therapeutic	O
approach	O
for	O
the	O
targeting	O
of	O
these	O
cells	O
in	O
brain	O
tumors	O
.	O

CONCLUSIONS	O
/	O
SIGNIFICANCE	O
:	O
Despite	O
advances	O
in	O
our	O
understanding	O
of	O
the	O
pathogenesis	O
of	O
MB	O
,	O
one	O
-	O
third	O
of	O
these	O
patients	B
remain	O
incurable	O
and	O
current	O
treatments	O
can	O
significantly	O
damage	O
long	O
-	O
term	O
survivors	O
.	O

Infection	O
with	O
MB	O
cells	O
in	O
an	O
induced	O
xenograft	O
model	O
in	O
the	O
mouse	B
cerebellum	O
and	O
the	O
use	O
of	O
an	O
adenovirus	O
carrying	O
miR-199b-5p	O
indicate	O
a	O
clinical	O
benefit	O
through	O
this	O
negative	O
influence	O
of	O
miR-199b-5p	O
on	O
tumor	O
growth	O
and	O
on	O
the	O
subset	O
of	O
MB	O
stem	O
-	O
cell	O
-	O
like	O
cells	O
,	O
providing	O
further	O
proof	O
of	O
concept	O
.	O

We	O
further	O
show	O
that	O
in	O
a	O
xenograft	O
model	O
,	O
MB	O
tumor	O
burden	O
can	O
be	O
reduced	O
,	O
indicating	O
the	O
use	O
of	O
miR199b-5p	O
as	O
an	O
adjuvant	O
therapy	O
after	O
surgery	O
,	O
in	O
combination	O
with	O
radiation	O
and	O
chemotherapy	O
,	O
for	O
the	O
improvement	O
of	O
anti	O
-	O
cancer	O
MB	O
therapies	O
and	O
patient	B
quality	O
of	O
life	O
.	O

Here	O
we	O
show	O
that	O
miR-199b-5p	O
expression	O
correlates	O
with	O
metastasis	O
spread	O
,	O
identifying	O
a	O
new	O
molecular	O
marker	O
for	O
a	O
poor	O
-	O
risk	O
class	O
in	O
patients	B
with	O
MB	O
.	O

These	O
data	O
showing	O
the	O
down	O
-	O
regulation	O
of	O
miR-199b-5p	O
in	O
metastatic	O
MBs	O
suggest	O
a	O
potential	O
silencing	O
mechanism	O
through	O
epigenetic	O
or	O
genetic	O
alterations	O
.	O

Furthermore	O
,	O
two	O
cell	O
lines	O
(	O
Med8a	O
and	O
UW228	O
)	O
showed	O
significant	O
up	O
-	O
regulation	O
of	O
miR-199b-5p	O
upon	O
treatment	O
.	O

Upon	O
induction	O
of	O
de	O
-	O
methylation	O
using	O
5-aza	O
-	O
deoxycytidine	O
,	O
lower	O
miR-199b-5p	O
expression	O
was	O
seen	O
in	O
a	O
panel	O
of	O
MB	O
cell	O
lines	O
,	O
supported	O
an	O
epigenetic	O
mechanism	O
of	O
regulation	O
.	O

Many	O
tools	O
have	O
been	O
developed	O
to	O
help	O
describe	O
the	O
repertoire	O
of	O
miRNAs	O
present	O
at	O
the	O
tissue	O
level	O
in	O
a	O
given	O
sample	O
.	O

To	O
understand	O
how	O
miRNAs	O
contribute	O
to	O
normal	O
biologic	O
functions	O
and	O
disease	O
states	O
,	O
it	O
is	O
critical	O
to	O
understand	O
the	O
miRNAs	O
that	O
are	O
expressed	O
in	O
particular	O
cell	O
types	O
under	O
a	O
range	O
of	O
conditions	O
.	O

Such	O
knowledge	O
is	O
especially	O
important	O
in	O
the	O
nervous	O
system	O
with	O
its	O
many	O
cell	O
types	O
,	O
microscopic	O
heterogeneity	O
with	O
regard	O
to	O
functionally	O
distinct	O
cell	O
groups	O
,	O
and	O
extreme	O
geometrical	O
complexity	O
in	O
cellular	O
shapes	O
.	O

However	O
,	O
tissue	O
level	O
miRNA	O
profiling	O
is	O
inadequate	O
to	O
pinpoint	O
the	O
cellular	O
and	O
sub	O
-	O
cellular	O
distribution	O
of	O
individual	O
miRNAs	O
.	O

In	O
situ	O
hybridization	O
is	O
a	O
necessary	O
experimental	O
complement	O
to	O
microRNA	O
(	O
miRNA	O
)	O
expression	O
profiling	O
in	O
the	O
human	B
brain	O
.	O

However	O
,	O
much	O
remains	O
to	O
be	O
learned	O
in	O
this	O
fast	O
-	O
paced	O
field	O
.	O

MicroRNAs	O
(	O
miRNAs	O
)	O
play	O
fundamental	O
roles	O
in	O
human	B
brain	O
neurochemistry	O
.	O

Thus	O
,	O
in	O
situ	O
hybridization	O
is	O
an	O
important	O
experimental	O
complement	O
to	O
tissue	O
level	O
miRNA	O
expression	O
profiling	O
.	O

We	O
have	O
found	O
that	O
in	O
situ	O
hybridization	O
shows	O
important	O
cerebral	O
cortical	O
lamina	O
-	O
specific	O
patterns	O
of	O
miRNA	O
expression	O
that	O
would	O
be	O
lost	O
on	O
most	O
tissue	O
level	O
expression	O
studies	O
,	O
and	O
these	O
lamina	O
-	O
specific	O
patterns	O
can	O
be	O
directly	O
relevant	O
to	O
human	B
brain	O
disease	O
.	O

Technical	O
and	O
theoretical	O
aspects	O
of	O
this	O
important	O
technique	O
are	O
described	O
,	O
especially	O
those	O
pertinent	O
to	O
studying	O
the	O
human	B
brain	O
.	O

The	O
expression	O
levels	O
of	O
most	O
miRNAs	O
were	O
in	O
accordance	O
with	O
previously	O
published	O
results	O
by	O
microarray	O
.	O

Their	O
frequency	O
distribution	O
was	O
approximately	O
a	O
normal	O
distribution	O
.	O

However	O
,	O
the	O
positive	O
rate	O
was	O
higher	O
than	O
that	O
detected	O
by	O
microarray	O
.	O

[	O
Profiling	O
of	O
microRNAs	O
in	O
mouse	B
brain	O
with	O
real	O
-	O
time	O
PCR	O
array	O
]	O
.	O

METHODS	O
:	O
Low	O
molecular	O
weight	O
RNA	O
from	O
cerebrum	O
of	O
five	O
C57BL	O
/	O
6J	O
mice	B
were	O
tailed	O
and	O
reverse	O
transcribed	O
by	O
extended	O
RT	O
-	O
primer	O
.	O

OBJECTIVE	O
:	O
To	O
examine	O
global	O
expression	O
levels	O
of	O
microRNAs	O
(	O
miRNAs	O
)	O
in	O
mouse	B
cerebrum	O
and	O
to	O
provide	O
an	O
important	O
basis	O
for	O
detailed	O
studies	O
of	O
individual	O
miRNAs	O
,	O
their	O
target	O
genes	O
,	O
the	O
miRNA	O
-	O
related	O
regulatory	O
networks	O
in	O
the	O
mammalian	O
central	O
nervous	O
system	O
,	O
and	O
their	O
implications	O
in	O
diseases	O
.	O

PCR	O
was	O
carried	O
out	O
at	O
different	O
annealing	O
temperatures	O
using	O
a	O
gradient	O
real	O
-	O
time	O
PCR	O
instrument	O
.	O

miRNA	O
primers	O
were	O
carefully	O
designed	O
and	O
arrayed	O
on	O
plates	O
according	O
to	O
the	O
Tm	O
of	O
each	O
primer	O
.	O

RESULTS	O
:	O
Among	O
the	O
285	O
miRNAs	O
detected	O
,	O
260	O
were	O
positive	O
with	O
varying	O
abundance	O
.	O

The	O
relative	O
expression	O
level	O
of	O
each	O
miRNA	O
was	O
calculated	O
using	O
5sRNA	O
for	O
normalization	O
.	O

Clusters	O
of	O
proximal	O
miRNAs	O
were	O
similar	O
or	O
quite	O
different	O
in	O
abundance	O
.	O

miRNAs	O
originating	O
from	O
the	O
same	O
hairpin	O
precursors	O
expressed	O
at	O
similar	O
or	O
significantly	O
different	O
levels	O
.	O

It	O
is	O
suggested	O
that	O
the	O
fate	O
of	O
miRNA	O
after	O
transcription	O
determined	O
their	O
abundance	O
.	O

CONCLUSION	O
:	O
Using	O
the	O
RNA	O
-	O
tailing	O
and	O
primer	O
-	O
extension	O
PCR	O
array	O
method	O
,	O
we	O
obtained	O
expression	O
profile	O
of	O
miRNA	O
in	O
mouse	B
cerebrum	O
,	O
especially	O
the	O
relative	O
expression	O
data	O
of	O
many	O
low	O
abundant	O
miRNA	O
in	O
mouse	B
cerebrum	O
,	O
which	O
will	O
be	O
of	O
special	O
help	O
for	O
studying	O
the	O
fine	O
-	O
tuning	O
function	O
of	O
low	O
-	O
level	O
miRNAs	O
.	O

Furthermore	O
,	O
methods	O
to	O
profile	O
miRNAs	O
from	O
formalin	O
-	O
fixed	O
,	O
paraffin	O
-	O
embedded	O
(	O
FFPE	O
)	O
archival	O
tissues	O
or	O
to	O
study	O
their	O
cellular	O
and	O
subcellular	O
localization	O
in	O
FFPE	O
tissues	O
have	O
been	O
lacking	O
.	O

Here	O
we	O
report	O
the	O
coordinated	O
miRNA	O
expression	O
analysis	O
from	O
the	O
tissue	O
level	O
to	O
the	O
subcellular	O
level	O
,	O
using	O
the	O
RAKE	O
(	O
RNA	O
-	O
primed	O
,	O
array	O
-	O
based	O
,	O
Klenow	O
Enzyme	O
)	O
miRNA	O
microarray	O
platform	O
in	O
conjunction	O
with	O
Locked	O
Nucleic	O
Acid	O
(	O
LNA	O
)	O
-based	O
in	O
situ	O
hybridization	O
(	O
LNA	O
-	O
ISH	O
)	O
on	O
archival	O
FFPE	O
human	B
brains	O
and	O
oligodendroglial	O
tumors	O
.	O

The	O
ability	O
to	O
profile	O
miRNAs	O
from	O
archival	O
tissues	O
at	O
the	O
tissue	O
level	O
,	O
by	O
RAKE	O
microarrays	O
,	O
and	O
at	O
the	O
cellular	O
level	O
by	O
LNA	O
-	O
ISH	O
,	O
will	O
accelerate	O
studies	O
of	O
miRNAs	O
in	O
human	B
diseases	O
.	O

RAKE	O
and	O
LNA	O
-	O
ISH	O
reveal	O
microRNA	O
expression	O
and	O
localization	O
in	O
archival	O
human	B
brain	O
.	O

microRNAs	O
(	O
miRNAs	O
)	O
are	O
small	O
(	O
approximately	O
22	O
nucleotide	O
)	O
regulatory	O
RNAs	O
which	O
play	O
fundamental	O
roles	O
in	O
many	O
biological	O
processes	O
.	O

Recent	O
studies	O
have	O
shown	O
that	O
the	O
expression	O
of	O
many	O
miRNAs	O
is	O
altered	O
in	O
various	O
human	B
tumors	O
and	O
some	O
miRNAs	O
may	O
function	O
as	O
oncogenes	O
or	O
tumor	O
suppressor	O
genes	O
.	O

However	O
,	O
with	O
the	O
exception	O
of	O
glioblastoma	O
multiforme	O
,	O
the	O
expression	O
of	O
miRNAs	O
in	O
brain	O
tumors	O
is	O
unknown	O
.	O

Thus	O
we	O
have	O
identified	O
the	O
miRNA	O
expression	O
signature	O
for	O
malignant	O
astrocytoma	O
,	O
in	O
particular	O
glioblastoma	O
,	O
and	O
showed	O
the	O
miRNA	O
involvement	O
and	O
their	O
importance	O
in	O
astrocytoma	O
development	O
.	O

Inhibition	O
of	O
two	O
glioblastoma	O
-	O
upregulated	O
miRNAs	O
(	O
miR-21	O
and	O
miR-23a	O
)	O
and	O
exogenous	O
overexpression	O
of	O
two	O
glioblastoma	O
-	O
downregulated	O
miRNAs	O
(	O
miR-218	O
and	O
miR-219	O
-	O
5p	O
)	O
resulted	O
in	O
reduced	O
soft	O
agar	O
colony	O
formation	O
but	O
showed	O
varying	O
effects	O
on	O
cell	O
proliferation	O
and	O
chemosensitivity	O
.	O

Among	O
them	O
,	O
glioblastoma	O
is	O
the	O
most	O
common	O
primary	O
brain	O
tumor	O
with	O
dismal	O
responses	O
to	O
all	O
therapeutic	O
modalities	O
.	O

Malignant	O
astrocytoma	O
includes	O
anaplastic	O
astrocytoma	O
(	O
grade	O
III	O
)	O
and	O
glioblastoma	O
(	O
grade	O
IV	O
)	O
.	O

Genome	O
-	O
wide	O
expression	O
profiling	O
identifies	O
deregulated	O
miRNAs	O
in	O
malignant	O
astrocytoma	O
.	O

The	O
differential	O
expression	O
pattern	O
of	O
nine	O
miRNAs	O
was	O
further	O
validated	O
by	O
real	O
-	O
time	O
RT	O
-	O
PCR	O
on	O
an	O
independent	O
set	O
of	O
malignant	O
astrocytomas	O
(	O
n=72	O
)	O
and	O
normal	O
samples	O
(	O
n=7	O
)	O
.	O

More	O
importantly	O
,	O
we	O
identified	O
a	O
most	O
discriminatory	O
23-miRNA	O
expression	O
signature	O
,	O
by	O
using	O
PAM	O
,	O
which	O
precisely	O
distinguished	O
glioblastoma	O
from	O
anaplastic	O
astrocytoma	O
with	O
an	O
accuracy	O
of	O
95	O
%	O
.	O

We	O
identified	O
several	O
differentially	O
regulated	O
miRNAs	O
between	O
these	O
groups	O
,	O
which	O
could	O
differentiate	O
glioma	O
grades	O
and	O
normal	O
brain	O
as	O
recognized	O
by	O
PCA	O
.	O

We	O
performed	O
a	O
large	O
-	O
scale	O
,	O
genome	O
-	O
wide	O
microRNA	O
(	O
miRNA	O
)	O
(	O
n=756	O
)	O
expression	O
profiling	O
of	O
26	O
glioblastoma	O
,	O
13	O
anaplastic	O
astrocytoma	O
and	O
7	O
normal	O
brain	O
samples	O
with	O
an	O
aim	O
to	O
find	O
deregulated	O
miRNA	O
in	O
malignant	O
astrocytoma	O
.	O

Our	O
findings	O
suggest	O
a	O
functional	O
collaboration	O
between	O
the	O
miR-17	O
approximately	O
92	O
cluster	O
and	O
the	O
SHH	O
signaling	O
pathway	O
in	O
the	O
development	O
of	O
MBs	O
in	O
mouse	B
and	O
man	B
.	O

Analysis	O
of	O
human	B
MBs	O
demonstrated	O
that	O
3	O
miR-17	O
approximately	O
92	O
cluster	O
miRNAs	O
(	O
miR-92	O
,	O
miR-19a	O
,	O
and	O
miR-20	O
)	O
were	O
also	O
overexpressed	O
in	O
human	B
MBs	O
with	O
a	O
constitutively	O
activated	O
Sonic	O
Hedgehog	O
(	O
SHH	O
)	O
signaling	O
pathway	O
,	O
but	O
not	O
in	O
other	O
forms	O
of	O
the	O
disease	O
.	O

To	O
test	O
whether	O
the	O
miR-17	O
approximately	O
92	O
cluster	O
could	O
promote	O
MB	O
formation	O
,	O
we	O
enforced	O
expression	O
of	O
these	O
miRNAs	O
in	O
GNPs	O
isolated	O
from	O
cerebella	O
of	O
postnatal	O
(	O
P	O
)	O
day	O
P6	O
Ink4c-	O
/	O
-	O
;	O
Ptch1+	O
/	O
-	O
mice	B
.	O

These	O
,	O
but	O
not	O
similarly	O
engineered	O
cells	O
from	O
Ink4c-	O
/	O
-	O
;	O
p53-	O
/	O
-	O
mice	B
,	O
formed	O
MBs	O
in	O
orthotopic	O
transplants	O
with	O
complete	O
penetrance	O
.	O

Interestingly	O
,	O
orthotopic	O
mouse	B
tumors	O
ectopically	O
expressing	O
miR-17	O
approximately	O
92	O
lost	O
expression	O
of	O
the	O
wild	O
-	O
type	O
Ptch1	O
allele	O
.	O

Some	O
are	O
thought	O
to	O
originate	O
from	O
cerebellar	O
granule	O
neuron	O
progenitors	O
(	O
GNPs	O
)	O
that	O
fail	O
to	O
undergo	O
normal	O
cell	O
cycle	O
exit	O
and	O
differentiation	O
.	O

Because	O
microRNAs	O
regulate	O
numerous	O
aspects	O
of	O
cellular	O
physiology	O
and	O
development	O
,	O
we	O
reasoned	O
that	O
alterations	O
in	O
miRNA	O
expression	O
might	O
contribute	O
to	O
MB	O
.	O
We	O
tested	O
this	O
hypothesis	O
using	O
2	O
spontaneous	O
mouse	B
MB	O
models	O
with	O
specific	O
initiating	O
mutations	O
,	O
Ink4c-	O
/	O
-	O
;	O
Ptch1+	O
/	O
-	O
and	O
Ink4c-	O
/	O
-	O
;	O
p53-	O
/	O
-	O
.	O

We	O
found	O
that	O
26	O
miRNAs	O
showed	O
increased	O
expression	O
and	O
24	O
miRNAs	O
showed	O
decreased	O
expression	O
in	O
proliferating	O
mouse	B
GNPs	O
and	O
MBs	O
relative	O
to	O
mature	O
mouse	B
cerebellum	O
,	O
regardless	O
of	O
genotype	O
.	O

Among	O
the	O
26	O
overexpressed	O
miRNAs	O
,	O
9	O
were	O
encoded	O
by	O
the	O
miR-17	O
approximately	O
92	O
cluster	O
family	O
,	O
a	O
group	O
of	O
microRNAs	O
implicated	O
as	O
oncogenes	O
in	O
several	O
tumor	O
types	O
.	O

The	O
miR-17~92	O
cluster	O
collaborates	O
with	O
the	O
Sonic	O
Hedgehog	O
pathway	O
in	O
medulloblastoma	O
.	O

Medulloblastomas	O
(	O
MBs	O
)	O
are	O
the	O
most	O
common	O
brain	O
tumors	O
in	O
children	B
.	O

Since	O
over	O
-	O
expression	O
of	O
human	B
SNCA	O
(	O
hSNCA	O
)	O
leads	O
to	O
death	O
of	O
dopaminergic	O
(	O
DA	O
)	O
neurons	O
in	O
human	B
,	O
rodent	O
and	O
fly	O
brain	O
,	O
hSNCA	O
gene	O
silencing	O
may	O
reduce	O
levels	O
of	O
toxic	O
forms	O
of	O
SNCA	O
and	O
ameliorate	O
degeneration	O
of	O
DA	O
neurons	O
in	O
PD	O
.	O

Alpha	O
-	O
synuclein	O
(	O
SNCA	O
)	O
,	O
an	O
abundantly	O
expressed	O
presynaptic	O
protein	O
,	O
is	O
implicated	O
in	O
Parkinson	O
's	O
disease	O
(	O
PD	O
)	O
.	O

A	O
microRNA	O
embedded	O
AAV	O
alpha	O
-	O
synuclein	O
gene	O
silencing	O
vector	O
for	O
dopaminergic	O
neurons	O
.	O

Our	O
in	O
vitro	O
data	O
suggest	O
that	O
this	O
miRNA	O
-	O
embedded	O
silencing	O
vector	O
may	O
be	O
ideal	O
for	O
chronic	O
in	O
vivo	O
SNCA	O
gene	O
silencing	O
in	O
DA	O
neurons	O
.	O

However	O
,	O
the	O
mir30	O
embedded	O
vector	O
was	O
significantly	O
less	O
toxic	O
to	O
both	O
PC12	O
and	O
SH	O
-	O
SY5Y	O
cells	O
.	O

In	O
DA	O
PC12	O
cells	O
,	O
neither	O
vector	O
decreased	O
expression	O
of	O
rat	B
SNCA	O
,	O
tyrosine	O
hydroxylase	O
(	O
TH	O
)	O
,	O
dopamine	O
transporter	O
(	O
DAT	O
)	O
or	O
the	O
vesicular	O
monoamine	O
transporter	O
(	O
VMAT	O
)	O
.	O

Both	O
vectors	O
silenced	O
hSNCA	O
to	O
the	O
same	O
extent	O
in	O
293	O
T	O
cells	O
transfected	O
with	O
hSNCA	O
.	O

The	O
same	O
hSNCA	O
silencing	O
sequence	O
(	O
shRNA	O
)	O
was	O
used	O
in	O
both	O
vectors	O
,	O
but	O
in	O
one	O
vector	O
,	O
the	O
shRNA	O
was	O
embedded	O
in	O
a	O
microRNA	O
backbone	O
and	O
driven	O
by	O
a	O
pol	O
II	O
promoter	O
,	O
and	O
in	O
the	O
other	O
the	O
shRNA	O
was	O
not	O
embedded	O
in	O
a	O
microRNA	O
and	O
was	O
driven	O
by	O
a	O
pol	O
III	O
promoter	O
.	O

To	O
begin	O
to	O
develop	O
a	O
gene	O
therapy	O
for	O
PD	O
based	O
on	O
hSNCA	O
gene	O
silencing	O
,	O
two	O
AAV	O
gene	O
silencing	O
vectors	O
were	O
designed	O
,	O
and	O
tested	O
for	O
efficiency	O
and	O
specificity	O
of	O
silencing	O
,	O
as	O
well	O
as	O
toxicity	O
in	O
vitro	O
.	O

Taken	O
together	O
,	O
induction	O
of	O
microRNA	O
expression	O
in	O
BMC	O
may	O
contribute	O
to	O
the	O
aberrant	O
systemic	O
decline	O
in	O
mRNA	O
levels	O
in	O
sporadic	O
AD	O
.	O

MicroRNA	O
expression	O
in	O
Alzheimer	O
blood	O
mononuclear	O
cells	O
.	O

Various	O
coding	O
genes	O
representing	O
multiple	O
functional	O
categories	O
are	O
downregulated	O
in	O
blood	O
mononuclear	O
cells	O
(	O
BMC	O
)	O
of	O
patients	B
with	O
sporadic	O
Alzheimer	O
disease	O
(	O
AD	O
)	O
.	O

Noncoding	O
microRNAs	O
(	O
miRNA	O
)	O
regulate	O
gene	O
expression	O
by	O
degrading	O
messages	O
or	O
inhibiting	O
translation	O
.	O

Using	O
BMC	O
as	O
a	O
paradigm	O
for	O
the	O
study	O
of	O
systemic	O
alterations	O
in	O
AD	O
,	O
we	O
investigated	O
whether	O
peripheral	O
miRNA	O
expression	O
is	O
altered	O
in	O
this	O
condition	O
.	O

MicroRNA	O
levels	O
were	O
assessed	O
using	O
the	O
microRNA	O
microarray	O
(	O
MMChip	O
)	O
containing	O
462	O
human	B
miRNA	O
,	O
and	O
the	O
results	O
validated	O
by	O
real	O
time	O
PCR	O
.	O

Sixteen	O
AD	O
patients	B
and	O
sixteen	O
normal	O
elderly	O
controls	O
(	O
NEC	O
)	O
were	O
matched	O
for	O
ethnicity	O
,	O
age	O
,	O
gender	O
and	O
education	O
.	O

The	O
expression	O
of	O
several	O
BMC	O
miRNAs	O
was	O
found	O
to	O
increase	O
in	O
AD	O
relative	O
to	O
NEC	O
levels	O
,	O
and	O
may	O
differ	O
between	O
AD	O
subjects	O
bearing	O
one	O
or	O
two	O
APOE4	O
alleles	O
.	O

As	O
compared	O
to	O
NEC	O
,	O
miRNAs	O
significantly	O
upregulated	O
in	O
AD	O
subjects	O
and	O
confirmed	O
by	O
qPCR	O
were	O
miR-34a	O
and	O
181b	O
.	O

Predicted	O
target	O
genes	O
downregulated	O
in	O
Alzheimer	O
BMC	O
that	O
correlated	O
with	O
the	O
upregulated	O
miRNAs	O
were	O
largely	O
represented	O
in	O
the	O
functional	O
categories	O
of	O
Transcription	O
/	O
Translation	O
and	O
Synaptic	O
Activity	O
.	O

Several	O
miRNAs	O
targeting	O
the	O
same	O
genes	O
were	O
within	O
the	O
functional	O
category	O
of	O
Injury	O
response	O
/	O
Redox	O
homeostasis	O
.	O

Despite	O
the	O
small	O
sample	O
available	O
,	O
we	O
can	O
show	O
that	O
this	O
approach	O
permits	O
identification	O
of	O
meaningful	O
structures	O
,	O
in	O
particular	O
two	O
polycistronic	O
miRNA	O
genes	O
related	O
to	O
transcriptional	O
activity	O
and	O
likely	O
to	O
be	O
relevant	O
in	O
the	O
discrimination	O
between	O
gliosarcomas	O
and	O
other	O
brain	O
tumors	O
.	O

Our	O
intention	O
is	O
to	O
identify	O
structures	O
that	O
contain	O
information	O
from	O
both	O
mRNAs	O
and	O
miRNAs	O
,	O
and	O
that	O
can	O
explain	O
the	O
complexity	O
of	O
the	O
data	O
.	O

RESULTS	O
:	O
We	O
use	O
Factor	O
Analysis	O
coupled	O
with	O
pre	O
-	O
established	O
knowledge	O
as	O
a	O
theoretical	O
base	O
to	O
achieve	O
this	O
goal	O
.	O

We	O
analyzed	O
one	O
of	O
the	O
(	O
currently	O
)	O
few	O
datasets	O
that	O
provide	O
both	O
transcriptional	O
and	O
post	O
-	O
transcriptional	O
data	O
of	O
the	O
same	O
samples	O
to	O
investigate	O
the	O
possibility	O
to	O
extract	O
more	O
information	O
,	O
using	O
a	O
joint	O
analysis	O
approach	O
.	O

CONCLUSIONS	O
:	O
This	O
suggests	O
the	O
need	O
to	O
develop	O
methodologies	O
to	O
simultaneously	O
mine	O
information	O
from	O
different	O
levels	O
of	O
biological	O
organization	O
,	O
rather	O
than	O
linking	O
separate	O
analyses	O
performed	O
in	O
parallel	O
.	O

However	O
,	O
to	O
date	O
,	O
most	O
computational	O
and	O
algorithmic	O
efforts	O
have	O
been	O
directed	O
at	O
mining	O
data	O
from	O
each	O
of	O
these	O
molecular	O
levels	O
(	O
genomic	O
,	O
transcriptional	O
,	O
etc	O
.	O
)	O
separately	O
.	O

In	O
view	O
of	O
the	O
rapid	O
advances	O
in	O
technology	O
(	O
new	O
generation	O
sequencing	O
,	O
high	O
-	O
throughput	O
proteomics	O
)	O
it	O
is	O
important	O
to	O
address	O
the	O
problem	O
of	O
analyzing	O
these	O
data	O
as	O
a	O
whole	O
,	O
i.e.	O
preserving	O
the	O
emergent	O
properties	O
that	O
appear	O
in	O
the	O
cellular	O
system	O
when	O
all	O
molecular	O
levels	O
are	O
interacting	O
.	O

Joint	O
analysis	O
of	O
transcriptional	O
and	O
post-	O
transcriptional	O
brain	O
tumor	O
data	O
:	O
searching	O
for	O
emergent	O
properties	O
of	O
cellular	O
systems	O
.	O

UNLABELLED	O
:	O
ABSTRACT	O
:	O
BACKGROUND	O
:	O
Advances	O
in	O
biotechnology	O
offer	O
a	O
fast	O
growing	O
variety	O
of	O
high	O
-	O
throughput	O
data	O
for	O
screening	O
molecular	O
activities	O
of	O
genomic	O
,	O
transcriptional	O
,	O
post	O
-	O
transcriptional	O
and	O
translational	O
observations	O
.	O

To	O
investigate	O
noncoding	O
tiny	O
microRNA	O
mediated	O
gene	O
regulation	O
,	O
miRanda	O
(	O
version	O
1.0b	O
)	O
was	O
used	O
to	O
predict	O
human	B
miRNA	O
target	O
sites	O
on	O
selected	O
29	O
genes	O
related	O
to	O
PD	O
.	O
To	O
verify	O
output	O
generated	O
from	O
miRanda	O
,	O
a	O
similar	O
analysis	O
was	O
performed	O
only	O
for	O
microRNA	O
target	O
sites	O
in	O
3'UTR	O
using	O
TargetScan	O
(	O
version	O
5.1	O
)	O
.	O

Data	O
extracted	O
by	O
miRanda	O
elucidates	O
the	O
mode	O
of	O
microRNA	O
action	O
based	O
on	O
the	O
location	O
of	O
target	O
sites	O
in	O
the	O
Parkinson	O
genes	O
.	O

Sites	O
prone	O
to	O
action	O
of	O
multiple	O
miRNAs	O
were	O
identified	O
as	O
""""	O
hot	O
spots	O
.	O
""""	O

Important	O
properties	O
of	O
each	O
miRNA	O
including	O
multiplicity	O
and	O
cooperativity	O
appear	O
to	O
contribute	O
towards	O
a	O
complex	O
interplay	O
between	O
miRNAs	O
and	O
their	O
targets	O
.	O

Two	O
sets	O
of	O
predicted	O
results	O
were	O
explored	O
for	O
the	O
occurrence	O
of	O
target	O
sites	O
of	O
112	O
miRNAs	O
expressed	O
in	O
midbrain	O
.	O

Overall	O
,	O
convergence	O
of	O
results	O
predicted	O
by	O
two	O
algorithms	O
revealed	O
that	O
48	O
target	O
sites	O
for	O
midbrain	O
-	O
specific	O
miRNA	O
occur	O
in	O
close	O
proximity	O
in	O
9	O
genes	O
.	O

This	O
study	O
will	O
pave	O
a	O
way	O
for	O
selection	O
of	O
potential	O
miRNA	O
candidates	O
for	O
Parkinson	O
's	O
disease	O
-	O
related	O
genes	O
for	O
quick	O
therapeutic	O
applications	O
and	O
diagnosis	O
.	O

Parkinson	O
's	O
disease	O
(	O
PD	O
)	O
is	O
a	O
complex	O
multigenic	O
neurodisorder	O
frequently	O
occurring	O
in	O
elderly	O
persons	O
.	O

Interaction	O
map	O
and	O
selection	O
of	O
microRNA	O
targets	O
in	O
Parkinson	O
's	O
disease	O
-	O
related	O
genes	O
.	O

These	O
studies	O
suggest	O
that	O
miRNAs	O
may	O
be	O
important	O
for	O
neuronal	O
survival	O
in	O
the	O
context	O
of	O
human	B
neurodegenerative	O
disease	O
.	O

These	O
studies	O
provide	O
the	O
foundation	O
to	O
define	O
the	O
miRNAs	O
involved	O
in	O
neurodegenerative	O
disease	O
,	O
and	O
the	O
biological	O
pathways	O
affected	O
.	O

These	O
studies	O
showed	O
that	O
upregulation	O
of	O
ban	O
mitigates	O
degeneration	O
induced	O
by	O
the	O
pathogenic	O
polyglutamine	O
(	O
polyQ	O
)	O
protein	O
Ataxin-3	O
,	O
which	O
is	O
mutated	O
in	O
the	O
human	B
polyglutamine	O
disease	O
spinocerebellar	O
ataxia	O
type	O
3	O
(	O
SCA3	O
)	O
.	O

To	O
address	O
the	O
broader	O
role	O
for	O
miRNAs	O
in	O
neuroprotection	O
,	O
we	O
also	O
showed	O
that	O
loss	O
of	O
all	O
miRNAs	O
,	O
by	O
dicer	O
mutation	O
,	O
dramatically	O
enhances	O
pathogenic	O
polyQ	O
protein	O
toxicity	O
in	O
flies	O
and	O
in	O
human	B
HeLa	O
cells	O
.	O

A	O
new	O
role	O
for	O
microRNA	O
pathways	O
:	O
modulation	O
of	O
degeneration	O
induced	O
by	O
pathogenic	O
human	B
disease	O
proteins	O
.	O

MicroRNAs	O
(	O
miRNAs	O
)	O
are	O
small	O
noncoding	O
RNAs	O
that	O
regulate	O
the	O
expression	O
of	O
target	O
transcript	O
mRNAs	O
.	O

Many	O
miRNAs	O
have	O
been	O
defined	O
,	O
however	O
their	O
roles	O
and	O
the	O
processes	O
influenced	O
by	O
miRNA	O
pathways	O
are	O
still	O
being	O
elucidated	O
.	O

A	O
role	O
for	O
miRNAs	O
in	O
development	O
and	O
cancer	O
has	O
been	O
described	O
.	O

We	O
recently	O
isolated	O
the	O
miRNA	O
bantam	O
(	O
ban	O
)	O
in	O
a	O
genetic	O
screen	O
for	O
modulators	O
of	O
pathogenicity	O
of	O
a	O
human	B
neurodegenerative	O
disease	O
model	O
in	O
Drosophila	O
.	O

CONCLUSIONS	O
/	O
SIGNIFICANCE	O
:	O
We	O
provide	O
a	O
list	O
of	O
ten	O
miRNA	O
loci	O
potentially	O
involved	O
in	O
the	O
development	O
of	O
blood	O
cancer	O
or	O
brain	O
tumors	O
.	O

There	O
is	O
independent	O
experimental	O
support	O
from	O
other	O
studies	O
for	O
the	O
involvement	O
of	O
miRNAs	O
from	O
at	O
least	O
three	O
CIS	O
-	O
associated	O
miRNA	O
loci	O
in	O
cancer	O
development	O
.	O

CIS	O
-	O
associated	O
miRNAs	O
on	O
average	O
are	O
more	O
conserved	O
in	O
vertebrates	O
than	O
miRNAs	O
associated	O
with	O
non	O
-	O
CIS	O
inserts	O
and	O
their	O
human	B
homologs	O
are	O
also	O
located	O
in	O
regions	O
perturbed	O
in	O
cancer	O
.	O

In	O
addition	O
we	O
show	O
that	O
miRNA	O
genes	O
are	O
enriched	O
around	O
promoter	O
and/or	O
terminator	O
regions	O
of	O
RefSeq	O
genes	O
in	O
both	O
mouse	B
and	O
human	B
.	O

Ten	O
CIS	O
-	O
associated	O
miRNA	O
loci	O
containing	O
22	O
miRNAs	O
are	O
located	O
within	O
10	O
kb	O
of	O
known	O
CIS	O
insertions	O
.	O

Only	O
one	O
CIS	O
-	O
associated	O
miRNA	O
locus	O
overlaps	O
a	O
RefSeq	O
protein	O
-	O
coding	O
gene	O
and	O
six	O
loci	O
are	O
located	O
more	O
than	O
10	O
kb	O
from	O
any	O
RefSeq	O
gene	O
.	O

METHODOLOGY	O
/	O
PRINCIPAL	O
FINDINGS	O
:	O
Using	O
a	O
public	O
database	O
of	O
mapped	O
retroviral	O
insertion	O
sites	O
from	O
various	O
mouse	B
models	O
of	O
cancer	O
we	O
demonstrate	O
that	O
MLV	O
-	O
derived	O
retroviral	O
inserts	O
are	O
enriched	O
in	O
close	O
proximity	O
to	O
mouse	B
miRNA	O
loci	O
.	O

Clustered	O
inserts	O
from	O
cancer	O
-	O
associated	O
regions	O
(	O
Common	O
Integration	O
Sites	O
,	O
CIS	O
)	O
have	O
a	O
higher	O
association	O
with	O
miRNAs	O
than	O
non	O
-	O
clustered	O
inserts	O
.	O

BACKGROUND	O
:	O
MicroRNAs	O
(	O
miRNAs	O
)	O
are	O
short	O
non	O
-	O
coding	O
RNAs	O
that	O
regulate	O
differentiation	O
and	O
development	O
in	O
many	O
organisms	O
and	O
play	O
an	O
important	O
role	O
in	O
cancer	O
.	O

Orthologous	O
microRNA	O
genes	O
are	O
located	O
in	O
cancer	O
-	O
associated	O
genomic	O
regions	O
in	O
human	B
and	O
mouse	B
.	O

Paired	O
Student	O
's	O
""""	O
t	O
""""	O
test	O
was	O
applied	O
to	O
the	O
scores	O
and	O
no	O
significant	O
difference	O
was	O
found	O
(	O
p	O
=	O
0.315	O
)	O
.	O

In	O
the	O
postoperative	O
period	O
the	O
mean	O
MMSE	O
score	O
was	O
28.40	O
(	O
SD	O
,	O
1.46	O
)	O
.	O

METHOD	O
:	O
A	O
consecutive	O
series	O
of	O
40	O
patients	B
who	O
underwent	O
microsurgical	O
clipping	O
for	O
UIA	O
were	O
studied	O
.	O

The	O
cognitive	O
assessment	O
(	O
Mini	O
Mental	O
State	O
Examination	O
,	O
MMSE	O
)	O
was	O
performed	O
immediately	O
before	O
and	O
at	O
least	O
one	O
month	O
after	O
surgery	O
.	O

Paired	O
Student	O
's	O
""""	O
t	O
""""	O
test	O
and	O
analysis	O
of	O
variance	O
(	O
ANOVA	O
)	O
were	O
used	O
for	O
statistical	O
purposes	O
.	O

RESULTS	O
:	O
The	O
mean	O
MMSE	O
score	O
in	O
the	O
preoperative	O
analysis	O
was	O
28.12	O
(	O
SD	O
,	O
1.34	O
)	O
.	O

Microsurgical	O
clipping	O
in	O
forty	O
patients	B
with	O
unruptured	O
anterior	O
cerebral	O
circulation	O
aneurysms	O
:	O
an	O
investigation	O
into	O
cognitive	O
outcome	O
.	O

OBJECTIVE	O
:	O
It	O
is	O
a	O
consensus	O
that	O
most	O
unruptured	O
intracranial	O
aneurysms	O
(	O
UIA	O
)	O
can	O
be	O
treated	O
with	O
acceptably	O
low	O
morbidity	O
.	O

However	O
,	O
some	O
studies	O
recently	O
reported	O
postoperative	O
cognitive	O
impairment	O
,	O
suggesting	O
that	O
it	O
could	O
be	O
attributable	O
to	O
surgical	O
damage	O
.	O

Our	O
goal	O
is	O
to	O
evaluate	O
cognitive	O
function	O
before	O
and	O
after	O
microsurgical	O
clipping	O
in	O
patients	B
with	O
UIA	O
.	O

ANOVA	O
did	O
not	O
find	O
independent	O
associations	O
between	O
MMSE	O
scores	O
and	O
age	O
,	O
hypertension	O
,	O
smoking	O
,	O
dyslipidemia	O
,	O
education	O
,	O
aneurysm	O
location	O
,	O
number	O
,	O
laterality	O
or	O
size	O
.	O

CONCLUSION	O
:	O
The	O
present	O
study	O
suggests	O
that	O
microsurgical	O
clipping	O
for	O
UIA	O
does	O
not	O
result	O
in	O
major	O
cognitive	O
dysfunction	O
as	O
determined	O
by	O
the	O
MMSE	O
.	O

MicroRNA	O
miR-133b	O
is	O
essential	O
for	O
functional	O
recovery	O
after	O
spinal	O
cord	O
injury	O
in	O
adult	O
zebrafish	B
.	O

MicroRNAs	O
(	O
miRNAs	O
)	O
play	O
important	O
roles	O
during	O
development	O
and	O
also	O
in	O
adult	O
organisms	O
by	O
regulating	O
the	O
expression	O
of	O
multiple	O
target	O
genes	O
.	O

Here	O
,	O
we	O
studied	O
the	O
function	O
of	O
miR-133b	O
during	O
zebrafish	B
spinal	O
cord	O
regeneration	O
and	O
show	O
upregulation	O
of	O
miR-133b	O
expression	O
in	O
regenerating	O
neurons	O
of	O
the	O
brainstem	O
after	O
transection	O
of	O
the	O
spinal	O
cord	O
.	O

miR-133b	O
has	O
been	O
shown	O
to	O
promote	O
tissue	O
regeneration	O
in	O
other	O
tissue	O
,	O
but	O
its	O
ability	O
to	O
do	O
so	O
in	O
the	O
nervous	O
system	O
has	O
yet	O
to	O
be	O
tested	O
.	O

Inhibition	O
of	O
miR-133b	O
expression	O
by	O
antisense	O
morpholino	O
(	O
MO	O
)	O
application	O
resulted	O
in	O
impaired	O
locomotor	O
recovery	O
and	O
reduced	O
regeneration	O
of	O
axons	O
from	O
neurons	O
in	O
the	O
nucleus	O
of	O
the	O
medial	O
longitudinal	O
fascicle	O
,	O
superior	O
reticular	O
formation	O
and	O
intermediate	O
reticular	O
formation	O
.	O

miR-133b	O
targets	O
the	O
small	O
GTPase	O
RhoA	O
,	O
which	O
is	O
an	O
inhibitor	O
of	O
axonal	O
growth	O
,	O
as	O
well	O
as	O
other	O
neurite	O
outgrowth	O
-	O
related	O
molecules	O
.	O

Our	O
results	O
indicate	O
that	O
miR-133b	O
is	O
an	O
important	O
determinant	O
in	O
spinal	O
cord	O
regeneration	O
of	O
adult	O
zebrafish	B
through	O
reduction	O
in	O
RhoA	O
protein	O
levels	O
by	O
direct	O
interaction	O
with	O
its	O
mRNA	O
.	O

While	O
RhoA	O
has	O
been	O
studied	O
as	O
a	O
therapeutic	O
target	O
in	O
spinal	O
cord	O
injury	O
,	O
this	O
is	O
the	O
first	O
demonstration	O
of	O
endogenous	O
regulation	O
of	O
RhoA	O
by	O
a	O
microRNA	O
that	O
is	O
required	O
for	O
spinal	O
cord	O
regeneration	O
in	O
zebrafish	B
.	O

The	O
ability	O
of	O
miR-133b	O
to	O
suppress	O
molecules	O
that	O
inhibit	O
axon	O
regrowth	O
may	O
underlie	O
the	O
capacity	O
for	O
adult	O
zebrafish	B
to	O
recover	O
locomotor	O
function	O
after	O
spinal	O
cord	O
injury	O
.	O

As	O
a	O
genetically	O
complex	O
disease	O
,	O
dysregulation	O
of	O
miRNA	O
expression	O
might	O
be	O
a	O
feature	O
of	O
autism	O
spectrum	O
disorders	O
(	O
ASDs	O
)	O
.	O

Using	O
multiplex	O
quantitative	O
polymerase	O
chain	O
reaction	O
(	O
PCR	O
)	O
,	O
we	O
compared	O
the	O
expression	O
of	O
466	O
human	B
miRNAs	O
from	O
postmortem	O
cerebellar	O
cortex	O
tissue	O
of	O
individuals	O
with	O
ASD	O
(	O
n	O
=	O
13	O
)	O
and	O
a	O
control	O
set	O
of	O
non	O
-	O
autistic	O
cerebellar	O
samples	O
(	O
n	O
=	O
13	O
)	O
.	O

microRNAs	O
(	O
miRNAs	O
)	O
are	O
approximately	O
21	O
nt	O
transcripts	O
capable	O
of	O
regulating	O
the	O
expression	O
of	O
many	O
mRNAs	O
and	O
are	O
abundant	O
in	O
the	O
brain	O
.	O

miRNAs	O
have	O
a	O
role	O
in	O
several	O
complex	O
diseases	O
including	O
cancer	O
as	O
well	O
as	O
some	O
neurological	O
diseases	O
such	O
as	O
Tourette	O
's	O
syndrome	O
and	O
Fragile	O
x	O
syndrome	O
.	O

To	O
validate	O
the	O
finding	O
,	O
we	O
reversed	O
the	O
analysis	O
and	O
compared	O
each	O
non	O
-	O
autism	O
control	O
to	O
a	O
single	O
mean	O
value	O
for	O
each	O
miRNA	O
across	O
all	O
autism	O
cases	O
.	O

In	O
this	O
analysis	O
,	O
the	O
number	O
of	O
dysregulated	O
miRNAs	O
fell	O
from	O
28	O
to	O
9	O
miRNAs	O
.	O

While	O
most	O
miRNAs	O
levels	O
showed	O
little	O
variation	O
across	O
all	O
samples	O
suggesting	O
that	O
autism	O
does	O
not	O
induce	O
global	O
dysfunction	O
of	O
miRNA	O
expression	O
,	O
some	O
miRNAs	O
among	O
the	O
autistic	O
samples	O
were	O
expressed	O
at	O
significantly	O
different	O
levels	O
compared	O
to	O
the	O
mean	O
control	O
value	O
.	O

Twenty	O
-	O
eight	O
miRNAs	O
were	O
expressed	O
at	O
significantly	O
different	O
levels	O
compared	O
to	O
the	O
non	O
-	O
autism	O
control	O
set	O
in	O
at	O
least	O
one	O
of	O
the	O
autism	O
samples	O
.	O

Among	O
the	O
predicted	O
targets	O
of	O
dysregulated	O
miRNAs	O
are	O
genes	O
that	O
are	O
known	O
genetic	O
causes	O
of	O
autism	O
such	O
Neurexin	O
and	O
SHANK3	O
.	O

Heterogeneous	O
dysregulation	O
of	O
microRNAs	O
across	O
the	O
autism	O
spectrum	O
.	O

This	O
study	O
finds	O
that	O
altered	O
miRNA	O
expression	O
levels	O
are	O
observed	O
in	O
postmortem	O
cerebellar	O
cortex	O
from	O
autism	O
patients	B
,	O
a	O
finding	O
which	O
suggests	O
that	O
dysregulation	O
of	O
miRNAs	O
may	O
contribute	O
to	O
autism	O
spectrum	O
phenotype	O
.	O

A	O
tight	O
correlation	O
between	O
these	O
miRNAs	O
and	O
APP	O
was	O
found	O
during	O
brain	O
development	O
and	O
in	O
differentiating	O
neurons	O
.	O

We	O
thus	O
identify	O
miRNAs	O
as	O
novel	O
endogenous	O
regulators	O
of	O
APP	O
expression	O
,	O
suggesting	O
that	O
variations	O
in	O
miRNA	O
expression	O
could	O
contribute	O
to	O
changes	O
in	O
APP	O
expression	O
in	O
the	O
brain	O
during	O
development	O
and	O
disease	O
.	O

This	O
possibility	O
is	O
further	O
corroborated	O
by	O
the	O
observation	O
that	O
a	O
statistically	O
significant	O
decrease	O
in	O
miR-106b	O
expression	O
was	O
found	O
in	O
sporadic	O
AD	O
patients	B
.	O

MicroRNA	O
regulation	O
of	O
Alzheimer	O
's	O
Amyloid	O
precursor	O
protein	O
expression	O
.	O

Gene	O
dosage	O
effects	O
of	O
Amyloid	O
precursor	O
protein	O
(	O
APP	O
)	O
can	O
cause	O
familial	O
AD	O
.	O
Recent	O
evidence	O
suggest	O
that	O
microRNA	O
(	O
miRNA	O
)	O
pathways	O
,	O
implicated	O
in	O
gene	O
transcriptional	O
control	O
,	O
could	O
be	O
involved	O
in	O
the	O
development	O
of	O
sporadic	O
Alzheimer	O
's	O
disease	O
(	O
AD	O
)	O
.	O

We	O
therefore	O
investigated	O
whether	O
miRNAs	O
could	O
participate	O
in	O
the	O
regulation	O
of	O
APP	O
gene	O
expression	O
.	O

We	O
show	O
that	O
miRNAs	O
belonging	O
to	O
the	O
miR-20a	O
family	O
(	O
that	O
is	O
,	O
miR-20a	O
,	O
miR-17	O
-	O
5p	O
and	O
miR-106b	O
)	O
could	O
regulate	O
APP	O
expression	O
in	O
vitro	O
and	O
at	O
the	O
endogenous	O
level	O
in	O
neuronal	O
cell	O
lines	O
.	O

We	O
concluded	O
that	O
patients	B
with	O
partial	O
recurrent	O
seizures	O
of	O
temporal	O
origin	O
have	O
poor	O
subjective	O
sleep	O
quality	O
that	O
improves	O
significantly	O
after	O
epilepsy	O
surgery	O
.	O

ESS	O
and	O
PSQI	O
scores	O
were	O
also	O
analyzed	O
by	O
gender	O
,	O
antiepileptic	O
drug	O
class	O
,	O
age	O
,	O
and	O
seizure	O
frequency	O
,	O
with	O
no	O
significant	O
differences	O
.	O

Global	O
PSQI	O
was	O
high	O
(	O
mean=5.65	O
SD=3.71	O
)	O
before	O
the	O
surgical	O
procedure	O
(	O
P<0.001	O
)	O
.	O

Two	O
questionnaires	O
were	O
used	O
to	O
assess	O
daytime	O
sleepiness	O
(	O
Epworth	O
Sleepiness	O
Scale	O
[	O
ESS	O
]	O
)	O
and	O
sleep	O
quality	O
(	O
Pittsburgh	O
Sleep	O
Quality	O
Index	O
[	O
PSQI	O
]	O
)	O
.	O

PSQI	O
evaluation	O
revealed	O
higher	O
and	O
statistically	O
significant	O
scores	O
in	O
three	O
components	O
as	O
well	O
as	O
in	O
the	O
global	O
score	O
,	O
when	O
analyzed	O
by	O
predominance	O
of	O
daytime	O
or	O
nocturnal	O
seizures	O
.	O

Evaluation	O
of	O
sleep	O
quality	O
in	O
patients	B
with	O
refractory	O
seizures	O
who	O
undergo	O
epilepsy	O
surgery	O
.	O

The	O
aim	O
of	O
the	O
study	O
was	O
to	O
evaluate	O
excessive	O
daytime	O
sleepiness	O
and	O
subjective	O
sleep	O
quality	O
in	O
patients	B
who	O
undergo	O
epilepsy	O
surgery	O
for	O
treatment	O
of	O
refractory	O
partial	O
seizures	O
.	O

Forty	O
-	O
eight	O
patients	B
were	O
enrolled	O
in	O
this	O
research	O
study	O
.	O

All	O
of	O
them	O
were	O
evaluated	O
2	O
days	O
before	O
and	O
3	O
months	O
after	O
the	O
surgery	O
.	O

Here	O
,	O
we	O
investigated	O
the	O
possibility	O
that	O
IFN	O
-	O
beta	O
may	O
induce	O
or	O
downregulate	O
cellular	O
microRNAs	O
(	O
miRNA	O
)	O
in	O
human	B
neoplasms	O
and	O
thereby	O
use	O
the	O
RNA	O
interference	O
system	O
to	O
show	O
antitumor	O
effects	O
.	O

Because	O
of	O
its	O
known	O
connection	O
to	O
glioma	O
biology	O
,	O
we	O
focused	O
on	O
miR-21	O
among	O
seven	O
miRNAs	O
influenced	O
by	O
IFN	O
-	O
beta	O
.	O

The	O
modulation	O
of	O
microRNAs	O
by	O
type	O
I	O
IFN	O
through	O
the	O
activation	O
of	O
signal	O
transducers	O
and	O
activators	O
of	O
transcription	O
3	O
in	O
human	B
glioma	O
.	O

Type	O
I	O
IFNs	O
are	O
involved	O
in	O
double	O
-	O
stranded	O
RNA	O
responses	O
.	O

The	O
levels	O
of	O
primary	O
miR-21	O
gene	O
transcripts	O
,	O
precursor	O
miR-21	O
,	O
and	O
mature	O
miR-21	O
decreased	O
6	O
hours	O
after	O
the	O
addition	O
of	O
IFN	O
-	O
beta	O
,	O
indicating	O
that	O
the	O
reduction	O
in	O
miR-21	O
levels	O
was	O
due	O
to	O
transcriptional	O
suppression	O
.	O

We	O
did	O
reporter	O
assays	O
to	O
elucidate	O
the	O
IFN	O
-	O
beta	O
-	O
mediated	O
suppression	O
of	O
miR-21	O
;	O
the	O
addition	O
of	O
signal	O
transducers	O
and	O
activators	O
of	O
transcription	O
3	O
(	O
STAT3	O
)	O
-expressing	O
vectors	O
induced	O
the	O
IFN	O
-	O
beta	O
-	O
mediated	O
suppression	O
of	O
miR-21	O
,	O
whereas	O
STAT3-inhibiting	O
agents	O
inhibited	O
the	O
miR-21	O
suppression	O
.	O

We	O
analyzed	O
the	O
effect	O
of	O
IFN	O
-	O
beta	O
treatment	O
on	O
miR-21	O
expression	O
in	O
glioma	O
cells	O
and	O
intracranial	O
glioma	O
xenografts	O
.	O

IFN	O
-	O
beta	O
treatment	O
reduced	O
miR-21	O
expression	O
in	O
glioma	O
cells	O
markedly	O
,	O
and	O
IFN	O
-	O
beta	O
administration	O
suppressed	O
the	O
growth	O
of	O
glioma	O
-	O
initiating	O
cell	O
-	O
derived	O
intracranial	O
tumors	O
.	O

Thus	O
,	O
the	O
results	O
of	O
our	O
study	O
show	O
that	O
the	O
downregulation	O
of	O
miR-21	O
contributes	O
to	O
the	O
antitumor	O
effects	O
of	O
IFN	O
-	O
beta	O
and	O
that	O
miR-21	O
expression	O
is	O
negatively	O
regulated	O
by	O
STAT3	O
activation	O
.	O

These	O
results	O
highlight	O
the	O
importance	O
of	O
understanding	O
the	O
transcriptional	O
regulation	O
of	O
the	O
miRNAs	O
involved	O
in	O
oncogenesis	O
.	O

This	O
work	O
represents	O
the	O
first	O
experimental	O
study	O
showing	O
that	O
an	O
miR-30-based	O
shRNA	O
construct	O
prevents	O
Oas1	O
pathway	O
associated	O
off	O
-	O
target	O
effects	O
,	O
which	O
we	O
consider	O
as	O
an	O
essential	O
prerequisite	O
for	O
shRNA	O
use	O
in	O
future	O
gene	O
therapeutic	O
approaches	O
.	O

Modification	O
of	O
the	O
shRNA	O
construct	O
by	O
implementing	O
features	O
of	O
the	O
naturally	O
occurring	O
microRNA-30	O
(	O
miR-30	O
)	O
precursor	O
avoided	O
Oas1	O
induction	O
in	O
transduced	O
primary	O
cultures	O
,	O
whereby	O
modification	O
of	O
the	O
passenger	O
strand	O
seems	O
to	O
be	O
a	O
crucial	O
feature	O
to	O
circumvent	O
interferon	O
-	O
stimulated	O
gene	O
expression	O
.	O

We	O
found	O
that	O
lentiviral	O
vector	O
(	O
LV	O
)	O
-mediated	O
expression	O
of	O
shRNAs	O
in	O
primary	O
cortical	O
cultures	O
resulted	O
in	O
strong	O
expression	O
of	O
the	O
interferon	O
-	O
stimulated	O
gene	O
oligoadenylate	O
synthetase	O
1	O
(	O
Oas1	O
)	O
,	O
which	O
was	O
accompanied	O
by	O
accelerated	O
apoptosis	O
and	O
substantial	O
net	O
neuron	O
loss	O
.	O

Prevention	O
of	O
interferon	O
-	O
stimulated	O
gene	O
expression	O
using	O
microRNA	O
-	O
designed	O
hairpins	O
.	O

However	O
,	O
growing	O
evidence	O
exists	O
that	O
the	O
expression	O
of	O
short	O
hairpin	O
RNAs	O
(	O
shRNAs	O
)	O
can	O
trigger	O
cellular	O
immune	O
response	O
resulting	O
in	O
unspecific	O
cellular	O
phenotypes	O
and	O
severe	O
side	O
effects	O
.	O

RNA	O
interference	O
allows	O
selective	O
gene	O
silencing	O
,	O
and	O
is	O
widely	O
used	O
for	O
functional	O
analysis	O
of	O
individual	O
genes	O
in	O
vertebrate	O
cells	O
and	O
represents	O
an	O
attractive	O
therapeutic	O
option	O
for	O
treating	O
central	O
nervous	O
system	O
diseases	O
.	O

The	O
basis	O
for	O
the	O
younger	O
age	O
at	O
symptom	O
onset	O
remains	O
obscure	O
.	O

CONCLUSIONS	O
:	O
An	O
earlier	O
age	O
at	O
symptom	O
onset	O
suggests	O
that	O
US	O
mainland	O
Latino	O
individuals	O
may	O
experience	O
an	O
increased	O
burden	O
of	O
AD	O
compared	O
with	O
Anglo	O
individuals	O
.	O

OBJECTIVE	O
:	O
To	O
compare	O
the	O
age	O
at	O
AD	O
symptom	O
onset	O
in	O
Latino	O
and	O
Anglo	O
individuals	O
.	O

BACKGROUND	O
:	O
Latino	O
individuals	O
are	O
the	O
largest	O
minority	O
group	O
and	O
the	O
fastest	O
growing	O
population	O
group	O
in	O
the	O
United	O
States	O
,	O
yet	O
there	O
are	O
few	O
studies	O
comparing	O
the	O
clinical	O
features	O
of	O
Alzheimer	O
disease	O
(	O
AD	O
)	O
in	O
this	O
population	O
with	O
those	O
found	O
in	O
Anglo	O
(	O
white	O
non	O
-	O
Latino	O
)	O
patients	B
.	O

Earlier	O
onset	O
of	O
Alzheimer	O
disease	O
symptoms	O
in	O
latino	O
individuals	O
compared	O
with	O
anglo	O
individuals	O
.	O

RESULTS	O
:	O
After	O
adjusting	O
for	O
center	O
,	O
sex	O
,	O
and	O
years	O
of	O
education	O
,	O
Latino	O
patients	B
had	O
a	O
mean	O
age	O
at	O
symptom	O
onset	O
6.8	O
years	O
earlier	O
(	O
95	O
%	O
confidence	O
interval	O
,	O
3.5	O
-	O
10.3	O
years	O
earlier	O
)	O
than	O
Anglo	O
patients	B
.	O

PATIENTS	B
:	O
We	O
evaluated	O
119	O
Latino	O
and	O
55	O
Anglo	O
patients	B
who	O
had	O
a	O
diagnosis	O
of	O
AD	O
.	O
MAIN	O
OUTCOME	O
MEASURE	O
:	O
Age	O
at	O
symptom	O
onset	O
.	O

SETTING	O
:	O
Five	O
National	O
Institute	O
on	O
Aging	O
-	O
sponsored	O
Alzheimer	O
's	O
Disease	O
Centers	O
with	O
experience	O
evaluating	O
Spanish	O
-	O
speaking	O
individuals	O
.	O

DESIGN	O
:	O
Cross	O
-	O
sectional	O
assessment	O
using	O
standardized	O
methods	O
to	O
collect	O
and	O
compare	O
age	O
at	O
AD	O
symptom	O
onset	O
,	O
demographic	O
variables	O
,	O
and	O
medical	O
variables	O
.	O

In	O
a	O
well	O
-	O
characterized	O
Belgian	O
group	O
of	O
358	O
AD	O
patients	B
and	O
462	O
controls	O
,	O
we	O
examined	O
whether	O
genetic	O
variability	O
in	O
microRNA	O
(	O
miRNA	O
)	O
binding	O
sites	O
of	O
APP	O
and	O
BACE1	O
or	O
in	O
associated	O
miRNAs	O
influenced	O
risk	O
for	O
AD	O
.	O
Direct	O
sequencing	O
identified	O
six	O
variants	O
in	O
the	O
3	O
'	O
untranslated	O
region	O
(	O
UTR	O
)	O
of	O
APP	O
and	O
29	O
variants	O
in	O
the	O
3	O
'	O
UTR	O
of	O
BACE1	O
,	O
of	O
which	O
few	O
variants	O
were	O
restricted	O
to	O
patients	B
:	O
in	O
APP	O
;	O
4	O
variants	O
in	O
6	O
patients	B
(	O
approximately	O
2	O
%	O
)	O
and	O
in	O
BACE1	O
;	O
7	O
variants	O
in	O
11	O
patients	B
(	O
approximately	O
3.5	O
%	O
)	O
.	O

Expression	O
levels	O
of	O
the	O
amyloid	O
precursor	O
protein	O
(	O
APP	O
)	O
and	O
beta	O
-	O
site	O
amyloid	O
(	O
Abeta	O
)	O
cleaving	O
enzyme	O
1	O
(	O
BACE1	O
)	O
have	O
been	O
implicated	O
in	O
Alzheimer	O
disease	O
(	O
AD	O
)	O
progression	O
.	O

APP	O
and	O
BACE1	O
miRNA	O
genetic	O
variability	O
has	O
no	O
major	O
role	O
in	O
risk	O
for	O
Alzheimer	O
disease	O
.	O

Further	O
genetic	O
screening	O
of	O
the	O
miR-29	O
cluster	O
encoding	O
the	O
miR-29a	O
/	O
b-1	O
genes	O
showed	O
10	O
variants	O
in	O
close	O
proximity	O
of	O
this	O
cluster	O
.	O

Association	O
studies	O
using	O
all	O
common	O
variants	O
detected	O
in	O
the	O
3	O
'	O
UTR	O
of	O
BACE1	O
and	O
the	O
miR-29	O
gene	O
cluster	O
did	O
not	O
identify	O
an	O
association	O
with	O
AD	O
risk	O
.	O

However	O
,	O
we	O
did	O
observe	O
statistical	O
interaction	O
between	O
rs535860	O
(	O
BACE1	O
3	O
'	O
UTR	O
)	O
and	O
rs34772568	O
(	O
near	O
miR29a	O
;	O
odds	O
ratio	O
[	O
OR	O
]	O
(	O
interaction	O
)	O
,	O
0.4	O
;	O
95	O
%	O
confidence	O
interval	O
[	O
CI	O
]	O
,	O
0.17	O
-	O
0.96	O
;	O
P=0.033	O
)	O
.	O

While	O
the	O
exact	O
role	O
of	O
the	O
patient	B
-	O
specific	O
miRNA	O
variants	O
within	O
the	O
3	O
'	O
UTR	O
region	O
of	O
APP	O
and	O
BACE1	O
demands	O
further	O
analyses	O
,	O
this	O
study	O
does	O
not	O
support	O
a	O
major	O
contribution	O
of	O
miRNA	O
genetic	O
variability	O
to	O
AD	O
pathogenesis	O
.	O

MicroRNAs	O
(	O
miRNAs	O
)	O
are	O
small	O
,	O
noncoding	O
RNAs	O
that	O
play	O
a	O
critical	O
role	O
in	O
developmental	O
and	O
physiological	O
processes	O
and	O
are	O
implicated	O
in	O
the	O
pathogenesis	O
of	O
several	O
human	B
diseases	O
,	O
including	O
cancer	O
.	O

Downregulation	O
of	O
Pdcd4	O
by	O
mir-21	O
facilitates	O
glioblastoma	O
proliferation	O
in	O
vivo	O
.	O

In	O
this	O
study	O
,	O
we	O
examined	O
the	O
role	O
of	O
oncogenic	O
mir-21	O
in	O
the	O
pathogenesis	O
of	O
glioblastoma	O
,	O
the	O
most	O
aggressive	O
form	O
of	O
primary	O
brain	O
tumor	O
.	O

They	O
function	O
by	O
regulating	O
target	O
gene	O
expression	O
post	O
-	O
transcriptionally	O
.	O

We	O
demonstrate	O
that	O
downregulation	O
of	O
mir-21	O
in	O
glioblastoma	O
-	O
derived	O
cell	O
lines	O
results	O
in	O
increased	O
expression	O
of	O
its	O
target	O
,	O
programmed	O
cell	O
death	O
4	O
(	O
Pdcd4	O
)	O
,	O
a	O
known	O
tumor	O
-	O
suppressor	O
gene	O
.	O

We	O
have	O
previously	O
reported	O
that	O
mir-21	O
is	O
expressed	O
at	O
higher	O
levels	O
in	O
primary	O
glioblastoma	O
-	O
tissue	O
and	O
glioblastoma	O
-	O
derived	O
cell	O
lines	O
than	O
in	O
normal	O
brain	O
tissue	O
.	O

Using	O
a	O
glioblastoma	O
xenograft	O
model	O
in	O
immune	O
-	O
deficient	O
nude	B
mice	I
,	O
we	O
observe	O
that	O
glioblastoma	O
-	O
derived	O
cell	O
lines	O
in	O
which	O
mir-21	O
levels	O
are	O
downregulated	O
or	O
Pdcd4	O
is	O
over	O
-	O
expressed	O
exhibit	O
decreased	O
tumor	O
formation	O
and	O
growth	O
.	O

In	O
addition	O
,	O
our	O
data	O
indicate	O
that	O
either	O
downregulation	O
of	O
mir-21	O
or	O
overexpression	O
of	O
its	O
target	O
,	O
Pdcd4	O
,	O
in	O
glioblastoma	O
-	O
derived	O
cell	O
lines	O
leads	O
to	O
decreased	O
proliferation	O
,	O
increased	O
apoptosis	O
,	O
and	O
decreased	O
colony	O
formation	O
in	O
soft	O
agar	O
.	O

Significantly	O
,	O
tumors	O
grow	O
when	O
the	O
glioblastoma	O
-	O
derived	O
cell	O
lines	O
are	O
transfected	O
with	O
anti	O
-	O
mir-21	O
and	O
siRNA	O
to	O
Pdcd4	O
,	O
confirming	O
that	O
the	O
tumor	O
growth	O
is	O
specifically	O
regulated	O
by	O
Pdcd4	O
.	O

These	O
critical	O
in	O
vivo	O
findings	O
demonstrate	O
an	O
important	O
functional	O
linkage	O
between	O
mir-21	O
and	O
Pdcd4	O
and	O
further	O
elucidate	O
the	O
molecular	O
mechanisms	O
by	O
which	O
the	O
known	O
high	O
level	O
of	O
mir-21	O
expression	O
in	O
glioblastoma	O
can	O
attribute	O
to	O
tumorigenesis	O
--	O
namely	O
,	O
inhibition	O
of	O
Pdcd4	O
and	O
its	O
tumor	O
-	O
suppressive	O
functions	O
.	O

We	O
conclude	O
that	O
miR-17	O
/	O
92	O
is	O
a	O
positive	O
effector	O
of	O
Shh	O
-	O
mediated	O
proliferation	O
and	O
that	O
aberrant	O
expression	O
/	O
amplification	O
of	O
this	O
miR	O
confers	O
a	O
growth	O
advantage	O
to	O
medulloblastomas	O
.	O

Ectopic	O
miR-17	O
/	O
92	O
expression	O
in	O
CGNPs	O
synergized	O
with	O
exogenous	O
Shh	O
to	O
increase	O
proliferation	O
and	O
also	O
enabled	O
them	O
to	O
proliferate	O
in	O
the	O
absence	O
of	O
Shh	O
.	O

In	O
CGNPs	O
,	O
the	O
Shh	O
effector	O
N	O
-	O
myc	O
,	O
but	O
not	O
Gli1	O
,	O
induced	O
miR-17	O
/	O
92	O
expression	O
.	O

Consistent	O
with	O
its	O
regulation	O
by	O
Shh	O
,	O
we	O
observed	O
that	O
Shh	O
treatment	O
of	O
primary	O
cerebellar	O
granule	O
neuron	O
precursors	O
(	O
CGNP	O
)	O
,	O
proposed	O
cells	O
of	O
origin	O
for	O
the	O
Shh	O
-	O
associated	O
medulloblastomas	O
,	O
resulted	O
in	O
increased	O
miR-17	O
/	O
92	O
expression	O
.	O

Medulloblastomas	O
in	O
which	O
miR-17	O
/	O
92	O
was	O
up	O
-	O
regulated	O
also	O
had	O
elevated	O
levels	O
of	O
MYC	O
/	O
MYCN	O
expression	O
.	O

Expression	O
of	O
miR-17	O
/	O
92	O
was	O
highest	O
in	O
the	O
subgroup	O
of	O
medulloblastomas	O
associated	O
with	O
activation	O
of	O
the	O
sonic	O
hedgehog	O
(	O
Shh	O
)	O
signaling	O
pathway	O
compared	O
with	O
other	O
subgroups	O
of	O
medulloblastoma	O
.	O

Profiling	O
the	O
expression	O
of	O
427	O
mature	O
microRNAs	O
(	O
miRNA	O
)	O
in	O
a	O
series	O
of	O
90	O
primary	O
human	B
medulloblastomas	O
revealed	O
that	O
components	O
of	O
the	O
miR-17	O
/	O
92	O
polycistron	O
are	O
the	O
most	O
highly	O
up	O
-	O
regulated	O
miRNAs	O
in	O
medulloblastoma	O
.	O

We	O
identified	O
recurrent	O
amplification	O
of	O
the	O
miR-17	O
/	O
92	O
polycistron	O
proto	O
-	O
oncogene	O
in	O
6	O
%	O
of	O
pediatric	O
medulloblastomas	O
by	O
high	O
-	O
resolution	O
single	O
-	O
nucleotide	O
polymorphism	O
genotyping	O
arrays	O
and	O
subsequent	O
interphase	O
fluorescence	O
in	O
situ	O
hybridization	O
on	O
a	O
human	B
medulloblastoma	O
tissue	O
microarray	O
.	O

Medulloblastoma	O
is	O
the	O
most	O
common	O
malignant	O
pediatric	O
brain	O
tumor	O
,	O
and	O
mechanisms	O
underlying	O
its	O
development	O
are	O
poorly	O
understood	O
.	O

The	O
miR-17	O
/	O
92	O
polycistron	O
is	O
up	O
-	O
regulated	O
in	O
sonic	O
hedgehog	O
-	O
driven	O
medulloblastomas	O
and	O
induced	O
by	O
N	O
-	O
myc	O
in	O
sonic	O
hedgehog	O
-	O
treated	O
cerebellar	O
neural	O
precursors	O
.	O

New	O
insights	O
into	O
non	O
-	O
coding	O
RNA	O
networks	O
in	O
Huntington	O
's	O
disease	O
.	O

MicroRNA	O
regulation	O
of	O
IFN	O
-	O
beta	O
protein	O
expression	O
:	O
rapid	O
and	O
sensitive	O
modulation	O
of	O
the	O
innate	O
immune	O
response	O
.	O

In	O
primary	O
primate	O
macrophages	O
,	O
the	O
main	O
cell	O
type	O
implicated	O
in	O
HIV	O
and	O
SIV	O
infection	O
in	O
the	O
CNS	O
,	O
specific	O
miRNAs	O
reduce	O
,	O
whereas	O
miRNA	O
inhibitors	O
enhance	O
,	O
IFN	O
-	O
beta	O
protein	O
production	O
.	O

The	O
potential	O
biologic	O
significance	O
of	O
this	O
regulation	O
is	O
supported	O
by	O
evidence	O
of	O
an	O
apparent	O
negative	O
feedback	O
loop	O
,	O
with	O
increased	O
expression	O
of	O
three	O
IFN	O
-	O
beta	O
-	O
regulating	O
miRNAs	O
by	O
primate	O
macrophages	O
exposed	O
to	O
recombinant	O
IFN	O
-	O
beta	O
or	O
stimulated	O
to	O
produce	O
IFN	O
-	O
beta	O
.	O

Thus	O
,	O
miRNAs	O
may	O
contribute	O
significantly	O
to	O
the	O
regulation	O
of	O
IFN	O
-	O
beta	O
in	O
innate	O
immune	O
responses	O
.	O

IFN	O
-	O
beta	O
production	O
is	O
an	O
inaugural	O
event	O
in	O
the	O
innate	O
immune	O
response	O
to	O
viral	O
infections	O
,	O
with	O
relatively	O
small	O
fold	O
changes	O
in	O
IFN	O
-	O
beta	O
expression	O
resulting	O
in	O
the	O
activation	O
of	O
important	O
antiviral	O
signaling	O
cascades	O
.	O

In	O
our	O
rapid	O
SIV	O
/	O
macaque	O
model	O
of	O
HIV	O
encephalitis	O
,	O
the	O
virus	O
enters	O
the	O
CNS	O
within	O
4	O
d	O
of	O
infection	O
,	O
accompanied	O
by	O
a	O
marked	O
IFN	O
-	O
beta	O
response	O
that	O
wanes	O
as	O
SIV	O
replication	O
is	O
controlled	O
.	O

The	O
centrality	O
of	O
IFN	O
-	O
beta	O
to	O
the	O
innate	O
antiviral	O
response	O
in	O
the	O
CNS	O
combines	O
with	O
the	O
potential	O
inflammatory	O
damage	O
associated	O
with	O
long	O
-	O
term	O
activation	O
of	O
this	O
pathway	O
to	O
suggest	O
that	O
IFN	O
-	O
beta	O
may	O
be	O
subject	O
to	O
regulatory	O
fine	O
-	O
tuning	O
in	O
addition	O
to	O
well	O
-	O
established	O
transcriptional	O
and	O
message	O
stability	O
mechanisms	O
of	O
regulation	O
.	O

In	O
this	O
paper	O
,	O
we	O
present	O
for	O
the	O
first	O
time	O
evidence	O
that	O
microRNAs	O
(	O
miRNAs	O
)	O
,	O
including	O
miR-26a	O
,	O
-34a	O
,	O
-145	O
,	O
and	O
let-7b	O
,	O
may	O
directly	O
regulate	O
IFN	O
-	O
beta	O
in	O
human	B
and	O
macaque	O
cells	O
.	O

Plasma	O
miRNAs	O
should	O
be	O
investigated	O
further	O
as	O
leading	O
indicators	O
of	O
HIV	O
diseases	O
as	O
early	O
as	O
acute	O
infection	O
.	O

CONCLUSION	O
:	O
:	O
Acute	O
-	O
phase	O
differential	O
expression	O
of	O
plasma	O
miRNAs	O
predicts	O
CNS	O
disease	O
and	O
suggests	O
that	O
CNS	O
damage	O
or	O
predisposition	O
to	O
disease	O
progression	O
begins	O
in	O
the	O
earliest	O
phase	O
of	O
infection	O
.	O

At	O
least	O
six	O
miRNAs	O
were	O
significantly	O
differentially	O
expressed	O
in	O
individuals	O
with	O
severe	O
versus	O
no	O
CNS	O
disease	O
;	O
in	O
an	O
unweighted	O
expression	O
test	O
,	O
they	O
predicted	O
CNS	O
disease	O
.	O

miRNAs	O
tracked	O
with	O
viral	O
load	O
and	O
platelet	O
count	O
were	O
also	O
predictors	O
of	O
CNS	O
disease	O
.	O

OBJECTIVE	O
:	O
:	O
Plasma	O
microRNAs	O
(	O
miRNAs	O
)	O
are	O
modulated	O
during	O
disease	O
and	O
are	O
emerging	O
biomarkers	O
;	O
they	O
have	O
not	O
been	O
characterized	O
in	O
HIV	O
infection	O
.	O

A	O
plasma	O
microRNA	O
signature	O
of	O
acute	O
lentiviral	O
infection	O
:	O
biomarkers	O
of	O
central	O
nervous	O
system	O
disease	O
.	O

miRNA	O
expression	O
was	O
compared	O
with	O
levels	O
of	O
cytokines	O
,	O
virus	O
,	O
and	O
plasma	O
platelet	O
count	O
.	O

METHODS	O
:	O
:	O
Plasma	O
miRNA	O
expression	O
profiles	O
were	O
determined	O
by	O
TaqMan	O
low	O
-	O
density	O
array	O
for	O
six	O
individuals	O
.	O

DESIGN	O
:	O
:	O
Plasma	O
samples	O
were	O
obtained	O
before	O
inoculation	O
and	O
10	O
days	O
after	O
inoculation	O
from	O
SIV	O
-	O
infected	O
macaques	B
.	O

Using	O
our	O
macaque	O
/	O
simian	O
immunodeficiency	O
virus	O
(	O
SIV	O
)	O
model	O
of	O
HIV	O
,	O
we	O
sought	O
to	O
identify	O
a	O
plasma	O
miRNA	O
profile	O
of	O
acute	O
lentiviral	O
infection	O
,	O
evaluate	O
its	O
relationship	O
with	O
known	O
cellular	O
and	O
viral	O
determinants	O
of	O
lentivirus	O
-	O
associated	O
central	O
nervous	O
system	O
(	O
CNS	O
)	O
disease	O
,	O
and	O
explore	O
the	O
potential	O
of	O
miRNAs	O
to	O
predict	O
CNS	O
disease	O
.	O

Several	O
differentially	O
expressed	O
miRNAs	O
correlated	O
with	O
CNS	O
disease	O
-	O
associated	O
cytokines	O
interleukin-6	O
and	O
CCL2	O
and	O
included	O
predicted	O
and/or	O
validated	O
regulators	O
of	O
the	O
corresponding	O
mRNAs	O
.	O

RESULTS	O
:	O
:	O
A	O
45-miRNA	O
signature	O
of	O
acute	O
infection	O
(	O
differential	O
expression	O
with	O
P	O
<	O
0.05	O
after	O
multiple	O
comparison	O
correction	O
)	O
classified	O
plasma	O
as	O
infected	O
or	O
not	O
.	O

Nineteen	O
individuals	O
were	O
used	O
to	O
validate	O
a	O
disease	O
prediction	O
test	O
.	O

miRNA	O
results	O
were	O
confirmed	O
by	O
single	O
miRNA	O
-	O
specific	O
assays	O
for	O
10	O
macaques	B
.	O

Identification	O
of	O
miRNA	O
changes	O
in	O
Alzheimer	O
's	O
disease	O
brain	O
and	O
CSF	O
yields	O
putative	O
biomarkers	O
and	O
insights	O
into	O
disease	O
pathways	O
.	O

MicroRNAs	O
have	O
essential	O
functional	O
roles	O
in	O
brain	O
development	O
and	O
neuronal	O
specification	O
but	O
their	O
roles	O
in	O
neurodegenerative	O
diseases	O
such	O
as	O
Alzheimer	O
's	O
disease	O
(	O
AD	O
)	O
is	O
unknown	O
.	O

Using	O
a	O
sensitive	O
qRT	O
-	O
PCR	O
platform	O
we	O
identified	O
regional	O
and	O
stage	O
-	O
specific	O
deregulation	O
of	O
miRNA	O
expression	O
in	O
AD	O
patient	B
brains	O
.	O

We	O
used	O
experimental	O
validation	O
in	O
addition	O
to	O
literature	O
to	O
reveal	O
how	O
the	O
deregulated	O
brain	O
microRNAs	O
are	O
biomarkers	O
for	O
known	O
and	O
novel	O
pathways	O
in	O
AD	O
pathogenesis	O
related	O
to	O
amyloid	O
processing	O
,	O
neurogenesis	O
,	O
insulin	O
resistance	O
,	O
and	O
innate	O
immunity	O
.	O

We	O
additionally	O
recovered	O
miRNAs	O
from	O
cerebrospinal	O
fluid	O
and	O
discovered	O
AD	O
-	O
specific	O
miRNA	O
changes	O
consistent	O
with	O
their	O
role	O
as	O
potential	O
biomarkers	O
of	O
disease	O
.	O

Regulation	O
of	O
oligodendrocyte	O
differentiation	O
and	O
myelination	O
.	O

These	O
recent	O
advances	O
provide	O
new	O
insight	O
into	O
how	O
remyelination	O
may	O
be	O
stimulated	O
in	O
demyelinating	O
disorders	O
such	O
as	O
multiple	O
sclerosis	O
.	O

Studies	O
have	O
also	O
demonstrated	O
an	O
unexpected	O
level	O
of	O
plasticity	O
of	O
myelin	O
in	O
the	O
adult	O
CNS	O
.	O

Recent	O
results	O
have	O
greatly	O
advanced	O
this	O
understanding	O
,	O
identifying	O
new	O
transcriptional	O
regulators	O
of	O
myelin	O
gene	O
expression	O
,	O
elucidating	O
vital	O
roles	O
for	O
microRNAs	O
in	O
controlling	O
myelination	O
,	O
and	O
clarifying	O
the	O
extracellular	O
signaling	O
mechanisms	O
that	O
orchestrate	O
the	O
development	O
of	O
myelin	O
.	O

Despite	O
the	O
importance	O
of	O
myelin	O
for	O
the	O
rapid	O
conduction	O
of	O
action	O
potentials	O
,	O
the	O
molecular	O
bases	O
of	O
oligodendrocyte	O
differentiation	O
and	O
central	O
nervous	O
system	O
(	O
CNS	O
)	O
myelination	O
are	O
still	O
incompletely	O
understood	O
.	O

In	O
sum	O
,	O
our	O
results	O
suggest	O
that	O
specific	O
miRNAs	O
are	O
involved	O
in	O
the	O
fine	O
-	O
tuning	O
of	O
APP	O
alternative	O
splicing	O
in	O
neurons	O
.	O

Finally	O
,	O
we	O
show	O
that	O
miR-124	O
is	O
down	O
-	O
regulated	O
in	O
AD	O
brain	O
.	O

Furthermore	O
,	O
PTBP1	O
levels	O
correlate	O
with	O
the	O
presence	O
of	O
APP	O
exons	O
7	O
and	O
8	O
,	O
while	O
PTBP2	O
levels	O
correlate	O
with	O
the	O
skipping	O
of	O
these	O
exons	O
during	O
neuronal	O
differentiation	O
.	O

Similar	O
results	O
were	O
obtained	O
by	O
depletion	O
of	O
endogenous	O
polypyrimidine	O
tract	O
binding	O
protein	O
1	O
(	O
PTBP1	O
)	O
in	O
cells	O
,	O
a	O
recognized	O
miR-124	O
target	O
gene	O
.	O

In	O
vivo	O
regulation	O
of	O
amyloid	O
precursor	O
protein	O
neuronal	O
splicing	O
by	O
microRNAs	O
.	O

The	O
β	O
-	O
amyloid	O
peptide	O
that	O
accumulate	O
in	O
Alzheimer	O
's	O
disease	O
(	O
AD	O
)	O
brain	O
derive	O
from	O
proteolytic	O
processing	O
of	O
the	O
amyloid	O
precursor	O
protein	O
(	O
APP	O
)	O
.	O

Here	O
,	O
we	O
present	O
evidence	O
that	O
,	O
besides	O
APP	O
expression	O
regulation	O
,	O
miRNAs	O
are	O
equally	O
involved	O
in	O
the	O
regulation	O
of	O
neuronal	O
APP	O
mRNA	O
alternative	O
splicing	O
.	O

Lack	O
of	O
miRNAs	O
in	O
post	O
-	O
mitotic	O
neurons	O
in	O
vivo	O
is	O
associated	O
with	O
APP	O
exons	O
7	O
and	O
8	O
inclusion	O
,	O
while	O
ectopic	O
expression	O
of	O
miR-124	O
,	O
an	O
abundant	O
neuronal	O
-	O
specific	O
miRNA	O
,	O
reversed	O
these	O
effects	O
in	O
cultured	O
neurons	O
.	O

Recent	O
evidence	O
suggest	O
that	O
microRNAs	O
(	O
miRNAs	O
)	O
participate	O
in	O
the	O
post	O
-	O
transcriptional	O
regulation	O
of	O
APP	O
expression	O
.	O

Because	O
gene	O
dosage	O
effects	O
of	O
the	O
APP	O
gene	O
can	O
cause	O
genetic	O
AD	O
,	O
dysregulation	O
of	O
the	O
miRNA	O
network	O
could	O
contribute	O
significantly	O
to	O
disease	O
.	O

Since	O
abnormal	O
neuronal	O
splicing	O
of	O
APP	O
affects	O
β	O
-	O
amyloid	O
peptide	O
production	O
,	O
these	O
results	O
could	O
contribute	O
to	O
the	O
understanding	O
of	O
the	O
implication	O
of	O
miRNAs	O
in	O
brain	O
health	O
and	O
disease	O
.	O

miR-182	O
as	O
a	O
prognostic	O
marker	O
for	O
glioma	O
progression	O
and	O
patient	B
survival	O
.	O

Taken	O
together	O
,	O
our	O
results	O
suggest	O
that	O
miR-182	O
could	O
be	O
a	O
valuable	O
marker	O
of	O
glioma	O
progression	O
and	O
that	O
high	O
miR-182	O
expression	O
is	O
associated	O
with	O
poor	O
overall	O
survival	O
in	O
patients	B
with	O
malignant	O
glioma	O
.	O

Moreover	O
,	O
the	O
correlations	O
of	O
miR-182	O
level	O
with	O
the	O
clinical	O
features	O
of	O
glioma	O
suggested	O
in	O
the	O
in	O
situ	O
hybridization	O
analysis	O
were	O
further	O
verified	O
by	O
the	O
real	O
-	O
time	O
RT	O
-	O
PCR	O
analysis	O
.	O

The	O
cumulative	O
5-year	O
survival	O
rate	O
of	O
glioma	O
patients	B
was	O
51.54	O
%	O
(	O
95	O
%	O
confidence	O
interval	O
,	O
0.435	O
to	O
0.596	O
)	O
in	O
the	O
low	O
miR-182-expression	O
group	O
,	O
whereas	O
it	O
was	O
only	O
7.23	O
%	O
(	O
95	O
%	O
confidence	O
interval	O
,	O
0.027	O
to	O
0.118	O
)	O
in	O
the	O
high	O
miR-182-expression	O
group	O
(	O
P	O
=	O
0.001	O
)	O
,	O
and	O
multivariate	O
Cox	O
regression	O
analysis	O
indicated	O
that	O
miR-182	O
expression	O
was	O
an	O
independent	O
prognostic	O
indicator	O
for	O
the	O
survival	O
of	O
glioma	O
patients	B
.	O

Statistical	O
analysis	O
revealed	O
a	O
significant	O
correlation	O
between	O
miR-182	O
expression	O
and	O
World	O
Health	O
Organization	O
glioma	O
grading	O
(	O
P	O
<	O
0.001	O
)	O
.	O

Elevated	O
expression	O
of	O
miR-182	O
was	O
further	O
identified	O
by	O
in	O
situ	O
hybridization	O
in	O
248	O
of	O
253	O
(	O
98	O
%	O
)	O
archived	O
human	B
glioma	O
biopsies	O
tested	O
.	O

Quantitative	O
PCR	O
analysis	O
showed	O
that	O
miR-182	O
was	O
significantly	O
increased	O
by	O
up	O
to	O
32-fold	O
in	O
glioma	O
tumors	O
compared	O
with	O
the	O
adjacent	O
nontumor	O
brain	O
tissues	O
obtained	O
from	O
the	O
same	O
patient	B
.	O

We	O
report	O
that	O
the	O
expression	O
level	O
of	O
miR-182	O
was	O
markedly	O
up	O
-	O
regulated	O
in	O
glioma	O
cell	O
lines	O
and	O
in	O
human	B
primary	O
glioma	O
specimens	O
.	O

Accumulating	O
evidence	O
indicates	O
that	O
miRNA	O
expression	O
can	O
be	O
used	O
as	O
a	O
diagnostic	O
and	O
prognostic	O
marker	O
for	O
human	B
cancers	O
.	O

A	O
greater	O
understanding	O
of	O
aberrant	O
miRNA	O
expression	O
in	O
pediatric	O
brain	O
tumors	O
may	O
aid	O
in	O
the	O
development	O
of	O
novel	O
therapies	O
.	O

The	O
characterization	O
of	O
tumor	O
-	O
specific	O
miRNA	O
signatures	O
may	O
aid	O
in	O
the	O
discovery	O
of	O
biomarkers	O
with	O
diagnostic	O
or	O
prognostic	O
utility	O
.	O

The	O
present	O
study	O
provides	O
an	O
initial	O
survey	O
of	O
miRNA	O
expression	O
in	O
pediatric	O
central	O
nervous	O
system	O
(	O
CNS	O
)	O
malignancies	O
including	O
atypical	O
teratoid	O
/	O
rhabdoid	O
tumor	O
,	O
ependymoma	O
,	O
glioblastoma	O
,	O
medulloblastoma	O
,	O
and	O
pilocytic	O
astrocytoma	O
.	O

PROCEDURE	O
:	O
MicroRNA	O
expression	O
in	O
pediatric	O
brain	O
tumors	O
and	O
normal	O
tissue	O
controls	O
was	O
examined	O
by	O
microarray	O
.	O

BACKGROUND	O
:	O
A	O
better	O
understanding	O
of	O
pediatric	O
brain	O
tumor	O
biology	O
is	O
needed	O
to	O
assist	O
in	O
the	O
development	O
of	O
less	O
toxic	O
therapies	O
and	O
to	O
provide	O
better	O
markers	O
for	O
disease	O
stratification	O
.	O

MicroRNAs	O
(	O
miRNA	O
)	O
may	O
play	O
a	O
significant	O
role	O
in	O
brain	O
tumor	O
biology	O
.	O

When	O
further	O
examined	O
by	O
qRT	O
-	O
PCR	O
,	O
these	O
miRNAs	O
demonstrated	O
differential	O
expression	O
that	O
significantly	O
correlated	O
with	O
the	O
microarray	O
findings	O
.	O

Distinctive	O
miRNA	O
expression	O
profiles	O
were	O
also	O
observed	O
in	O
the	O
different	O
pediatric	O
brain	O
tumor	O
types	O
.	O

Three	O
aberrantly	O
expressed	O
miRNAs	O
were	O
further	O
studied	O
in	O
a	O
larger	O
cohort	O
by	O
quantitative	O
real	O
-	O
time	O
PCR	O
(	O
qRT	O
-	O
PCR	O
)	O
.	O

RESULTS	O
:	O
MicroRNA-129	O
,	O
miR-142	O
-	O
5p	O
,	O
and	O
miR-25	O
were	O
differentially	O
expressed	O
in	O
every	O
pediatric	O
brain	O
tumor	O
type	O
compared	O
to	O
normal	O
tissue	O
controls	O
as	O
measured	O
by	O
microarray	O
.	O

CONCLUSIONS	O
:	O
MicroRNAs	O
are	O
differentially	O
expressed	O
between	O
pediatric	O
CNS	O
neoplasms	O
and	O
normal	O
tissue	O
suggesting	O
that	O
they	O
may	O
play	O
a	O
significant	O
role	O
in	O
oncogenesis	O
.	O

Survey	O
of	O
MicroRNA	O
expression	O
in	O
pediatric	O
brain	O
tumors	O
.	O

Recently	O
,	O
we	O
have	O
found	O
that	O
microRNA	O
(	O
miRNA	O
)	O
miR-145	O
is	O
the	O
most	O
abundant	O
miRNA	O
in	O
normal	O
vascular	O
walls	O
and	O
in	O
freshly	O
isolated	O
VSMCs	O
;	O
however	O
,	O
the	O
role	O
of	O
miR-145	O
in	O
VSMC	O
phenotypic	O
modulation	O
and	O
vascular	O
diseases	O
is	O
currently	O
unknown	O
.	O

Phenotypic	O
modulation	O
of	O
vascular	O
smooth	O
muscle	O
cells	O
(	O
VSMCs	O
)	O
plays	O
a	O
critical	O
role	O
in	O
the	O
pathogenesis	O
of	O
a	O
variety	O
of	O
proliferative	O
vascular	O
diseases	O
.	O

More	O
importantly	O
,	O
both	O
in	O
cultured	O
rat	B
VSMCs	O
in	O
vitro	O
and	O
in	O
balloon	O
-	O
injured	O
rat	B
carotid	O
arteries	O
in	O
vivo	O
,	O
we	O
demonstrate	O
that	O
the	O
noncoding	O
RNA	O
miR-145	O
is	O
a	O
novel	O
phenotypic	O
marker	O
and	O
a	O
novel	O
phenotypic	O
modulator	O
of	O
VSMCs	O
.	O

Here	O
we	O
find	O
that	O
miR-145	O
is	O
selectively	O
expressed	O
in	O
VSMCs	O
of	O
the	O
vascular	O
wall	O
and	O
its	O
expression	O
is	O
significantly	O
downregulated	O
in	O
the	O
vascular	O
walls	O
with	O
neointimal	O
lesion	O
formation	O
and	O
in	O
cultured	O
dedifferentiated	O
VSMCs	O
.	O

MicroRNA-145	O
,	O
a	O
novel	O
smooth	O
muscle	O
cell	O
phenotypic	O
marker	O
and	O
modulator	O
,	O
controls	O
vascular	O
neointimal	O
lesion	O
formation	O
.	O

These	O
novel	O
findings	O
may	O
have	O
extensive	O
implications	O
for	O
the	O
diagnosis	O
and	O
therapy	O
of	O
a	O
variety	O
of	O
proliferative	O
vascular	O
diseases	O
.	O

We	O
have	O
further	O
identified	O
that	O
miR-145-mediated	O
phenotypic	O
modulation	O
of	O
VSMCs	O
is	O
through	O
its	O
target	O
gene	O
KLF5	O
and	O
its	O
downstream	O
signaling	O
molecule	O
,	O
myocardin	O
.	O

VSMC	O
differentiation	O
marker	O
genes	O
such	O
as	O
SM	O
alpha	O
-	O
actin	O
,	O
calponin	O
,	O
and	O
SM	O
-	O
MHC	O
are	O
upregulated	O
by	O
premiR-145	O
or	O
adenovirus	O
expressing	O
miR-145	O
(	O
Ad	O
-	O
miR-145	O
)	O
but	O
are	O
downregulated	O
by	O
the	O
miR-145	O
inhibitor	O
2'OMe	O
-	O
miR-145	O
.	O

We	O
conclude	O
that	O
miR-145	O
is	O
a	O
novel	O
VSMC	O
phenotypic	O
marker	O
and	O
modulator	O
that	O
is	O
able	O
of	O
controlling	O
vascular	O
neointimal	O
lesion	O
formation	O
.	O

Finally	O
,	O
restoration	O
of	O
miR-145	O
in	O
balloon	O
-	O
injured	O
arteries	O
via	O
Ad	O
-	O
miR-145	O
inhibits	O
neointimal	O
growth	O
.	O

In	O
this	O
review	O
,	O
we	O
summarise	O
the	O
current	O
knowledge	O
of	O
miR-21	O
functions	O
in	O
human	B
disease	O
,	O
with	O
an	O
emphasis	O
on	O
its	O
regulation	O
,	O
oncogenic	O
role	O
,	O
targets	O
in	O
human	B
cancers	O
,	O
potential	O
as	O
a	O
disease	O
biomarker	O
and	O
novel	O
therapeutic	O
target	O
in	O
oncology	O
.	O

However	O
,	O
an	O
miR-21	O
knockout	O
mouse	B
has	O
not	O
yet	O
been	O
generated	O
,	O
and	O
the	O
data	O
about	O
miR-21	O
functions	O
in	O
normal	O
cells	O
are	O
still	O
very	O
limited	O
.	O

Since	O
its	O
identification	O
3	O
years	O
ago	O
as	O
the	O
miRNA	O
most	O
commonly	O
and	O
strongly	O
up	O
-	O
regulated	O
in	O
human	B
brain	O
tumour	O
glioblastoma	O
[	O
1	O
]	O
,	O
miR-21	O
has	O
attracted	O
the	O
attention	O
of	O
researchers	O
in	O
various	O
fields	O
,	O
such	O
as	O
development	O
,	O
oncology	O
,	O
stem	O
cell	O
biology	O
and	O
aging	O
,	O
becoming	O
one	O
of	O
the	O
most	O
studied	O
miRNAs	O
,	O
along	O
with	O
let-7	O
,	O
miR-17	O
-	O
92	O
cluster	O
(	O
'	O
oncomir-1	O
'	O
)	O
,	O
miR-155	O
and	O
a	O
few	O
others	O
.	O

Particular	O
miRNAs	O
emerge	O
as	O
principal	O
regulators	O
that	O
control	O
major	O
cell	O
functions	O
in	O
various	O
physiological	O
and	O
pathophysiological	O
settings	O
.	O

miR-21	O
:	O
a	O
small	O
multi	O
-	O
faceted	O
RNA	O
.	O

More	O
than	O
1000	O
microRNAs	O
(	O
miRNAs	O
)	O
are	O
expressed	O
in	O
human	B
cells	O
,	O
some	O
tissue	O
or	O
cell	O
type	O
specific	O
,	O
others	O
considered	O
as	O
house	O
-	O
keeping	O
molecules	O
.	O

Functions	O
and	O
direct	O
mRNA	O
targets	O
for	O
some	O
miRNAs	O
have	O
been	O
relatively	O
well	O
studied	O
over	O
the	O
last	O
years	O
.	O

Every	O
miRNA	O
potentially	O
regulates	O
the	O
expression	O
of	O
numerous	O
protein	O
-	O
coding	O
genes	O
(	O
tens	O
to	O
hundreds	O
)	O
,	O
but	O
it	O
has	O
become	O
increasingly	O
clear	O
that	O
not	O
all	O
miRNAs	O
are	O
equally	O
important	O
;	O
diverse	O
high	O
-	O
throughput	O
screenings	O
of	O
various	O
systems	O
have	O
identified	O
a	O
limited	O
number	O
of	O
key	O
functional	O
miRNAs	O
over	O
and	O
over	O
again	O
.	O

MicroRNAs	O
and	O
regenerative	O
medicine	O
.	O

Recently	O
,	O
researchers	O
have	O
demonstrated	O
the	O
crucial	O
roles	O
of	O
microRNAs	O
,	O
not	O
only	O
in	O
the	O
differentiation	O
and	O
proliferation	O
of	O
stem	O
cells	O
,	O
which	O
have	O
a	O
key	O
function	O
in	O
the	O
regeneration	O
and	O
transplantation	O
of	O
organs	O
,	O
but	O
also	O
in	O
oncogenesis	O
.	O

In	O
this	O
paper	O
,	O
we	O
review	O
the	O
prospects	O
of	O
microRNAs	O
as	O
future	O
therapies	O
in	O
regenerative	O
medicine	O
.	O

The	O
combination	O
of	O
microRNAs	O
and	O
regenerative	O
medicine	O
is	O
an	O
emerging	O
interdisciplinary	O
medical	O
field	O
that	O
can	O
yield	O
exciting	O
new	O
possibilities	O
for	O
clinical	O
medicine	O
.	O

MicroRNAs	O
,	O
identified	O
only	O
relatively	O
recently	O
,	O
are	O
regulators	O
of	O
gene	O
expression	O
with	O
potential	O
medical	O
benefits	O
.	O

Further	O
,	O
microRNAs	O
have	O
been	O
indicated	O
to	O
be	O
involved	O
in	O
diverse	O
biological	O
processes	O
,	O
suggesting	O
the	O
potential	O
role	O
of	O
these	O
molecules	O
in	O
the	O
treatment	O
of	O
diseases	O
.	O

Several	O
lines	O
of	O
indirect	O
evidence	O
show	O
that	O
the	O
initiation	O
and	O
maintenance	O
of	O
cancer	O
stem	O
cells	O
might	O
also	O
be	O
under	O
the	O
control	O
of	O
microRNAs	O
.	O

Expression	O
levels	O
of	O
select	O
protein	O
-	O
coding	O
genes	O
and	O
miRNAs	O
could	O
classify	O
an	O
independent	O
set	O
of	O
medulloblastomas	O
.	O

Twelve	O
of	O
31	O
medulloblastomas	O
were	O
found	O
to	O
overexpress	O
genes	O
belonging	O
to	O
the	O
canonical	O
WNT	O
signaling	O
pathway	O
and	O
carry	O
a	O
mutation	O
in	O
CTNNB1	O
gene	O
.	O

In	O
order	O
to	O
get	O
a	O
better	O
understanding	O
of	O
medulloblastoma	O
biology	O
,	O
miRNA	O
profiling	O
of	O
medulloblastomas	O
was	O
carried	O
out	O
in	O
parallel	O
with	O
expression	O
profiling	O
of	O
protein	O
-	O
coding	O
genes	O
.	O

MATERIALS	O
AND	O
METHODS	O
:	O
miRNA	O
profiling	O
of	O
medulloblastomas	O
was	O
carried	O
out	O
using	O
Taqman	O
Low	O
Density	O
Array	O
v	O
1.0	O
having	O
365	O
human	B
microRNAs	O
.	O

In	O
parallel	O
,	O
genome	O
-	O
wide	O
expression	O
profiling	O
of	O
protein	O
-	O
coding	O
genes	O
was	O
carried	O
out	O
using	O
Affymetrix	O
gene	O
1.0	O
ST	O
arrays	O
.	O

RESULTS	O
:	O
Both	O
the	O
profiling	O
studies	O
identified	O
four	O
molecular	O
subtypes	O
of	O
medulloblastomas	O
.	O

Distinctive	O
microRNA	O
signature	O
of	O
medulloblastomas	O
associated	O
with	O
the	O
WNT	O
signaling	O
pathway	O
.	O

AIM	O
:	O
Medulloblastoma	O
is	O
a	O
malignant	O
brain	O
tumor	O
that	O
occurs	O
predominantly	O
in	O
children	B
.	O

Current	O
risk	O
stratification	O
based	O
on	O
clinical	O
parameters	O
is	O
inadequate	O
for	O
accurate	O
prognostication	O
.	O

MicroRNA	O
expression	O
is	O
known	O
to	O
be	O
deregulated	O
in	O
various	O
cancers	O
and	O
has	O
been	O
found	O
to	O
be	O
useful	O
in	O
predicting	O
tumor	O
behavior	O
.	O

A	O
number	O
of	O
miRNAs	O
like	O
miR-193a	O
,	O
miR-224	O
/	O
miR-452	O
cluster	O
,	O
miR-182	O
/	O
miR-183	O
/	O
miR-96	O
cluster	O
,	O
and	O
miR-148a	O
having	O
potential	O
tumor	O
/	O
metastasis	O
suppressive	O
activity	O
were	O
found	O
to	O
be	O
overexpressed	O
in	O
the	O
WNT	O
signaling	O
associated	O
medulloblastomas	O
.	O

CONCLUSION	O
:	O
Expression	O
level	O
of	O
tumor	O
/	O
metastasis	O
suppressive	O
miRNAs	O
in	O
the	O
WNT	O
signaling	O
associated	O
medulloblastomas	O
is	O
likely	O
to	O
determine	O
their	O
response	O
to	O
treatment	O
,	O
and	O
thus	O
,	O
these	O
miRNAs	O
would	O
be	O
important	O
biomarkers	O
for	O
risk	O
stratification	O
within	O
the	O
WNT	O
signaling	O
associated	O
medulloblastomas	O
.	O

Exogenous	O
expression	O
of	O
miR-193a	O
and	O
miR-224	O
,	O
two	O
miRNAs	O
that	O
have	O
the	O
highest	O
WNT	O
pathway	O
specific	O
upregulation	O
,	O
was	O
found	O
to	O
inhibit	O
proliferation	O
,	O
increase	O
radiation	O
sensitivity	O
and	O
reduce	O
anchorage	O
-	O
independent	O
growth	O
of	O
medulloblastoma	O
cells	O
.	O

MicroRNAs	O
in	O
CNS	O
injury	O
:	O
potential	O
roles	O
and	O
therapeutic	O
implications	O
.	O

We	O
now	O
report	O
clinical	O
and	O
genetic	O
findings	O
in	O
nine	O
additional	O
European	O
families	O
with	O
myoclonus	O
-	O
dystonia	O
syndrome	O
.	O

Mutations	O
in	O
the	O
gene	O
for	O
epsilon	O
-	O
sarcoglycan	O
(	O
SGCE	O
)	O
have	O
been	O
found	O
to	O
cause	O
myoclonus	O
-	O
dystonia	O
syndrome	O
.	O

Six	O
novel	O
and	O
one	O
previously	O
known	O
heterozygous	O
SGCE	O
mutations	O
were	O
identified	O
.	O

The	O
clinical	O
presentation	O
in	O
24	O
affecteds	O
was	O
homogeneous	O
with	O
myoclonus	O
predominantly	O
of	O
neck	O
and	O
upper	O
limbs	O
in	O
23	O
of	O
them	O
and	O
dystonia	O
,	O
presenting	O
as	O
cervical	O
dystonia	O
and/or	O
writer	O
's	O
cramp	O
,	O
in	O
13	O
cases	O
.	O

SGCE	O
deficiency	O
seems	O
to	O
be	O
the	O
common	O
pathogenetic	O
mechanism	O
in	O
myoclonus	O
-	O
dystonia	O
syndrome	O
.	O

Myoclonus	O
-	O
dystonia	O
syndrome	O
:	O
epsilon	O
-	O
sarcoglycan	O
mutations	O
and	O
phenotype	O
.	O

Ameliorating	O
amyotrophic	O
lateral	O
sclerosis	O
.	O

This	O
review	O
summarizes	O
recent	O
findings	O
of	O
miRNA	O
study	O
in	O
brain	O
tumors	O
.	O

Several	O
deregulated	O
miRNAs	O
uncovered	O
in	O
glioblastomas	O
and	O
medulloblastomas	O
have	O
their	O
gene	O
targets	O
and	O
the	O
associated	O
genetic	O
pathways	O
identified	O
.	O

Moreover	O
,	O
specific	O
miRNA	O
subsets	O
may	O
have	O
potential	O
diagnostic	O
and	O
prognostic	O
values	O
in	O
some	O
brain	O
tumors	O
.	O

Expression	O
profiling	O
has	O
unveiled	O
miRNA	O
signatures	O
that	O
not	O
only	O
distinguish	O
brain	O
tumors	O
from	O
normal	O
tissues	O
,	O
but	O
can	O
also	O
differentiate	O
histotypes	O
or	O
molecular	O
subtypes	O
with	O
altered	O
genetic	O
pathways	O
.	O

Recent	O
years	O
have	O
seen	O
considerable	O
progress	O
in	O
miRNA	O
research	O
in	O
brain	O
tumors	O
,	O
particularly	O
in	O
glioblastomas	O
and	O
medulloblastomas	O
,	O
providing	O
novel	O
insights	O
into	O
the	O
pathogenesis	O
of	O
these	O
malignant	O
lesions	O
.	O

Emerging	O
evidence	O
indicates	O
that	O
miRNAs	O
play	O
an	O
important	O
role	O
in	O
the	O
development	O
of	O
human	B
cancers	O
,	O
with	O
their	O
deregulation	O
resulting	O
in	O
altered	O
activity	O
of	O
downstream	O
tumor	O
suppressors	O
,	O
oncogenes	O
and	O
other	O
signaling	O
molecules	O
.	O

MicroRNAs	O
(	O
miRNAs	O
)	O
are	O
short	O
non	O
-	O
protein	O
-	O
coding	O
RNAs	O
that	O
function	O
as	O
key	O
regulators	O
of	O
diverse	O
biological	O
processes	O
through	O
negative	O
control	O
on	O
gene	O
expression	O
at	O
the	O
post	O
-	O
transcriptional	O
level	O
.	O

Oncogenic	O
role	O
of	O
microRNAs	O
in	O
brain	O
tumors	O
.	O

Pathway	O
analyses	O
showed	O
that	O
majority	O
of	O
these	O
miRNAs	O
are	O
involved	O
in	O
the	O
neuronal	O
development	O
and	O
function	O
.	O

In	O
this	O
study	O
,	O
we	O
report	O
for	O
the	O
first	O
time	O
that	O
VEEV	O
infection	O
in	O
mice	B
brain	O
causes	O
modulation	O
of	O
miRNA	O
expression	O
.	O

Target	O
gene	O
prediction	O
of	O
the	O
modulated	O
miRNAs	O
correlates	O
with	O
our	O
recently	O
reported	O
mRNA	O
expression	O
in	O
VEEV	O
infected	O
mice	B
brain	O
.	O

Recent	O
studies	O
have	O
shown	O
that	O
cellular	O
miRNA	O
plays	O
a	O
very	O
important	O
role	O
in	O
the	O
pathogenesis	O
of	O
viral	O
infection	O
.	O

MicroRNAs	O
(	O
miRNA	O
)	O
are	O
small	O
RNA	O
(	O
approximately	O
22nts	O
)	O
molecules	O
that	O
are	O
expressed	O
endogenously	O
in	O
cells	O
and	O
play	O
an	O
important	O
role	O
in	O
regulating	O
gene	O
expression	O
.	O

VEEV	O
is	O
infectious	O
in	O
aerosol	O
form	O
and	O
is	O
a	O
potential	O
biothreat	O
agent	O
.	O

Venezuelan	O
equine	O
encephalitis	O
virus	O
(	O
VEEV	O
)	O
is	O
an	O
RNA	O
virus	O
and	O
is	O
a	O
member	O
of	O
the	O
genus	O
Alphavirus	O
in	O
the	O
family	O
Togaviridae	O
.	O

Analysis	O
of	O
microRNAs	O
induced	O
by	O
Venezuelan	O
equine	O
encephalitis	O
virus	O
infection	O
in	O
mouse	B
brain	O
.	O

Additionally	O
,	O
a	O
control	O
shRNA	O
containing	O
mismatches	O
also	O
induced	O
toxicity	O
,	O
although	O
it	O
did	O
not	O
reduce	O
HDh	O
mRNA	O
expression	O
.	O

Interestingly	O
,	O
the	O
toxic	O
shRNAs	O
generated	O
higher	O
antisense	O
RNA	O
levels	O
,	O
compared	O
with	O
the	O
nontoxic	O
shRNA	O
.	O

These	O
results	O
demonstrate	O
that	O
the	O
robust	O
levels	O
of	O
antisense	O
RNAs	O
emerging	O
from	O
shRNA	O
expression	O
systems	O
can	O
be	O
problematic	O
in	O
the	O
mouse	B
brain	O
.	O

Importantly	O
,	O
when	O
sequences	O
that	O
were	O
toxic	O
in	O
the	O
context	O
of	O
shRNAs	O
were	O
placed	O
into	O
artificial	O
microRNA	O
(	O
miRNA	O
)	O
expression	O
systems	O
,	O
molecular	O
and	O
neuropathological	O
readouts	O
of	O
neurotoxicity	O
were	O
significantly	O
attenuated	O
without	O
compromising	O
mouse	B
HDh	O
silencing	O
efficacy	O
.	O

Artificial	O
miRNAs	O
mitigate	O
shRNA	O
-	O
mediated	O
toxicity	O
in	O
the	O
brain	O
:	O
implications	O
for	O
the	O
therapeutic	O
development	O
of	O
RNAi	O
.	O

Huntington	O
's	O
disease	O
(	O
HD	O
)	O
is	O
a	O
fatal	O
,	O
dominant	O
neurodegenerative	O
disease	O
caused	O
by	O
a	O
polyglutamine	O
repeat	O
expansion	O
in	O
exon	O
1	O
of	O
the	O
HD	O
gene	O
,	O
which	O
encodes	O
the	O
huntingtin	O
protein	O
.	O

We	O
and	O
others	O
have	O
shown	O
that	O
RNAi	O
is	O
a	O
candidate	O
therapy	O
for	O
HD	O
because	O
expression	O
of	O
inhibitory	O
RNAs	O
targeting	O
mutant	O
human	B
HD	O
transgenes	O
improved	O
neuropathology	O
and	O
behavioral	O
deficits	O
in	O
HD	O
mouse	B
models	O
.	O

Here	O
,	O
we	O
developed	O
shRNAs	O
targeting	O
conserved	O
sequences	O
in	O
human	B
HD	O
and	O
mouse	B
HD	O
homolog	O
(	O
HDh	O
)	O
mRNAs	O
to	O
initiate	O
preclinical	O
testing	O
in	O
a	O
knockin	O
mouse	B
model	O
of	O
HD	O
.	O

We	O
screened	O
35	O
shRNAs	O
in	O
vitro	O
and	O
subsequently	O
narrowed	O
our	O
focus	O
to	O
three	O
candidates	O
for	O
in	O
vivo	O
testing	O
.	O

Unexpectedly	O
,	O
two	O
active	O
shRNAs	O
induced	O
significant	O
neurotoxicity	O
in	O
mouse	B
striatum	O
,	O
although	O
HDh	O
mRNA	O
expression	O
was	O
reduced	O
to	O
similar	O
levels	O
by	O
all	O
three	O
.	O

Thus	O
,	O
miRNA	O
-	O
based	O
approaches	O
may	O
provide	O
more	O
appropriate	O
biological	O
tools	O
for	O
expressing	O
inhibitory	O
RNAs	O
in	O
the	O
brain	O
,	O
the	O
implications	O
of	O
which	O
are	O
crucial	O
to	O
the	O
development	O
of	O
RNAi	O
for	O
both	O
basic	O
biological	O
and	O
therapeutic	O
applications	O
.	O

These	O
findings	O
call	O
attention	O
to	O
the	O
potential	O
of	O
microRNAs	O
to	O
provide	O
etiologic	O
insights	O
as	O
well	O
as	O
to	O
serve	O
as	O
both	O
diagnostic	O
markers	O
and	O
therapeutic	O
targets	O
for	O
many	O
different	O
tumor	O
types	O
.	O

Our	O
results	O
provide	O
evidence	O
that	O
microRNA	O
expression	O
patterns	O
may	O
mark	O
specific	O
biological	O
characteristics	O
of	O
tumors	O
and/or	O
mediate	O
biological	O
activities	O
important	O
for	O
the	O
pathobiology	O
of	O
malignant	O
tumors	O
.	O

Agglomerative	O
hierarchical	O
clustering	O
analysis	O
of	O
microRNA	O
expression	O
revealed	O
four	O
groups	O
among	O
the	O
NCI-60	O
cell	O
lines	O
consisting	O
of	O
hematologic	O
,	O
colon	O
,	O
central	O
nervous	O
system	O
,	O
and	O
melanoma	O
tumor	O
-	O
derived	O
cell	O
lines	O
clustered	O
in	O
a	O
manner	O
that	O
reflected	O
their	O
tissue	O
of	O
origin	O
.	O

Most	O
microRNAs	O
were	O
expressed	O
at	O
lower	O
levels	O
in	O
tumor	O
-	O
derived	O
cell	O
lines	O
compared	O
with	O
the	O
corresponding	O
normal	O
tissue	O
.	O

We	O
also	O
identified	O
specific	O
microRNA	O
expression	O
patterns	O
that	O
correlated	O
with	O
the	O
proliferation	O
indices	O
of	O
the	O
NCI-60	O
cell	O
lines	O
,	O
and	O
we	O
developed	O
evidence	O
for	O
the	O
identification	O
of	O
specific	O
microRNAs	O
as	O
candidate	O
oncogenes	O
and	O
tumor	O
suppressor	O
genes	O
in	O
different	O
tumor	O
types	O
.	O

We	O
identified	O
specific	O
subsets	O
of	O
microRNAs	O
that	O
provide	O
candidate	O
molecular	O
signatures	O
characteristic	O
of	O
the	O
tumor	O
-	O
derived	O
cell	O
lines	O
belonging	O
to	O
these	O
four	O
clusters	O
.	O

They	O
play	O
a	O
critical	O
role	O
in	O
developmental	O
and	O
physiologic	O
processes	O
and	O
are	O
implicated	O
in	O
the	O
pathogenesis	O
of	O
several	O
human	B
diseases	O
including	O
cancer	O
.	O

MicroRNAs	O
are	O
small	O
noncoding	O
RNAs	O
that	O
function	O
by	O
regulating	O
target	O
gene	O
expression	O
posttranscriptionally	O
.	O

To	O
quantify	O
microRNA	O
expression	O
,	O
we	O
employed	O
a	O
highly	O
sensitive	O
technique	O
that	O
uses	O
stem	O
-	O
loop	O
primers	O
for	O
reverse	O
transcription	O
followed	O
by	O
real	O
-	O
time	O
PCR	O
.	O

We	O
examined	O
the	O
expression	O
profiles	O
of	O
241	O
human	B
microRNAs	O
in	O
normal	O
tissues	O
and	O
the	O
NCI-60	O
panel	O
of	O
human	B
tumor	O
-	O
derived	O
cell	O
lines	O
.	O

Characterization	O
of	O
microRNA	O
expression	O
levels	O
and	O
their	O
biological	O
correlates	O
in	O
human	B
cancer	O
cell	O
lines	O
.	O

Predictive	O
miRNAs	O
could	O
be	O
potentially	O
useful	O
diagnostic	O
markers	O
,	O
improving	O
the	O
classification	O
of	O
pituitary	O
adenomas	O
.	O

Several	O
of	O
the	O
identified	O
miRNAs	O
are	O
involved	O
in	O
cell	O
proliferation	O
and	O
apoptosis	O
,	O
suggesting	O
that	O
their	O
deregulated	O
expression	O
may	O
be	O
involved	O
in	O
pituitary	O
tumorigenesis	O
.	O

Identification	O
of	O
differentially	O
expressed	O
microRNAs	O
by	O
microarray	O
:	O
a	O
possible	O
role	O
for	O
microRNA	O
genes	O
in	O
pituitary	O
adenomas	O
.	O

MicroRNAs	O
(	O
miRNAs	O
)	O
are	O
small	O
non	O
-	O
coding	O
RNAs	O
that	O
control	O
gene	O
expression	O
by	O
targeting	O
mRNA	O
.	O

It	O
has	O
been	O
demonstrated	O
that	O
miRNA	O
expression	O
is	O
altered	O
in	O
many	O
human	B
cancers	O
,	O
suggesting	O
that	O
they	O
may	O
play	O
a	O
role	O
in	O
human	B
neoplasia	O
.	O

To	O
determine	O
whether	O
miRNA	O
expression	O
is	O
altered	O
in	O
pituitary	O
adenomas	O
,	O
we	O
analyzed	O
the	O
entire	O
miRNAome	O
in	O
32	O
pituitary	O
adenomas	O
and	O
in	O
6	O
normal	O
pituitary	O
samples	O
by	O
microarray	O
and	O
by	O
Real	O
-	O
Time	O
PCR	O
.	O

Here	O
,	O
we	O
show	O
that	O
30	O
miRNAs	O
are	O
differentially	O
expressed	O
between	O
normal	O
pituitary	O
and	O
pituitary	O
adenomas	O
.	O

Moreover	O
,	O
24	O
miRNAs	O
were	O
identified	O
as	O
a	O
predictive	O
signature	O
of	O
pituitary	O
adenoma	O
and	O
29	O
miRNAs	O
were	O
able	O
to	O
predict	O
pituitary	O
adenoma	O
histotype	O
.	O

miRNA	O
expression	O
could	O
differentiate	O
micro-	O
from	O
macro	O
-	O
adenomas	O
and	O
treated	O
from	O
non	O
-	O
treated	O
patient	B
samples	O
.	O

Recent	O
evidence	O
suggests	O
that	O
both	O
development	O
and	O
proper	O
function	O
of	O
central	O
nervous	O
system	O
require	O
intricate	O
spatiotemporal	O
expression	O
of	O
a	O
wide	O
repertoire	O
of	O
small	O
regulatory	O
RNAs	O
.	O

Increasingly	O
complex	O
networks	O
of	O
small	O
RNAs	O
act	O
through	O
RNA	O
interference	O
pathway	O
to	O
regulate	O
gene	O
expression	O
.	O

Small	O
regulatory	O
RNAs	O
in	O
neurodevelopmental	O
disorders	O
.	O

Here	O
,	O
we	O
will	O
review	O
recent	O
progress	O
made	O
toward	O
understanding	O
roles	O
of	O
small	O
regulatory	O
RNAs	O
in	O
neurodevelopmental	O
disorders	O
and	O
discuss	O
the	O
potential	O
involvement	O
of	O
newly	O
discovered	O
classes	O
of	O
small	O
RNAs	O
in	O
these	O
disorders	O
.	O

Misregulation	O
of	O
these	O
small	O
regulatory	O
RNAs	O
could	O
contribute	O
to	O
the	O
abnormalities	O
in	O
brain	O
development	O
that	O
are	O
associated	O
with	O
neurodevelopmental	O
disorders	O
.	O

Comparison	O
of	O
mouse	B
cerebellar	O
development	O
and	O
medulloblastoma	O
demonstrates	O
a	O
shared	O
miRNA	O
-	O
mRNA	O
co	O
-	O
expression	O
program	O
for	O
brain	O
-	O
specific	O
neurologic	O
processes	O
such	O
as	O
synaptic	O
transmission	O
and	O
exocytosis	O
,	O
in	O
which	O
miRNA	O
target	O
expression	O
increases	O
with	O
the	O
accumulation	O
of	O
multiple	O
miRNAs	O
in	O
developing	O
cerebellum	O
and	O
decreases	O
with	O
the	O
loss	O
of	O
these	O
miRNAs	O
in	O
brain	O
tumors	O
.	O

These	O
findings	O
demonstrate	O
the	O
context	O
-	O
dependence	O
of	O
miRNA	O
-	O
mRNA	O
co	O
-	O
expression	O
.	O

Although	O
miRNAs	O
in	O
general	O
suppress	O
target	O
mRNA	O
messages	O
,	O
many	O
predicted	O
miRNA	O
targets	O
demonstrate	O
a	O
significantly	O
higher	O
level	O
of	O
co	O
-	O
expression	O
than	O
non	O
-	O
target	O
genes	O
in	O
developing	O
cerebellum	O
.	O

This	O
phenomenon	O
is	O
tissue	O
specific	O
since	O
it	O
is	O
not	O
observed	O
in	O
developing	O
lungs	O
.	O

Towards	O
that	O
goal	O
,	O
we	O
examined	O
miRNA	O
-	O
mRNA	O
interactions	O
by	O
measuring	O
miRNA	O
and	O
mRNA	O
in	O
the	O
same	O
tissue	O
during	O
development	O
and	O
also	O
in	O
malignant	O
conditions	O
.	O

We	O
identified	O
significant	O
miRNA	O
-	O
mediated	O
biological	O
process	O
categories	O
in	O
developing	O
mouse	B
cerebellum	O
and	O
lung	O
using	O
non	O
-	O
targeted	O
mRNA	O
expression	O
as	O
the	O
negative	O
control	O
.	O

Tissue	O
and	O
process	O
specific	O
microRNA	O
-	O
mRNA	O
co	O
-	O
expression	O
in	O
mammalian	O
development	O
and	O
malignancy	O
.	O

An	O
association	O
between	O
enrichment	O
and	O
depletion	O
of	O
microRNA	O
(	O
miRNA	O
)	O
binding	O
sites	O
,	O
3	O
'	O
UTR	O
length	O
,	O
and	O
mRNA	O
expression	O
has	O
been	O
demonstrated	O
in	O
various	O
developing	O
tissues	O
and	O
tissues	O
from	O
different	O
mature	O
organs	O
;	O
but	O
functional	O
,	O
context	O
-	O
dependent	O
miRNA	O
regulations	O
have	O
yet	O
to	O
be	O
elucidated	O
.	O

These	O
concepts	O
will	O
be	O
explored	O
in	O
this	O
article	O
.	O

This	O
encourages	O
the	O
idea	O
that	O
certain	O
miRs	O
allow	O
continued	O
tumor	O
growth	O
through	O
the	O
suppression	O
of	O
differentiation	O
and	O
the	O
maintenance	O
of	O
the	O
stem	O
cell	O
-	O
like	O
properties	O
of	O
tumor	O
cells	O
.	O

At	O
the	O
same	O
time	O
,	O
it	O
has	O
become	O
clear	O
that	O
one	O
of	O
the	O
major	O
roles	O
that	O
microRNAs	O
play	O
is	O
in	O
the	O
regulation	O
of	O
stem	O
cell	O
biology	O
,	O
differentiation	O
,	O
and	O
cell	O
'	O
identity	O
'	O
.	O

Recent	O
data	O
draw	O
close	O
parallels	O
between	O
cancer	O
,	O
including	O
glial	O
brain	O
tumors	O
,	O
and	O
the	O
biology	O
of	O
stem	O
and	O
progenitor	O
cells	O
.	O

Interestingly	O
,	O
initial	O
studies	O
in	O
the	O
incurable	O
brain	O
tumor	O
glioblastoma	O
multiforme	O
strongly	O
suggest	O
that	O
microRNAs	O
involved	O
in	O
neural	O
development	O
play	O
a	O
role	O
in	O
this	O
disease	O
.	O

For	O
example	O
,	O
microRNAs	O
have	O
been	O
increasingly	O
implicated	O
in	O
the	O
regulation	O
of	O
neural	O
differentiation	O
.	O

MicroRNAs	O
and	O
glioblastoma	O
;	O
the	O
stem	O
cell	O
connection	O
.	O

MiRNAs	O
may	O
be	O
a	O
new	O
therapeutic	O
target	O
for	O
proliferative	O
vascular	O
diseases	O
such	O
as	O
atherosclerosis	O
,	O
postangioplasty	O
restenosis	O
,	O
transplantation	O
arteriopathy	O
,	O
and	O
stroke	O
.	O

The	O
results	O
suggest	O
that	O
miRNAs	O
are	O
novel	O
regulatory	O
RNAs	O
for	O
neointimal	O
lesion	O
formation	O
.	O

MicroRNAs	O
(	O
miRNAs	O
)	O
are	O
a	O
recently	O
discovered	O
class	O
of	O
endogenous	O
,	O
small	O
,	O
noncoding	O
RNAs	O
that	O
regulate	O
about	O
30	O
%	O
of	O
the	O
encoding	O
genes	O
of	O
the	O
human	B
genome	O
.	O

MicroRNA	O
expression	O
signature	O
and	O
antisense	O
-	O
mediated	O
depletion	O
reveal	O
an	O
essential	O
role	O
of	O
MicroRNA	O
in	O
vascular	O
neointimal	O
lesion	O
formation	O
.	O

Western	O
blot	O
analysis	O
demonstrated	O
that	O
PTEN	O
and	O
Bcl-2	O
were	O
involved	O
in	O
miR-21-mediated	O
cellular	O
effects	O
.	O

MiR-21-mediated	O
cellular	O
effects	O
were	O
further	O
confirmed	O
in	O
vivo	O
in	O
balloon	O
-	O
injured	O
rat	B
carotid	O
arteries	O
.	O

Depletion	O
of	O
miR-21	O
resulted	O
in	O
decreased	O
cell	O
proliferation	O
and	O
increased	O
cell	O
apoptosis	O
in	O
a	O
dose	O
-	O
dependent	O
manner	O
.	O

In	O
vitro	O
,	O
the	O
expression	O
level	O
of	O
miR-21	O
in	O
dedifferentiated	O
vascular	O
smooth	O
muscle	O
cells	O
was	O
significantly	O
higher	O
than	O
that	O
in	O
fresh	O
isolated	O
differentiated	O
cells	O
.	O

Modulating	O
an	O
aberrantly	O
overexpressed	O
miRNA	O
,	O
miR-21	O
,	O
via	O
antisense	O
-	O
mediated	O
depletion	O
(	O
knock	O
-	O
down	O
)	O
had	O
a	O
significant	O
negative	O
effect	O
on	O
neointimal	O
lesion	O
formation	O
.	O

The	O
aberrantly	O
expressed	O
miRNAs	O
were	O
further	O
confirmed	O
by	O
Northern	O
blot	O
and	O
quantitative	O
real	O
-	O
time	O
polymerase	O
chain	O
reaction	O
.	O

Using	O
microarray	O
analysis	O
,	O
we	O
demonstrated	O
for	O
the	O
first	O
time	O
that	O
miRNAs	O
are	O
aberrantly	O
expressed	O
in	O
the	O
vascular	O
walls	O
after	O
balloon	O
injury	O
.	O

However	O
,	O
the	O
role	O
of	O
miRNAs	O
in	O
vascular	O
disease	O
is	O
currently	O
completely	O
unknown	O
.	O

MicroRNA-223	O
expression	O
in	O
neutrophils	O
in	O
the	O
early	O
phase	O
of	O
secondary	O
damage	O
after	O
spinal	O
cord	O
injury	O
.	O

MicroRNA	O
(	O
miR	O
)	O
s	O
are	O
short	O
non	O
-	O
coding	O
RNAs	O
that	O
suppress	O
the	O
translation	O
of	O
target	O
genes	O
,	O
and	O
play	O
an	O
important	O
role	O
in	O
gene	O
regulation	O
.	O

Despite	O
this	O
prominence	O
,	O
there	O
are	O
few	O
reports	O
that	O
refer	O
to	O
the	O
expression	O
of	O
miRs	O
after	O
spinal	O
cord	O
injury	O
(	O
SCI	O
)	O
.	O

Previously	O
,	O
we	O
reported	O
on	O
miR-223	O
expression	O
after	O
SCI	O
in	O
mice	B
.	O

The	O
purpose	O
of	O
this	O
study	O
is	O
to	O
reveal	O
the	O
distribution	O
of	O
miR-223	O
and	O
identify	O
the	O
cells	O
that	O
express	O
miR-223	O
in	O
the	O
injured	O
spinal	O
cord	O
.	O

Quantitative	O
polymerase	O
chain	O
reaction	O
analysis	O
revealed	O
high	O
expression	O
of	O
miR-223	O
at	O
12h	O
after	O
SCI	O
.	O
Double	O
staining	O
of	O
in	O
situ	O
hybridization	O
and	O
immunohistochemistry	O
showed	O
that	O
the	O
signals	O
of	O
miR-223	O
merged	O
with	O
Gr-1	O
positive	O
neutrophils	O
.	O

Our	O
data	O
indicate	O
that	O
miR-223	O
might	O
regulate	O
neutrophils	O
in	O
the	O
early	O
phase	O
after	O
SCI	O
.	O

Point	O
mutations	O
in	O
exon	O
1	O
of	O
the	O
NR4A2	O
gene	O
are	O
not	O
a	O
major	O
cause	O
of	O
familial	O
Parkinson	O
's	O
disease	O
.	O

Our	O
results	O
suggest	O
that	O
miR-124a	O
may	O
play	O
a	O
role	O
in	O
GBM	O
migration	O
,	O
and	O
that	O
targeted	O
delivery	O
of	O
miR-124a	O
may	O
be	O
a	O
novel	O
inhibitor	O
of	O
GBM	O
invasion	O
.	O

Glioblastoma	O
(	O
GBM	O
)	O
represents	O
a	O
formidable	O
clinical	O
challenge	O
for	O
both	O
patients	B
and	O
treating	O
physicians	O
.	O

Due	O
to	O
better	O
local	O
treatments	O
and	O
prolonged	O
patient	B
survival	O
,	O
remote	O
recurrences	O
are	O
increasingly	O
observed	O
,	O
underpinning	O
the	O
importance	O
of	O
targeting	O
tumour	O
migration	O
and	O
attachment	O
.	O

Aberrant	O
expression	O
of	O
microRNA	O
(	O
miRNA	O
)	O
is	O
commonly	O
associated	O
with	O
cancer	O
and	O
loss	O
of	O
miR-124a	O
has	O
previously	O
been	O
implicated	O
to	O
function	O
as	O
a	O
tumour	O
suppressor	O
.	O

The	O
assessment	O
of	O
miR-124a	O
in	O
clinical	O
specimens	O
has	O
been	O
limited	O
and	O
a	O
potential	O
role	O
in	O
migration	O
and	O
invasion	O
has	O
been	O
unexplored	O
until	O
now	O
.	O

We	O
measured	O
the	O
expression	O
levels	O
of	O
mature	O
miR-124a	O
in	O
a	O
retrospective	O
series	O
of	O
119	O
cases	O
of	O
histologically	O
confirmed	O
GBM	O
and	O
found	O
its	O
expression	O
was	O
markedly	O
lower	O
in	O
over	O
80	O
%	O
of	O
the	O
GBM	O
clinical	O
specimens	O
compared	O
to	O
normal	O
brain	O
tissue	O
.	O

The	O
level	O
of	O
reduction	O
in	O
the	O
clinical	O
cohort	O
varied	O
significantly	O
and	O
patients	B
with	O
lower	O
than	O
the	O
average	O
miR-124a	O
expression	O
levels	O
displayed	O
shorter	O
survival	O
times	O
.	O

Endogenous	O
miR-124a	O
expression	O
and	O
the	O
protein	O
expression	O
of	O
three	O
of	O
its	O
targets	O
;	O
IQ	O
motif	O
containing	O
GTPase	O
activating	O
protein	O
1	O
(	O
IQGAP1	O
)	O
,	O
laminin	O
γ1	O
(	O
LAMC1	O
)	O
and	O
integrin	O
β1	O
(	O
ITGB1	O
)	O
were	O
significantly	O
reciprocally	O
associated	O
in	O
the	O
majority	O
of	O
the	O
clinical	O
cases	O
.	O

We	O
confirmed	O
this	O
association	O
in	O
our	O
in	O
vitro	O
model	O
.	O

miR-124a	O
is	O
frequently	O
down	O
-	O
regulated	O
in	O
glioblastoma	O
and	O
is	O
involved	O
in	O
migration	O
and	O
invasion	O
.	O

Functionally	O
,	O
the	O
ectopic	O
expression	O
of	O
mature	O
miR-124a	O
in	O
a	O
GBM	O
cell	O
line	O
resulted	O
in	O
significant	O
inhibition	O
of	O
migration	O
and	O
invasion	O
,	O
demonstrating	O
a	O
role	O
for	O
miR-124a	O
in	O
promoting	O
tumour	O
invasiveness	O
.	O

In	O
a	O
pilot	O
study	O
we	O
could	O
show	O
that	O
hsa	O
-	O
miR-342	O
-	O
3p	O
was	O
also	O
upregulated	O
in	O
brain	O
samples	O
of	O
human	B
type	O
1	O
and	O
type	O
2	O
sporadic	O
CJD	O
.	O

Our	O
study	O
revealed	O
significant	O
upregulation	O
of	O
hsa	O
-	O
miR-342	O
-	O
3p	O
and	O
hsa	O
-	O
miR-494	O
in	O
the	O
brains	O
of	O
BSE	O
-	O
infected	O
macaques	O
compared	O
to	O
non	O
-	O
infected	O
animals	O
.	O

Shock	O
-	O
frozen	O
brain	O
sections	O
of	O
six	O
BSE	O
-	O
infected	O
and	O
five	O
non	O
-	O
infected	O
macaques	O
were	O
used	O
to	O
validate	O
regulated	O
miRNA	O
candidates	O
by	O
two	O
independent	O
qRT	O
-	O
PCR	O
-	O
based	O
methods	O
.	O

We	O
have	O
applied	O
miRNA	O
-	O
microarrays	O
to	O
identify	O
deregulated	O
miRNA	O
candidates	O
in	O
brains	O
of	O
BSE	O
-	O
infected	O
macaques	O
.	O

Therefore	O
,	O
we	O
hypothesized	O
that	O
miRNAs	O
are	O
also	O
regulated	O
in	O
response	O
to	O
human	B
prion	O
disease	O
.	O

Among	O
other	O
functions	O
they	O
contribute	O
to	O
neuronal	O
development	O
and	O
survival	O
.	O

Recently	O
,	O
the	O
lack	O
of	O
miRNA	O
processing	O
has	O
been	O
shown	O
to	O
promote	O
neurodegeneration	O
and	O
deregulation	O
of	O
several	O
miRNAs	O
has	O
been	O
reported	O
to	O
be	O
associated	O
with	O
Scrapie	O
in	O
mice	B
.	O

ABSTRACT	O
:	O
The	O
aim	O
of	O
our	O
study	O
was	O
to	O
analyze	O
the	O
differential	O
expression	O
of	O
miRNAs	O
in	O
the	O
brains	O
of	O
BSE	O
-	O
infected	O
cynomolgus	O
macaques	O
as	O
a	O
model	O
for	O
Creutzfeldt	O
-	O
Jakob	O
disease	O
(	O
CJD	O
)	O
.	O

MicroRNAs	O
(	O
miRNAs	O
)	O
are	O
small	O
noncoding	O
RNAs	O
regulating	O
gene	O
expression	O
by	O
mRNA	O
targeting	O
.	O

Upregulation	O
of	O
miRNA	O
hsa	O
-	O
miR-342	O
-	O
3p	O
in	O
experimental	O
and	O
idiopathic	O
prion	O
disease	O
.	O

With	O
respect	O
to	O
the	O
reported	O
regulation	O
of	O
this	O
miRNA	O
in	O
Scrapie	O
-	O
infected	O
mice	B
,	O
we	O
propose	O
that	O
upregulation	O
of	O
hsa	O
-	O
miR-342	O
-	O
3p	O
may	O
be	O
a	O
general	O
phenomenon	O
in	O
late	O
stage	O
prion	O
disease	O
and	O
might	O
be	O
used	O
as	O
a	O
novel	O
marker	O
for	O
animal	O
and	O
human	B
TSEs	O
.	O

A	O
specific	O
miRNA	O
signature	O
in	O
the	O
peripheral	O
blood	O
of	O
glioblastoma	O
patients	B
.	O

Biomarkers	O
for	O
the	O
disease	O
would	O
be	O
desirable	O
in	O
order	O
to	O
allow	O
for	O
an	O
early	O
detection	O
of	O
tumor	O
progression	O
or	O
to	O
indicate	O
rapidly	O
growing	O
tumor	O
subtypes	O
requiring	O
more	O
intensive	O
therapy	O
.	O

The	O
prognosis	O
of	O
patients	B
afflicted	O
by	O
glioblastoma	O
remains	O
poor	O
.	O

To	O
this	O
end	O
,	O
miRNA	O
profiles	O
from	O
the	O
blood	O
of	O
20	O
patients	B
with	O
glioblastoma	O
and	O
20	O
age-	O
and	O
sex	O
-	O
matched	O
healthy	O
controls	O
were	O
compared	O
.	O

In	O
this	O
study	O
,	O
we	O
investigated	O
whether	O
a	O
blood	O
-	O
derived	O
specific	O
miRNA	O
fingerprint	O
can	O
be	O
defined	O
in	O
patients	B
with	O
glioblastoma	O
.	O

Of	O
these	O
,	O
two	O
candidates	O
,	O
miR-128	O
(	O
up	O
-	O
regulated	O
)	O
and	O
miR-342	O
-	O
3p	O
(	O
down	O
-	O
regulated	O
)	O
,	O
remained	O
significant	O
after	O
correcting	O
for	O
multiple	O
testing	O
by	O
Benjamini	O
-	O
Hochberg	O
adjustment	O
with	O
a	O
p	O
-	O
value	O
of	O
0.025	O
.	O

Of	O
1158	O
tested	O
miRNAs	O
,	O
52	O
were	O
significantly	O
deregulated	O
,	O
as	O
assessed	O
by	O
unadjusted	O
Student	O
's	O
t	O
-	O
test	O
at	O
an	O
alpha	O
level	O
of	O
0.05	O
.	O

The	O
altered	O
expression	O
of	O
these	O
two	O
biomarkers	O
was	O
confirmed	O
in	O
a	O
second	O
cohort	O
of	O
glioblastoma	O
patients	B
and	O
healthy	O
controls	O
by	O
real	O
-	O
time	O
PCR	O
and	O
validated	O
for	O
patients	B
who	O
had	O
received	O
neither	O
radio-	O
nor	O
chemotherapy	O
and	O
for	O
patients	B
who	O
had	O
their	O
glioblastomas	O
resected	O
more	O
than	O
6	O
months	O
ago	O
.	O

Moreover	O
,	O
using	O
machine	O
learning	O
,	O
a	O
comprehensive	O
miRNA	O
signature	O
was	O
obtained	O
that	O
allowed	O
for	O
the	O
discrimination	O
between	O
blood	O
samples	O
of	O
glioblastoma	O
patients	B
and	O
healthy	O
controls	O
with	O
an	O
accuracy	O
of	O
81	O
%	O
[	O
95	O
%	O
confidence	O
interval	O
(	O
CI	O
)	O
78	O
-	O
84	O
%	O
]	O
,	O
specificity	O
of	O
79	O
%	O
(	O
95	O
%	O
CI	O
75	O
-	O
83	O
%	O
)	O
and	O
sensitivity	O
of	O
83	O
%	O
(	O
95	O
%	O
CI	O
71	O
-	O
85	O
%	O
)	O
.	O

In	O
summary	O
,	O
our	O
proof	O
-	O
of	O
-	O
concept	O
study	O
demonstrates	O
that	O
blood	O
-	O
derived	O
glioblastoma	O
-	O
associated	O
characteristic	O
miRNA	O
fingerprints	O
may	O
be	O
suitable	O
biomarkers	O
and	O
warrant	O
further	O
exploration	O
.	O

Knockdown	O
of	O
miR-21	O
in	O
cultured	O
glioblastoma	O
cells	O
triggers	O
activation	O
of	O
caspases	O
and	O
leads	O
to	O
increased	O
apoptotic	O
cell	O
death	O
.	O

Our	O
studies	O
show	O
markedly	O
elevated	O
miR-21	O
levels	O
in	O
human	B
glioblastoma	O
tumor	O
tissues	O
,	O
early	O
-	O
passage	O
glioblastoma	O
cultures	O
,	O
and	O
in	O
six	O
established	O
glioblastoma	O
cell	O
lines	O
(	O
A172	O
,	O
U87	O
,	O
U373	O
,	O
LN229	O
,	O
LN428	O
,	O
and	O
LN308	O
)	O
compared	O
with	O
nonneoplastic	O
fetal	O
and	O
adult	O
brain	O
tissues	O
and	O
compared	O
with	O
cultured	O
nonneoplastic	O
glial	O
cells	O
.	O

Our	O
data	O
suggest	O
that	O
aberrantly	O
expressed	O
miR-21	O
may	O
contribute	O
to	O
the	O
malignant	O
phenotype	O
by	O
blocking	O
expression	O
of	O
critical	O
apoptosis	O
-	O
related	O
genes	O
.	O

MicroRNAs	O
(	O
miRNAs	O
)	O
are	O
small	O
noncoding	O
RNA	O
molecules	O
that	O
regulate	O
protein	O
expression	O
by	O
targeting	O
the	O
mRNA	O
of	O
protein	O
-	O
coding	O
genes	O
for	O
either	O
cleavage	O
or	O
repression	O
of	O
translation	O
.	O

MicroRNA-21	O
is	O
an	O
antiapoptotic	O
factor	O
in	O
human	B
glioblastoma	O
cells	O
.	O

Here	O
we	O
show	O
that	O
the	O
highly	O
malignant	O
human	B
brain	O
tumor	O
,	O
glioblastoma	O
,	O
strongly	O
over	O
-	O
expresses	O
a	O
specific	O
miRNA	O
,	O
miR-21	O
.	O

The	O
roles	O
of	O
miRNAs	O
in	O
lineage	O
determination	O
and	O
proliferation	O
as	O
well	O
as	O
the	O
location	O
of	O
several	O
miRNA	O
genes	O
at	O
sites	O
of	O
translocation	O
breakpoints	O
or	O
deletions	O
has	O
led	O
to	O
the	O
speculation	O
that	O
miRNAs	O
could	O
be	O
important	O
factors	O
in	O
the	O
development	O
or	O
maintenance	O
of	O
the	O
neoplastic	O
state	O
.	O

The	O
study	O
of	O
this	O
novel	O
layer	O
of	O
gene	O
regulation	O
therefore	O
promises	O
to	O
enrich	O
our	O
knowledge	O
of	O
brain	O
function	O
and	O
pathology	O
.	O

MiRNAs	O
function	O
at	O
all	O
stages	O
of	O
neuronal	O
development	O
,	O
ranging	O
from	O
the	O
initial	O
specification	O
of	O
neuronal	O
cell	O
types	O
to	O
the	O
formation	O
and	O
plasticity	O
of	O
synaptic	O
connections	O
between	O
individual	O
neurons	O
.	O

Moreover	O
,	O
links	O
between	O
miRNA	O
dysfunction	O
and	O
neurological	O
diseases	O
become	O
more	O
and	O
more	O
apparent	O
.	O

The	O
development	O
and	O
function	O
of	O
the	O
nervous	O
system	O
is	O
orchestrated	O
by	O
a	O
plethora	O
of	O
gene	O
regulatory	O
mechanisms	O
.	O

MicroRNAs	O
(	O
miRNAs	O
)	O
,	O
an	O
abundant	O
class	O
of	O
small	O
non	O
-	O
coding	O
RNAs	O
,	O
are	O
emerging	O
as	O
important	O
post	O
-	O
transcriptional	O
regulators	O
of	O
gene	O
expression	O
in	O
the	O
brain	O
.	O

MicroRNA	O
function	O
in	O
neuronal	O
development	O
,	O
plasticity	O
and	O
disease	O
.	O

METHODS	O
:	O
We	O
prospectively	O
collected	O
surgical	O
outcome	O
data	O
for	O
2	O
to	O
11	O
years	O
for	O
134	O
consecutive	O
patients	B
who	O
specifically	O
had	O
MTLE	O
and	O
unilateral	O
HS	O
,	O
according	O
to	O
magnetic	O
resonance	O
imaging	O
(	O
MRI	O
)	O
and	O
confirmed	O
by	O
histopathology	O
.	O

PURPOSE	O
:	O
Surgical	O
results	O
in	O
patients	B
with	O
mesial	O
temporal	O
lobe	O
epilepsy	O
due	O
to	O
hippocampal	O
sclerosis	O
(	O
MTLE	O
/	O
HS	O
)	O
are	O
often	O
reported	O
in	O
conjunction	O
with	O
other	O
etiologies	O
of	O
TLE	O
.	O

Survival	O
analysis	O
of	O
the	O
surgical	O
outcome	O
of	O
temporal	O
lobe	O
epilepsy	O
due	O
to	O
hippocampal	O
sclerosis	O
.	O

Of	O
the	O
patients	B
tested	O
,	O
26	O
%	O
of	O
those	O
operated	O
on	O
the	O
left	O
side	O
and	O
22	O
%	O
of	O
those	O
operated	O
on	O
the	O
right	O
had	O
postoperative	O
decline	O
of	O
>	O
1	O
SD	O
in	O
verbal	O
or	O
visual	O
memory	O
,	O
respectively	O
.	O

CONCLUSIONS	O
:	O
High	O
rates	O
of	O
seizure	O
freedom	O
can	O
be	O
obtained	O
and	O
remain	O
stable	O
over	O
the	O
years	O
in	O
patients	B
operated	O
on	O
for	O
unilateral	O
MTLE	O
/	O
HS	O
,	O
even	O
in	O
countries	O
with	O
limited	O
resources	O
.	O

RESULTS	O
:	O
Kaplan	O
-	O
Meier	O
estimates	O
of	O
complete	O
seizure	O
freedom	O
(	O
Engel	O
's	O
class	O
IA	O
)	O
for	O
years	O
1	O
,	O
2	O
,	O
5	O
,	O
and	O
10	O
were	O
85	O
%	O
,	O
77	O
%	O
,	O
74	O
%	O
,	O
and	O
66	O
%	O
,	O
and	O
of	O
Engel	O
's	O
class	O
I	O
were	O
89	O
%	O
,	O
86	O
%	O
,	O
83	O
%	O
,	O
and	O
81	O
%	O
.	O

Only	O
nine	O
(	O
6.7	O
%	O
)	O
patients	B
had	O
outcome	O
classes	O
III	O
or	O
IV	O
at	O
any	O
point	O
during	O
follow	O
-	O
up	O
.	O

Sixty	O
-	O
five	O
had	O
postoperative	O
neuropsychological	O
testing	O
.	O

Outcome	O
was	O
analyzed	O
by	O
using	O
Engel	O
's	O
classification	O
(	O
a	O
)	O
through	O
Kaplan	O
-	O
Meier	O
estimated	O
survival	O
curves	O
(	O
as	O
a	O
function	O
of	O
the	O
time	O
to	O
seizure	O
recurrence	O
)	O
,	O
(	O
b	O
)	O
as	O
percentage	O
of	O
patients	B
in	O
each	O
outcome	O
class	O
on	O
a	O
yearly	O
basis	O
,	O
and	O
(	O
c	O
)	O
at	O
the	O
last	O
updated	O
follow	O
-	O
up	O
.	O

The	O
clinical	O
relevance	O
of	O
our	O
findings	O
was	O
evaluated	O
in	O
HIV	O
-	O
encephalitis	O
(	O
HIVE	O
)	O
brain	O
samples	O
in	O
which	O
decreased	O
levels	O
of	O
MCP-2	O
and	O
increased	O
levels	O
of	O
mir-146a	O
were	O
observed	O
,	O
suggesting	O
a	O
role	O
for	O
mir-146a	O
in	O
the	O
maintenance	O
of	O
HIV	O
-	O
mediated	O
chronic	O
inflammation	O
of	O
the	O
brain	O
.	O

We	O
further	O
show	O
that	O
CCL8	O
/	O
MCP-2	O
is	O
a	O
target	O
for	O
mir-146a	O
in	O
HIV-1	O
infected	O
microglia	O
,	O
as	O
overexpression	O
of	O
mir-146a	O
prevented	O
HIV	O
-	O
induced	O
secretion	O
of	O
MCP-2	O
chemokine	O
.	O

In	O
the	O
present	O
study	O
,	O
we	O
have	O
analyzed	O
changes	O
in	O
the	O
expression	O
of	O
mir-146a	O
in	O
primary	O
human	B
fetal	O
microglial	O
cells	O
upon	O
infection	O
with	O
HIV-1	O
and	O
found	O
increased	O
expression	O
of	O
mir-146a	O
.	O

MicroRNA	O
-	O
mediated	O
regulation	O
of	O
gene	O
expression	O
appears	O
to	O
be	O
involved	O
in	O
a	O
variety	O
of	O
cellular	O
processes	O
,	O
including	O
development	O
,	O
differentiation	O
,	O
proliferation	O
,	O
and	O
apoptosis	O
.	O

CCL8	O
/	O
MCP-2	O
is	O
a	O
target	O
for	O
mir-146a	O
in	O
HIV-1-infected	O
human	O
microglial	O
cells	O
.	O

Among	O
the	O
predicted	O
gene	O
targets	O
for	O
mir-146a	O
,	O
the	O
chemokine	O
CCL8	O
/	O
MCP-2	O
is	O
a	O
ligand	O
for	O
the	O
CCR5	O
chemokine	O
receptor	O
and	O
a	O
potent	O
inhibitor	O
of	O
CD4	O
/	O
CCR5-mediated	O
HIV-1	O
entry	O
and	O
replication	O
.	O

Mir-146a	O
is	O
thought	O
to	O
be	O
involved	O
in	O
the	O
regulation	O
of	O
the	O
innate	O
immune	O
response	O
,	O
and	O
its	O
expression	O
is	O
increased	O
in	O
tissues	O
associated	O
with	O
chronic	O
inflammation	O
.	O

Key	O
microRNAs	O
have	O
been	O
identified	O
as	O
essential	O
for	O
a	O
variety	O
of	O
cellular	O
events	O
including	O
cell	O
lineage	O
determination	O
,	O
proliferation	O
,	O
apoptosis	O
,	O
DNA	O
repair	O
,	O
and	O
cytoskeletal	O
organization	O
;	O
most	O
,	O
if	O
not	O
all	O
,	O
acting	O
to	O
fine	O
-	O
tune	O
gene	O
expression	O
at	O
the	O
post	O
-	O
transcriptional	O
level	O
in	O
a	O
host	O
of	O
cellular	O
signaling	O
networks	O
.	O

Their	O
discovery	O
has	O
evoked	O
great	O
excitement	O
in	O
biomedical	O
research	O
for	O
their	O
promise	O
as	O
potential	O
disease	O
biomarkers	O
and	O
therapeutic	O
targets	O
.	O

MicroRNAs	O
are	O
one	O
of	O
the	O
major	O
noncoding	O
RNAs	O
that	O
function	O
as	O
negative	O
regulators	O
to	O
silence	O
or	O
suppress	O
gene	O
expression	O
via	O
translational	O
inhibition	O
or	O
message	O
degradation	O
.	O

Unlike	O
the	O
familial	O
forms	O
of	O
AD	O
,	O
the	O
genetic	O
and	O
environmental	O
risks	O
factors	O
identified	O
for	O
sporadic	O
AD	O
are	O
extensive	O
.	O

Understanding	O
complex	O
diseases	O
such	O
as	O
sporadic	O
Alzheimer	O
disease	O
(	O
AD	O
)	O
has	O
been	O
a	O
major	O
challenge	O
.	O

MicroRNA	O
:	O
Implications	O
for	O
Alzheimer	O
Disease	O
and	O
other	O
Human	B
CNS	O
Disorders	O
.	O

Here	O
,	O
the	O
current	O
understanding	O
of	O
the	O
role	O
of	O
miRNAs	O
in	O
the	O
central	O
nervous	O
system	O
is	O
reviewed	O
with	O
emphasis	O
on	O
their	O
impact	O
on	O
the	O
etiopathogenesis	O
of	O
sporadic	O
AD	O
.	O

Dysfunctional	O
microRNA	O
-	O
mediated	O
regulation	O
has	O
been	O
implicated	O
in	O
the	O
pathogenesis	O
of	O
many	O
disease	O
states	O
.	O

We	O
explored	O
the	O
role	O
of	O
microRNAs	O
(	O
miRNAs	O
)	O
in	O
glioma	O
progression	O
by	O
investigating	O
the	O
expression	O
profiles	O
of	O
157	O
miRNAs	O
in	O
four	O
patients	B
with	O
primary	O
WHO	O
grade	O
II	O
gliomas	O
that	O
spontaneously	O
progressed	O
to	O
WHO	O
grade	O
IV	O
secondary	O
glioblastomas	O
.	O

Thereby	O
,	O
we	O
identified	O
12	O
miRNAs	O
(	O
miR-9	O
,	O
miR-15a	O
,	O
miR-16	O
,	O
miR-17	O
,	O
miR-19a	O
,	O
miR-20a	O
,	O
miR-21	O
,	O
miR-25	O
,	O
miR-28	O
,	O
miR-130b	O
,	O
miR-140	O
and	O
miR-210	O
)	O
showing	O
increased	O
expression	O
,	O
and	O
two	O
miRNAs	O
(	O
miR-184	O
and	O
miR-328	O
)	O
showing	O
reduced	O
expression	O
upon	O
progression	O
.	O

Identification	O
and	O
functional	O
characterization	O
of	O
microRNAs	O
involved	O
in	O
the	O
malignant	O
progression	O
of	O
gliomas	O
.	O

Diffuse	O
astrocytoma	O
of	O
World	O
Health	O
Organization	O
(	O
WHO	O
)	O
grade	O
II	O
has	O
an	O
inherent	O
tendency	O
to	O
spontaneously	O
progress	O
to	O
anaplastic	O
astrocytoma	O
WHO	O
grade	O
III	O
or	O
secondary	O
glioblastoma	O
WHO	O
grade	O
IV	O
.	O

Taken	O
together	O
,	O
our	O
results	O
support	O
an	O
important	O
role	O
of	O
altered	O
miRNA	O
expression	O
in	O
gliomas	O
,	O
and	O
suggest	O
miR-17	O
and	O
miR-184	O
as	O
interesting	O
candidates	O
contributing	O
to	O
glioma	O
progression	O
.	O

Using	O
mRNA	O
and	O
protein	O
expression	O
profiling	O
,	O
we	O
identified	O
distinct	O
sets	O
of	O
transcripts	O
and	O
proteins	O
that	O
were	O
differentially	O
expressed	O
after	O
inhibition	O
of	O
miR-17	O
or	O
overexpression	O
of	O
miR-184	O
in	O
glioma	O
cells	O
.	O

These	O
studies	O
revealed	O
miRNA	O
-	O
specific	O
influences	O
on	O
the	O
viability	O
,	O
proliferation	O
,	O
apoptosis	O
and	O
invasive	O
growth	O
properties	O
of	O
A172	O
and	O
T98	O
G	O
glioma	O
cells	O
in	O
vitro	O
.	O

Validation	O
experiments	O
on	O
independent	O
series	O
of	O
primary	O
low	O
-	O
grade	O
and	O
secondary	O
high	O
-	O
grade	O
astrocytomas	O
confirmed	O
miR-17	O
and	O
miR-184	O
as	O
promising	O
candidates	O
,	O
which	O
were	O
selected	O
for	O
functional	O
analyses	O
.	O

MicroRNAs	O
(	O
miRNAs	O
)	O
in	O
neurodegenerative	O
diseases	O
.	O

Prior	O
studies	O
have	O
shown	O
that	O
RNAs	O
are	O
pathologically	O
altered	O
during	O
the	O
inexorable	O
course	O
of	O
some	O
NDs	O
.	O

Aging	O
-	O
related	O
neurodegenerative	O
diseases	O
(	O
NDs	O
)	O
are	O
the	O
culmination	O
of	O
many	O
different	O
genetic	O
and	O
environmental	O
influences	O
.	O

miRNAs	O
are	O
brain	O
-	O
enriched	O
,	O
small	O
(	O
approximately	O
22	O
nucleotides	O
)	O
non	O
-	O
coding	O
RNAs	O
that	O
participate	O
in	O
mRNA	O
translational	O
regulation	O
.	O

Recent	O
evidence	O
suggests	O
that	O
microRNAs	O
(	O
miRNAs	O
)	O
may	O
be	O
a	O
contributing	O
factor	O
in	O
neurodegeneration	O
.	O

Research	O
about	O
miRNAs	O
in	O
the	O
context	O
of	O
neurodegeneration	O
is	O
accumulating	O
rapidly	O
,	O
and	O
the	O
goal	O
of	O
this	O
review	O
is	O
to	O
provide	O
perspective	O
for	O
these	O
new	O
data	O
that	O
may	O
be	O
helpful	O
to	O
specialists	O
in	O
either	O
field	O
.	O

Although	O
discovered	O
in	O
the	O
framework	O
of	O
worm	O
development	O
,	O
miRNAs	O
are	O
now	O
appreciated	O
to	O
play	O
a	O
dynamic	O
role	O
in	O
many	O
mammalian	O
brain	O
-	O
related	O
biochemical	O
pathways	O
,	O
including	O
neuroplasticity	O
and	O
stress	O
responses	O
.	O

Recently	O
published	O
studies	O
pertaining	O
to	O
the	O
roles	O
of	O
miRNAs	O
in	O
NDs	O
--	O
including	O
Alzheimer	O
's	O
disease	O
,	O
Parkinson	O
's	O
disease	O
and	O
triplet	O
repeat	O
disorders	O
-	O
are	O
described	O
.	O

An	O
overview	O
is	O
provided	O
about	O
the	O
normal	O
functions	O
for	O
miRNAs	O
,	O
including	O
some	O
of	O
the	O
newer	O
concepts	O
related	O
to	O
the	O
human	B
brain	O
.	O

Finally	O
,	O
a	O
discussion	O
is	O
included	O
with	O
theoretical	O
syntheses	O
and	O
possible	O
future	O
directions	O
in	O
exploring	O
the	O
nexus	O
between	O
miRNA	O
and	O
ND	O
research	O
.	O

MicroRNA-328	O
(	O
miR-328	O
)	O
is	O
underexpressed	O
in	O
many	O
cancers	O
including	O
glioblastoma	O
multiforme	O
and	O
contributes	O
to	O
tumor	O
resistance	O
to	O
chemotherapy	O
.	O

MicroRNAs	O
control	O
a	O
wide	O
array	O
of	O
biological	O
processes	O
(	O
e.g.	O
,	O
cell	O
differentiation	O
,	O
proliferation	O
and	O
apoptosis	O
)	O
whose	O
dysregulation	O
is	O
a	O
hallmark	O
of	O
cancer	O
.	O

ABCG2	O
,	O
which	O
encodes	O
an	O
ATP	O
-	O
binding	O
cassette	O
transporter	O
protein	O
,	O
is	O
associated	O
with	O
the	O
phenotype	O
of	O
cancer	O
stem	O
cells	O
and	O
is	O
used	O
to	O
define	O
the	O
pluripotential	O
side	O
population	O
cells	O
by	O
flow	O
cytometry	O
and	O
slide	O
-	O
cytometry	O
.	O

Downregulation	O
of	O
ABCG2	O
expression	O
in	O
glioblastoma	O
cancer	O
stem	O
cells	O
with	O
miRNA-328	O
may	O
decrease	O
their	O
chemoresistance	O
.	O

Thus	O
,	O
we	O
hypothesize	O
that	O
modulating	O
ABCG2	O
expression	O
by	O
targeting	O
miRNA-328	O
in	O
glioblastoma	O
cancer	O
stem	O
cells	O
could	O
represent	O
a	O
promising	O
strategy	O
for	O
therapeutic	O
manipulation	O
to	O
increase	O
the	O
efficacy	O
of	O
chemotherapeutic	O
agents	O
for	O
glioblastoma	O
,	O
a	O
highly	O
lethal	O
type	O
of	O
cancer	O
.	O

ABCG2	O
is	O
associated	O
with	O
multi	O
-	O
drug	O
resistance	O
and	O
is	O
also	O
highly	O
expressed	O
in	O
glioblastoma	O
.	O

Some	O
preliminary	O
studies	O
have	O
shown	O
that	O
ABCG2	O
is	O
the	O
target	O
gene	O
for	O
miRNA-328	O
.	O

Traumatic	O
brain	O
injury	O
(	O
TBI	O
)	O
initiates	O
many	O
different	O
signaling	O
cascades	O
throughout	O
the	O
brain	O
that	O
impact	O
both	O
pathophysiological	O
and	O
neuroprotective	O
processes	O
.	O

Altered	O
expression	O
of	O
miRNA-21	O
and	O
its	O
targets	O
in	O
the	O
hippocampus	O
after	O
traumatic	O
brain	O
injury	O
.	O

In	O
situ	O
localization	O
of	O
miR-21	O
transcripts	O
indicates	O
widespread	O
expression	O
in	O
normal	O
brain	O
,	O
with	O
a	O
pronounced	O
increase	O
in	O
expression	O
after	O
TBI	O
evident	O
throughout	O
the	O
cortex	O
and	O
hippocampus	O
,	O
including	O
the	O
dentate	O
gyrus	O
and	O
CA3	O
cell	O
layer	O
.	O

We	O
report	O
that	O
miR-21	O
expression	O
is	O
significantly	O
up	O
-	O
regulated	O
in	O
the	O
hippocampus	O
after	O
rodent	O
TBI	O
,	O
with	O
expression	O
levels	O
peaking	O
by	O
3	O
days	O
postinjury	O
and	O
returning	O
to	O
near	O
sham	O
levels	O
by	O
15	O
days	O
postinjury	O
.	O

MicroRNAs	O
(	O
miRNAs	O
)	O
are	O
an	O
important	O
class	O
of	O
noncoding	O
regulatory	O
RNAs	O
providing	O
an	O
epigenetic	O
mechanism	O
for	O
the	O
regulation	O
of	O
protein	O
expression	O
levels	O
of	O
target	O
genes	O
.	O

Cellular	O
mechanisms	O
that	O
can	O
modulate	O
these	O
processes	O
may	O
play	O
an	O
important	O
role	O
in	O
determining	O
the	O
nature	O
and	O
extent	O
of	O
the	O
damage	O
suffered	O
after	O
TBI	O
and	O
therefore	O
influence	O
overall	O
outcome	O
after	O
injury	O
.	O

These	O
results	O
suggest	O
that	O
increased	O
miR-21	O
expression	O
in	O
the	O
hippocampus	O
may	O
influence	O
multiple	O
components	O
of	O
TBI	O
pathophysiology	O
.	O

Analysis	O
of	O
these	O
genes	O
'	O
annotated	O
Gene	O
Ontology	O
molecular	O
function	O
and	O
biological	O
process	O
terms	O
revealed	O
an	O
overrepresentation	O
of	O
genes	O
involved	O
in	O
enzyme	O
-	O
linked	O
receptor	O
signaling	O
,	O
transcriptional	O
regulation	O
,	O
and	O
developmental	O
processes	O
.	O

We	O
used	O
a	O
combination	O
of	O
the	O
miRanda	O
,	O
TargetScan	O
,	O
and	O
PicTar	O
prediction	O
algorithms	O
to	O
identify	O
99	O
potential	O
target	O
genes	O
that	O
possess	O
miR-21	O
binding	O
sites	O
within	O
their	O
3	O
'	O
untranslated	O
regions	O
.	O

This	O
is	O
the	O
first	O
study	O
suggesting	O
that	O
plasma	O
miRs	O
might	O
be	O
used	O
as	O
biomarkers	O
for	O
HD	O
.	O

Huntington	O
's	O
disease	O
(	O
HD	O
)	O
is	O
a	O
devastating	O
,	O
neurodegenerative	O
condition	O
,	O
which	O
lacks	O
effective	O
treatment	O
.	O

Hsa	O
-	O
miR-34b	O
is	O
a	O
plasma	O
-	O
stable	O
microRNA	O
that	O
is	O
elevated	O
in	O
pre	O
-	O
manifest	O
Huntington	O
's	O
disease	O
.	O

Importantly	O
,	O
miRs	O
are	O
present	O
in	O
a	O
bio	O
-	O
stable	O
form	O
in	O
human	B
peripheral	O
blood	O
plasma	O
and	O
have	O
recently	O
been	O
shown	O
to	O
be	O
useful	O
biomarkers	O
in	O
other	O
diseases	O
.	O

Normal	O
Huntingtin	O
(	O
HTT	O
)	O
and	O
mutant	O
Huntingtin	O
(	O
mHTT	O
)	O
are	O
expressed	O
in	O
multiple	O
tissues	O
and	O
can	O
alter	O
transcription	O
of	O
microRNAs	O
(	O
miRs	O
)	O
.	O

In	O
a	O
cell	O
line	O
over	O
-	O
expressing	O
mHTT	O
-	O
Exon-1	O
,	O
miR	O
microarray	O
analysis	O
was	O
used	O
to	O
identify	O
candidate	O
miRs	O
.	O

We	O
therefore	O
sought	O
to	O
identify	O
potential	O
miR	O
biomarkers	O
of	O
HD	O
that	O
are	O
present	O
in	O
,	O
and	O
have	O
functional	O
consequences	O
for	O
,	O
neuronal	O
and	O
non	O
-	O
neuronal	O
tissues	O
.	O

We	O
found	O
that	O
miR-34b	O
is	O
significantly	O
elevated	O
in	O
response	O
to	O
mHTT	O
-	O
Exon-1	O
,	O
and	O
its	O
blockade	O
alters	O
the	O
toxicity	O
of	O
mHTT	O
-	O
Exon-1	O
in	O
vitro	O
.	O

We	O
then	O
examined	O
their	O
presence	O
and	O
bio	O
-	O
stability	O
in	O
control	O
and	O
HD	O
plasma	O
.	O

We	O
also	O
show	O
that	O
miR-34b	O
is	O
detectable	O
in	O
plasma	O
from	O
small	O
input	O
volumes	O
and	O
is	O
insensitive	O
to	O
freeze	O
-	O
thaw	O
-	O
induced	O
RNA	O
degradation	O
.	O

Interestingly	O
,	O
miR-34b	O
is	O
significantly	O
elevated	O
in	O
plasma	O
from	O
HD	O
gene	O
carriers	O
prior	O
to	O
symptom	O
onset	O
.	O

MiRNA	O
expression	O
profiling	O
of	O
human	B
tumors	O
has	O
led	O
to	O
the	O
identification	O
of	O
signatures	O
correlated	O
with	O
the	O
tumor	O
diagnosis	O
,	O
staging	O
,	O
progression	O
,	O
prognosis	O
and	O
response	O
to	O
treatment	O
.	O

MiRNA	O
fingerprinting	O
can	O
therefore	O
be	O
added	O
to	O
the	O
diagnostic	O
and	O
prognostic	O
tools	O
used	O
by	O
medical	O
oncologists	O
.	O

Furthermore	O
,	O
new	O
therapeutic	O
strategies	O
involving	O
miRNA	O
silencing	O
or	O
miRNA	O
mimics	O
could	O
be	O
proposed	O
based	O
on	O
the	O
roles	O
of	O
these	O
small	O
non	O
-	O
coding	O
RNAs	O
as	O
oncogenes	O
and	O
tumor	O
suppressors	O
in	O
brain	O
tumors	O
.	O

MicroRNA	O
involvement	O
in	O
brain	O
tumors	O
:	O
from	O
bench	O
to	O
bedside	O
.	O

MicroRNAs	O
(	O
miRNAs	O
)	O
,	O
a	O
novel	O
class	O
of	O
small	O
non	O
-	O
coding	O
RNAs	O
,	O
are	O
effective	O
post	O
-	O
transcriptional	O
regulators	O
of	O
gene	O
expression	O
,	O
exhibiting	O
,	O
when	O
altered	O
in	O
human	B
tumors	O
,	O
both	O
oncogenic	O
and	O
tumor	O
suppressive	O
potential	O
.	O

Recently	O
,	O
miRNA	O
involvement	O
in	O
the	O
pathophysiology	O
of	O
brain	O
cancer	O
has	O
been	O
assessed	O
.	O

Aberrant	O
gene	O
expression	O
is	O
the	O
main	O
mechanism	O
of	O
miRNAs	O
dysfunction	O
in	O
cancer	O
,	O
with	O
abnormal	O
expression	O
levels	O
of	O
mature	O
and/or	O
precursor	O
miRNA	O
expression	O
in	O
tumor	O
samples	O
versus	O
normal	O
.	O

MiRNA	O
germline	O
and	O
somatic	O
mutations	O
or	O
polymorphisms	O
in	O
the	O
protein	O
coding	O
messenger	O
RNA	O
targeted	O
by	O
miRNAs	O
may	O
also	O
occur	O
,	O
contributing	O
to	O
cancer	O
predisposition	O
,	O
initiation	O
and/or	O
progression	O
.	O

If	O
present	O
in	O
somatic	O
cells	O
,	O
miRNA	O
alterations	O
may	O
play	O
a	O
role	O
in	O
tumor	O
initiation	O
,	O
while	O
if	O
present	O
in	O
germ	O
line	O
cells	O
they	O
could	O
constitute	O
a	O
cancer	O
predisposing	O
event	O
.	O

Additionally	O
,	O
gene	O
ontology	O
analyses	O
of	O
the	O
target	O
genes	O
suggested	O
a	O
distinct	O
role	O
for	O
each	O
miRNA	O
.	O

Our	O
results	O
show	O
that	O
NPC	O
fibroblasts	O
have	O
an	O
altered	O
miRNA	O
expression	O
profile	O
and	O
certain	O
miRNAs	O
have	O
importance	O
in	O
disease	O
pathogenesis	O
as	O
well	O
as	O
the	O
therapeutic	O
capacity	O
to	O
correct	O
lipid	O
related	O
pathophysiologies	O
in	O
the	O
NPC	O
cells	O
.	O

Expression	O
differences	O
between	O
the	O
healthy	O
and	O
NPC	O
cells	O
were	O
detected	O
according	O
to	O
the	O
relative	O
quantification	O
values	O
.	O

Target	O
genes	O
were	O
predicted	O
by	O
using	O
three	O
different	O
algorithms	O
and	O
classified	O
regarding	O
NPC	O
related	O
biological	O
processes	O
and	O
cellular	O
components	O
.	O

We	O
found	O
that	O
three	O
miRNAs	O
,	O
miR-196a	O
,	O
miR-196b	O
and	O
miR-296	O
were	O
up	O
-	O
regulated	O
(	O
>	O
3.5-fold	O
increase	O
,	O
p<0.05	O
)	O
whereas	O
38	O
miRNAs	O
were	O
significantly	O
down	O
-	O
regulated	O
in	O
NPC	O
cells	O
(	O
>	O
3.5-fold	O
decrease	O
,	O
p<0.05	O
)	O
.	O

Among	O
these	O
non	O
-	O
coding	O
RNAs	O
,	O
miR-98	O
was	O
the	O
most	O
down	O
-	O
regulated	O
(	O
-33.3-fold	O
)	O
miRNA	O
and	O
miR-143	O
,	O
the	O
lipid	O
biosynthesis	O
associated	O
miRNA	O
,	O
had	O
a	O
20-fold	O
decreased	O
expression	O
in	O
the	O
NPC	O
cells	O
.	O

Dysregulation	O
of	O
miRNA	O
expression	O
may	O
lead	O
to	O
severe	O
pathophysiologies	O
in	O
human	B
cells	O
.	O

Niemann	O
-	O
Pick	O
type	O
C	O
(	O
NPC	O
)	O
disease	O
is	O
a	O
complex	O
lipid	O
storage	O
disease	O
characterized	O
by	O
late	O
endosomal	O
-	O
lysosomal	O
accumulation	O
of	O
multiple	O
lipid	O
molecules	O
.	O

Our	O
aim	O
was	O
to	O
characterize	O
the	O
miRNA	O
profile	O
in	O
NPC	O
fibroblasts	O
as	O
they	O
may	O
play	O
an	O
active	O
role	O
in	O
the	O
NPC	O
disease	O
associated	O
changes	O
in	O
the	O
cellular	O
physiology	O
.	O

To	O
investigate	O
the	O
miRNA	O
expression	O
,	O
total	O
RNAs	O
were	O
isolated	O
from	O
cultured	O
human	B
NPC	O
fibroblasts	O
and	O
healthy	O
fibroblasts	O
and	O
then	O
,	O
TaqMan	O
Low	O
-	O
Density	O
Array	O
system	O
containing	O
365	O
mature	O
human	B
miRNAs	O
was	O
used	O
.	O

MicroRNAs	O
(	O
miRNAs	O
)	O
are	O
non	O
-	O
coding	O
RNAs	O
that	O
regulate	O
gene	O
expression	O
at	O
post	O
-	O
transcriptional	O
level	O
.	O

Niemann	O
-	O
Pick	O
type	O
C	O
fibroblasts	O
have	O
a	O
distinct	O
microRNA	O
profile	O
related	O
to	O
lipid	O
metabolism	O
and	O
certain	O
cellular	O
components	O
.	O

RESULTS	O
:	O
We	O
detected	O
a	O
total	O
of	O
360	O
miRNAs	O
.	O

Selective	O
miRNAs	O
then	O
were	O
synthesized	O
and	O
transfected	O
into	O
Neuro-2a	O
cells	O
before	O
oxygen	O
-	O
glucose	O
deprivation	O
.	O

Transfections	O
of	O
some	O
of	O
these	O
were	O
neuroprotective	O
in	O
in	O
vitro	O
ischemia	O
.	O

Two	O
miRNA	O
families	O
,	O
miR-200	O
and	O
miR-182	O
,	O
were	O
selectively	O
upregulated	O
at	O
3	O
hours	O
after	O
ischemic	O
preconditioning	O
.	O

Although	O
miRNAs	O
control	O
a	O
number	O
of	O
conditions	O
and	O
diseases	O
,	O
few	O
neuroprotective	O
miRNAs	O
have	O
been	O
described	O
.	O

In	O
this	O
study	O
,	O
we	O
investigated	O
neuroprotective	O
miRNAs	O
induced	O
early	O
in	O
ischemic	O
preconditioning	O
.	O

METHODS	O
:	O
Ischemic	O
preconditioning	O
or	O
focal	O
cerebral	O
ischemia	O
was	O
induced	O
in	O
mice	B
by	O
transient	O
occlusion	O
of	O
the	O
middle	O
cerebral	O
artery	O
for	O
15	O
or	O
120	O
minutes	O
.	O

We	O
prepared	O
RNA	O
samples	O
from	O
the	O
ischemic	O
cortex	O
at	O
3	O
or	O
24	O
hours	O
after	O
the	O
onset	O
of	O
ischemia	O
.	O

MicroRNAs	O
induced	O
during	O
ischemic	O
preconditioning	O
.	O

BACKGROUND	O
AND	O
PURPOSE	O
:	O
MicroRNAs	O
(	O
miRNA	O
)	O
are	O
single	O
-	O
stranded	O
short	O
RNA	O
molecules	O
that	O
regulate	O
gene	O
expression	O
by	O
either	O
degradation	O
or	O
translational	O
repression	O
of	O
mRNA	O
.	O

Among	O
them	O
,	O
miR-200b	O
,	O
miR-200c	O
,	O
and	O
miR-429	O
targeted	O
prolyl	O
hydroxylase	O
2	O
and	O
had	O
the	O
best	O
neuroprotective	O
effect	O
.	O

CONCLUSIONS	O
:	O
Two	O
miRNA	O
families	O
,	O
miR-200	O
and	O
miR-182	O
,	O
were	O
upregulated	O
early	O
after	O
ischemic	O
preconditioning	O
and	O
the	O
miR-200	O
family	O
was	O
neuroprotective	O
mainly	O
by	O
downregulating	O
prolyl	O
hydroxylase	O
2	O
levels	O
.	O

These	O
miRNAs	O
may	O
be	O
useful	O
in	O
future	O
research	O
and	O
therapeutic	O
applications	O
.	O

Frequent	O
amplification	O
of	O
a	O
chr19q13.41	O
microRNA	O
polycistron	O
in	O
aggressive	O
primitive	O
neuroectodermal	O
brain	O
tumors	O
.	O

microRNA	O
(	O
miRNA	O
)	O
cluster	O
(	O
C19MC	O
)	O
in	O
11	O
/	O
45	O
(	O
approximately	O
25	O
%	O
)	O
primary	O
CNS	O
-	O
PNET	O
,	O
which	O
results	O
in	O
striking	O
overexpression	O
of	O
miR-517c	O
and	O
520	O
g	O
.	O

We	O
discovered	O
a	O
high	O
-	O
level	O
amplicon	O
involving	O
the	O
chr19q13.41	O

Remarkably	O
,	O
the	O
C19MC	O
amplicon	O
,	O
which	O
is	O
very	O
rare	O
in	O
other	O
brain	O
tumors	O
(	O
1	O
/	O
263	O
)	O
,	O
identifies	O
an	O
aggressive	O
subgroup	O
of	O
CNS	O
-	O
PNET	O
with	O
distinct	O
gene	O
-	O
expression	O
profiles	O
,	O
characteristic	O
histology	O
,	O
and	O
dismal	O
survival	O
.	O

Constitutive	O
expression	O
of	O
miR-517c	O
or	O
520	O
g	O
promotes	O
in	O
vitro	O
and	O
in	O
vivo	O
oncogenicity	O
,	O
modulates	O
cell	O
survival	O
,	O
and	O
robustly	O
enhances	O
growth	O
of	O
untransformed	O
human	B
neural	O
stem	O
cells	O
(	O
hNSCs	O
)	O
in	O
part	O
by	O
upregulating	O
WNT	O
pathway	O
signaling	O
and	O
restricting	O
differentiation	O
of	O
hNSCs	O
.	O

Our	O
data	O
implicate	O
miR-517c	O
and	O
520	O
g	O
as	O
oncogenes	O
and	O
promising	O
biological	O
markers	O
for	O
CNS	O
-	O
PNET	O
and	O
provide	O
important	O
insights	O
into	O
oncogenic	O
properties	O
of	O
the	O
C19MC	O
locus	O
.	O

A	O
significant	O
association	O
with	O
death	O
was	O
found	O
for	O
major	O
adverse	O
events	O
,	O
medical	O
adverse	O
events	O
,	O
and	O
nosocomial	O
infections	O
,	O
with	O
adjusted	O
odds	O
ratio	O
estimates	O
of	O
3.74	O
[	O
95	O
%	O
confidence	O
interval	O
(	O
CI	O
)	O
1.64	O
-	O
8.54	O
]	O
,	O
3.71	O
(	O
95	O
%	O
CI	O
1.61	O
-	O
8.53	O
)	O
,	O
and	O
3.22	O
(	O
95	O
%	O
CI	O
1.21	O
-	O
8.59	O
)	O
,	O
respectively	O
.	O

CONCLUSION	O
:	O
Adverse	O
events	O
,	O
mostly	O
severe	O
,	O
predominated	O
among	O
deceased	O
patients	B
,	O
resulting	O
mainly	O
from	O
diagnostic	O
or	O
therapeutic	O
procedures	O
and	O
nursing	O
activities	O
.	O

In	O
spite	O
of	O
limitations	O
concerning	O
the	O
observational	O
retrospective	O
nature	O
of	O
this	O
study	O
,	O
we	O
found	O
that	O
severe	O
adverse	O
events	O
,	O
medical	O
adverse	O
events	O
,	O
and	O
nosocomial	O
infections	O
were	O
significantly	O
associated	O
with	O
death	O
in	O
stroke	O
patients	B
.	O

OBJECTIVES	O
:	O
To	O
identify	O
the	O
occurrence	O
of	O
adverse	O
events	O
in	O
stroke	O
patients	B
presenting	O
to	O
the	O
emergency	O
department	O
of	O
a	O
tertiary	O
university	O
facility	O
,	O
and	O
to	O
disclose	O
the	O
categories	O
of	O
adverse	O
events	O
associated	O
with	O
death	O
.	O

Adverse	O
events	O
and	O
death	O
in	O
stroke	O
patients	B
admitted	O
to	O
the	O
emergency	O
department	O
of	O
a	O
tertiary	O
university	O
hospital	O
.	O

Major	O
adverse	O
events	O
equaled	O
54.1	O
%	O
of	O
all	O
events	O
(	O
659	O
episodes	O
)	O
:	O
538	O
events	O
in	O
143	O
cases	O
and	O
121	O
in	O
65	O
controls	O
.	O

RESULTS	O
:	O
Adverse	O
events	O
totaled	O
1218	O
and	O
occurred	O
in	O
295	O
patients	B
:	O
932	O
events	O
(	O
76.5	O
%	O
)	O
in	O
170	O
cases	O
and	O
286	O
(	O
23.5	O
%	O
)	O
in	O
125	O
controls	O
.	O

Nursing	O
(	O
38.4	O
%	O
)	O
and	O
medical	O
(	O
31	O
%	O
)	O
adverse	O
events	O
represented	O
the	O
most	O
common	O
related	O
professional	O
categories	O
.	O

Diagnostic	O
or	O
therapeutic	O
procedures	O
and	O
nursing	O
activities	O
accounted	O
for	O
55.2	O
%	O
of	O
events	O
.	O

The	O
cases	O
comprised	O
234	O
consecutive	O
deaths	O
and	O
the	O
controls	O
234	O
discharged	O
patients	B
,	O
matched	O
for	O
primary	O
diagnosis	O
and	O
admission	O
period	O
.	O

METHODS	O
:	O
This	O
matched	O
case	O
-	O
control	O
study	O
enrolled	O
468	O
patients	B
admitted	O
with	O
stroke	O
to	O
the	O
emergency	O
department	O
from	O
March	O
1996	O
to	O
September	O
1999	O
.	O

The	O
association	O
with	O
death	O
was	O
analysed	O
by	O
conditional	O
logistic	O
regression	O
.	O

Adverse	O
events	O
,	O
detected	O
by	O
chart	O
review	O
,	O
were	O
classified	O
according	O
to	O
the	O
degree	O
of	O
severity	O
,	O
immediate	O
causes	O
,	O
and	O
professional	O
category	O
.	O

Our	O
findings	O
suggest	O
that	O
microRNAs	O
are	O
important	O
determinants	O
of	O
glioblastoma	O
subclasses	O
through	O
their	O
ability	O
to	O
regulate	O
developmental	O
growth	O
and	O
differentiation	O
programs	O
in	O
several	O
transformed	O
neural	O
precursor	O
cell	O
types	O
.	O

Foremost	O
among	O
these	O
is	O
miR-9	O
,	O
which	O
suppresses	O
mesenchymal	O
differentiation	O
in	O
glioblastoma	O
by	O
downregulating	O
expression	O
of	O
JAK	O
kinases	O
and	O
inhibiting	O
activation	O
of	O
STAT3	O
.	O

Taken	O
together	O
,	O
our	O
results	O
define	O
developmental	O
microRNA	O
expression	O
signatures	O
that	O
both	O
characterize	O
and	O
contribute	O
to	O
the	O
phenotypic	O
diversity	O
of	O
glioblastoma	O
subclasses	O
,	O
thereby	O
providing	O
an	O
expanded	O
framework	O
for	O
understanding	O
the	O
pathogenesis	O
of	O
glioblastoma	O
in	O
a	O
human	O
neurodevelopmental	O
context	O
.	O

These	O
microRNA	O
-	O
based	O
glioblastoma	O
subclasses	O
displayed	O
microRNA	O
and	O
mRNA	O
expression	O
signatures	O
resembling	O
those	O
of	O
radial	O
glia	O
,	O
oligoneuronal	O
precursors	O
,	O
neuronal	O
precursors	O
,	O
neuroepithelial	O
/	O
neural	O
crest	O
precursors	O
,	O
or	O
astrocyte	O
precursors	O
.	O

In	O
this	O
study	O
,	O
we	O
analyzed	O
261	O
microRNA	O
expression	O
profiles	O
from	O
The	O
Cancer	O
Genome	O
Atlas	O
(	O
TCGA	O
)	O
,	O
identifying	O
five	O
clinically	O
and	O
genetically	O
distinct	O
subclasses	O
of	O
glioblastoma	O
that	O
each	O
related	O
to	O
a	O
different	O
neural	O
precursor	O
cell	O
type	O
.	O

We	O
also	O
identified	O
several	O
microRNAs	O
as	O
potent	O
regulators	O
of	O
subclass	O
-	O
specific	O
gene	O
expression	O
networks	O
in	O
glioblastoma	O
.	O

Each	O
subclass	O
was	O
determined	O
to	O
be	O
genetically	O
distinct	O
,	O
based	O
on	O
the	O
significant	O
differences	O
they	O
displayed	O
in	O
terms	O
of	O
patient	B
race	O
,	O
age	O
,	O
treatment	O
response	O
,	O
and	O
survival	O
.	O

mRNA	O
expression	O
profiling	O
has	O
suggested	O
the	O
existence	O
of	O
multiple	O
glioblastoma	O
subclasses	O
,	O
but	O
their	O
number	O
and	O
characteristics	O
vary	O
among	O
studies	O
and	O
the	O
etiology	O
underlying	O
their	O
development	O
is	O
unclear	O
.	O

A	O
developmental	O
taxonomy	O
of	O
glioblastoma	O
defined	O
and	O
maintained	O
by	O
MicroRNAs	O
.	O

These	O
findings	O
reveal	O
a	O
novel	O
mechanism	O
of	O
targeted	O
intercellular	O
protein	O
regulation	O
between	O
brain	O
tumor	O
cells	O
.	O

Here	O
,	O
we	O
transformed	O
rat	B
9L	O
gliosarcoma	O
cells	O
to	O
express	O
cel	O
-	O
miR-67	O
,	O
a	O
miRNA	O
that	O
lacks	O
homology	O
in	O
rat	B
.	O

Coculture	O
of	O
these	O
cells	O
with	O
cells	O
that	O
expressed	O
a	O
luciferase	O
reporter	O
that	O
contained	O
a	O
complementary	O
sequence	O
to	O
cel	O
-	O
miR-67	O
resulted	O
in	O
significant	O
suppression	O
of	O
luciferase	O
expression	O
.	O

Functional	O
microRNA	O
is	O
transferred	O
between	O
glioma	O
cells	O
.	O

MicroRNAs	O
(	O
miRNA	O
)	O
are	O
single	O
-	O
stranded	O
17-	O
to	O
27-nucleotide	O
RNA	O
molecules	O
that	O
regulate	O
gene	O
expression	O
by	O
posttranscriptional	O
silencing	O
of	O
target	O
mRNAs	O
.	O

Finally	O
,	O
in	O
situ	O
hybridization	O
revealed	O
the	O
presence	O
of	O
cel	O
-	O
miR-67	O
in	O
cel	O
-	O
miR-67-null	O
9L	O
cells	O
after	O
coculture	O
with	O
cel	O
-	O
miR-67-expressing	O
cells	O
.	O

Our	O
data	O
show	O
that	O
miRNA	O
transcribed	O
in	O
glioma	O
cells	O
can	O
be	O
transferred	O
to	O
adjacent	O
cells	O
and	O
induces	O
targeted	O
inhibition	O
of	O
protein	O
expression	O
in	O
the	O
acceptor	O
cells	O
.	O

This	O
effect	O
was	O
also	O
observed	O
in	O
the	O
U87-MG	O
human	B
glioma	O
cell	O
line	O
.	O

Moreover	O
,	O
luciferase	O
suppression	O
was	O
inhibited	O
by	O
the	O
addition	O
of	O
carbenoxolone	O
to	O
cocultures	O
,	O
suggesting	O
that	O
gap	O
junction	O
communication	O
regulates	O
intercellular	O
transfer	O
of	O
miRNA	O
.	O

miRNAs	O
are	O
small	O
,	O
endogenously	O
expressed	O
noncoding	O
RNAs	O
that	O
regulate	O
gene	O
expression	O
,	O
mainly	O
at	O
the	O
post	O
-	O
transcriptional	O
level	O
,	O
via	O
degradation	O
or	O
translational	O
inhibition	O
of	O
their	O
target	O
mRNAs	O
.	O

Functionally	O
,	O
an	O
individual	O
miRNA	O
can	O
regulate	O
the	O
expression	O
of	O
multiple	O
target	O
genes	O
.	O

miRNAs	O
:	O
roles	O
and	O
clinical	O
applications	O
in	O
vascular	O
disease	O
.	O

The	O
study	O
of	O
miRNAs	O
is	O
rapidly	O
growing	O
and	O
recent	O
studies	O
have	O
revealed	O
a	O
significant	O
role	O
of	O
miRNAs	O
in	O
vascular	O
biology	O
and	O
disease	O
.	O

Many	O
miRNAs	O
are	O
highly	O
expressed	O
in	O
the	O
vasculature	O
,	O
and	O
their	O
expression	O
is	O
dysregulated	O
in	O
diseased	O
vessels	O
.	O

Several	O
miRNAs	O
have	O
been	O
found	O
to	O
be	O
critical	O
modulators	O
of	O
vascular	O
pathologies	O
,	O
such	O
as	O
atherosclerosis	O
,	O
lipoprotein	O
metabolism	O
,	O
inflammation	O
,	O
arterial	O
remodeling	O
,	O
angiogenesis	O
,	O
smooth	O
muscle	O
cell	O
regeneration	O
,	O
hypertension	O
,	O
apoptosis	O
,	O
neointimal	O
hyperplasia	O
and	O
signal	O
transduction	O
pathways	O
.	O

Thus	O
,	O
miRNAs	O
may	O
serve	O
as	O
novel	O
biomarkers	O
and/or	O
therapeutic	O
targets	O
for	O
vascular	O
disease	O
.	O

This	O
article	O
summarizes	O
the	O
current	O
studies	O
related	O
to	O
the	O
disease	O
correlations	O
and	O
functional	O
roles	O
of	O
miRNAs	O
in	O
the	O
vascular	O
system	O
and	O
discusses	O
the	O
potential	O
applications	O
of	O
miRNAs	O
in	O
vascular	O
disease	O
.	O

Moreover	O
,	O
bioinformatics	O
analyses	O
revealed	O
a	O
theoretical	O
basis	O
for	O
many	O
other	O
potential	O
interactions	O
between	O
natural	O
antisense	O
transcripts	O
and	O
miRNAs	O
at	O
the	O
binding	O
sites	O
of	O
the	O
latter	O
.	O

In	O
addition	O
,	O
mammalian	O
genomes	O
contain	O
numerous	O
natural	O
antisense	O
transcripts	O
,	O
most	O
of	O
which	O
appear	O
to	O
be	O
non	O
-	O
protein	O
-	O
coding	O
RNAs	O
(	O
ncRNAs	O
)	O
.	O

BACKGROUND	O
:	O
MicroRNAs	O
(	O
miRNAs	O
)	O
have	O
the	O
potential	O
to	O
regulate	O
diverse	O
sets	O
of	O
mRNA	O
targets	O
.	O

Evidence	O
for	O
natural	O
antisense	O
transcript	O
-	O
mediated	O
inhibition	O
of	O
microRNA	O
function	O
.	O

Indeed	O
,	O
miR-485	O
-	O
5p	O
and	O
BACE1-antisense	O
compete	O
for	O
binding	O
within	O
the	O
same	O
region	O
in	O
the	O
open	O
reading	O
frame	O
of	O
the	O
BACE1	O
mRNA	O
.	O

RESULTS	O
:	O
We	O
report	O
here	O
that	O
BACE1-antisense	O
prevents	O
miRNA	O
-	O
induced	O
repression	O
of	O
BACE1	O
mRNA	O
by	O
masking	O
the	O
binding	O
site	O
for	O
miR-485	O
-	O
5p	O
.	O

The	O
BACE1-antisense	O
transcript	O
is	O
markedly	O
up	O
-	O
regulated	O
in	O
brain	O
samples	O
from	O
Alzheimer	O
's	O
disease	O
patients	B
and	O
promotes	O
the	O
stability	O
of	O
the	O
(	O
sense	O
)	O
BACE1	O
transcript	O
.	O

We	O
have	O
recently	O
identified	O
and	O
characterized	O
a	O
highly	O
conserved	O
non	O
-	O
coding	O
antisense	O
transcript	O
for	O
beta	O
-	O
secretase-1	O
(	O
BACE1	O
)	O
,	O
a	O
critical	O
enzyme	O
in	O
Alzheimer	O
's	O
disease	O
pathophysiology	O
.	O

We	O
observed	O
opposing	O
effects	O
of	O
BACE1-antisense	O
and	O
miR-485	O
-	O
5p	O
on	O
BACE1	O
protein	O
in	O
vitro	O
and	O
showed	O
that	O
Locked	O
Nucleic	O
Acid	O
-	O
antimiR	O
mediated	O
knockdown	O
of	O
miR-485	O
-	O
5p	O
as	O
well	O
as	O
BACE1-antisense	O
over	O
-	O
expression	O
can	O
prevent	O
the	O
miRNA	O
-	O
induced	O
BACE1	O
suppression	O
.	O

We	O
found	O
that	O
the	O
expression	O
of	O
BACE1-antisense	O
as	O
well	O
as	O
miR-485	O
-	O
5p	O
are	O
dysregulated	O
in	O
RNA	O
samples	O
from	O
Alzheimer	O
's	O
disease	O
subjects	O
compared	O
to	O
control	O
individuals	O
.	O

CONCLUSIONS	O
:	O
Our	O
data	O
demonstrate	O
an	O
interface	O
between	O
two	O
distinct	O
groups	O
of	O
regulatory	O
RNAs	O
in	O
the	O
computation	O
of	O
BACE1	O
gene	O
expression	O
.	O

Mice	B
deficient	O
in	O
cystathionine	O
beta	O
synthase	O
display	O
altered	O
homocysteine	O
remethylation	O
pathway	O
.	O

In	O
order	O
to	O
show	O
the	O
effects	O
of	O
CBS	O
deficiency	O
onto	O
the	O
activity	O
of	O
the	O
enzymes	O
involved	O
in	O
the	O
remethylation	O
pathway	O
,	O
we	O
used	O
the	O
well	O
characterized	O
genetic	O
model	O
of	O
severe	O
hyperhomocysteinemia	O
in	O
mice	B
.	O

Cystathionine	O
beta	O
synthase	O
(	O
CBS	O
)	O
deficiency	O
is	O
a	O
metabolic	O
disorder	O
that	O
is	O
biochemically	O
characterized	O
by	O
severe	O
hyperhomocysteinemia	O
.	O

We	O
showed	O
that	O
CBS	O
deficiency	O
in	O
mice	B
reduced	O
hepatic	O
methionine	O
synthase	O
and	O
betaine	O
-	O
homocysteine	O
methyltransferase	O
activities	O
,	O
whereas	O
5,10-methylene	O
tetrahydrofolate	O
reductase	O
activity	O
was	O
increased	O
.	O

Western	O
blot	O
analysis	O
of	O
human	B
glioblastoma	O
specimens	O
showed	O
high	O
levels	O
of	O
PKM2	O
protein	O
,	O
but	O
none	O
was	O
observed	O
in	O
normal	O
brain	O
samples	O
.	O

Our	O
data	O
suggest	O
PKM2	O
inhibition	O
as	O
a	O
therapy	O
for	O
glioblastoma	O
,	O
with	O
the	O
potential	O
for	O
minimal	O
toxicity	O
to	O
the	O
brain	O
.	O

Strikingly	O
,	O
cells	O
with	O
high	O
levels	O
of	O
PKM2	O
expressed	O
lower	O
levels	O
of	O
miR-326	O
,	O
suggestive	O
of	O
endogenous	O
regulation	O
of	O
PKM2	O
by	O
miR-326	O
.	O

Emerging	O
studies	O
have	O
identified	O
microRNAs	O
(	O
miRNAs	O
)	O
as	O
possible	O
therapeutic	O
tools	O
for	O
the	O
treatment	O
of	O
glioma	O
,	O
the	O
most	O
aggressive	O
brain	O
tumor	O
.	O

Pyruvate	O
kinase	O
M2	O
is	O
a	O
target	O
of	O
the	O
tumor	O
-	O
suppressive	O
microRNA-326	O
and	O
regulates	O
the	O
survival	O
of	O
glioma	O
cells	O
.	O

Their	O
important	O
targets	O
in	O
this	O
tumor	O
are	O
not	O
well	O
understood	O
.	O

We	O
recently	O
found	O
that	O
the	O
Notch	O
pathway	O
is	O
a	O
target	O
of	O
miRNA-326	O
.	O

Ectopic	O
expression	O
of	O
miRNA-326	O
in	O
glioma	O
and	O
glioma	O
stem	O
cells	O
induced	O
their	O
apoptosis	O
and	O
reduced	O
their	O
metabolic	O
activity	O
.	O

Computational	O
target	O
gene	O
prediction	O
revealed	O
pyruvate	O
kinase	O
type	O
M2	O
(	O
PKM2	O
)	O
as	O
another	O
target	O
of	O
miRNA-326	O
.	O

PKM2	O
has	O
recently	O
been	O
shown	O
to	O
play	O
a	O
key	O
role	O
in	O
cancer	O
cell	O
metabolism	O
.	O

To	O
investigate	O
whether	O
it	O
might	O
be	O
a	O
functionally	O
important	O
target	O
of	O
miR-326	O
,	O
we	O
used	O
RNA	O
interference	O
to	O
knockdown	O
PKM2	O
expression	O
in	O
glioma	O
cells	O
.	O

Transfection	O
of	O
the	O
established	O
glioma	O
and	O
glioma	O
stem	O
cells	O
with	O
PKM2	O
siRNA	O
reduced	O
their	O
growth	O
,	O
cellular	O
invasion	O
,	O
metabolic	O
activity	O
,	O
ATP	O
and	O
glutathione	O
levels	O
,	O
and	O
activated	O
AMP	O
-	O
activated	O
protein	O
kinase	O
.	O

The	O
cytotoxic	O
effects	O
exhibited	O
by	O
PKM2	O
knockdown	O
in	O
glioma	O
and	O
glioma	O
stem	O
cells	O
were	O
not	O
observed	O
in	O
transformed	O
human	B
astrocytes	O
.	O

Interestingly	O
,	O
the	O
above	O
data	O
suggested	O
that	O
in	O
both	O
the	O
PTEN	O
mutant	O
and	O
the	O
wild	O
-	O
type	O
GBM	O
cells	O
,	O
miR-21	O
blockage	O
increased	O
the	O
chemosensitivity	O
to	O
taxol	O
.	O

It	O
is	O
worth	O
noting	O
that	O
the	O
miR-21	O
inhibitor	O
additively	O
interacted	O
with	O
taxol	O
on	O
U251cells	O
and	O
synergistically	O
on	O
LN229	O
cells	O
.	O

Furthermore	O
,	O
the	O
miR-21	O
inhibitor	O
significantly	O
enhanced	O
apoptosis	O
in	O
both	O
U251	O
cells	O
and	O
LN229	O
cells	O
,	O
and	O
cell	O
invasiveness	O
was	O
obviously	O
weakened	O
.	O

The	O
data	O
strongly	O
suggested	O
that	O
a	O
regulatory	O
loop	O
between	O
miR-21	O
and	O
STAT3	O
might	O
provide	O
an	O
insight	O
into	O
the	O
mechanism	O
of	O
modulating	O
EGFR	O
/	O
STAT3	O
signaling	O
.	O

CONCLUSIONS	O
:	O
Taken	O
together	O
,	O
the	O
miR-21	O
inhibitor	O
could	O
enhance	O
the	O
chemo	O
-	O
sensitivity	O
of	O
human	B
glioblastoma	O
cells	O
to	O
taxol	O
.	O

Thus	O
,	O
the	O
miR-21	O
inhibitor	O
might	O
interrupt	O
the	O
activity	O
of	O
EGFR	O
pathways	O
,	O
independently	O
of	O
PTEN	O
status	O
.	O

Meanwhile	O
,	O
the	O
expression	O
of	O
STAT3	O
and	O
p	O
-	O
STAT3	O
decreased	O
to	O
relatively	O
low	O
levels	O
after	O
miR-21	O
inhibitor	O
and	O
taxol	O
treatment	O
.	O

A	O
combination	O
of	O
miR-21	O
inhibitor	O
and	O
taxol	O
could	O
be	O
an	O
effective	O
therapeutic	O
strategy	O
for	O
controlling	O
the	O
growth	O
of	O
GBM	O
by	O
inhibiting	O
STAT3	O
expression	O
and	O
phosphorylation	O
.	O

Expression	O
of	O
miR-21	O
was	O
investigated	O
by	O
RT	O
-	O
PCR	O
,	O
and	O
western	O
blotting	O
was	O
performed	O
to	O
evaluate	O
malignancy	O
related	O
protein	O
alteration	O
.	O

RESULTS	O
:	O
IC	O
(	O
50	O
)	O
values	O
were	O
dramatically	O
decreased	O
in	O
cells	O
treated	O
with	O
miR-21	O
inhibitor	O
combine	O
with	O
taxol	O
,	O
to	O
a	O
greater	O
extent	O
than	O
those	O
treated	O
with	O
taxol	O
alone	O
.	O

The	O
mechanism	O
between	O
the	O
miR-21	O
inhibitor	O
and	O
the	O
anticancer	O
drug	O
taxol	O
was	O
analyzed	O
using	O
the	O
Zheng	O
-	O
Jun	O
Jin	O
method	O
.	O

Annexin	O
V	O
/	O
PI	O
staining	O
was	O
performed	O
,	O
and	O
apoptosis	O
and	O
the	O
cell	O
cycle	O
were	O
evaluated	O
by	O
flow	O
cytometry	O
analysis	O
.	O

BACKGROUND	O
:	O
Substantial	O
data	O
indicate	O
that	O
the	O
oncogene	O
microRNA	O
21	O
(	O
miR-21	O
)	O
is	O
significantly	O
elevated	O
in	O
glioblastoma	O
multiforme	O
(	O
GBM	O
)	O
and	O
regulates	O
multiple	O
genes	O
associated	O
with	O
cancer	O
cell	O
proliferation	O
,	O
apoptosis	O
,	O
and	O
invasiveness	O
.	O

MicroRNA-21	O
inhibitor	O
sensitizes	O
human	B
glioblastoma	O
cells	O
U251	O
(	O
PTEN	O
-	O
mutant	O
)	O
and	O
LN229	O
(	O
PTEN	O
-	O
wild	O
type	O
)	O
to	O
taxol	O
.	O

The	O
50	O
%	O
inhibitory	O
concentration	O
and	O
cell	O
viability	O
were	O
determined	O
by	O
the	O
MTT	O
assay	O
.	O

METHODS	O
:	O
Human	B
glioblastoma	O
U251	O
(	O
PTEN	O
-	O
mutant	O
)	O
and	O
LN229	O
(	O
PTEN	O
wild	O
-	O
type	O
)	O
cells	O
were	O
treated	O
with	O
taxol	O
and	O
the	O
miR-21	O
inhibitor	O
(	O
in	O
a	O
poly	O
(	O
amidoamine	O
)	O
(	O
PAMAM	O
)	O
dendrimer	O
)	O
,	O
alone	O
or	O
in	O
combination	O
.	O

So	O
far	O
,	O
the	O
effect	O
of	O
downregulating	O
miR-21	O
to	O
enhance	O
the	O
chemotherapeutic	O
effect	O
to	O
taxol	O
has	O
not	O
been	O
studied	O
in	O
human	B
GBM	O
.	O

Thus	O
,	O
miR-21	O
can	O
theoretically	O
become	O
a	O
target	O
to	O
enhance	O
the	O
chemotherapeutic	O
effect	O
in	O
cancer	O
therapy	O
.	O

MiR-107	O
is	O
reduced	O
in	O
Alzheimer	O
's	O
disease	O
brain	O
neocortex	O
:	O
validation	O
study	O
.	O

MiR-107	O
is	O
a	O
microRNA	O
(	O
miRNA	O
)	O
that	O
we	O
reported	O
previously	O
to	O
have	O
decreased	O
expression	O
in	O
the	O
temporal	O
cortical	O
gray	O
matter	O
early	O
in	O
the	O
progression	O
of	O
Alzheimer	O
's	O
disease	O
(	O
AD	O
)	O
.	O

Correlation	O
was	O
observed	O
between	O
decreased	O
miR-107	O
expression	O
and	O
increased	O
neuritic	O
plaque	O
counts	O
(	O
P	O
<	O
0.05	O
)	O
and	O
neurofibrillary	O
tangle	O
counts	O
(	O
P	O
<	O
0.02	O
)	O
in	O
adjacent	O
brain	O
tissue	O
.	O

Adjusted	O
miR-107	O
and	O
BACE1	O
mRNA	O
levels	O
tended	O
to	O
correlate	O
negatively	O
(	O
trend	O
with	O
regression	O
P	O
<	O
0.07	O
)	O
.	O

Here	O
we	O
study	O
a	O
new	O
group	O
of	O
well	O
-	O
characterized	O
human	B
temporal	O
cortex	O
samples	O
(	O
N=19	O
)	O
.	O

MiR-107	O
expression	O
was	O
assessed	O
,	O
normalized	O
to	O
miR-124	O
and	O
let-7a	O
.	O

In	O
sum	O
,	O
miR-107	O
expression	O
tends	O
to	O
be	O
lower	O
relative	O
to	O
other	O
miRNAs	O
as	O
AD	O
progresses	O
.	O

MicroRNAs	O
:	O
biology	O
and	O
roles	O
in	O
neurodegeneration	O
and	O
brain	O
tumours	O
.	O

Introduction	O
and	O
historical	O
background	O
.	O

Small	O
RNAs	O
are	O
short	O
(	O
approximately	O
18	O
to	O
30	O
nucleotides	O
)	O
,	O
non	O
-	O
coding	O
RNA	O
molecules	O
that	O
can	O
regulate	O
gene	O
expression	O
in	O
both	O
the	O
cytoplasm	O
and	O
the	O
nucleus	O
via	O
post	O
-	O
transcriptional	O
gene	O
silencing	O
(	O
PTGS	O
)	O
,	O
chromatin	O
-	O
dependent	O
gene	O
silencing	O
(	O
CDGS	O
)	O
or	O
RNA	O
activation	O
(	O
RNAa	O
)	O
.	O

Novel	O
functions	O
for	O
small	O
RNA	O
molecules	O
.	O

Research	O
has	O
indicated	O
that	O
small	O
RNAs	O
play	O
important	O
roles	O
in	O
cellular	O
processes	O
such	O
as	O
cell	O
differentiation	O
,	O
growth	O
/	O
proliferation	O
,	O
migration	O
,	O
apoptosis	O
/	O
death	O
,	O
metabolism	O
and	O
defense	O
.	O

Three	O
classes	O
of	O
small	O
RNAs	O
have	O
been	O
defined	O
:	O
microRNAs	O
(	O
miRNAs	O
)	O
,	O
siRNAs	O
and	O
Piwi	O
-	O
interacting	O
RNAs	O
(	O
piRNAs	O
)	O
.	O

More	O
interestingly	O
,	O
increasing	O
evidence	O
indicates	O
that	O
small	O
RNAs	O
are	O
involved	O
in	O
the	O
pathogenesis	O
of	O
diverse	O
diseases	O
including	O
cancer	O
,	O
cardiovascular	O
disease	O
,	O
stroke	O
,	O
neurodegenerative	O
disease	O
,	O
diabetes	O
,	O
liver	O
disease	O
,	O
kidney	O
disease	O
and	O
infectious	O
disease	O
.	O

Accordingly	O
,	O
small	O
RNAs	O
are	O
critical	O
regulators	O
of	O
normal	O
development	O
and	O
physiology	O
.	O

Additionally	O
,	O
small	O
RNAs	O
may	O
serve	O
as	O
novel	O
biomarkers	O
and	O
therapeutic	O
targets	O
for	O
the	O
majority	O
of	O
diseases	O
.	O

More	O
than	O
20	O
clinical	O
trials	O
are	O
ongoing	O
to	O
evaluate	O
therapies	O
based	O
on	O
small	O
RNA	O
.	O

These	O
novel	O
findings	O
suggest	O
that	O
miR-21	O
may	O
be	O
an	O
attractive	O
therapeutic	O
molecule	O
for	O
treatment	O
of	O
stroke	O
.	O

MicroRNAs	O
are	O
small	O
RNAs	O
that	O
attenuate	O
protein	O
expression	O
by	O
complementary	O
binding	O
to	O
the	O
3'-UTR	O
of	O
a	O
target	O
mRNA	O
.	O

MicroRNA-21	O
protects	O
neurons	O
from	O
ischemic	O
death	O
.	O

In	O
particular	O
,	O
microRNA-21	O
(	O
miR-21	O
)	O
is	O
a	O
strong	O
antiapoptotic	O
factor	O
in	O
some	O
biological	O
systems	O
.	O

Currently	O
,	O
very	O
little	O
is	O
known	O
about	O
microRNAs	O
after	O
cerebral	O
ischemia	O
.	O

We	O
employed	O
in	O
situ	O
hybridization	O
and	O
laser	O
capture	O
microdissection	O
in	O
combination	O
with	O
real	O
-	O
time	O
RT	O
-	O
PCR	O
to	O
investigate	O
the	O
expression	O
of	O
miR-21	O
after	O
stroke	O
.	O

We	O
investigated	O
the	O
role	O
of	O
miR-21	O
after	O
stroke	O
in	O
the	O
rat	B
.	O

In	O
vitro	O
,	O
overexpression	O
of	O
miR-21	O
in	O
cultured	O
cortical	O
neurons	O
substantially	O
suppressed	O
oxygen	O
and	O
glucose	O
deprivation	O
-	O
induced	O
apoptotic	O
cell	O
death	O
,	O
whereas	O
attenuation	O
of	O
endogenous	O
miR-21	O
by	O
antisense	O
inhibition	O
exacerbated	O
cell	O
death	O
after	O
oxygen	O
and	O
glucose	O
deprivation	O
.	O

In	O
situ	O
hybridization	O
revealed	O
that	O
miR-21	O
expression	O
was	O
upregulated	O
in	O
neurons	O
of	O
the	O
ischemic	O
boundary	O
zone	O
,	O
and	O
quantitative	O
real	O
-	O
time	O
RT	O
-	O
PCR	O
analysis	O
revealed	O
that	O
stroke	O
increased	O
mature	O
miR-21	O
levels	O
by	O
approximately	O
threefold	O
in	O
neurons	O
isolated	O
from	O
the	O
ischemic	O
boundary	O
zone	O
by	O
laser	O
capture	O
microdissection	O
as	O
compared	O
with	O
homologous	O
contralateral	O
neurons	O
2	O
days	O
(	O
n	O
=	O
4	O
;	O
P	O
<	O
0.05	O
)	O
and	O
7	O
days	O
(	O
n	O
=	O
3	O
;	O
P	O
<	O
0.05	O
)	O
after	O
stroke	O
.	O

Our	O
data	O
indicate	O
that	O
overexpression	O
of	O
miR-21	O
protects	O
against	O
ischemic	O
neuronal	O
death	O
,	O
and	O
that	O
downregulation	O
of	O
FASLG	O
,	O
a	O
tumor	O
necrosis	O
factor	O
-	O
α	O
family	O
member	O
and	O
an	O
important	O
cell	O
death	O
-	O
inducing	O
ligand	O
whose	O
gene	O
is	O
targeted	O
by	O
miR-21	O
,	O
probably	O
mediates	O
the	O
neuroprotective	O
effect	O
.	O

Moreover	O
,	O
overexpression	O
of	O
miR-21	O
in	O
neurons	O
significantly	O
reduced	O
FASLG	O
levels	O
,	O
and	O
introduction	O
of	O
an	O
miR-21	O
mimic	O
into	O
293-HEK	O
cells	O
substantially	O
reduced	O
luciferase	O
activity	O
in	O
a	O
reporter	O
system	O
containing	O
the	O
3'-UTR	O
of	O
Faslg	O
.	O

We	O
also	O
discuss	O
the	O
implications	O
of	O
these	O
findings	O
with	O
respect	O
to	O
the	O
involvement	O
of	O
miRNAs	O
in	O
the	O
etiopathology	O
of	O
brain	O
disorders	O
and	O
pinpoint	O
the	O
emerging	O
therapeutic	O
potential	O
of	O
miRNAs	O
for	O
the	O
treatment	O
of	O
human	B
diseases	O
.	O

They	O
are	O
now	O
thought	O
to	O
be	O
involved	O
in	O
the	O
control	O
of	O
about	O
one	O
third	O
of	O
all	O
protein	O
-	O
coding	O
genes	O
and	O
play	O
a	O
role	O
in	O
the	O
majority	O
of	O
cellular	O
processes	O
that	O
have	O
been	O
studied	O
.	O

We	O
focus	O
on	O
the	O
role	O
of	O
the	O
miRNA	O
pathway	O
in	O
brain	O
development	O
,	O
function	O
,	O
and	O
disease	O
by	O
highlighting	O
recent	O
observations	O
with	O
respect	O
to	O
miRNA	O
-	O
mediated	O
gene	O
regulation	O
in	O
neuronal	O
differentiation	O
,	O
synaptic	O
plasticity	O
,	O
and	O
the	O
circadian	O
clock	O
.	O

MicroRNAs	O
in	O
brain	O
function	O
and	O
disease	O
.	O

MicroRNAs	O
(	O
miRNAs	O
)	O
,	O
a	O
class	O
of	O
small	O
,	O
non	O
-	O
protein	O
-	O
coding	O
transcripts	O
about	O
21	O
nucleotides	O
long	O
,	O
have	O
recently	O
entered	O
center	O
stage	O
in	O
the	O
study	O
of	O
posttranscriptional	O
gene	O
regulation	O
.	O

This	O
mechanism	O
may	O
have	O
broad	O
implications	O
for	O
microRNA	O
-	O
regulated	O
macrophage	O
activation	O
in	O
inflammatory	O
diseases	O
.	O

Our	O
findings	O
suggest	O
that	O
microRNA	O
dysregulated	O
in	O
multiple	O
sclerosis	O
lesions	O
reduce	O
CD47	O
in	O
brain	O
resident	O
cells	O
,	O
releasing	O
macrophages	O
from	O
inhibitory	O
control	O
,	O
thereby	O
promoting	O
phagocytosis	O
of	O
myelin	O
.	O

Three	O
microRNA	O
upregulated	O
in	O
active	O
multiple	O
sclerosis	O
lesions	O
(	O
microRNA-34a	O
,	O
microRNA-155	O
and	O
microRNA-326	O
)	O
targeted	O
the	O
3'-untranslated	O
region	O
of	O
CD47	O
in	O
reporter	O
assays	O
,	O
with	O
microRNA-155	O
even	O
at	O
two	O
distinct	O
sites	O
.	O

This	O
converged	O
on	O
CD47	O
,	O
which	O
functions	O
as	O
a	O
'	O
do	O
n't	O
eat	O
me	O
'	O
signal	O
inhibiting	O
macrophage	O
activity	O
.	O

We	O
established	O
microRNA	O
profiles	O
from	O
active	O
and	O
inactive	O
multiple	O
sclerosis	O
lesions	O
.	O

Using	O
laser	O
capture	O
microdissection	O
from	O
multiple	O
sclerosis	O
lesions	O
to	O
pool	O
single	O
cells	O
and	O
in	O
vitro	O
cultures	O
,	O
we	O
assigned	O
differentially	O
expressed	O
microRNA	O
to	O
specific	O
cell	O
types	O
.	O

MicroRNA	O
profiling	O
of	O
multiple	O
sclerosis	O
lesions	O
identifies	O
modulators	O
of	O
the	O
regulatory	O
protein	O
CD47	O
.	O

This	O
was	O
confirmed	O
with	O
astrocyte	O
cultures	O
from	O
microRNA-155-|-lacZ	O
mice	B
.	O

We	O
matched	O
microRNA	O
upregulated	O
in	O
phagocytically	O
active	O
multiple	O
sclerosis	O
lesions	O
with	O
downregulated	O
protein	O
coding	O
transcripts	O
.	O

Astrocytes	O
contained	O
all	O
10	O
microRNA	O
that	O
were	O
most	O
strongly	O
upregulated	O
in	O
active	O
multiple	O
sclerosis	O
lesions	O
,	O
including	O
microRNA-155	O
,	O
which	O
is	O
known	O
to	O
modulate	O
immune	O
responses	O
in	O
different	O
ways	O
but	O
so	O
far	O
had	O
not	O
been	O
assigned	O
to	O
central	O
nervous	O
system	O
resident	O
cells	O
.	O

MicroRNA-155	O
was	O
expressed	O
in	O
human	B
astrocytes	O
in	O
situ	O
,	O
and	O
further	O
induced	O
with	O
cytokines	O
in	O
human	B
astrocytes	O
in	O
vitro	O
.	O

This	O
approach	O
protected	O
HSCs	O
from	O
GALC	O
toxicity	O
and	O
allowed	O
successful	O
treatment	O
of	O
a	O
mouse	B
GLD	O
model	O
,	O
providing	O
a	O
rationale	O
to	O
explore	O
HSC	O
-	O
based	O
gene	O
therapy	O
for	O
GLD	O
.	O

Globoid	O
cell	O
leukodystrophy	O
(	O
GLD	O
;	O
also	O
known	O
as	O
Krabbe	O
disease	O
)	O
is	O
an	O
invariably	O
fatal	O
lysosomal	O
storage	O
disorder	O
caused	O
by	O
mutations	O
in	O
the	O
galactocerebrosidase	O
(	O
GALC	O
)	O
gene	O
.	O

Hematopoietic	O
stem	O
cell	O
(	O
HSC	O
)	O
-based	O
gene	O
therapy	O
is	O
being	O
explored	O
for	O
GLD	O
;	O
however	O
,	O
we	O
found	O
that	O
forced	O
GALC	O
expression	O
was	O
toxic	O
to	O
HSCs	O
and	O
early	O
progenitors	O
,	O
highlighting	O
the	O
need	O
for	O
improved	O
regulation	O
of	O
vector	O
expression	O
.	O

Identification	O
of	O
hematopoietic	O
stem	O
cell	O
-	O
specific	O
miRNAs	O
enables	O
gene	O
therapy	O
of	O
globoid	O
cell	O
leukodystrophy	O
.	O

Moreover	O
,	O
repopulating	O
HSCs	O
could	O
be	O
purified	O
solely	O
on	O
the	O
basis	O
of	O
miRNA	O
expression	O
,	O
providing	O
a	O
new	O
method	O
relevant	O
for	O
human	B
HSC	O
isolation	O
.	O

By	O
incorporating	O
miR-126	O
target	O
sequences	O
into	O
a	O
GALC	O
-	O
expressing	O
vector	O
,	O
we	O
suppressed	O
GALC	O
expression	O
in	O
HSCs	O
while	O
maintaining	O
robust	O
expression	O
in	O
mature	O
hematopoietic	O
cells	O
.	O

We	O
used	O
a	O
genetic	O
reporter	O
strategy	O
based	O
on	O
lentiviral	O
vectors	O
to	O
detect	O
microRNA	O
activity	O
in	O
hematopoietic	O
cells	O
at	O
single	O
-	O
cell	O
resolution	O
.	O

We	O
report	O
that	O
miR-126	O
and	O
miR-130a	O
were	O
expressed	O
in	O
HSCs	O
and	O
early	O
progenitors	O
from	O
both	O
mice	B
and	O
humans	B
,	O
but	O
not	O
in	O
differentiated	O
progeny	O
.	O

MicroRNAs	O
(	O
miRNAs	O
)	O
predominantly	O
induce	O
translational	O
repression	O
and	O
are	O
emerging	O
as	O
a	O
major	O
regulators	O
of	O
mRNA	O
and	O
subsequent	O
protein	O
expression	O
after	O
ischemia	O
.	O

The	O
miRNA	O
miR-23a	O
was	O
predicted	O
to	O
bind	O
XIAP	O
mRNA	O
.	O

miR-23a	O
directly	O
bound	O
the	O
3	O
'	O
UTR	O
of	O
XIAP	O
,	O
and	O
miR-23a	O
inhibition	O
led	O
to	O
an	O
increase	O
in	O
XIAP	O
mRNA	O
in	O
vitro	O
,	O
demonstrating	O
that	O
XIAP	O
is	O
a	O
previously	O
uncharacterized	O
target	O
for	O
miR-23a	O
.	O

Embelin	O
treatment	O
significantly	O
exacerbated	O
stroke	O
-	O
induced	O
injury	O
in	O
females	O
but	O
had	O
no	O
effect	O
in	O
males	O
,	O
demonstrating	O
that	O
XIAP	O
is	O
an	O
important	O
mediator	O
of	O
sex	O
-	O
specific	O
responses	O
after	O
stroke	O
.	O

miR-23a	O
levels	O
differed	O
in	O
male	O
and	O
female	O
ischemic	O
brains	O
,	O
providing	O
evidence	O
for	O
sex	O
-	O
specific	O
miRNA	O
expression	O
in	O
stroke	O
.	O

Embelin	O
,	O
a	O
small	O
-	O
molecule	O
inhibitor	O
of	O
XIAP	O
,	O
decreased	O
the	O
interaction	O
between	O
XIAP	O
and	O
caspase-3	O
and	O
led	O
to	O
enhanced	O
caspase	O
activity	O
.	O

It	O
is	O
increasingly	O
recognized	O
that	O
the	O
mechanisms	O
underlying	O
ischemic	O
cell	O
death	O
are	O
sexually	O
dimorphic	O
.	O

miR-23a	O
regulation	O
of	O
X	O
-	O
linked	O
inhibitor	O
of	O
apoptosis	O
(	O
XIAP	O
)	O
contributes	O
to	O
sex	O
differences	O
in	O
the	O
response	O
to	O
cerebral	O
ischemia	O
.	O

In	O
contrast	O
,	O
ischemic	O
cell	O
death	O
in	O
females	O
is	O
primarily	O
triggered	O
by	O
mitochondrial	O
cytochrome	O
c	O
release	O
with	O
subsequent	O
caspase	O
activation	O
.	O

Stroke	O
-	O
induced	O
cell	O
death	O
in	O
males	O
is	O
initiated	O
by	O
the	O
mitochondrial	O
release	O
of	O
apoptosis	O
-	O
inducing	O
factor	O
,	O
resulting	O
in	O
caspase	O
-	O
independent	O
cell	O
death	O
.	O

XIAP	O
mRNA	O
levels	O
were	O
higher	O
in	O
females	O
at	O
baseline	O
.	O

Because	O
X	O
-	O
linked	O
inhibitor	O
of	O
apoptosis	O
(	O
XIAP	O
)	O
is	O
the	O
primary	O
endogenous	O
inhibitor	O
of	O
caspases	O
,	O
its	O
regulation	O
may	O
play	O
a	O
unique	O
role	O
in	O
the	O
response	O
to	O
injury	O
in	O
females	O
.	O

However	O
,	O
XIAP	O
protein	O
levels	O
were	O
decreased	O
in	O
both	O
sexes	O
after	O
stroke	O
.	O

Stroke	O
induced	O
a	O
significant	O
decrease	O
in	O
XIAP	O
mRNA	O
in	O
females	O
,	O
whereas	O
no	O
changes	O
were	O
seen	O
in	O
the	O
male	O
brain	O
.	O

The	O
genomic	O
sequences	O
predict	O
that	O
miRNAs	O
are	O
likely	O
to	O
be	O
derived	O
from	O
larger	O
precursors	O
that	O
have	O
the	O
capacity	O
to	O
form	O
stem	O
-	O
loop	O
structures	O
.	O

Here	O
we	O
report	O
that	O
Gemin3	O
and	O
Gemin4	O
are	O
also	O
in	O
a	O
separate	O
complex	O
that	O
contains	O
eIF2C2	O
,	O
a	O
member	O
of	O
the	O
Argonaute	O
protein	O
family	O
.	O

The	O
SMN	O
complex	O
has	O
critical	O
functions	O
in	O
the	O
assembly	O
/	O
restructuring	O
of	O
diverse	O
ribonucleoprotein	O
(	O
RNP	O
)	O
complexes	O
.	O

We	O
describe	O
40	O
miRNAs	O
,	O
a	O
few	O
of	O
which	O
are	O
identical	O
to	O
recently	O
described	O
human	B
miRNAs	O
,	O
a	O
class	O
of	O
small	O
endogenous	O
RNAs	O
.	O

This	O
novel	O
complex	O
is	O
a	O
large	O
approximately	O
15S	O
RNP	O
that	O
contains	O
numerous	O
microRNAs	O
(	O
miRNAs	O
)	O
.	O

miRNPs	O
:	O
a	O
novel	O
class	O
of	O
ribonucleoproteins	O
containing	O
numerous	O
microRNAs	O
.	O

Reduction	O
in	O
SMN	O
protein	O
results	O
in	O
Spinal	O
muscular	O
atrophy	O
(	O
SMA	O
)	O
,	O
a	O
common	O
neurodegenerative	O
disease	O
.	O

Gemin3	O
is	O
a	O
DEAD	O
-	O
box	O
RNA	O
helicase	O
that	O
binds	O
to	O
the	O
Survival	O
of	O
Motor	O
Neurons	O
(	O
SMN	O
)	O
protein	O
and	O
is	O
a	O
component	O
of	O
the	O
SMN	O
complex	O
,	O
which	O
also	O
comprises	O
SMN	O
,	O
Gemin2	O
,	O
Gemin4	O
,	O
Gemin5	O
,	O
and	O
Gemin6	O
.	O

We	O
also	O
demonstrate	O
that	O
the	O
single	O
-	O
nucleotide	O
polymorphism	O
(	O
SNP	O
)	O
that	O
is	O
located	O
immediately	O
adjacent	O
(	O
3	O
'	O
)	O
to	O
the	O
repeats	O
of	O
the	O
SCA3	O
transcript	O
modulates	O
the	O
structures	O
formed	O
by	O
these	O
sequences	O
,	O
and	O
may	O
have	O
functional	O
significance	O
,	O
as	O
only	O
one	O
of	O
its	O
variants	O
is	O
selected	O
in	O
human	B
evolution	O
.	O

We	O
provide	O
evidence	O
that	O
the	O
hairpin	O
structure	O
formed	O
by	O
CAG	O
repeats	O
in	O
mRNA	O
fragments	O
is	O
preserved	O
in	O
full	O
-	O
length	O
mRNA	O
.	O

Here	O
,	O
we	O
show	O
that	O
the	O
structures	O
formed	O
by	O
the	O
repeats	O
and	O
their	O
natural	O
flanking	O
sequences	O
in	O
the	O
spinocerebellar	O
ataxia	O
(	O
SCA	O
)	O
type	O
3	O
and	O
type	O
6	O
,	O
and	O
dentatorubral	O
-	O
palidoluysian	O
atrophy	O
(	O
DRPLA	O
)	O
transcripts	O
have	O
different	O
molecular	O
architectures	O
which	O
may	O
have	O
functional	O
meaning	O
.	O

The	O
expanded	O
CAG	O
repeats	O
are	O
present	O
in	O
transcripts	O
from	O
several	O
mutant	O
genes	O
associated	O
with	O
hereditary	O
neurodegenerative	O
diseases	O
but	O
their	O
contribution	O
to	O
pathogenesis	O
has	O
not	O
been	O
documented	O
convincingly	O
.	O

CAG	O
repeats	O
are	O
present	O
in	O
numerous	O
human	B
transcripts	O
but	O
neither	O
their	O
structures	O
nor	O
physiological	O
functions	O
have	O
been	O
satisfactorily	O
recognized	O
.	O

Molecular	O
architecture	O
of	O
CAG	O
repeats	O
in	O
human	B
disease	O
related	O
transcripts	O
.	O

Defective	O
RNA	O
metabolism	O
is	O
an	O
emerging	O
mechanism	O
involved	O
in	O
ALS	O
pathogenesis	O
and	O
possibly	O
in	O
other	O
neurodegenerative	O
disorders	O
.	O

miRNA	O
malfunction	O
causes	O
spinal	O
motor	O
neuron	O
disease	O
.	O

Thus	O
,	O
mice	B
that	O
do	O
not	O
process	O
miRNA	O
in	O
SMNs	O
exhibit	O
hallmarks	O
of	O
spinal	O
muscular	O
atrophy	O
(	O
SMA	O
)	O
,	O
including	O
sclerosis	O
of	O
the	O
spinal	O
cord	O
ventral	O
horns	O
,	O
aberrant	O
end	O
plate	O
architecture	O
,	O
and	O
myofiber	O
atrophy	O
with	O
signs	O
of	O
denervation	O
.	O

Here	O
,	O
we	O
show	O
that	O
microRNA	O
(	O
miRNA	O
)	O
activity	O
is	O
essential	O
for	O
long	O
-	O
term	O
survival	O
of	O
postmitotic	O
spinal	O
motor	O
neurons	O
(	O
SMNs	O
)	O
in	O
vivo	O
.	O

We	O
demonstrate	O
that	O
the	O
heavy	O
neurofilament	O
subunit	O
is	O
a	O
target	O
of	O
miR-9	O
,	O
a	O
miRNA	O
that	O
is	O
specifically	O
down	O
-	O
regulated	O
in	O
a	O
genetic	O
model	O
of	O
SMA	O
.	O

Furthermore	O
,	O
a	O
neurofilament	O
heavy	O
subunit	O
previously	O
implicated	O
in	O
motor	O
neuron	O
degeneration	O
is	O
specifically	O
up	O
-	O
regulated	O
in	O
miRNA	O
-	O
deficient	O
SMNs	O
.	O

These	O
data	O
provide	O
evidence	O
for	O
miRNA	O
function	O
in	O
SMN	O
diseases	O
and	O
emphasize	O
the	O
potential	O
role	O
of	O
miR-9-based	O
regulatory	O
mechanisms	O
in	O
adult	O
neurons	O
and	O
neurodegenerative	O
states	O
.	O

Proteasomal	O
degradation	O
of	O
myocardin	O
is	O
required	O
for	O
its	O
transcriptional	O
activity	O
in	O
vascular	O
smooth	O
muscle	O
cells	O
.	O

Myocardin	O
is	O
a	O
transcriptional	O
co	O
-	O
activator	O
of	O
serum	O
response	O
factor	O
(	O
SRF	O
)	O
and	O
can	O
be	O
degraded	O
through	O
ubiquitin	O
-	O
proteasome	O
system	O
.	O

Our	O
preliminary	O
studies	O
unexpectedly	O
revealed	O
that	O
accumulation	O
of	O
myocardin	O
in	O
response	O
to	O
proteasome	O
inhibition	O
by	O
MG132	O
or	O
lactacystin	O
resulted	O
in	O
decrease	O
of	O
transcriptional	O
activity	O
of	O
myocardin	O
as	O
indicated	O
by	O
reduced	O
expression	O
of	O
SMC	O
contractile	O
marker	O
genes	O
(	O
SM	O
α	O
-	O
actin	O
,	O
SM22	O
,	O
and	O
calponin	O
)	O
and	O
muscle	O
-	O
enriched	O
microRNAs	O
(	O
miR-143	O
/	O
145	O
and	O
miR-1	O
/	O
133a	O
)	O
,	O
and	O
reduced	O
contractility	O
of	O
human	B
vascular	O
smooth	O
muscle	O
cells	O
(	O
SMCs	O
)	O
embedded	O
in	O
collagen	O
gel	O
lattices	O
,	O
suggesting	O
that	O
myocardin	O
degradation	O
is	O
required	O
for	O
its	O
transcriptional	O
activity	O
.	O

Further	O
studies	O
using	O
chromatin	O
immunoprecipitation	O
assay	O
revealed	O
that	O
proteasome	O
inhibition	O
,	O
although	O
increased	O
the	O
occupancy	O
of	O
myocardin	O
and	O
SRF	O
on	O
the	O
promoter	O
of	O
SM	O
α	O
-	O
actin	O
gene	O
,	O
abolished	O
myocardin	O
-	O
dependent	O
recruitment	O
of	O
RNA	O
polymerase	O
II	O
.	O

We	O
further	O
examined	O
the	O
degradation	O
of	O
myocardin	O
in	O
epithelioid	O
and	O
spindle	O
-	O
shaped	O
SMCs	O
and	O
revealed	O
that	O
myocardin	O
in	O
more	O
differentiated	O
spindle	O
-	O
shaped	O
SMCs	O
was	O
more	O
quickly	O
degraded	O
and	O
had	O
shorter	O
half	O
-	O
life	O
than	O
in	O
epithelioid	O
SMCs	O
.	O

In	O
neointimal	O
lesions	O
,	O
we	O
found	O
that	O
stabilization	O
of	O
myocardin	O
protein	O
was	O
companied	O
by	O
downregulation	O
of	O
transcripts	O
of	O
ubiquitin	O
and	O
proteasome	O
subunits	O
,	O
further	O
illustrating	O
the	O
mechanism	O
underlying	O
reduction	O
of	O
myocardin	O
transcriptional	O
activity	O
.	O

In	O
summary	O
,	O
our	O
results	O
have	O
suggested	O
that	O
proteasomal	O
degradation	O
of	O
myocardin	O
is	O
required	O
for	O
its	O
transcriptional	O
activity	O
.	O

However	O
,	O
prior	O
to	O
expression	O
,	O
it	O
is	O
necessary	O
to	O
convert	O
the	O
single	O
-	O
stranded	O
DNA	O
genome	O
into	O
double	O
-	O
stranded	O
DNA	O
,	O
which	O
hinders	O
the	O
efficiency	O
of	O
these	O
vectors	O
.	O

Numerous	O
studies	O
and	O
clinical	O
trials	O
have	O
demonstrated	O
the	O
efficacy	O
of	O
recombinant	O
adeno	O
-	O
associated	O
virus	O
gene	O
delivery	O
vectors	O
.	O

[	O
Trends	O
in	O
development	O
of	O
self	O
-	O
complementary	O
adeno	O
-	O
associated	O
virus	O
vector	O
]	O
.	O

We	O
can	O
entirely	O
circumvent	O
this	O
step	O
through	O
the	O
use	O
of	O
self	O
-	O
complementary	O
recombinant	O
adeno	O
-	O
associated	O
virus	O
vector	O
(	O
scrAAV	O
)	O
.	O

ScrAAV	O
packages	O
an	O
inverted	O
repeat	O
genome	O
that	O
can	O
fold	O
into	O
double	O
-	O
stranded	O
DNA	O
without	O
the	O
requirement	O
for	O
DNA	O
synthesis	O
or	O
base	O
-	O
pairing	O
between	O
multiple	O
vector	O
genomes	O
.	O

By	O
using	O
scrAAV	O
,	O
we	O
could	O
increase	O
expression	O
efficiency	O
and	O
reduce	O
immune	O
response	O
caused	O
by	O
vectors	O
themselves	O
.	O

Therefore	O
,	O
it	O
is	O
a	O
promising	O
vector	O
for	O
gene	O
therapy	O
.	O

So	O
far	O
,	O
it	O
has	O
been	O
used	O
in	O
the	O
treatment	O
of	O
hepatic	O
diseases	O
,	O
central	O
nervous	O
system	O
diseases	O
,	O
and	O
eye	O
diseases	O
.	O

It	O
has	O
also	O
been	O
used	O
in	O
the	O
modifications	O
of	O
stem	O
cells	O
and	O
as	O
vectors	O
for	O
siRNA	O
/	O
miRNA	O
and	O
ribozymes	O
.	O

In	O
this	O
review	O
,	O
we	O
focused	O
on	O
the	O
preparation	O
,	O
expression	O
and	O
location	O
of	O
scrAAV	O
both	O
in	O
vitro	O
and	O
in	O
vivo	O
.	O

We	O
mainly	O
introduced	O
the	O
recent	O
progress	O
of	O
scrAAV	O
based	O
therapy	O
of	O
Hemophilia	O
B	O
,	O
in	O
order	O
to	O
elucidate	O
the	O
potential	O
and	O
prospects	O
of	O
scrAAV	O
in	O
gene	O
therapy	O
.	O

Since	O
neuron	O
-	O
specific	O
microRNA-7	O
is	O
downregulated	O
in	O
gliomas	O
but	O
highly	O
expressed	O
in	O
normal	O
brain	O
tissue	O
,	O
we	O
engineered	O
a	O
microRNA	O
-	O
sensitive	O
virus	O
containing	O
target	O
sites	O
for	O
microRNA-7	O
in	O
the	O
3'-untranslated	O
region	O
of	O
the	O
viral	O
fusion	O
gene	O
.	O

Recent	O
preclinical	O
studies	O
have	O
shown	O
that	O
the	O
cellular	O
tropism	O
of	O
several	O
viruses	O
can	O
be	O
controlled	O
by	O
inserting	O
microRNA	O
-	O
target	O
sequences	O
into	O
their	O
genomes	O
,	O
thereby	O
inhibiting	O
spread	O
in	O
tissues	O
expressing	O
cognate	O
microRNAs	O
.	O

Oncolytic	O
measles	O
viruses	O
(	O
MV	O
)	O
derived	O
from	O
the	O
live	O
attenuated	O
vaccine	O
strain	O
have	O
been	O
engineered	O
for	O
increased	O
tumor	O
-	O
cell	O
specificity	O
,	O
and	O
are	O
currently	O
under	O
investigation	O
in	O
clinical	O
trials	O
including	O
a	O
phase	O
I	O
study	O
for	O
glioblastoma	O
multiforme	O
(	O
GBM	O
)	O
.	O

MicroRNA	O
-	O
sensitive	O
oncolytic	O
measles	O
viruses	O
for	O
cancer	O
-	O
specific	O
vector	O
tropism	O
.	O

This	O
is	O
proof	O
-	O
of	O
-	O
concept	O
that	O
tropism	O
restriction	O
by	O
tissue	O
-	O
specific	O
microRNAs	O
can	O
be	O
adapted	O
to	O
oncolytic	O
MV	O
to	O
regulate	O
viral	O
replication	O
and	O
gene	O
expression	O
to	O
maximize	O
tumor	O
specificity	O
without	O
compromising	O
oncolytic	O
efficacy	O
.	O

Furthermore	O
,	O
microRNA	O
-	O
mediated	O
inhibition	O
protected	O
genetically	O
modified	O
mice	B
susceptible	O
to	O
MV	O
infection	O
from	O
a	O
potentially	O
lethal	O
intracerebral	O
challenge	O
.	O

Importantly	O
,	O
endogenous	O
microRNA-7	O
expression	O
in	O
primary	O
human	B
brain	O
resections	O
tightly	O
restricted	O
replication	O
and	O
spread	O
of	O
microRNA	O
-	O
sensitive	O
virus	O
.	O

In	O
presence	O
of	O
microRNA-7	O
this	O
modification	O
inhibits	O
translation	O
of	O
envelope	O
proteins	O
,	O
restricts	O
viral	O
spread	O
,	O
and	O
progeny	O
production	O
.	O

Even	O
though	O
highly	O
attenuated	O
in	O
presence	O
of	O
microRNA-7	O
,	O
this	O
virus	O
retained	O
full	O
efficacy	O
against	O
glioblastoma	O
xenografts	O
.	O

Expression	O
profile	O
of	O
MicroRNAs	O
in	O
young	O
stroke	O
patients	B
.	O

BACKGROUND	O
:	O
The	O
methods	O
currently	O
available	O
for	O
diagnosis	O
and	O
prognosis	O
of	O
cerebral	O
ischaemia	O
still	O
require	O
further	O
improvements	O
.	O

Blood	O
samples	O
from	O
normal	O
(	O
n=5	O
)	O
individuals	O
were	O
used	O
as	O
controls	O
.	O

Total	O
RNA	O
extracted	O
from	O
whole	O
blood	O
was	O
subjected	O
to	O
miroRNA	O
profiling	O
and	O
real	O
-	O
time	O
PCR	O
analysis	O
.	O

miRNAs	O
that	O
are	O
implicated	O
in	O
the	O
endothelial	O
/	O
vascular	O
function	O
,	O
erythropoiesis	O
,	O
angiogenesis	O
and	O
neural	O
function	O
showed	O
differential	O
expression	O
profile	O
as	O
compared	O
to	O
the	O
normal	O
control	O
.	O

Interestingly	O
,	O
miRNAs	O
that	O
are	O
involved	O
in	O
hypoxic	O
conditions	O
have	O
also	O
been	O
found	O
in	O
our	O
miRNA	O
profiles	O
.	O

Micro	O
-	O
RNAs	O
(	O
small	O
non	O
-	O
coding	O
RNAs	O
)	O
have	O
been	O
recently	O
reported	O
as	O
useful	O
biomarkers	O
in	O
diseases	O
such	O
as	O
cancer	O
and	O
diabetes	O
.	O

We	O
therefore	O
carried	O
out	O
microRNA	O
(	O
miRNA	O
)	O
profiling	O
from	O
peripheral	O
blood	O
to	O
detect	O
and	O
identify	O
characteristic	O
patterns	O
in	O
ischaemic	O
stroke	O
.	O

METHODS	O
/	O
PRINCIPAL	O
FINDINGS	O
:	O
The	O
ischaemic	O
stroke	O
patients	B
aged	O
between	O
18	O
-	O
49	O
years	O
,	O
characterized	O
based	O
on	O
World	O
Health	O
Organization	O
clinical	O
criteria	O
were	O
further	O
classified	O
according	O
to	O
TOAST	O
classification	O
,	O
a	O
)	O
Large	O
-	O
vessel	O
atherosclerosis	O
[	O
n=8	O
]	O
b	O
)	O
Small	O
-	O
vessel	O
disease	O
[	O
n=3	O
]	O
c	O
)	O
Cardioembolism	O
[	O
n=5	O
]	O
d	O
)	O
Undetermined	O
cause	O
[	O
n=3	O
]	O
.	O

The	O
patients	B
'	O
functional	O
status	O
at	O
the	O
time	O
of	O
blood	O
sampling	O
(	O
at	O
the	O
outpatient	O
clinics	O
)	O
was	O
evaluated	O
with	O
the	O
modified	O
Rankin	O
Scale	O
(	O
mRS	O
)	O
.	O

CONCLUSION	O
:	O
We	O
demonstrate	O
that	O
the	O
peripheral	O
blood	O
miRNAs	O
and	O
their	O
profiles	O
can	O
be	O
developed	O
as	O
biomarkers	O
in	O
diagnosis	O
and	O
prognosis	O
of	O
cerebral	O
ischaemic	O
stroke	O
.	O

The	O
dysregulated	O
miRNAs	O
have	O
been	O
detectable	O
even	O
after	O
several	O
months	O
from	O
the	O
onset	O
of	O
stroke	O
in	O
what	O
is	O
usually	O
regarded	O
as	O
neurologically	O
stable	O
patients	B
.	O

Finally	O
,	O
the	O
association	O
of	O
the	O
variant	O
with	O
stroke	O
was	O
tested	O
in	O
438	O
stroke	O
patients	B
and	O
890	O
controls	O
,	O
and	O
replicated	O
in	O
an	O
independent	O
population	O
of	O
1791	O
stroke	O
patients	B
and	O
1843	O
controls	O
.	O

The	O
TT	O
genotype	O
resulted	O
in	O
a	O
significant	O
reduction	O
in	O
overall	O
stroke	O
risk	O
{	O
OR	O
,	O
0.51	O
[	O
95	O
%	O
confidence	O
interval	O
(	O
CI	O
)	O
,	O
0.36	O
-	O
0.74	O
]	O
,	O
P	O
=	O
0.0003	O
}	O
,	O
ischemic	O
stroke	O
[	O
OR	O
,	O
0.56	O
(	O
95	O
%	O
CI	O
,	O
0.36	O
-	O
0.85	O
)	O
,	O
P	O
=	O
0.007	O
]	O
and	O
hemorrhagic	O
stroke	O
[	O
OR	O
,	O
0.46	O
(	O
95	O
%	O
CI	O
,	O
0.26	O
-	O
0.80	O
)	O
,	O
P	O
=	O
0.007	O
]	O
.	O

We	O
found	O
that	O
the	O
A	O
allele	O
of	O
rs2507800	O
suppressed	O
angiopoietin-1	O
translation	O
by	O
facilitating	O
miR-211	O
binding	O
,	O
but	O
not	O
the	O
T	O
allele	O
.	O

Subjects	O
carrying	O
the	O
TT	O
genotype	O
had	O
higher	O
plasma	O
angiopoietin-1	O
levels	O
than	O
those	O
with	O
the	O
A	O
allele	O
.	O

To	O
test	O
our	O
hypothesis	O
,	O
a	O
predicted	O
microRNA	O
-	O
binding	O
site	O
was	O
found	O
in	O
the	O
3'-UTR	O
of	O
angiopoietin-1	O
using	O
bioinformatics	O
;	O
variant	O
rs2507800	O
was	O
identified	O
to	O
be	O
located	O
in	O
the	O
miR-211-binding	O
site	O
of	O
angiopoietin-1	O
.	O

Secondly	O
,	O
the	O
effects	O
of	O
the	O
identified	O
variant	O
on	O
angiopoietin-1	O
translation	O
were	O
assessed	O
using	O
a	O
luciferase	O
reporter	O
assay	O
and	O
ELISA	O
.	O

Angiopoietin-1	O
is	O
a	O
vascular	O
strengthening	O
factor	O
during	O
vascular	O
development	O
and	O
a	O
protective	O
factor	O
for	O
pathological	O
vascular	O
inflammation	O
and	O
leakage	O
.	O

Brain	O
vascular	O
leaking	O
and	O
inflammation	O
are	O
two	O
important	O
pathological	O
processes	O
of	O
stroke	O
;	O
therefore	O
,	O
we	O
hypothesized	O
that	O
variants	O
of	O
the	O
microRNA	O
-	O
binding	O
site	O
in	O
angiopoietin-1	O
would	O
affect	O
its	O
expression	O
and	O
confer	O
a	O
risk	O
of	O
stroke	O
.	O

A	O
functional	O
variant	O
in	O
the	O
3'-UTR	O
of	O
angiopoietin-1	O
might	O
reduce	O
stroke	O
risk	O
by	O
interfering	O
with	O
the	O
binding	O
efficiency	O
of	O
microRNA	O
211	O
.	O

Our	O
results	O
provide	O
evidence	O
that	O
the	O
TT	O
genotype	O
(	O
rs2507800	O
)	O
in	O
the	O
3'-UTR	O
of	O
angiopoietin-1	O
might	O
reduce	O
the	O
risk	O
of	O
stroke	O
by	O
interfering	O
with	O
miR-211	O
binding	O
.	O

These	O
results	O
were	O
confirmed	O
in	O
an	O
independent	O
study	O
.	O

We	O
also	O
indentified	O
97	O
differentially	O
expressed	O
microRNAs	O
among	O
240	O
tumor	O
and	O
10	O
normal	O
samples	O
.	O

22	O
of	O
which	O
have	O
been	O
reported	O
to	O
affect	O
glioblastoma	O
and	O
50	O
of	O
which	O
were	O
implicated	O
in	O
other	O
cancers	O
and	O
brain	O
diseases	O
.	O

Though	O
a	O
lot	O
of	O
research	O
has	O
been	O
focused	O
on	O
this	O
disease	O
,	O
the	O
causes	O
and	O
pathogenesis	O
of	O
glioblastoma	O
have	O
not	O
been	O
indentified	O
clearly	O
.	O

RESULTS	O
:	O
We	O
indentified	O
1,236	O
significantly	O
differentially	O
expressed	O
genes	O
,	O
and	O
30	O
pathways	O
enriched	O
in	O
the	O
set	O
of	O
differentially	O
expressed	O
genes	O
among	O
243	O
tumor	O
and	O
11	O
normal	O
samples	O
.	O

Investigation	O
gene	O
and	O
microRNA	O
expression	O
in	O
glioblastoma	O
.	O

BACKGROUND	O
:	O
Glioblastoma	O
is	O
the	O
most	O
common	O
primary	O
brain	O
tumor	O
in	O
adults	O
.	O

CONCLUSION	O
:	O
We	O
investigated	O
gene	O
and	O
microRNA	O
Expression	O
in	O
Glioblastoma	O
and	O
gave	O
a	O
comprehensive	O
function	O
study	O
of	O
differential	O
expressed	O
gene	O
and	O
microRNA	O
in	O
glioblastoma	O
patients	B
.	O

Further	O
function	O
analysis	O
of	O
target	O
genes	O
suggested	O
that	O
microRNAs	O
most	O
frequently	O
targeted	O
genes	O
associated	O
with	O
Cell	O
Signalling	O
and	O
Nervous	O
System	O
.	O

We	O
found	O
two	O
experimentally	O
validated	O
microRNA	O
targets	O
and	O
1,094	O
miRNA	O
-	O
target	O
gene	O
pairs	O
in	O
our	O
datasets	O
which	O
were	O
predicted	O
by	O
miRanda	O
algorithm	O
,	O
8	O
of	O
the	O
target	O
genes	O
were	O
tumor	O
suppressor	O
genes	O
and	O
3	O
were	O
oncogenes	O
.	O

We	O
regressed	O
gene	O
expression	O
on	O
microRNA	O
expression	O
in	O
237	O
tumor	O
tissues	O
and	O
10	O
normal	O
tissues	O
comprehensively	O
.	O

These	O
findings	O
gave	O
important	O
clues	O
to	O
study	O
of	O
the	O
carcinogenic	O
process	O
in	O
glioblastomas	O
.	O

Does	O
the	O
effect	O
of	O
microRNAs	O
in	O
vascular	O
neointimal	O
formation	O
depend	O
on	O
cell	O
cycle	O
phase	O
?	O

CONCLUSION	O
:	O
Our	O
results	O
indicate	O
a	O
time	O
-	O
dependent	O
expression	O
pattern	O
of	O
miR-223	O
and	O
miR-124a	O
in	O
a	O
mouse	B
model	O
of	O
SCI	O
.	O

In	O
this	O
study	O
,	O
the	O
time	O
course	O
of	O
miRNA-223	O
expression	O
may	O
be	O
related	O
to	O
inflammatory	O
responses	O
after	O
SCI	O
,	O
and	O
the	O
time	O
course	O
of	O
decreased	O
miR-124a	O
expression	O
may	O
reflect	O
cell	O
death	O
.	O

However	O
,	O
miR-124a	O
,	O
which	O
was	O
present	O
in	O
the	O
normal	O
spinal	O
cord	O
,	O
was	O
not	O
observed	O
at	O
the	O
injured	O
site	O
.	O

RESULTS	O
:	O
Quantitative	O
PCR	O
revealed	O
two	O
peaks	O
of	O
miR-223	O
expression	O
at	O
6	O
and	O
12	O
h	O
and	O
3	O
days	O
after	O
SCI	O
.	O
MiR-124a	O
expression	O
decreased	O
significantly	O
from	O
1	O
day	O
to	O
7	O
days	O
after	O
SCI	O
.	O

In	O
situ	O
hybridization	O
demonstrated	O
the	O
presence	O
of	O
miR-223	O
around	O
the	O
injured	O
site	O
.	O

METHODS	O
:	O
We	O
examined	O
the	O
expression	O
of	O
miRNA	O
(	O
miR	O
)	O
-223	O
and	O
miR-124a	O
in	O
a	O
mouse	B
model	O
at	O
6	O
h	O
,	O
12	O
h	O
,	O
1	O
day	O
,	O
3	O
days	O
and	O
7	O
days	O
after	O
SCI	O
using	O
quantitative	O
PCR	O
.	O

The	O
miRNA	O
expression	O
was	O
confirmed	O
by	O
in	O
situ	O
hybridization	O
.	O

MiRNAs	O
are	O
short	O
noncoding	O
RNAs	O
that	O
suppress	O
the	O
translation	O
of	O
target	O
genes	O
by	O
binding	O
to	O
their	O
mRNAs	O
,	O
and	O
play	O
a	O
central	O
role	O
in	O
gene	O
regulation	O
in	O
health	O
and	O
disease	O
.	O

The	O
purpose	O
of	O
this	O
study	O
was	O
to	O
examine	O
miRNA	O
expression	O
after	O
SCI	O
.	O
SETTING	O
:	O
Department	O
of	O
Orthopaedic	O
Surgery	O
,	O
Graduate	O
School	O
of	O
Biomedical	O
Sciences	O
,	O
Hiroshima	O
University	O
.	O

STUDY	O
DESIGN	O
:	O
We	O
investigated	O
microRNA	O
(	O
miRNA	O
)	O
expression	O
after	O
spinal	O
cord	O
injury	O
(	O
SCI	O
)	O
in	O
mice	B
.	O

OBJECTIVES	O
:	O
The	O
recent	O
discovery	O
of	O
miRNAs	O
suggests	O
a	O
novel	O
regulatory	O
control	O
over	O
gene	O
expression	O
during	O
plant	O
and	O
animal	O
development	O
.	O

Responses	O
of	O
microRNAs	O
124a	O
and	O
223	O
following	O
spinal	O
cord	O
injury	O
in	O
mice	B
.	O

The	O
characteristics	O
of	O
tumors	O
induced	O
in	O
NG2-KO	O
were	O
compared	O
to	O
those	O
of	O
tumors	O
induced	O
in	O
wild	O
type	O
mice	B
by	O
immunostaining	O
for	O
different	O
cell	O
lineage	O
markers	O
and	O
by	O
transplantation	O
assays	O
in	O
adult	O
mice	B
.	O

METHODS	O
:	O
The	O
survival	O
curves	O
of	O
NG2-KO	O
mice	B
overexpressing	O
PDGF	O
-	O
B	O
were	O
compared	O
to	O
controls	O
by	O
using	O
a	O
Log	O
-	O
rank	O
test	O
.	O

We	O
have	O
recently	O
generated	O
a	O
glioma	O
model	O
based	O
on	O
the	O
overexpression	O
of	O
PDGF	O
-	O
B	O
in	O
neural	O
progenitors	O
and	O
here	O
we	O
investigated	O
the	O
possible	O
relevance	O
of	O
NG2	O
during	O
PDGF	O
-	O
driven	O
gliomagenesis	O
.	O

NG2	O
has	O
been	O
shown	O
to	O
function	O
as	O
a	O
co	O
-	O
receptor	O
for	O
PDGF	O
ligands	O
whose	O
aberrant	O
expression	O
is	O
common	O
in	O
gliomas	O
.	O

BACKGROUND	O
:	O
In	O
the	O
last	O
years	O
,	O
the	O
transmembrane	O
proteoglycan	O
NG2	O
has	O
gained	O
interest	O
as	O
a	O
therapeutic	O
target	O
for	O
the	O
treatment	O
of	O
diverse	O
tumor	O
types	O
,	O
including	O
gliomas	O
,	O
because	O
increases	O
of	O
its	O
expression	O
correlate	O
with	O
dismal	O
prognosis	O
.	O

PDGF	O
-	O
B	O
-	O
driven	O
gliomagenesis	O
can	O
occur	O
in	O
the	O
absence	O
of	O
the	O
proteoglycan	O
NG2	O
.	O

On	O
the	O
basis	O
of	O
the	O
data	O
obtained	O
,	O
we	O
therefore	O
suggest	O
that	O
the	O
role	O
of	O
NG2	O
as	O
a	O
target	O
molecule	O
for	O
glioma	O
treatment	O
should	O
be	O
carefully	O
reconsidered	O
.	O

CONCLUSIONS	O
:	O
Our	O
analysis	O
,	O
using	O
both	O
NG2-KO	O
mice	B
and	O
a	O
miRNA	O
based	O
silencing	O
approach	O
,	O
clearly	O
demonstrates	O
that	O
NG2	O
is	O
not	O
required	O
for	O
PDGF	O
-	O
B	O
to	O
efficiently	O
induce	O
and	O
maintain	O
gliomas	O
from	O
neural	O
progenitors	O
.	O

RESULTS	O
:	O
We	O
showed	O
that	O
the	O
lack	O
of	O
NG2	O
does	O
not	O
appreciably	O
affect	O
any	O
of	O
the	O
characterized	O
steps	O
of	O
PDGF	O
-	O
driven	O
brain	O
tumorigenesis	O
,	O
such	O
as	O
oligodendrocyte	O
progenitor	O
cells	O
(	O
OPC	O
)	O
induction	O
,	O
the	O
recruitment	O
of	O
bystander	O
OPCs	O
and	O
the	O
progression	O
to	O
full	O
malignancy	O
,	O
which	O
take	O
place	O
as	O
in	O
wild	O
type	O
animals	O
.	O

Aberrant	O
microRNA	O
expression	O
in	O
the	O
brains	O
of	O
neurodegenerative	O
diseases	O
:	O
miR-29a	O
decreased	O
in	O
Alzheimer	O
disease	O
brains	O
targets	O
neurone	O
navigator	O
3	O
.	O
AIMS	O
:	O
MicroRNAs	O
(	O
miRNAs	O
)	O
are	O
small	O
non	O
-	O
coding	O
RNAs	O
that	O
regulate	O
translational	O
repression	O
of	O
target	O
mRNAs	O
.	O

MiR-29a	O
-	O
mediated	O
down	O
-	O
regulation	O
of	O
NAV3	O
was	O
verified	O
by	O
the	O
luciferase	O
reporter	O
assay	O
.	O

However	O
,	O
we	O
found	O
significant	O
down	O
-	O
regulation	O
of	O
miR-29a	O
in	O
Alzheimer	O
disease	O
(	O
AD	O
)	O
brains	O
.	O

The	O
database	O
search	O
on	O
TargetScan	O
,	O
PicTar	O
and	O
miRBase	O
Target	O
identified	O
neurone	O
navigator	O
3	O
(	O
NAV3	O
)	O
,	O
a	O
regulator	O
of	O
axon	O
guidance	O
,	O
as	O
a	O
principal	O
target	O
of	O
miR-29a	O
,	O
and	O
actually	O
NAV3	O
mRNA	O
levels	O
were	O
elevated	O
in	O
AD	O
brains	O
.	O

This	O
was	O
followed	O
by	O
enlargement	O
of	O
study	O
population	O
with	O
quantitative	O
RT	O
-	O
PCR	O
analysis	O
(	O
n	O
=	O
21	O
)	O
.	O

RESULTS	O
:	O
By	O
microarray	O
analysis	O
,	O
we	O
identified	O
up	O
-	O
regulation	O
of	O
miR-29a	O
,	O
miR-29b	O
and	O
miR-338	O
-	O
3p	O
in	O
amyotrophic	O
lateral	O
sclerosis	O
brains	O
,	O
but	O
due	O
to	O
a	O
great	O
interindividual	O
variation	O
,	O
we	O
could	O
not	O
validate	O
these	O
results	O
by	O
quantitative	O
RT	O
-	O
PCR	O
.	O

To	O
identify	O
miRNAs	O
closely	O
associated	O
with	O
neurodegeneration	O
,	O
we	O
performed	O
miRNA	O
expression	O
profiling	O
of	O
brain	O
tissues	O
of	O
various	O
neurodegenerative	O
diseases	O
.	O

METHODS	O
:	O
We	O
initially	O
studied	O
the	O
frontal	O
cortex	O
derived	O
from	O
three	O
amyotrophic	O
lateral	O
sclerosis	O
patients	B
by	O
using	O
a	O
microarray	O
of	O
723	O
human	B
miRNAs	O
.	O

Accumulating	O
evidence	O
indicates	O
that	O
various	O
miRNAs	O
,	O
expressed	O
in	O
a	O
spatially	O
and	O
temporally	O
controlled	O
that	O
manner	O
in	O
the	O
brain	O
plays	O
a	O
key	O
role	O
in	O
neuronal	O
development	O
.	O

However	O
,	O
at	O
present	O
,	O
the	O
pathological	O
implication	O
of	O
aberrant	O
miRNA	O
expression	O
in	O
neurodegenerative	O
events	O
remains	O
largely	O
unknown	O
.	O

By	O
immunohistochemistry	O
,	O
NAV3	O
expression	O
was	O
most	O
evidently	O
enhanced	O
in	O
degenerating	O
pyramidal	O
neurones	O
in	O
the	O
cerebral	O
cortex	O
of	O
AD	O
.	O
CONCLUSIONS	O
:	O
These	O
observations	O
suggest	O
the	O
hypothesis	O
that	O
underexpression	O
of	O
miR-29a	O
affects	O
neurodegenerative	O
processes	O
by	O
enhancing	O
neuronal	O
NAV3	O
expression	O
in	O
AD	O
brains	O
.	O

The	O
emerging	O
therapeutic	O
role	O
of	O
RNA	O
interference	O
in	O
disorders	O
of	O
the	O
central	O
nervous	O
system	O
.	O

Knockdown	O
of	O
GAD67	O
protein	O
levels	O
normalizes	O
neuronal	O
activity	O
in	O
a	O
rat	B
model	O
of	O
Parkinson	O
's	O
disease	O
.	O

METHODS	O
:	O
To	O
normalize	O
the	O
GAD67	O
expression	O
in	O
the	O
striatum	O
after	O
dopamine	O
depletion	O
,	O
we	O
developed	O
several	O
lentiviral	O
vectors	O
that	O
express	O
RNA	O
interference	O
(	O
RNAi	O
)	O
directed	O
against	O
GAD67	O
mitochondrial	O
RNA	O
.	O

The	O
vectors	O
were	O
injected	O
into	O
the	O
striatum	O
of	O
hemiparkinsonian	O
rats	B
and	O
the	O
level	O
of	O
GAD67	O
protein	O
as	O
well	O
as	O
a	O
marker	O
of	O
neuronal	O
activity	O
,	O
mtCO1	O
,	O
was	O
analyzed	O
using	O
western	O
blots	O
.	O

BACKGROUND	O
:	O
Dopamine	O
depletion	O
of	O
the	O
striatum	O
is	O
one	O
of	O
the	O
hallmarks	O
of	O
Parkinson	O
's	O
disease	O
.	O

The	O
loss	O
of	O
dopamine	O
upregulates	O
GAD67	O
expression	O
in	O
the	O
striatal	O
projection	O
neurons	O
and	O
causes	O
other	O
changes	O
in	O
the	O
activity	O
of	O
the	O
basal	O
ganglia	O
circuit	O
.	O

Using	O
a	O
lentiviral	O
vectors	O
with	O
a	O
synthetic	O
miRNA	O
scaffold	O
to	O
deliver	O
RNAi	O
,	O
we	O
were	O
able	O
to	O
normalize	O
the	O
GAD67	O
protein	O
levels	O
in	O
the	O
parkinsonian	O
rat	B
striatum	O
.	O

In	O
addition	O
,	O
we	O
were	O
able	O
to	O
normalize	O
the	O
increased	O
neural	O
activity	O
,	O
which	O
resulted	O
from	O
the	O
loss	O
of	O
dopamine	O
as	O
measured	O
by	O
the	O
marker	O
mtCO1	O
.	O

RESULTS	O
:	O
Unilateral	O
lesions	O
of	O
the	O
dopamine	O
neurons	O
in	O
substantia	O
nigra	O
resulted	O
in	O
an	O
increased	O
level	O
of	O
GAD67	O
protein	O
in	O
the	O
ipsilateral	O
striatum	O
.	O

Furthermore	O
,	O
we	O
detected	O
significantly	O
higher	O
levels	O
of	O
mtCO1	O
,	O
after	O
dopamine	O
depletion	O
in	O
the	O
striatum	O
.	O

CONCLUSIONS	O
:	O
We	O
conclude	O
that	O
RNAi	O
directed	O
against	O
GAD67	O
may	O
be	O
a	O
valid	O
approach	O
to	O
correct	O
the	O
dysregulation	O
of	O
the	O
basal	O
ganglia	O
circuit	O
in	O
a	O
rat	B
model	O
of	O
Parkinson	O
's	O
disease	O
.	O

The	O
possibility	O
to	O
correct	O
for	O
a	O
loss	O
of	O
dopamine	O
using	O
nondopamimetic	O
tools	O
is	O
interesting	O
because	O
it	O
may	O
be	O
more	O
directed	O
towards	O
the	O
casual	O
mechanisms	O
of	O
the	O
motor	O
symptoms	O
.	O

Copyright	O
©	O
2011	O
John	O
Wiley	O
&	O
Sons	O
,	O
Ltd.	O

MicroRNAs	O
(	O
miRNAs	O
)	O
are	O
small	O
noncoding	O
RNA	O
molecules	O
that	O
regulate	O
protein	O
expression	O
by	O
cleaving	O
or	O
repressing	O
the	O
translation	O
of	O
target	O
mRNAs	O
.	O

MiR-21	O
protected	O
human	B
glioblastoma	O
U87MG	O
cells	O
from	O
chemotherapeutic	O
drug	O
temozolomide	O
induced	O
apoptosis	O
by	O
decreasing	O
Bax	O
/	O
Bcl-2	O
ratio	O
and	O
caspase-3	O
activity	O
.	O

Several	O
miRNAs	O
have	O
been	O
recently	O
reported	O
to	O
be	O
involved	O
in	O
modulation	O
of	O
glioma	O
development	O
,	O
especially	O
some	O
up	O
-	O
regulated	O
miRNAs	O
,	O
such	O
as	O
microRNA-21	O
(	O
miR-21	O
)	O
,	O
which	O
has	O
been	O
found	O
to	O
function	O
as	O
an	O
oncogene	O
in	O
cultured	O
glioblastoma	O
multiforme	O
cells	O
.	O

In	O
mammal	O
animals	O
,	O
their	O
function	O
mainly	O
represses	O
the	O
target	O
mRNAs	O
transcripts	O
via	O
imperfectly	O
complementary	O
to	O
the	O
3'UTR	O
of	O
target	O
mRNAs	O
.	O

However	O
,	O
resistance	O
develops	O
quickly	O
and	O
with	O
high	O
frequency	O
.	O

Temozolomide	O
(	O
TMZ	O
)	O
,	O
an	O
alkylating	O
agent	O
,	O
is	O
a	O
promising	O
chemotherapeutic	O
agent	O
for	O
treating	O
glioblastoma	O
.	O

Our	O
studies	O
showed	O
that	O
TMZ	O
markedly	O
enhanced	O
apoptosis	O
in	O
U87MG	O
cells	O
compared	O
with	O
untreated	O
cells	O
(	O
P<0.05	O
)	O
.	O

To	O
explore	O
the	O
mechanism	O
of	O
resistance	O
,	O
we	O
found	O
that	O
miR-21	O
could	O
protect	O
human	B
glioblastoma	O
U87MG	O
cells	O
from	O
TMZ	O
induced	O
apoptosis	O
.	O

However	O
,	O
over	O
-	O
express	O
miR-21	O
in	O
U87MG	O
cells	O
could	O
significantly	O
reduce	O
TMZ	O
-	O
induced	O
apoptosis	O
(	O
P<0.05	O
)	O
.	O

Pro	O
-	O
apoptotic	O
Bax	O
and	O
anti	O
-	O
apoptotic	O
Bcl-2	O
proteins	O
are	O
known	O
to	O
regulate	O
the	O
apoptosis	O
of	O
glioma	O
cells	O
.	O

Further	O
research	O
demonstrated	O
that	O
the	O
mechanism	O
was	O
associated	O
with	O
a	O
shift	O
in	O
Bax	O
/	O
Bcl-2	O
ratio	O
and	O
change	O
in	O
caspase-3	O
activity	O
.	O

Bax	O
is	O
shown	O
to	O
correlate	O
with	O
an	O
increased	O
survival	O
of	O
glioblastoma	O
multiforme	O
patients	B
.	O

However	O
,	O
such	O
effect	O
was	O
partly	O
prevented	O
by	O
treatment	O
of	O
cells	O
with	O
miR-21	O
overexpression	O
before	O
,	O
which	O
appeared	O
to	O
downregulate	O
the	O
Bax	O
expression	O
,	O
upregulate	O
the	O
Bcl-2	O
expression	O
and	O
decrease	O
caspase-3	O
activity	O
.	O

Compared	O
to	O
control	O
cells	O
,	O
cells	O
treated	O
with	O
TMZ	O
showed	O
a	O
significant	O
increase	O
in	O
the	O
Bax	O
/	O
Bcl-2	O
ratio	O
and	O
caspase-3	O
activity	O
(	O
P<0.01	O
)	O
.	O

Taken	O
together	O
,	O
these	O
results	O
suggested	O
that	O
over	O
-	O
express	O
miR-21	O
could	O
inhibit	O
TMZ	O
-	O
induced	O
apoptosis	O
in	O
U87MG	O
cells	O
,	O
at	O
least	O
in	O
part	O
,	O
by	O
decreasing	O
Bax	O
/	O
Bcl-2	O
ratio	O
and	O
caspase-3	O
activity	O
,	O
which	O
highlighted	O
the	O
possibility	O
of	O
miR-21	O
overexpression	O
in	O
the	O
clinical	O
resistance	O
to	O
chemotherapeutic	O
therapy	O
of	O
TMZ	O
.	O

Bcl-2	O
,	O
resistance	O
to	O
induction	O
of	O
apoptosis	O
,	O
constitutes	O
one	O
major	O
obstacle	O
to	O
chemotherapy	O
in	O
many	O
cancer	O
cells	O
.	O

CONCLUSIONS	O
:	O
Our	O
results	O
indicate	O
that	O
altered	O
miRNAs	O
expression	O
is	O
involved	O
in	O
GH	O
-	O
secreting	O
pituitary	O
adenomas	O
transformation	O
,	O
which	O
will	O
shed	O
light	O
on	O
the	O
mechanisms	O
for	O
the	O
treatment	O
of	O
acromegaly	O
by	O
SSA	O
.	O

Identification	O
and	O
characterization	O
of	O
the	O
targets	O
of	O
altered	O
miRNAs	O
genes	O
may	O
elucidate	O
molecular	O
mechanisms	O
involved	O
in	O
the	O
pathogenesis	O
of	O
pituitary	O
adenoma	O
.	O

Several	O
identified	O
miRNAs	O
may	O
be	O
involved	O
in	O
cell	O
proliferation	O
,	O
apoptosis	O
,	O
cancer	O
development	O
and	O
progression	O
.	O

Seven	O
miRNAs	O
were	O
differentially	O
expressed	O
between	O
SSA	O
responders	O
or	O
GH	O
nonresponders	O
.	O

RESULTS	O
:	O
Fifty	O
-	O
two	O
miRNAs	O
were	O
differentially	O
expressed	O
between	O
GH	O
-	O
secreting	O
pituitary	O
adenomas	O
and	O
normal	O
pituitaries	O
.	O

We	O
analyzed	O
the	O
miRNAs	O
in	O
21	O
GH	O
-	O
secreting	O
pituitary	O
adenomas	O
and	O
6	O
normal	O
pituitaries	O
by	O
miRCURY	O
™	O
LNA	O
array	O
and	O
some	O
differentially	O
expressed	O
miRNAs	O
were	O
validated	O
by	O
quantitative	O
real	O
-	O
time	O
PCR	O
.	O

Thirteen	O
miRNAs	O
were	O
differentially	O
expressed	O
between	O
tumor	O
samples	O
from	O
lanreotide	O
-	O
treated	O
patients	B
and	O
those	O
from	O
lanreotide	O
-	O
untreated	O
patients	B
.	O

Differential	O
expression	O
of	O
9	O
miRNAs	O
was	O
observed	O
between	O
micro-	O
and	O
macro	O
-	O
adenomas	O
.	O

Differential	O
expression	O
of	O
microRNAs	O
in	O
GH	O
-	O
secreting	O
pituitary	O
adenomas	O
.	O

BACKGROUND	O
:	O
The	O
purpose	O
of	O
this	O
study	O
was	O
to	O
(	O
1	O
)	O
identify	O
specific	O
miRNAs	O
in	O
growth	O
hormones	O
(	O
GH	O
)	O
-secreting	O
pituitary	O
adenomas	O
;	O
(	O
2	O
)	O
determine	O
the	O
relationship	O
between	O
the	O
expression	O
of	O
these	O
miRNAs	O
and	O
tumor	O
size	O
,	O
somatostatin	O
analogs	O
treatment	O
,	O
and	O
responsiveness	O
to	O
somatostatin	O
analogs	O
(	O
SSA	O
)	O
.	O

METHODS	O
:	O
Fifteen	O
GH	O
-	O
secreting	O
adenomas	O
patients	B
were	O
treated	O
with	O
lanreotide	O
for	O
4	O
months	O
before	O
surgery	O
.	O

Patients	B
with	O
50	O
%	O
reduction	O
of	O
GH	O
secretion	O
by	O
lanreotide	O
were	O
considered	O
as	O
SSA	O
responders	O
,	O
while	O
patients	B
with	O
less	O
than	O
50	O
%	O
of	O
GH	O
reduction	O
were	O
considered	O
as	O
SSA	O
nonresponders	O
.	O

Hypoxia	O
induces	O
microRNA	O
miR-210	O
in	O
vitro	O
and	O
in	O
vivo	O
ephrin	O
-	O
A3	O
and	O
neuronal	O
pentraxin	O
1	O
are	O
potentially	O
regulated	O
by	O
miR-210	O
.	O

Shortage	O
of	O
oxygen	O
is	O
one	O
of	O
the	O
prime	O
stress	O
conditions	O
in	O
tissues	O
.	O

In	O
this	O
study	O
,	O
we	O
looked	O
for	O
microRNAs	O
expressed	O
during	O
hypoxia	O
and	O
showed	O
that	O
miR-210	O
expression	O
was	O
upregulated	O
in	O
response	O
to	O
hypoxia	O
in	O
vitro	O
and	O
in	O
vivo	O
.	O

An	O
active	O
form	O
of	O
the	O
HIF-1alpha	O
induced	O
the	O
expression	O
of	O
miR-210	O
,	O
showing	O
the	O
involvement	O
of	O
the	O
HIF-1	O
signaling	O
pathway	O
in	O
miR-210	O
gene	O
transcription	O
.	O

Furthermore	O
,	O
miR-210	O
was	O
shown	O
to	O
bind	O
to	O
the	O
predicted	O
target	O
sites	O
of	O
ephrin	O
-	O
A3	O
or	O
neuronal	O
pentraxin	O
1	O
,	O
causing	O
repression	O
in	O
luciferase	O
reporter	O
activity	O
.	O

Thus	O
,	O
the	O
regulatory	O
effects	O
of	O
miR-210	O
on	O
its	O
targets	O
in	O
vivo	O
need	O
to	O
be	O
further	O
characterized	O
.	O

Contrary	O
to	O
the	O
microRNA	O
-	O
mediated	O
repression	O
hypothesis	O
,	O
ephrin	O
-	O
A3	O
was	O
expressed	O
at	O
very	O
high	O
levels	O
in	O
post	O
-	O
ischemic	O
mouse	B
hippocampus	O
in	O
vivo	O
.	O

We	O
recently	O
showed	O
in	O
HeLa	O
cells	O
that	O
two	O
components	O
of	O
the	O
SMN	O
complex	O
,	O
Gemin3	O
and	O
Gemin4	O
,	O
together	O
with	O
the	O
argonaute	O
protein	O
eIF2C2	O
,	O
also	O
associate	O
with	O
microRNAs	O
(	O
miRNAs	O
)	O
as	O
part	O
of	O
a	O
novel	O
class	O
of	O
RNPs	O
termed	O
miRNPs	O
.	O

SMN	O
is	O
part	O
of	O
a	O
large	O
complex	O
that	O
functions	O
in	O
the	O
assembly	O
/	O
restructuring	O
of	O
ribonucleoprotein	O
(	O
RNP	O
)	O
complexes	O
.	O

Spinal	O
muscular	O
atrophy	O
(	O
SMA	O
)	O
is	O
a	O
common	O
neurodegenerative	O
disease	O
that	O
is	O
caused	O
by	O
deletions	O
or	O
loss	O
-	O
of	O
-	O
function	O
mutations	O
in	O
the	O
Survival	O
of	O
Motor	O
Neuron	O
(	O
SMN	O
)	O
protein	O
.	O

Numerous	O
microRNPs	O
in	O
neuronal	O
cells	O
containing	O
novel	O
microRNAs	O
.	O

The	O
chromosomal	O
locations	O
of	O
most	O
of	O
the	O
novel	O
miRNAs	O
were	O
identified	O
and	O
indicate	O
some	O
phylogenetic	O
conservation	O
of	O
the	O
likely	O
precursor	O
structures	O
.	O

Interestingly	O
the	O
gene	O
locus	O
of	O
one	O
miRNA	O
,	O
miR-175	O
,	O
is	O
a	O
candidate	O
region	O
for	O
two	O
neurologic	O
diseases	O
:	O
early	O
-	O
onset	O
parkinsonism	O
(	O
Waisman	O
syndrome	O
)	O
and	O
X	O
-	O
linked	O
mental	O
retardation	O
(	O
MRX3	O
)	O
.	O

Here	O
we	O
report	O
on	O
miRNPs	O
isolated	O
from	O
neuronal	O
cell	O
lines	O
of	O
mouse	B
and	O
human	B
,	O
and	O
describe	O
53	O
novel	O
miRNAs	O
.	O

Several	O
of	O
these	O
miRNAs	O
are	O
conserved	O
in	O
divergent	O
organisms	O
,	O
including	O
rat	B
,	O
zebrafish	B
,	O
pufferfish	O
,	O
and	O
the	O
nematode	B
Caenorhabditis	B
elegans	I
.	O

Also	O
,	O
several	O
miRNAs	O
identified	O
as	O
part	O
of	O
miRNPs	O
in	O
these	O
cells	O
appear	O
to	O
constitute	O
two	O
distinct	O
subfamilies	O
.	O

These	O
subfamilies	O
comprise	O
multiple	O
copies	O
of	O
miRNAs	O
on	O
different	O
chromosomes	O
,	O
suggesting	O
an	O
important	O
function	O
in	O
the	O
regulation	O
of	O
gene	O
expression	O
.	O

Cells	O
stably	O
transfected	O
with	O
LAT	O
or	O
trigeminal	O
ganglionic	O
neurons	O
of	O
mice	O
infected	O
with	O
a	O
LAT	O
expressing	O
virus	O
appeared	O
to	O
express	O
the	O
L2	O
or	O
L8	O
ORF	O
.	O

Peptide	O
-	O
specific	O
immunoglobulin	O
G	O
(	O
IgG	O
)	O
was	O
generated	O
against	O
open	O
reading	O
frames	O
(	O
ORFs	O
)	O
that	O
are	O
located	O
within	O
the	O
first	O
1.5	O
kb	O
of	O
LAT	O
coding	O
sequences	O
.	O

Only	O
L2	O
ORF	O
expression	O
was	O
readily	O
detected	O
in	O
trigeminal	O
ganglionic	O
neurons	O
of	O
latently	O
infected	O
mice	B
.	O

Expression	O
of	O
the	O
first	O
1.5	O
kb	O
of	O
the	O
latency	O
-	O
associated	O
transcript	O
(	O
LAT	O
)	O
that	O
is	O
encoded	O
by	O
herpes	O
simplex	O
virus	O
type	O
1	O
(	O
HSV-1	O
)	O
is	O
sufficient	O
for	O
wild	O
-	O
type	O
(	O
wt	O
)	O
levels	O
of	O
reactivation	O
from	O
latency	O
in	O
small	O
animal	O
models	O
.	O

Identification	O
of	O
herpes	O
simplex	O
virus	O
type	O
1	O
proteins	O
encoded	O
within	O
the	O
first	O
1.5	O
kb	O
of	O
the	O
latency	O
-	O
associated	O
transcript	O
.	O

Here	O
we	O
show	O
that	O
human	B
platelets	O
harbor	O
an	O
abundant	O
and	O
diverse	O
array	O
of	O
microRNAs	O
(	O
miRNAs	O
)	O
,	O
which	O
are	O
known	O
as	O
key	O
regulators	O
of	O
mRNA	O
translation	O
in	O
other	O
cell	O
types	O
.	O

Further	O
analyses	O
revealed	O
that	O
platelets	O
contain	O
the	O
Dicer	O
and	O
Argonaute	O
2	O
(	O
Ago2	O
)	O
complexes	O
,	O
which	O
function	O
in	O
the	O
processing	O
of	O
exogenous	O
miRNA	O
precursors	O
and	O
the	O
control	O
of	O
specific	O
reporter	O
transcripts	O
,	O
respectively	O
.	O

Detection	O
of	O
the	O
receptor	O
P2Y	O
(	O
12	O
)	O
mRNA	O
in	O
Ago2	O
immunoprecipitates	O
suggests	O
that	O
P2Y	O
(	O
12	O
)	O
expression	O
may	O
be	O
subjected	O
to	O
miRNA	O
control	O
in	O
human	B
platelets	O
.	O

Our	O
study	O
lends	O
an	O
additional	O
level	O
of	O
complexity	O
to	O
the	O
control	O
of	O
gene	O
expression	O
in	O
these	O
anucleate	O
elements	O
of	O
the	O
cardiovascular	O
system	O
.	O

Existence	O
of	O
a	O
microRNA	O
pathway	O
in	O
anucleate	O
platelets	O
.	O

Platelets	O
have	O
a	O
crucial	O
role	O
in	O
the	O
maintenance	O
of	O
hemostasis	O
as	O
well	O
as	O
in	O
thrombosis	O
and	O
vessel	O
occlusion	O
,	O
which	O
underlie	O
stroke	O
and	O
acute	O
coronary	O
syndromes	O
.	O

Anucleate	O
platelets	O
contain	O
mRNAs	O
and	O
are	O
capable	O
of	O
protein	O
synthesis	O
,	O
raising	O
the	O
issue	O
of	O
how	O
these	O
mRNAs	O
are	O
regulated	O
.	O

Mutations	O
in	O
the	O
Drosophila	O
gene	O
lethal	O
(	O
3	O
)	O
malignant	O
brain	O
tumor	O
cause	O
malignant	O
growth	O
in	O
the	O
larval	O
brain	O
.	O

Here	O
we	O
show	O
that	O
l	O
(	O
3	O
)	O
mbt	O
tumors	O
exhibited	O
a	O
soma	O
-	O
to	O
-	O
germline	O
transformation	O
through	O
the	O
ectopic	O
expression	O
of	O
genes	O
normally	O
required	O
for	O
germline	O
stemness	O
,	O
fitness	O
,	O
or	O
longevity	O
.	O

Orthologs	O
of	O
some	O
of	O
these	O
genes	O
were	O
also	O
expressed	O
in	O
human	B
somatic	O
tumors	O
.	O

In	O
addition	O
,	O
inactivation	O
of	O
any	O
of	O
the	O
germline	O
genes	O
nanos	O
,	O
vasa	O
,	O
piwi	O
,	O
or	O
aubergine	O
suppressed	O
l	O
(	O
3	O
)	O
mbt	O
malignant	O
growth	O
.	O

Ectopic	O
expression	O
of	O
germline	O
genes	O
drives	O
malignant	O
brain	O
tumor	O
growth	O
in	O
Drosophila	O
.	O

Model	O
organisms	O
such	O
as	O
the	O
fruit	O
fly	O
Drosophila	B
melanogaster	I
can	O
help	O
to	O
elucidate	O
the	O
molecular	O
basis	O
of	O
complex	O
diseases	O
such	O
as	O
cancer	O
.	O

Our	O
results	O
demonstrate	O
that	O
germline	O
traits	O
are	O
necessary	O
for	O
tumor	O
growth	O
in	O
this	O
Drosophila	B
model	O
and	O
suggest	O
that	O
inactivation	O
of	O
germline	O
genes	O
might	O
have	O
tumor	O
-	O
suppressing	O
effects	O
in	O
other	O
species	O
.	O

TAKE	O
HOME	O
MESSAGE	O
:	O
Based	O
on	O
current	O
data	O
,	O
although	O
limited	O
,	O
the	O
mesenchymal	O
-	O
epithelial	O
transition	O
is	O
proposed	O
to	O
be	O
one	O
of	O
the	O
important	O
ways	O
for	O
MSCs	O
to	O
participate	O
tissue	O
repair	O
.	O

AREAS	O
COVERED	O
IN	O
THIS	O
REVIEW	O
:	O
This	O
review	O
focuses	O
on	O
recent	O
understanding	O
on	O
MSC	O
's	O
basic	O
biological	O
characteristics	O
and	O
the	O
mechanisms	O
underlying	O
the	O
therapeutic	O
effects	O
of	O
MSCs	O
in	O
vivo	O
.	O

IMPORTANCE	O
OF	O
THE	O
FIELD	O
:	O
The	O
pan	O
-	O
tissue	O
existence	O
and	O
multipotency	O
of	O
differentiation	O
make	O
mesenchymal	O
stem	O
cells	O
(	O
MSCs	O
)	O
an	O
attractive	O
source	O
of	O
cells	O
as	O
tissue	O
repair	O
cells	O
,	O
seeds	O
of	O
engineered	O
tissue	O
,	O
vehicles	O
for	O
gene	O
therapy	O
or	O
in	O
combination	O
to	O
promote	O
tissue	O
regeneration	O
in	O
wound	O
healing	O
and	O
disease	O
recovery	O
.	O

More	O
insight	O
into	O
mesenchymal	O
stem	O
cells	O
and	O
their	O
effects	O
inside	O
the	O
body	O
.	O

As	O
examples	O
,	O
a	O
detailed	O
description	O
is	O
given	O
on	O
the	O
regeneration	O
of	O
functional	O
sweat	O
glands	O
on	O
burned	O
skin	O
as	O
well	O
as	O
neural	O
cells	O
in	O
middle	O
cerebral	O
artery	O
occlusion	O
(	O
MCAO	O
)	O
animals	O
upon	O
MSC	O
transplantation	O
.	O

The	O
mechanisms	O
of	O
therapeutic	O
effects	O
of	O
MSCs	O
are	O
attributed	O
to	O
their	O
ability	O
to	O
migrate	O
along	O
chemokine	O
gradients	O
,	O
differentiate	O
into	O
tissue	O
-	O
specific	O
cells	O
,	O
enhance	O
angiogenesis	O
of	O
wound	O
tissue	O
and	O
regulate	O
immune	O
response	O
.	O

Special	O
attention	O
is	O
given	O
to	O
miRNA	O
expression	O
and	O
its	O
relationship	O
with	O
the	O
characteristics	O
of	O
MSCs	O
.	O

WHAT	O
THE	O
READER	O
WILL	O
GAIN	O
:	O
The	O
gene	O
expression	O
profiles	O
for	O
mRNA	O
,	O
protein	O
,	O
microRNA	O
and	O
cell	O
surface	O
marker	O
of	O
MSCs	O
are	O
summarized	O
.	O

We	O
also	O
identified	O
a	O
potential	O
feedback	O
loop	O
between	O
LKB1	O
and	O
miR-451	O
,	O
which	O
allows	O
a	O
sustained	O
and	O
robust	O
response	O
to	O
glucose	O
deprivation	O
.	O

We	O
then	O
found	O
that	O
by	O
targeting	O
the	O
LKB1	O
kinase	O
complex	O
miR-451	O
suppresses	O
the	O
activity	O
of	O
downstream	O
protein	O
kinases	O
including	O
the	O
major	O
energy	O
biosensor	O
AMPK	O
.	O

We	O
initially	O
identified	O
miR-451	O
due	O
to	O
its	O
downregulation	O
in	O
a	O
glioma	O
cell	O
migration	O
assay	O
.	O

Under	O
conditions	O
of	O
glucose	O
withdrawal	O
,	O
miR-451	O
downregulation	O
is	O
necessary	O
for	O
AMPK	O
pathway	O
activation	O
,	O
leading	O
to	O
suppressed	O
proliferation	O
rates	O
,	O
increased	O
cell	O
survival	O
and	O
migration	O
.	O

MiR-451	O
levels	O
are	O
regulated	O
by	O
glucose	O
;	O
under	O
conditions	O
of	O
abundant	O
energy	O
miR-451	O
expression	O
is	O
high	O
,	O
and	O
the	O
suppression	O
of	O
AMPK	O
signaling	O
allows	O
cells	O
to	O
maintain	O
elevated	O
proliferation	O
rates	O
via	O
unrestrained	O
mTOR	O
activation	O
.	O

Incomplete	O
knowledge	O
of	O
the	O
molecular	O
biology	O
,	O
genetics	O
,	O
causes	O
and	O
cellular	O
origin	O
of	O
these	O
tumors	O
may	O
limit	O
the	O
development	O
of	O
improved	O
therapeutics	O
.	O

Glioblastoma	O
,	O
the	O
most	O
common	O
and	O
aggressive	O
primary	O
brain	O
tumor	O
,	O
is	O
rapidly	O
growing	O
and	O
highly	O
infiltrative	O
.	O

Here	O
we	O
will	O
discuss	O
further	O
our	O
recently	O
published	O
data	O
on	O
the	O
role	O
of	O
miR-451	O
in	O
the	O
biology	O
of	O
glioblastoma	O
.	O

A	O
major	O
and	O
fundamental	O
advance	O
in	O
recent	O
years	O
has	O
been	O
the	O
identification	O
of	O
microRNAs	O
as	O
highly	O
conserved	O
regulators	O
of	O
gene	O
expression	O
.	O

microRNA-451	O
:	O
A	O
conditional	O
switch	O
controlling	O
glioma	O
cell	O
proliferation	O
and	O
migration	O
.	O

This	O
data	O
will	O
be	O
discussed	O
in	O
the	O
context	O
of	O
potential	O
biological	O
significance	O
and	O
therapeutic	O
implications	O
.	O

MicroRNA	O
expression	O
in	O
the	O
blood	O
and	O
brain	O
of	O
rats	B
subjected	O
to	O
transient	O
focal	O
ischemia	O
by	O
middle	O
cerebral	O
artery	O
occlusion	O
.	O

BACKGROUND	O
AND	O
PURPOSE	O
:	O
Several	O
hundred	O
small	O
RNAs	O
called	O
microRNAs	O
(	O
miRNAs	O
)	O
have	O
been	O
identified	O
and	O
characterized	O
from	O
various	O
organisms	O
,	O
including	O
humans	B
.	O

In	O
humans	B
,	O
some	O
of	O
these	O
miRNAs	O
have	O
been	O
found	O
to	O
regulate	O
(	O
patho	O
)	O
physiologic	O
conditions	O
such	O
as	O
tumor	O
progression	O
/	O
regression	O
,	O
cholesterol	O
and	O
glucose	O
homeostasis	O
,	O
etc	O
.	O

In	O
this	O
report	O
,	O
we	O
present	O
data	O
on	O
the	O
miRNAs	O
expressed	O
under	O
ischemic	O
conditions	O
in	O
both	O
the	O
brain	O
and	O
blood	O
of	O
rats	B
subjected	O
to	O
middle	O
cerebral	O
artery	O
occlusion	O
(	O
MCAo	O
)	O
.	O

METHODS	O
:	O
Sprague	O
-	O
Dawley	O
rats	B
subjected	O
to	O
MCAo	O
were	O
reperfused	O
for	O
either	O
24	O
or	O
48	O
hours	O
,	O
and	O
both	O
blood	O
and	O
brain	O
samples	O
were	O
harvested	O
.	O

miRNA	O
expression	O
profiling	O
and	O
oligonucleotide	O
microarray	O
were	O
carried	O
out	O
,	O
and	O
the	O
data	O
were	O
validated	O
by	O
quantitative	O
real	O
-	O
time	O
polymerase	O
chain	O
reaction	O
and	O
correlated	O
with	O
published	O
data	O
on	O
protein	O
and	O
gene	O
expression	O
in	O
MCAo	O
rats	B
.	O

RESULTS	O
:	O
We	O
report	O
here	O
for	O
the	O
first	O
time	O
the	O
involvement	O
of	O
miRNA	O
regulation	O
in	O
brain	O
pathogenesis	O
associated	O
with	O
MCAo	O
.	O

Comparison	O
with	O
the	O
corresponding	O
DNA	O
microarray	O
data	O
revealed	O
that	O
the	O
target	O
mRNA	O
expression	O
is	O
correlated	O
with	O
the	O
regulation	O
of	O
miRNA	O
.	O

We	O
have	O
also	O
provided	O
evidence	O
that	O
some	O
of	O
the	O
miRNAs	O
that	O
are	O
highly	O
expressed	O
in	O
the	O
ischemic	O
brain	O
can	O
be	O
detected	O
in	O
blood	O
samples	O
.	O

CONCLUSIONS	O
:	O
Further	O
studies	O
are	O
needed	O
to	O
evaluate	O
the	O
possible	O
use	O
of	O
miRNAs	O
as	O
biomarkers	O
in	O
stroke	O
and	O
related	O
pathologies	O
.	O

An	O
association	O
study	O
of	O
rs9897526	O
and	O
rs5848	O
was	O
carried	O
out	O
in	O
an	O
Italian	O
population	O
and	O
in	O
a	O
replication	O
population	O
of	O
European	O
American	O
patients	B
and	O
controls	O
.	O

The	O
influence	O
of	O
GRN	O
genetic	O
variability	O
on	O
susceptibility	O
to	O
AD	O
and	O
on	O
expression	O
levels	O
in	O
a	O
series	O
of	O
neuropathologically	O
-	O
confirmed	O
AD	O
patients	B
as	O
well	O
as	O
in	O
peripheral	O
mononuclear	O
cells	O
(	O
PBMC	O
)	O
and	O
in	O
cells	O
isolated	O
from	O
cerebrospinal	O
fluid	O
(	O
CSF	O
)	O
was	O
investigated	O
.	O

Mutations	O
in	O
the	O
progranulin	O
gene	O
(	O
GRN	O
)	O
,	O
causative	O
for	O
Frontotemporal	O
Lobar	O
Degeneration	O
with	O
ubiquitin	O
-	O
immunoreactive	O
neuronal	O
inclusions	O
(	O
FTLD	O
-	O
U	O
)	O
,	O
could	O
also	O
be	O
associated	O
with	O
Alzheimer	O
's	O
disease	O
(	O
AD	O
)	O
.	O

Rs5848	O
variant	O
influences	O
GRN	O
mRNA	O
levels	O
in	O
brain	O
and	O
peripheral	O
mononuclear	O
cells	O
in	O
patients	B
with	O
Alzheimer	O
's	O
disease	O
.	O

Despite	O
no	O
significant	O
differences	O
were	O
found	O
in	O
the	O
relative	O
PBMC	O
and	O
CSF	O
GRN	O
expression	O
in	O
patients	B
compared	O
to	O
controls	O
,	O
stratifying	O
patients	B
according	O
to	O
the	O
presence	O
of	O
rs5848	O
T	O
allele	O
,	O
a	O
0.57-fold	O
decrease	O
in	O
GRN	O
mRNA	O
levels	O
over	O
C	O
carriers	O
was	O
found	O
in	O
PBMC	O
(	O
1.22	O
+	O
/-	O
0.23	O
versus	O
0.70	O
+	O
/-	O
0.12	O
,	O
P	O
=	O
0.04	O
)	O
.	O

Patients	B
carrying	O
the	O
rs5848	O
TT	O
genotype	O
had	O
the	O
lowest	O
GRN	O
expression	O
levels	O
(	O
0.96	O
+	O
/-	O
0.12	O
,	O
P	O
=	O
0.014	O
)	O
.	O

GRN	O
expression	O
in	O
the	O
parietal	O
lobe	O
of	O
AD	O
cases	O
showed	O
a	O
0.76-fold	O
decrease	O
compared	O
with	O
controls	O
(	O
1.31	O
+	O
/-	O
0.07	O
versus	O
1.73	O
+	O
/-	O
0.12	O
,	O
P	O
=	O
0.0025	O
)	O
.	O

None	O
of	O
the	O
variants	O
tested	O
act	O
as	O
unequivocal	O
susceptibility	O
factor	O
in	O
both	O
populations	O
although	O
rs9897526	O
anticipated	O
the	O
onset	O
of	O
the	O
disease	O
in	O
the	O
Italian	O
population	O
.	O

Similarly	O
to	O
data	O
obtained	O
in	O
brain	O
samples	O
,	O
patients	O
carrying	O
the	O
TT	O
genotype	O
showed	O
the	O
lowest	O
GRN	O
mRNA	O
levels	O
(	O
TT	O
=	O
0.46	O
+	O
/-	O
0.14	O
,	O
CC	O
=	O
1.22	O
+	O
/-	O
0.23	O
;	O
P	O
=	O
0.013	O
)	O
.	O

These	O
data	O
argue	O
against	O
a	O
direct	O
role	O
of	O
GRN	O
as	O
a	O
susceptibility	O
factor	O
for	O
sporadic	O
AD	O
but	O
support	O
a	O
role	O
of	O
GRN	O
as	O
a	O
disease	O
-	O
modifying	O
gene	O
,	O
possibly	O
contributing	O
to	O
the	O
failure	O
of	O
neuronal	O
survival	O
.	O

Yet	O
,	O
genetic	O
testing	O
for	O
CADASIL	O
is	O
associated	O
with	O
a	O
nameable	O
proportion	O
of	O
false	O
-	O
negative	O
results	O
.	O

Thus	O
,	O
genetic	O
testing	O
should	O
initially	O
be	O
focused	O
on	O
these	O
exons	O
,	O
with	O
some	O
variation	O
depending	O
on	O
the	O
population	O
in	O
whom	O
it	O
is	O
being	O
performed	O
.	O

CONCLUSIONS	O
:	O
Almost	O
90	O
%	O
of	O
mutations	O
could	O
be	O
detected	O
within	O
a	O
few	O
exons	O
(	O
exons	O
2	O
-	O
6	O
)	O
.	O

Cases	O
with	O
a	O
high	O
index	O
of	O
clinical	O
suspicion	O
should	O
be	O
investigated	O
by	O
skin	O
biopsy	O
if	O
genetic	O
testing	O
is	O
negative	O
.	O

Of	O
the	O
mutations	O
,	O
58.3	O
%	O
were	O
located	O
in	O
exon	O
4	O
and	O
85.8	O
%	O
in	O
exons	O
2	O
through	O
6	O
.	O

In	O
5	O
patients	B
(	O
4.0	O
%	O
)	O
,	O
no	O
mutation	O
was	O
identified	O
.	O

Results	O
were	O
compared	O
with	O
those	O
of	O
previously	O
published	O
studies	O
.	O

RESULTS	O
:	O
We	O
detected	O
54	O
distinct	O
mutations	O
(	O
117	O
missense	O
mutations	O
and	O
3	O
in	O
-	O
frame	O
deletions	O
)	O
in	O
120	O
(	O
96.0	O
%	O
)	O
of	O
the	O
125	O
patients	B
.	O

BACKGROUND	O
:	O
Mutations	O
in	O
the	O
NOTCH3	O
gene	O
are	O
the	O
cause	O
of	O
cerebral	O
autosomal	O
dominant	O
arteriopathy	O
with	O
subcortical	O
infarcts	O
and	O
leukoencephalopathy	O
(	O
CADASIL	O
)	O
,	O
which	O
is	O
an	O
important	O
cause	O
of	O
stroke	O
in	O
young	O
adults	O
.	O

Spectrum	O
of	O
mutations	O
in	O
biopsy	O
-	O
proven	O
CADASIL	O
:	O
implications	O
for	O
diagnostic	O
strategies	O
.	O

DESIGN	O
:	O
Screening	O
for	O
NOTCH3	O
mutations	O
was	O
performed	O
in	O
125	O
unrelated	O
German	O
CADASIL	O
patients	B
with	O
biopsy	O
-	O
proven	O
disease	O
by	O
direct	O
sequencing	O
of	O
exons	O
coding	O
for	O
epidermal	O
growth	O
factor	O
-	O
like	O
repeats	O
.	O

OBJECTIVES	O
:	O
To	O
identify	O
the	O
spectrum	O
of	O
NOTCH3	O
mutations	O
in	O
CADASIL	O
and	O
to	O
discuss	O
the	O
implications	O
for	O
diagnostic	O
strategies	O
.	O

Identification	O
of	O
the	O
mutation	O
is	O
critical	O
for	O
genetic	O
counseling	O
and	O
testing	O
of	O
relatives	O
at	O
risk	O
.	O

Mutations	O
are	O
typically	O
located	O
within	O
epidermal	O
growth	O
factor	O
-	O
like	O
repeat	O
domains	O
in	O
the	O
extracellular	O
part	O
of	O
the	O
Notch3	O
receptor	O
.	O

Molecular	O
biology	O
.	O

miRNAs	O
in	O
neurodegeneration	O
.	O

HIV-1-infected	B
opiate	O
abusers	O
often	O
exhibit	O
an	O
accelerated	O
form	O
of	O
HIV-1-associated	B
dementia	O
and	O
enhanced	O
neurological	O
dysfunction	O
.	O

Morphine	O
treatment	O
of	O
human	B
monocyte	O
-	O
derived	O
macrophages	O
induces	O
differential	O
miRNA	O
and	O
protein	O
expression	O
:	O
impact	O
on	O
inflammation	O
and	O
oxidative	O
stress	O
in	O
the	O
central	O
nervous	O
system	O
.	O

In	O
order	O
to	O
understand	O
the	O
role	O
of	O
morphine	O
in	O
this	O
process	O
,	O
we	O
performed	O
a	O
genome	O
-	O
wide	O
association	O
study	O
at	O
the	O
micro	O
RNA	O
(	O
miRNA	O
)	O
and	O
protein	O
levels	O
in	O
human	B
monocyte	O
-	O
derived	O
macrophages	O
(	O
h	O
-	O
mdms	O
)	O
.	O

Productive	O
HIV-1	B
infection	O
of	O
microglia	O
and	O
perivascular	O
macrophages	O
and	O
the	O
resultant	O
secretion	O
of	O
neurotoxic	O
molecules	O
by	O
these	O
cells	O
contribute	O
to	O
this	O
phenomenon	O
.	O

Computational	O
analysis	O
predicted	O
fibroblast	O
growth	O
factor-2	O
(	O
FGF-2	O
)	O
as	O
the	O
strongest	O
target	O
gene	O
for	O
hsa	O
-	O
miR15b	O
.	O

A	O
total	O
of	O
26	O
differentially	O
expressed	O
miRNA	O
were	O
identified	O
(	O
P	O
<	O
0.01	O
)	O
,	O
of	O
which	O
hsa	O
-	O
miR-15b	O
and	O
hsa	O
-	O
miR-181b	O
had	O
the	O
greatest	O
increase	O
and	O
decrease	O
in	O
expression	O
levels	O
,	O
respectively	O
.	O

Both	O
hsa	O
-	O
miR-15b	O
and	O
hsa	O
-	O
miR-181b	O
have	O
several	O
predicted	O
gene	O
targets	O
involved	O
in	O
inflammation	O
and	O
T	O
-	O
cell	O
activation	O
pathways	O
.	O

Of	O
note	O
,	O
we	O
observed	O
a	O
decrease	O
in	O
FGF-2	O
protein	O
expression	O
in	O
response	O
to	O
morphine	O
.	O

Moreover	O
,	O
proteomic	O
analysis	O
revealed	O
the	O
induction	O
of	O
mitochondrial	O
superoxide	O
dismutase	O
in	O
response	O
to	O
morphine	O
treatment	O
.	O

In	O
this	O
context	O
,	O
we	O
observed	O
induction	O
of	O
MCP-2	O
and	O
IL-6	O
by	O
morphine	O
.	O

Of	O
note	O
,	O
differentially	O
expressed	O
miRNAs	O
(	O
hsa	O
-	O
miR-15b	O
and	O
181-b	O
)	O
may	O
have	O
a	O
potential	O
role	O
in	O
regulating	O
these	O
processes	O
.	O

Collectively	O
,	O
these	O
observations	O
demonstrate	O
that	O
morphine	O
induces	O
inflammation	O
and	O
oxidative	O
stress	O
in	O
h	O
-	O
mdms	O
thereby	O
contributing	O
to	O
expansion	O
of	O
HIV-1	B
CNS	O
reservoir	O
expansion	O
and	O
disease	O
progression	O
.	O

HIV-1	B
infection	O
did	O
not	O
induce	O
mitochondrial	O
superoxide	O
dismutase	O
.	O

The	O
advent	O
of	O
next	O
-	O
generation	O
sequencing	O
technologies	O
promises	O
to	O
greatly	O
transform	O
our	O
understanding	O
of	O
medulloblastoma	O
pathogenesis	O
in	O
the	O
next	O
few	O
years	O
,	O
permitting	O
comprehensive	O
analyses	O
of	O
all	O
aspects	O
of	O
the	O
genome	O
and	O
increasing	O
the	O
likelihood	O
that	O
genomic	O
medicine	O
will	O
become	O
part	O
of	O
the	O
routine	O
diagnosis	O
and	O
treatment	O
of	O
medulloblastoma	O
.	O

The	O
application	O
of	O
high	O
-	O
resolution	O
microarray	O
platforms	O
to	O
the	O
study	O
of	O
medulloblastoma	O
has	O
revealed	O
new	O
oncogenes	O
and	O
tumor	O
suppressors	O
and	O
has	O
implicated	O
changes	O
in	O
DNA	O
copy	O
number	O
,	O
gene	O
expression	O
,	O
and	O
methylation	O
state	O
in	O
its	O
etiology	O
.	O

Additionally	O
,	O
the	O
integration	O
of	O
medulloblastoma	O
genomics	O
with	O
patient	O
clinical	O
data	O
has	O
confirmed	O
molecular	O
markers	O
of	O
prognostic	O
significance	O
and	O
highlighted	O
the	O
potential	O
utility	O
of	O
molecular	O
disease	O
stratification	O
.	O

Genomics	O
of	O
medulloblastoma	O
:	O
from	O
Giemsa	O
-	O
banding	O
to	O
next	O
-	O
generation	O
sequencing	O
in	O
20	O
years	O
.	O

Advances	O
in	O
the	O
field	O
of	O
genomics	O
have	O
recently	O
enabled	O
the	O
unprecedented	O
characterization	O
of	O
the	O
cancer	O
genome	O
,	O
providing	O
novel	O
insight	O
into	O
the	O
molecular	O
mechanisms	O
underlying	O
malignancies	O
in	O
humans	B
.	O

RESULTS	O
:	O
We	O
hypothesized	O
that	O
schizophrenia	O
might	O
be	O
associated	O
with	O
altered	O
miRNA	O
profiles	O
.	O

To	O
investigate	O
this	O
possibility	O
we	O
compared	O
the	O
expression	O
of	O
264	O
human	B
miRNAs	O
from	O
postmortem	O
prefrontal	O
cortex	O
tissue	O
of	O
individuals	O
with	O
schizophrenia	O
(	O
n	O
=	O
13	O
)	O
or	O
schizoaffective	O
disorder	O
(	O
n	O
=	O
2	O
)	O
to	O
tissue	O
of	O
21	O
psychiatrically	O
unaffected	O
individuals	O
using	O
a	O
custom	O
miRNA	O
microarray	O
.	O

Allowing	O
a	O
5	O
%	O
false	O
discovery	O
rate	O
,	O
we	O
found	O
that	O
16	O
miRNAs	O
were	O
differentially	O
expressed	O
in	O
prefrontal	O
cortex	O
of	O
patient	B
subjects	O
,	O
with	O
15	O
expressed	O
at	O
lower	O
levels	O
(	O
fold	O
change	O
0.63	O
to	O
0.89	O
)	O
and	O
1	O
at	O
a	O
higher	O
level	O
(	O
fold	O
change	O
1.77	O
)	O
than	O
in	O
the	O
psychiatrically	O
unaffected	O
comparison	O
subjects	O
.	O

The	O
expression	O
levels	O
of	O
12	O
selected	O
miRNAs	O
were	O
also	O
determined	O
by	O
quantitative	O
RT	O
-	O
PCR	O
in	O
our	O
lab	O
.	O

For	O
the	O
eight	O
miRNAs	O
distinguished	O
by	O
being	O
expressed	O
at	O
lower	O
microarray	O
levels	O
in	O
schizophrenia	O
samples	O
versus	O
comparison	O
samples	O
,	O
seven	O
were	O
also	O
expressed	O
at	O
lower	O
levels	O
with	O
quantitative	O
RT	O
-	O
PCR	O
.	O

CONCLUSION	O
:	O
This	O
study	O
is	O
the	O
first	O
to	O
find	O
altered	O
miRNA	O
profiles	O
in	O
postmortem	O
prefrontal	O
cortex	O
from	O
schizophrenia	O
patients	B
.	O

microRNA	O
expression	O
in	O
the	O
prefrontal	O
cortex	O
of	O
individuals	O
with	O
schizophrenia	O
and	O
schizoaffective	O
disorder	O
.	O

BACKGROUND	O
:	O
microRNAs	O
(	O
miRNAs	O
)	O
are	O
small	O
,	O
noncoding	O
RNA	O
molecules	O
that	O
are	O
now	O
thought	O
to	O
regulate	O
the	O
expression	O
of	O
many	O
mRNAs	O
.	O

They	O
have	O
been	O
implicated	O
in	O
the	O
etiology	O
of	O
a	O
variety	O
of	O
complex	O
diseases	O
,	O
including	O
Tourette	O
's	O
syndrome	O
,	O
Fragile	O
x	O
syndrome	O
,	O
and	O
several	O
types	O
of	O
cancer	O
.	O

Here	O
,	O
we	O
report	O
an	O
elegant	O
mechanism	O
of	O
Tau	O
degradation	O
involving	O
the	O
cochaperone	O
BAG2	O
.	O

The	O
BAG2	O
/	O
Hsp70	O
complex	O
is	O
tethered	O
to	O
the	O
microtubule	O
and	O
this	O
complex	O
can	O
capture	O
and	O
deliver	O
Tau	O
to	O
the	O
proteasome	O
for	O
ubiquitin	O
-	O
independent	O
degradation	O
.	O

The	O
components	O
of	O
a	O
Tau	O
protein	O
triage	O
system	O
consisting	O
of	O
CHIP	O
/	O
Hsp70	O
and	O
other	O
chaperones	O
have	O
begun	O
to	O
emerge	O
.	O

However	O
,	O
the	O
site	O
of	O
triage	O
and	O
the	O
master	O
regulatory	O
elements	O
are	O
unknown	O
.	O

Tau	O
inclusions	O
are	O
a	O
prominent	O
feature	O
of	O
many	O
neurodegenerative	O
diseases	O
including	O
Alzheimer	O
's	O
disease	O
.	O

Their	O
accumulation	O
in	O
neurons	O
as	O
ubiquitinated	O
filaments	O
suggests	O
a	O
failure	O
in	O
the	O
degradation	O
limb	O
of	O
the	O
Tau	O
pathway	O
.	O

The	O
cochaperone	O
BAG2	O
sweeps	O
paired	O
helical	O
filament-	O
insoluble	O
tau	O
from	O
the	O
microtubule	O
.	O

Thus	O
,	O
we	O
propose	O
that	O
ubiquitinated	O
Tau	O
inclusions	O
arise	O
due	O
to	O
shunting	O
of	O
Tau	O
degradation	O
toward	O
a	O
less	O
efficient	O
ubiquitin	O
-	O
dependent	O
pathway	O
.	O

This	O
complex	O
preferentially	O
degrades	O
Sarkosyl	O
insoluble	O
Tau	O
and	O
phosphorylated	O
Tau	O
.	O

BAG2	O
levels	O
in	O
cells	O
are	O
under	O
the	O
physiological	O
control	O
of	O
the	O
microRNA	O
miR-128a	O
,	O
which	O
can	O
tune	O
paired	O
helical	O
filament	O
Tau	O
levels	O
in	O
neurons	O
.	O

We	O
explored	O
to	O
what	O
extent	O
abnormalities	O
of	O
echogenicity	O
of	O
the	O
periventricular	O
crossroads	O
correlate	O
with	O
changes	O
in	O
size	O
of	O
the	O
corpus	O
callosum	O
.	O

These	O
lesions	O
damage	O
the	O
periventricular	O
crossroads	O
of	O
commissural	O
,	O
projection	O
and	O
associative	O
pathways	O
,	O
which	O
are	O
in	O
a	O
close	O
topographical	O
relationship	O
with	O
the	O
lateral	O
ventricles	O
.	O

Periventricular	O
areas	O
,	O
which	O
topographically	O
correspond	O
to	O
the	O
frontal	O
,	O
main	O
and	O
occipital	O
crossroad	O
,	O
were	O
readily	O
visualized	O
by	O
cranial	O
ultrasound	O
scans	O
,	O
performed	O
during	O
the	O
first	O
two	O
weeks	O
after	O
birth	O
.	O

Our	O
study	O
included	O
nine	O
infants	O
(	O
gestation	O
from	O
26	O
-	O
41	O
weeks	O
;	O
birth	O
weight	O
between	O
938	O
-	O
4450	O
grams	O
)	O
with	O
perinatal	O
brain	O
injury	O
.	O

We	O
found	O
a	O
statistically	O
significant	O
correlation	O
between	O
the	O
increased	O
echogenicity	O
in	O
the	O
crossroad	O
areas	O
and	O
the	O
decrease	O
of	O
the	O
corpus	O
callosum	O
midsagittal	O
area	O
(	O
p	O
<	O
0.05	O
)	O
.	O

Corpus	O
callosum	O
mediosagittal	O
area	O
measurements	O
were	O
performed	O
using	O
magnetic	O
resonance	O
images	O
,	O
acquired	O
between	O
the	O
first	O
and	O
sixth	O
postnatal	O
month	O
(	O
postmenstrual	O
age	O
40	O
-	O
49	O
weeks	O
)	O
.	O

This	O
supports	O
the	O
hypothesis	O
that	O
callosal	O
fibers	O
can	O
be	O
damaged	O
,	O
during	O
growth	O
through	O
the	O
periventricular	O
crossroads	O
of	O
pathways	O
.	O

Changes	O
of	O
the	O
corpus	O
callosum	O
in	O
children	B
who	O
suffered	O
perinatal	O
injury	O
of	O
the	O
periventricular	O
crossroads	O
of	O
pathways	O
.	O

There	O
is	O
a	O
high	O
incidence	O
of	O
periventricular	O
leukomalacia	O
,	O
caused	O
by	O
hypoxia	O
-	O
ischemia	O
,	O
in	O
preterm	O
infants	O
.	O

miR-15a	O
and	O
miR-16	O
-	O
1	O
down	O
-	O
regulation	O
in	O
pituitary	O
adenomas	O
.	O

We	O
found	O
that	O
miR-15a	O
and	O
miR-16	O
-	O
1	O
are	O
expressed	O
at	O
lower	O
levels	O
in	O
pituitary	O
adenomas	O
as	O
compared	O
to	O
normal	O
pituitary	O
tissue	O
.	O

We	O
explored	O
miR-15a	O
and	O
miR-16	O
-	O
1	O
expression	O
in	O
10	O
GH	O
-	O
secreting	O
and	O
in	O
10	O
PRL	O
-	O
secreting	O
pituitary	O
macroadenomas	O
by	O
Northern	O
blot	O
,	O
and	O
investigated	O
the	O
possible	O
correlation	O
with	O
in	O
vivo	O
and	O
in	O
vitro	O
characteristics	O
.	O

Therefore	O
,	O
miR15	O
and	O
miR16	O
down	O
-	O
regulation	O
in	O
pituitary	O
adenomas	O
correlates	O
with	O
a	O
greater	O
tumor	O
diameter	O
and	O
a	O
lower	O
p43	O
secretion	O
,	O
suggesting	O
that	O
these	O
genes	O
may	O
,	O
at	O
least	O
in	O
part	O
,	O
influence	O
tumor	O
growth	O
.	O

Moreover	O
,	O
their	O
expression	O
inversely	O
correlates	O
with	O
tumor	O
diameter	O
and	O
with	O
RARS	O
expression	O
(	O
P	O
<	O
0.05	O
)	O
,	O
but	O
directly	O
correlates	O
with	O
p43	O
secretion	O
(	O
P	O
<	O
0.02	O
)	O
.	O

miR-15a	O
and	O
miR-16	O
-	O
1	O
genes	O
are	O
located	O
at	O
chromosome	O
13q14	O
,	O
a	O
region	O
which	O
is	O
frequently	O
deleted	O
in	O
pituitary	O
tumors	O
.	O

Micro	O
RNAs	O
(	O
miRs	O
)	O
are	O
small	O
noncoding	O
RNAs	O
,	O
functioning	O
as	O
antisense	O
regulators	O
of	O
other	O
RNAs	O
.	O

When	O
secreted	O
,	O
p43	O
regulates	O
local	O
inflammatory	O
response	O
and	O
macrophage	O
chemotaxis	O
,	O
and	O
seems	O
to	O
have	O
anti	O
-	O
neoplastic	O
properties	O
in	O
mice	B
.	O

An	O
inverse	O
correlation	O
has	O
been	O
shown	O
in	O
B	O
cell	O
chronic	O
lymphocytic	O
leukemia	O
(	O
B	O
-	O
CLL	O
)	O
between	O
miR-15a	O
and	O
miR-16	O
-	O
1	O
expression	O
and	O
the	O
expression	O
levels	O
of	O
arginyl	O
-	O
tRNA	O
synthetase	O
(	O
RARS	O
)	O
,	O
an	O
enzyme	O
which	O
associates	O
with	O
the	O
cofactor	O
p43	O
in	O
the	O
aminoacyl	O
-	O
tRNA	O
synthetase	O
complex	O
.	O

These	O
results	O
confirm	O
those	O
of	O
other	O
studies	O
with	O
animals	O
and	O
humans	B
using	O
novel	O
imaging	O
techniques	O
,	O
suggesting	O
that	O
the	O
motor	O
homunculus	O
may	O
not	O
always	O
be	O
considered	O
a	O
definite	O
and	O
absolute	O
representation	O
of	O
M1	O
.	O

The	O
results	O
of	O
this	O
study	O
challenge	O
the	O
notion	O
of	O
orderly	O
topographic	O
relationships	O
between	O
the	O
human	B
sensorimotor	O
functions	O
and	O
their	O
representation	O
in	O
the	O
primary	O
motor	O
cortex	O
.	O

Electrode	O
position	O
was	O
represented	O
graphically	O
whenever	O
a	O
stimulus	O
was	O
delivered	O
.	O

A	O
total	O
of	O
43	O
maps	O
from	O
36	O
patients	B
were	O
analyzed	O
.	O

The	O
authors	O
found	O
variations	O
in	O
the	O
organization	O
of	O
M1	O
(	O
primary	O
motor	O
cortex	O
)	O
in	O
seven	O
patients	B
(	O
19.4	O
%	O
)	O
.	O

Four	O
patients	B
(	O
11.1	O
%	O
)	O
presented	O
mosaicism	O
(	O
overlapping	O
of	O
functional	O
areas	O
)	O
,	O
two	O
(	O
5.6	O
%	O
)	O
presented	O
variability	O
(	O
inverted	O
disposition	O
of	O
M1	O
functional	O
areas	O
)	O
,	O
and	O
one	O
(	O
2.8	O
%	O
)	O
had	O
both	O
.	O

Functional	O
variability	O
of	O
the	O
human	B
cortical	O
motor	O
map	O
:	O
electrical	O
stimulation	O
findings	O
in	O
perirolandic	O
epilepsy	O
surgery	O
.	O

The	O
purpose	O
of	O
this	O
study	O
was	O
to	O
assess	O
the	O
cortical	O
representation	O
of	O
sensorimotor	O
functions	O
in	O
patients	B
undergoing	O
perirolandic	O
epilepsy	O
surgery	O
,	O
focusing	O
on	O
somatotopy	O
,	O
mosaicism	O
,	O
and	O
variability	O
of	O
function	O
in	O
relation	O
to	O
the	O
classic	O
motor	O
homunculus	O
.	O

The	O
authors	O
studied	O
36	O
patients	B
in	O
whom	O
intraoperative	O
or	O
extraoperative	O
electrical	O
cortical	O
stimulation	O
to	O
map	O
motor	O
functions	O
was	O
performed	O
.	O

A	O
computer	O
program	O
was	O
devised	O
to	O
register	O
electrode	O
number	O
,	O
stimulation	O
parameters	O
,	O
and	O
response	O
to	O
each	O
stimulus	O
.	O

Finally	O
,	O
we	O
will	O
discuss	O
fundamental	O
issues	O
to	O
be	O
considered	O
in	O
study	O
design	O
when	O
targeting	O
the	O
epigenome	O
.	O

Pharmacology	O
of	O
epigenetics	O
in	O
brain	O
disorders	O
.	O

Epigenetics	O
is	O
a	O
rapidly	O
growing	O
field	O
and	O
holds	O
great	O
promise	O
for	O
a	O
range	O
of	O
human	B
diseases	O
,	O
including	O
brain	O
disorders	O
such	O
as	O
Rett	O
syndrome	O
,	O
anxiety	O
and	O
depressive	O
disorders	O
,	O
schizophrenia	O
,	O
Alzheimer	O
disease	O
and	O
Huntington	O
disease	O
.	O

This	O
review	O
is	O
concerned	O
with	O
the	O
pharmacology	O
of	O
epigenetics	O
to	O
treat	O
disorders	O
of	O
the	O
epigenome	O
whether	O
induced	O
developmentally	O
or	O
manifested	O
/	O
acquired	O
later	O
in	O
life	O
.	O

In	O
particular	O
,	O
we	O
will	O
focus	O
on	O
brain	O
disorders	O
and	O
their	O
treatment	O
by	O
drugs	O
that	O
modify	O
the	O
epigenome	O
.	O

While	O
the	O
use	O
of	O
DNA	O
methyl	O
transferase	O
inhibitors	O
and	O
histone	O
deacetylase	O
inhibitors	O
in	O
in	O
vitro	O
and	O
in	O
vivo	O
models	O
have	O
demonstrated	O
improvements	O
in	O
disease	O
-	O
related	O
deficits	O
,	O
clinical	O
trials	O
in	O
humans	B
have	O
been	O
less	O
promising	O
.	O

We	O
will	O
address	O
recent	O
advances	O
in	O
our	O
understanding	O
of	O
the	O
complexity	O
of	O
the	O
epigenome	O
with	O
its	O
many	O
molecular	O
players	O
,	O
and	O
discuss	O
evidence	O
for	O
a	O
compromised	O
epigenome	O
in	O
the	O
context	O
of	O
an	O
ageing	O
or	O
diseased	O
brain	O
.	O

We	O
will	O
also	O
draw	O
on	O
examples	O
of	O
species	O
differences	O
that	O
may	O
exist	O
between	O
humans	B
and	O
model	O
systems	O
,	O
emphasizing	O
the	O
need	O
for	O
more	O
robust	O
pre	O
-	O
clinical	O
testing	O
.	O

The	O
authors	O
review	O
the	O
literature	O
on	O
the	O
role	O
of	O
miRNAs	O
in	O
the	O
formation	O
and	O
propagation	O
of	O
gliomas	O
and	O
medulloblastomas	O
,	O
highlighting	O
the	O
potential	O
of	O
these	O
molecules	O
and	O
their	O
inhibitors	O
as	O
therapeutics	O
.	O

In	O
addition	O
to	O
the	O
established	O
role	O
of	O
miRNAs	O
as	O
developmental	O
regulators	O
of	O
normal	O
cellular	O
function	O
,	O
they	O
have	O
recently	O
been	O
shown	O
to	O
be	O
important	O
players	O
in	O
pathological	O
states	O
such	O
as	O
cancer	O
.	O

The	O
many	O
roles	O
of	O
microRNAs	O
in	O
brain	O
tumor	O
biology	O
.	O

MicroRNAs	O
(	O
miRNAs	O
)	O
are	O
now	O
recognized	O
as	O
the	O
primary	O
RNAs	O
involved	O
in	O
the	O
purposeful	O
silencing	O
of	O
the	O
cell	O
's	O
own	O
message	O
.	O

This	O
review	O
discusses	O
potential	O
RNAi	O
-	O
based	O
targets	O
that	O
are	O
of	O
interest	O
for	O
epilepsy	O
therapy	O
,	O
including	O
adenosine	O
kinase	O
(	O
ADK	O
)	O
,	O
the	O
key	O
negative	O
regulator	O
of	O
the	O
brain	O
's	O
endogenous	O
anticonvulsant	O
adenosine	O
.	O

Therapeutic	O
RNAi	O
has	O
been	O
widely	O
explored	O
for	O
dominant	O
targets	O
involved	O
in	O
neurodegenerative	O
diseases	O
;	O
however	O
,	O
their	O
use	O
for	O
epilepsy	O
therapy	O
has	O
received	O
less	O
attention	O
.	O

Therefore	O
,	O
RNAi	O
-	O
strategies	O
aimed	O
at	O
reducing	O
ADK	O
(	O
and	O
increasing	O
adenosine	O
)	O
are	O
based	O
on	O
a	O
direct	O
neurochemical	O
rationale	O
that	O
has	O
recently	O
been	O
explored	O
experimentally	O
using	O
ex	O
vivo	O
and	O
in	O
vivo	O
gene	O
therapy	O
approaches	O
.	O

Overexpression	O
of	O
ADK	O
,	O
and	O
the	O
resulting	O
adenosine	O
deficiency	O
,	O
are	O
pathologic	O
hallmarks	O
of	O
the	O
sclerotic	O
epileptic	O
brain	O
,	O
and	O
have	O
been	O
implicated	O
in	O
seizure	O
generation	O
.	O

Inhibitory	O
RNA	O
in	O
epilepsy	O
:	O
research	O
tools	O
and	O
therapeutic	O
perspectives	O
.	O

In	O
contrast	O
to	O
conventional	O
antiepileptic	O
drugs	O
(	O
AEDs	O
)	O
that	O
target	O
specific	O
proteins	O
such	O
as	O
ion	O
channels	O
or	O
receptors	O
,	O
RNAi	O
-	O
based	O
therapeutics	O
exploit	O
an	O
endogenous	O
regulatory	O
mechanism	O
of	O
gene	O
expression	O
and	O
thereby	O
are	O
poised	O
to	O
prevent	O
or	O
reverse	O
pathogenetic	O
mechanisms	O
involved	O
in	O
seizure	O
development	O
.	O

Since	O
its	O
discovery	O
a	O
decade	O
ago	O
,	O
RNA	O
interference	O
(	O
RNAi	O
)	O
has	O
been	O
developed	O
not	O
only	O
into	O
powerful	O
experimental	O
tools	O
but	O
also	O
into	O
promising	O
novel	O
therapeutics	O
.	O

Technical	O
issues	O
and	O
challenges	O
remain	O
before	O
those	O
promising	O
tools	O
can	O
be	O
developed	O
into	O
future	O
therapeutics	O
for	O
epilepsy	O
.	O

Micro	O
RNAs	O
(	O
miRNAs	O
)	O
are	O
post	O
-	O
transcriptional	O
modulators	O
of	O
gene	O
expression	O
that	O
regulate	O
the	O
stability	O
and	O
translation	O
of	O
their	O
target	O
messenger	O
RNAs	O
(	O
mRNAs	O
)	O
.	O

Micro	O
RNA-125b	O
(	O
miRNA-125b	O
)	O
function	O
in	O
astrogliosis	O
and	O
glial	O
cell	O
proliferation	O
.	O

In	O
vitro	O
,	O
anti	O
-	O
miRNA-125b	O
added	O
exogenously	O
to	O
IL-6-stressed	O
NHA	O
cultures	O
attenuated	O
both	O
glial	O
cell	O
proliferation	O
and	O
increased	O
the	O
expression	O
of	O
the	O
cyclin	O
-	O
dependent	O
kinase	O
inhibitor	O
2A	O
(	O
CDKN2A	O
)	O
,	O
a	O
miRNA-125b	O
target	O
and	O
negative	O
regulator	O
of	O
cell	O
growth	O
.	O

Here	O
we	O
report	O
that	O
the	O
levels	O
of	O
a	O
human	B
brain	O
-	O
enriched	O
miRNA-125b	O
are	O
up	O
-	O
regulated	O
in	O
interleukin-6	O
(	O
IL-6	O
)	O
-stressed	O
normal	O
human	B
astrocytes	O
(	O
NHA	O
)	O
,	O
a	O
treatment	O
known	O
to	O
induce	O
astrogliosis	O
.	O

The	O
results	O
suggest	O
that	O
miRNA-125b	O
up	O
-	O
regulation	O
contributes	O
to	O
astrogliosis	O
and	O
to	O
defects	O
in	O
the	O
cell	O
cycle	O
that	O
are	O
characteristic	O
of	O
degenerating	O
brain	O
tissues	O
.	O

A	O
strong	O
positive	O
correlation	O
between	O
miRNA-125b	O
abundance	O
and	O
the	O
glial	O
cell	O
markers	O
glial	O
fibrillary	O
acidic	O
protein	O
(	O
GFAP	O
)	O
and	O
vimentin	O
,	O
and	O
CDKN2A	O
down	O
-	O
regulation	O
was	O
noted	O
in	O
advanced	O
Alzheimer	O
's	O
disease	O
(	O
AD	O
)	O
and	O
in	O
Down	O
's	O
syndrome	O
(	O
DS	O
)	O
brain	O
,	O
chronic	O
neurological	O
disorders	O
associated	O
with	O
astrogliosis	O
.	O

Recently	O
,	O
it	O
was	O
demonstrated	O
that	O
podoplanin	O
membrane	O
sialo	O
-	O
glycoprotein	O
encoded	O
by	O
PDPN	O
gene	O
is	O
over	O
-	O
expressed	O
and	O
related	O
to	O
cellular	O
invasion	O
in	O
astrocytic	O
tumors	O
;	O
however	O
the	O
mechanisms	O
of	O
regulation	O
are	O
still	O
unknown	O
.	O

Glioblastoma	O
is	O
the	O
most	O
frequent	O
and	O
malignant	O
brain	O
tumor	O
,	O
characterized	O
by	O
an	O
elevated	O
capacity	O
for	O
cellular	O
proliferation	O
and	O
invasion	O
.	O

miR-29b	O
and	O
miR-125a	O
regulate	O
podoplanin	O
and	O
suppress	O
invasion	O
in	O
glioblastoma	O
.	O

Taken	O
together	O
,	O
these	O
results	O
suggest	O
that	O
miR-29b	O
and	O
miR-125a	O
represent	O
potential	O
therapeutic	O
targets	O
in	O
glioblastoma	O
.	O

In	O
this	O
study	O
,	O
we	O
focused	O
on	O
miR-29b	O
and	O
miR-125a	O
,	O
which	O
were	O
predicted	O
to	O
regulate	O
PDPN	O
,	O
and	O
demonstrated	O
that	O
these	O
microRNAs	O
directly	O
target	O
the	O
3	O
'	O
untranslated	O
region	O
of	O
PDPN	O
and	O
inhibit	O
invasion	O
,	O
apoptosis	O
,	O
and	O
proliferation	O
of	O
glioblastomas	O
.	O

Furthermore	O
,	O
we	O
report	O
that	O
miR-29b	O
and	O
miR-125a	O
are	O
downregulated	O
in	O
glioblastomas	O
and	O
also	O
in	O
CD133-positive	O
cells	O
.	O

MicroRNAs	O
are	O
noncoding	O
RNAs	O
that	O
regulate	O
gene	O
expression	O
and	O
several	O
biological	O
processes	O
and	O
diseases	O
,	O
including	O
cancer	O
.	O

Nevertheless	O
,	O
their	O
roles	O
in	O
invasion	O
,	O
proliferation	O
,	O
and	O
apoptosis	O
of	O
glioblastoma	O
are	O
not	O
completely	O
understood	O
.	O

MicroRNAs	O
and	O
apoptosis	O
:	O
implications	O
in	O
the	O
molecular	O
therapy	O
of	O
human	B
disease	O
.	O

1	O
.	O
MicroRNAs	O
(	O
miRNAs	O
)	O
,	O
the	O
small	O
non	O
-	O
coding	O
RNAs	O
of	O
approximately	O
22	O
nucleotides	O
,	O
are	O
now	O
recognized	O
as	O
a	O
very	O
large	O
family	O
present	O
throughout	O
the	O
genomes	O
of	O
plants	O
and	O
metazoans	O
.	O

These	O
small	O
transcripts	O
modulate	O
protein	O
expression	O
by	O
binding	O
to	O
complementary	O
or	O
partially	O
complementary	O
target	O
protein	O
-	O
coding	O
mRNAs	O
and	O
targeting	O
them	O
for	O
degradation	O
or	O
translational	O
inhibition	O
.	O

2	O
.	O
The	O
discovery	O
of	O
miRNAs	O
has	O
revolutionized	O
our	O
understanding	O
of	O
the	O
mechanisms	O
that	O
regulate	O
gene	O
expression	O
,	O
with	O
the	O
addition	O
of	O
an	O
entirely	O
novel	O
level	O
of	O
regulatory	O
control	O
.	O

3	O
.	O
One	O
of	O
the	O
most	O
active	O
fields	O
of	O
miRNA	O
research	O
is	O
miRNA	O
regulation	O
of	O
apoptosis	O
,	O
a	O
programmed	O
cell	O
death	O
implicated	O
in	O
many	O
human	B
diseases	O
,	O
such	O
as	O
cancer	O
,	O
Alzheimer	O
's	O
disease	O
,	O
hypertrophy	O
and	O
heart	O
failure	O
.	O

Indeed	O
,	O
aberrant	O
miRNA	O
expression	O
has	O
been	O
documented	O
in	O
human	B
disease	O
as	O
well	O
as	O
in	O
animal	O
models	O
,	O
with	O
evidence	O
for	O
a	O
causative	O
role	O
in	O
tumourigenesis	O
.	O

We	O
now	O
know	O
that	O
miRNAs	O
play	O
pivotal	O
roles	O
in	O
diverse	O
processes	O
,	O
such	O
as	O
development	O
and	O
differentiation	O
,	O
control	O
of	O
cell	O
proliferation	O
and	O
death	O
,	O
stress	O
response	O
and	O
metabolism	O
.	O

Considerable	O
information	O
on	O
miRNAs	O
has	O
been	O
accumulated	O
in	O
this	O
rapidly	O
evolving	O
research	O
field	O
.	O

4	O
.	O
The	O
present	O
review	O
provides	O
a	O
comprehensive	O
summary	O
and	O
analysis	O
of	O
the	O
currently	O
available	O
data	O
,	O
focusing	O
on	O
the	O
transcriptional	O
controls	O
,	O
target	O
genes	O
and	O
signalling	O
pathways	O
linking	O
the	O
apoptosis	O
-	O
regulating	O
miRNAs	O
and	O
apoptotic	O
cell	O
death	O
.	O

Thus	O
far	O
,	O
nearly	O
30	O
of	O
500	O
human	B
miRNAs	O
have	O
been	O
validated	O
experimentally	O
to	O
regulate	O
apoptosis	O
;	O
this	O
number	O
is	O
likely	O
to	O
increase	O
with	O
future	O
studies	O
.	O

We	O
also	O
found	O
that	O
miR-326	O
promoted	O
T	O
(	O
H	O
)	O
-17	O
differentiation	O
by	O
targeting	O
Ets-1	O
,	O
a	O
negative	O
regulator	O
of	O
T	O
(	O
H	O
)	O
-17	O
differentiation	O
.	O

Our	O
data	O
show	O
a	O
critical	O
role	O
for	O
microRNA	O
in	O
T	O
(	O
H	O
)	O
-17	O
differentiation	O
and	O
the	O
pathogenesis	O
of	O
multiple	O
sclerosis	O
.	O

Interleukin	O
17	O
(	O
IL-17	O
)	O
-producing	O
T	O
helper	O
cells	O
(	O
T	O
(	O
H	O
)	O
-17	O
cells	O
)	O
are	O
increasingly	O
recognized	O
as	O
key	O
participants	O
in	O
various	O
autoimmune	O
diseases	O
,	O
including	O
multiple	O
sclerosis	O
.	O

Although	O
sets	O
of	O
transcription	O
factors	O
and	O
cytokines	O
are	O
known	O
to	O
regulate	O
T	O
(	O
H	O
)	O
-17	O
differentiation	O
,	O
the	O
role	O
of	O
noncoding	O
RNA	O
is	O
poorly	O
understood	O
.	O

Here	O
we	O
identify	O
a	O
T	O
(	O
H	O
)	O
-17	O
cell	O
-	O
associated	O
microRNA	O
,	O
miR-326	O
,	O
whose	O
expression	O
was	O
highly	O
correlated	O
with	O
disease	O
severity	O
in	O
patients	B
with	O
multiple	O
sclerosis	O
and	O
mice	B
with	O
experimental	O
autoimmune	O
encephalomyelitis	O
(	O
EAE	O
)	O
.	O

In	O
vivo	O
silencing	O
of	O
miR-326	O
resulted	O
in	O
fewer	O
T	O
(	O
H	O
)	O
-17	O
cells	O
and	O
mild	O
EAE	O
,	O
and	O
its	O
overexpression	O
led	O
to	O
more	O
T	O
(	O
H	O
)	O
-17	O
cells	O
and	O
severe	O
EAE	O
.	O

MicroRNA	O
miR-326	O
regulates	O
TH-17	O
differentiation	O
and	O
is	O
associated	O
with	O
the	O
pathogenesis	O
of	O
multiple	O
sclerosis	O
.	O

Additionally	O
,	O
several	O
research	O
groups	O
have	O
established	O
that	O
inserting	O
microRNA	O
(	O
miRNA	O
)	O
-targeted	O
sequences	O
into	O
the	O
adenoviral	O
genome	O
can	O
modulate	O
adenoviral	O
protein	O
expression	O
to	O
confer	O
tissue	O
and	O
tumor	O
selectivity	O
.	O

It	O
has	O
been	O
suggested	O
that	O
the	O
use	O
of	O
autophagy	O
inducers	O
,	O
such	O
as	O
rapamycin	O
,	O
can	O
enhance	O
the	O
oncolytic	O
potency	O
of	O
recombinant	O
adenoviruses	O
.	O

This	O
review	O
discusses	O
three	O
aspects	O
of	O
the	O
use	O
of	O
oncolytic	O
adenoviruses	O
to	O
treat	O
cancer	O
:	O
(	O
i	O
)	O
the	O
induction	O
of	O
autophagy	O
and	O
autophagic	O
cell	O
death	O
during	O
adenoviral	O
replication	O
;	O
(	O
ii	O
)	O
the	O
opportunities	O
and	O
strategies	O
involved	O
in	O
the	O
exploitation	O
of	O
miRNA	O
specificity	O
to	O
generate	O
tissue-	O
and	O
tumor	O
-	O
selective	O
oncolytic	O
viruses	O
;	O
and	O
(	O
iii	O
)	O
the	O
rationale	O
for	O
combining	O
oncolytic	O
adenoviruses	O
with	O
chemotherapeutic	O
agents	O
.	O

Furthermore	O
,	O
the	O
capability	O
of	O
adenoviruses	O
to	O
inhibit	O
the	O
expression	O
of	O
the	O
DNA	O
repair	O
enzyme	O
MGMT	O
and	O
to	O
chemosensitize	O
glioma	O
cells	O
to	O
temozolomide	O
has	O
been	O
demonstrated	O
.	O

In	O
recent	O
years	O
,	O
oncolytic	O
viruses	O
have	O
been	O
genetically	O
engineered	O
to	O
target	O
cancer	O
cells	O
selectively	O
.	O

Oncolytic	O
adenoviruses	O
for	O
the	O
treatment	O
of	O
brain	O
tumors	O
.	O

The	O
observation	O
that	O
cells	O
infected	O
with	O
replication	O
-	O
competent	O
adenoviruses	O
undergo	O
autophagy	O
has	O
provided	O
new	O
options	O
for	O
investigating	O
the	O
mechanism	O
of	O
adenovirus	O
-	O
induced	O
cell	O
death	O
.	O

Adenovirus	O
is	O
one	O
such	O
oncolytic	O
virus	O
that	O
is	O
being	O
tested	O
in	O
clinical	O
trials	O
for	O
the	O
treatment	O
of	O
cancer	O
.	O

Parkinson	O
disease	O
(	O
PD	O
)	O
is	O
a	O
common	O
neurodegenerative	O
disorder	O
caused	O
by	O
environmental	O
and	O
genetic	O
factors	O
.	O

Variation	O
in	O
the	O
miRNA-433	O
binding	O
site	O
of	O
FGF20	O
confers	O
risk	O
for	O
Parkinson	O
disease	O
by	O
overexpression	O
of	O
alpha	O
-	O
synuclein	O
.	O

Subsequently	O
,	O
fibroblast	O
growth	O
factor	O
20	O
(	O
FGF20	O
)	O
at	O
8p21.3	O
-	O
22	O
was	O
identified	O
as	O
a	O
risk	O
factor	O
in	O
several	O
association	O
studies	O
.	O

We	O
have	O
previously	O
shown	O
linkage	O
of	O
PD	O
to	O
chromosome	O
8p	O
.	O

In	O
a	O
sample	O
of	O
729	O
nuclear	O
families	O
with	O
1089	O
affected	O
and	O
1165	O
unaffected	O
individuals	O
,	O
the	O
strongest	O
evidence	O
of	O
association	O
came	O
from	O
rs12720208	O
in	O
the	O
3	O
'	O
untranslated	O
region	O
of	O
FGF20	O
.	O

To	O
identify	O
the	O
risk	O
-	O
conferring	O
polymorphism	O
in	O
FGF20	O
,	O
we	O
performed	O
genetic	O
and	O
functional	O
analysis	O
of	O
single	O
-	O
nucleotide	O
polymorphisms	O
within	O
the	O
gene	O
.	O

In	O
a	O
cell	O
-	O
based	O
system	O
and	O
in	O
PD	O
brains	O
,	O
this	O
increase	O
in	O
translation	O
of	O
FGF20	O
is	O
correlated	O
with	O
increased	O
alpha	O
-	O
synuclein	O
expression	O
,	O
which	O
has	O
previously	O
been	O
shown	O
to	O
cause	O
PD	O
through	O
both	O
overexpression	O
and	O
point	O
mutations	O
.	O

We	O
show	O
in	O
several	O
functional	O
assays	O
that	O
the	O
risk	O
allele	O
for	O
rs12720208	O
disrupts	O
a	O
binding	O
site	O
for	O
microRNA-433	O
,	O
increasing	O
translation	O
of	O
FGF20	O
in	O
vitro	O
and	O
in	O
vivo	O
.	O

We	O
propose	O
this	O
is	O
likely	O
to	O
be	O
a	O
common	O
mechanism	O
of	O
genetic	O
modulation	O
of	O
individual	O
susceptibility	O
to	O
complex	O
disease	O
.	O

We	O
suggest	O
a	O
novel	O
mechanism	O
of	O
action	O
for	O
PD	O
risk	O
in	O
which	O
the	O
modulation	O
of	O
the	O
susceptibility	O
gene	O
's	O
translation	O
by	O
common	O
variations	O
interfere	O
with	O
the	O
regulation	O
mechanisms	O
of	O
microRNA	O
.	O

BACE1	O
mRNA	O
levels	O
tended	O
to	O
increase	O
as	O
miR-107	O
levels	O
decreased	O
in	O
the	O
progression	O
of	O
AD	O
.	O
Cell	O
culture	O
reporter	O
assays	O
performed	O
with	O
a	O
subset	O
of	O
the	O
predicted	O
miR-107	O
binding	O
sites	O
indicate	O
the	O
presence	O
of	O
at	O
least	O
one	O
physiological	O
miR-107	O
miRNA	O
recognition	O
sequence	O
in	O
the	O
3'-UTR	O
of	O
BACE1	O
mRNA	O
.	O

Computational	O
analysis	O
predicted	O
that	O
the	O
3'-untranslated	O
region	O
(	O
UTR	O
)	O
of	O
beta	O
-	O
site	O
amyloid	O
precursor	O
protein	O
-	O
cleaving	O
enzyme	O
1	O
(	O
BACE1	O
)	O
mRNA	O
is	O
targeted	O
multiply	O
by	O
miR-107	O
.	O

From	O
the	O
same	O
RNA	O
material	O
analyzed	O
on	O
miRNA	O
microarrays	O
,	O
mRNA	O
expression	O
profiling	O
was	O
performed	O
using	O
Affymetrix	O
Exon	O
Array	O
microarrays	O
on	O
nondemented	O
,	O
MCI	O
,	O
and	O
AD	O
patients	B
.	O

Among	O
the	O
AD	O
-	O
related	O
miRNA	O
expression	O
changes	O
,	O
miR-107	O
was	O
exceptional	O
because	O
miR-107	O
levels	O
decreased	O
significantly	O
even	O
in	O
patients	B
with	O
the	O
earliest	O
stages	O
of	O
pathology	O
.	O

In	O
situ	O
hybridization	O
with	O
cross	O
-	O
comparison	O
to	O
neuropathology	O
demonstrated	O
that	O
particular	O
cerebral	O
cortical	O
laminas	O
involved	O
by	O
AD	O
pathology	O
exhibit	O
diminished	O
neuronal	O
miR-107	O
expression	O
.	O

We	O
used	O
miRNA	O
expression	O
microarrays	O
on	O
RNA	O
extracted	O
from	O
human	B
brain	O
tissue	O
from	O
the	O
University	O
of	O
Kentucky	O
Alzheimer	O
's	O
Disease	O
Center	O
Brain	O
Bank	O
with	O
near	O
-	O
optimal	O
clinicopathological	O
correlation	O
.	O

Cases	O
were	O
separated	O
into	O
four	O
groups	O
:	O
elderly	O
nondemented	O
with	O
negligible	O
AD	O
-	O
type	O
pathology	O
,	O
nondemented	O
with	O
incipient	O
AD	O
pathology	O
,	O
mild	O
cognitive	O
impairment	O
(	O
MCI	O
)	O
with	O
moderate	O
AD	O
pathology	O
,	O
and	O
AD	O
.	O

MicroRNAs	O
(	O
miRNAs	O
)	O
are	O
small	O
regulatory	O
RNAs	O
that	O
participate	O
in	O
posttranscriptional	O
gene	O
regulation	O
in	O
a	O
sequence	O
-	O
specific	O
manner	O
.	O

However	O
,	O
little	O
is	O
understood	O
about	O
the	O
role	O
(	O
s	O
)	O
of	O
miRNAs	O
in	O
Alzheimer	O
's	O
disease	O
(	O
AD	O
)	O
.	O

Together	O
,	O
the	O
coordinated	O
application	O
of	O
miRNA	O
profiling	O
,	O
Affymetrix	O
microarrays	O
,	O
new	O
bioinformatics	O
predictions	O
,	O
in	O
situ	O
hybridization	O
,	O
and	O
biochemical	O
validation	O
indicate	O
that	O
miR-107	O
may	O
be	O
involved	O
in	O
accelerated	O
disease	O
progression	O
through	O
regulation	O
of	O
BACE1	O
.	O

The	O
expression	O
of	O
microRNA	O
miR-107	O
decreases	O
early	O
in	O
Alzheimer	O
's	O
disease	O
and	O
may	O
accelerate	O
disease	O
progression	O
through	O
regulation	O
of	O
beta	O
-	O
site	O
amyloid	O
precursor	O
protein	O
-	O
cleaving	O
enzyme	O
1	O
.	O

We	O
report	O
here	O
on	O
a	O
patient	B
who	O
was	O
treated	O
for	O
an	O
atypical	O
brain	O
meningioma	O
with	O
multiple	O
surgeries	O
and	O
multiple	O
sessions	O
of	O
stereotactic	O
radiosurgery	O
with	O
good	O
control	O
of	O
his	O
brain	O
disease	O
.	O

Thirteen	O
years	O
after	O
diagnosis	O
,	O
he	O
developed	O
bilateral	O
large	O
sacroiliac	O
and	O
abdominal	O
metastases	O
.	O

Extracranial	O
metastases	O
from	O
brain	O
meningiomas	O
is	O
a	O
rare	O
,	O
but	O
well	O
-	O
documented	O
entity	O
.	O

Metastases	O
occur	O
mostly	O
in	O
the	O
lungs	O
,	O
pleura	O
and	O
liver	O
,	O
but	O
may	O
also	O
affect	O
lymph	O
nodes	O
and	O
bones	O
.	O

Extraneural	O
metastases	O
from	O
cranial	O
meningioma	O
:	O
a	O
case	O
report	O
.	O

Here	O
we	O
expand	O
the	O
role	O
of	O
GRN	O
in	O
FTLD	O
-	O
U	O
and	O
demonstrate	O
that	O
a	O
common	O
genetic	O
variant	O
(	O
rs5848	O
)	O
,	O
located	O
in	O
the	O
3'-untranslated	O
region	O
(	O
UTR	O
)	O
of	O
GRN	O
in	O
a	O
binding	O
-	O
site	O
for	O
miR-659	O
,	O
is	O
a	O
major	O
susceptibility	O
factor	O
for	O
FTLD	O
-	O
U.	O

Loss	O
-	O
of	O
-	O
function	O
mutations	O
in	O
progranulin	O
(	O
GRN	O
)	O
cause	O
ubiquitin-	O
and	O
TAR	O
DNA	O
-	O
binding	O
protein	O
43	O
(	O
TDP-43	O
)	O
-positive	O
frontotemporal	O
dementia	O
(	O
FTLD	O
-	O
U	O
)	O
,	O
a	O
progressive	O
neurodegenerative	O
disease	O
affecting	O
approximately	O
10	O
%	O
of	O
early	O
-	O
onset	O
dementia	O
patients	B
.	O

Common	O
variation	O
in	O
the	O
miR-659	O
binding	O
-	O
site	O
of	O
GRN	O
is	O
a	O
major	O
risk	O
factor	O
for	O
TDP43-positive	O
frontotemporal	O
dementia	O
.	O

In	O
support	O
of	O
these	O
findings	O
,	O
the	O
neuropathology	O
of	O
homozygous	O
rs5848	O
T	O
-	O
allele	O
carriers	O
frequently	O
resembled	O
the	O
pathological	O
FTLD	O
-	O
U	O
subtype	O
of	O
GRN	O
mutation	O
carriers	O
.	O

A	O
significant	O
reduction	O
in	O
GRN	O
protein	O
was	O
observed	O
in	O
homozygous	O
T	O
-	O
allele	O
carriers	O
in	O
vivo	O
,	O
through	O
biochemical	O
and	O
immunohistochemical	O
methods	O
,	O
mimicking	O
the	O
effect	O
of	O
heterozygous	O
loss	O
-	O
of	O
-	O
function	O
GRN	O
mutations	O
.	O

We	O
further	O
demonstrate	O
that	O
miR-659	O
can	O
regulate	O
GRN	O
expression	O
in	O
vitro	O
,	O
with	O
miR-659	O
binding	O
more	O
efficiently	O
to	O
the	O
high	O
risk	O
T	O
-	O
allele	O
of	O
rs5848	O
resulting	O
in	O
augmented	O
translational	O
inhibition	O
of	O
GRN	O
.	O

In	O
a	O
series	O
of	O
pathologically	O
confirmed	O
FTLD	O
-	O
U	O
patients	B
without	O
GRN	O
mutations	O
,	O
we	O
show	O
that	O
carriers	O
homozygous	O
for	O
the	O
T	O
-	O
allele	O
of	O
rs5848	O
have	O
a	O
3.2-fold	O
increased	O
risk	O
to	O
develop	O
FTLD	O
-	O
U	O
compared	O
with	O
homozygous	O
C	O
-	O
allele	O
carriers	O
(	O
95	O
%	O
CI	O
:	O
1.50	O
-	O
6.73	O
)	O
.	O

Translational	O
regulation	O
by	O
miRNAs	O
may	O
represent	O
a	O
common	O
mechanism	O
underlying	O
complex	O
neurodegenerative	O
disorders	O
.	O

We	O
suggest	O
that	O
the	O
expression	O
of	O
GRN	O
is	O
regulated	O
by	O
miRNAs	O
and	O
that	O
common	O
genetic	O
variability	O
in	O
a	O
miRNA	O
binding	O
-	O
site	O
can	O
significantly	O
increase	O
the	O
risk	O
for	O
FTLD	O
-	O
U.	O

Here	O
,	O
we	O
discuss	O
recent	O
data	O
that	O
support	O
a	O
view	O
that	O
endolysosomal	O
positioning	O
of	O
RNA	O
might	O
facilitate	O
intercellular	O
transmission	O
of	O
RNA	O
and	O
host	O
defence	O
against	O
viruses	O
and	O
retrotransposons	O
.	O

Positioning	O
of	O
RNA	O
regulatory	O
mechanisms	O
on	O
endolysosomal	O
membranes	O
might	O
permit	O
rapid	O
and	O
localized	O
control	O
of	O
microRNA	O
(	O
miRNA	O
)	O
gene	O
regulatory	O
programs	O
and	O
mRNA	O
translation	O
in	O
response	O
to	O
environmental	O
signals	O
,	O
such	O
as	O
activated	O
plasma	O
membrane	O
receptors	O
transported	O
on	O
endosomes	O
.	O

Finally	O
,	O
we	O
suggest	O
that	O
the	O
pathology	O
of	O
several	O
conditions	O
,	O
including	O
Huntington	O
's	O
disease	O
,	O
might	O
be	O
a	O
consequence	O
of	O
the	O
disruption	O
of	O
the	O
control	O
of	O
RNA	O
via	O
endolysosomal	O
membranes	O
.	O

Control	O
of	O
RNA	O
silencing	O
and	O
localization	O
by	O
endolysosomes	O
.	O

Recent	O
advances	O
in	O
the	O
cell	O
biology	O
of	O
RNA	O
silencing	O
have	O
unraveled	O
an	O
intriguing	O
association	O
of	O
post	O
-	O
transcriptionally	O
regulated	O
RNA	O
with	O
endolysosomal	O
membranes	O
in	O
several	O
circumstances	O
of	O
mRNA	O
localization	O
,	O
microRNA	O
activity	O
and	O
viral	O
RNA	O
transport	O
and	O
packaging	O
.	O

Endolysosomal	O
membranes	O
are	O
a	O
nexus	O
of	O
communication	O
and	O
transport	O
between	O
cells	O
and	O
their	O
exterior	O
environment	O
for	O
signaling	O
receptors	O
,	O
pathogens	O
and	O
nutrients	O
.	O

The	O
method	O
by	O
which	O
MSCs	O
could	O
be	O
applied	O
for	O
future	O
therapies	O
might	O
require	O
trans	O
-	O
disciplinary	O
approaches	O
for	O
personalized	O
treatments	O
.	O

Implantation	O
of	O
adult	O
human	B
mesenchymal	O
stem	O
cells	O
(	O
MSCs	O
)	O
to	O
treat	O
neural	O
disorders	O
shows	O
promise	O
.	O

Depending	O
on	O
their	O
microenvironment	O
,	O
MSCs	O
could	O
potentially	O
be	O
used	O
for	O
the	O
repair	O
and/or	O
replacement	O
of	O
neurons	O
in	O
traumatic	O
brain	O
injury	O
or	O
the	O
treatment	O
of	O
Parkinson	O
's	O
disease	O
.	O

This	O
cross	O
-	O
disciplinary	O
review	O
incorporates	O
aspects	O
of	O
neuroscience	O
,	O
stem	O
cell	O
biology	O
,	O
cancer	O
biology	O
and	O
immunology	O
to	O
discuss	O
interactions	O
between	O
inflammatory	O
mediators	O
and	O
MSCs	O
.	O

We	O
first	O
discuss	O
the	O
role	O
of	O
microRNAs	O
(	O
miRNAs	O
)	O
in	O
neurological	O
development	O
.	O

Neurogenesis	O
:	O
role	O
for	O
microRNAs	O
and	O
mesenchymal	O
stem	O
cells	O
in	O
pathological	O
states	O
.	O

Exploring	O
the	O
predisposition	O
of	O
MSCs	O
to	O
oncogenesis	O
is	O
critical	O
for	O
translational	O
science	O
since	O
the	O
implementation	O
of	O
safeguarding	O
measures	O
prior	O
to	O
therapy	O
can	O
lead	O
to	O
the	O
successful	O
delivery	O
of	O
stem	O
cells	O
to	O
patients	B
.	O

The	O
administration	O
of	O
effective	O
and	O
safe	O
MSC	O
therapy	O
must	O
acknowledge	O
immune	O
mediators	O
that	O
may	O
predispose	O
the	O
early	O
differentiating	O
MSCs	O
to	O
oncogenic	O
insults	O
.	O

Secondly	O
,	O
we	O
discuss	O
the	O
ability	O
of	O
MSCs	O
to	O
transdifferentiate	O
into	O
functional	O
neurons	O
,	O
which	O
are	O
regulated	O
by	O
miRNAs	O
,	O
and	O
the	O
implications	O
of	O
these	O
cells	O
for	O
the	O
therapy	O
of	O
neuropathological	O
states	O
.	O

Immune	O
mediators	O
could	O
be	O
central	O
to	O
MSC	O
responses	O
within	O
a	O
region	O
of	O
tissue	O
injury	O
and	O
are	O
also	O
discussed	O
in	O
detail	O
.	O

Thus	O
,	O
we	O
discuss	O
a	O
key	O
gene	O
,	O
RE-1	O
silencing	O
transcription	O
factor	O
(	O
REST	O
)	O
,	O
based	O
on	O
its	O
dual	O
role	O
in	O
neurogenesis	O
and	O
cancer	O
development	O
.	O

Finally	O
,	O
a	O
phylogenetic	O
analysis	O
shows	O
that	O
ADCK3	O
belongs	O
to	O
the	O
family	O
of	O
atypical	O
kinases	O
,	O
which	O
includes	O
phosphoinositide	O
and	O
choline	O
kinases	O
,	O
suggesting	O
that	O
ADCK3	O
plays	O
an	O
indirect	O
regulatory	O
role	O
in	O
ubiquinone	O
biosynthesis	O
possibly	O
as	O
part	O
of	O
a	O
feedback	O
loop	O
that	O
regulates	O
ATP	O
production	O
.	O

ADCK3	O
,	O
an	O
ancestral	O
kinase	O
,	O
is	O
mutated	O
in	O
a	O
form	O
of	O
recessive	O
ataxia	O
associated	O
with	O
coenzyme	O
Q10	O
deficiency	O
.	O

Muscle	O
coenzyme	O
Q	O
(	O
10	O
)	O
(	O
CoQ	O
(	O
10	O
)	O
or	O
ubiquinone	O
)	O
deficiency	O
has	O
been	O
identified	O
in	O
more	O
than	O
20	O
patients	B
with	O
presumed	O
autosomal	O
-	O
recessive	O
ataxia	O
.	O

However	O
,	O
mutations	O
in	O
genes	O
required	O
for	O
CoQ	O
(	O
10	O
)	O
biosynthetic	O
pathway	O
have	O
been	O
identified	O
only	O
in	O
patients	B
with	O
infantile	O
-	O
onset	O
multisystemic	O
diseases	O
or	O
isolated	O
nephropathy	O
.	O

Our	O
SNP	O
-	O
based	O
genome	O
-	O
wide	O
scan	O
in	O
a	O
large	O
consanguineous	O
family	O
revealed	O
a	O
locus	O
for	O
autosomal	O
-	O
recessive	O
ataxia	O
at	O
chromosome	O
1q41	O
.	O

The	O
causative	O
mutation	O
is	O
a	O
homozygous	O
splice	O
-	O
site	O
mutation	O
in	O
the	O
aarF	O
-	O
domain	O
-	O
containing	O
kinase	O
3	O
gene	O
(	O
ADCK3	O
)	O
.	O

Five	O
additional	O
mutations	O
in	O
ADCK3	O
were	O
found	O
in	O
three	O
patients	B
with	O
sporadic	O
ataxia	O
,	O
including	O
one	O
known	O
to	O
have	O
CoQ	O
(	O
10	O
)	O
deficiency	O
in	O
muscle	O
.	O

All	O
of	O
the	O
patients	B
have	O
childhood	O
-	O
onset	O
cerebellar	O
ataxia	O
with	O
slow	O
progression	O
,	O
and	O
three	O
of	O
six	O
have	O
mildly	O
elevated	O
lactate	O
levels	O
.	O

ADCK3	O
is	O
a	O
mitochondrial	O
protein	O
homologous	O
to	O
the	O
yeast	O
COQ8	O
and	O
the	O
bacterial	O
UbiB	O
proteins	O
,	O
which	O
are	O
required	O
for	O
CoQ	O
biosynthesis	O
.	O

Three	O
out	O
of	O
four	O
patients	B
tested	O
showed	O
a	O
low	O
endogenous	O
pool	O
of	O
CoQ	O
(	O
10	O
)	O
in	O
their	O
fibroblasts	O
or	O
lymphoblasts	O
,	O
and	O
two	O
out	O
of	O
three	O
patients	B
showed	O
impaired	O
ubiquinone	O
synthesis	O
,	O
strongly	O
suggesting	O
that	O
ADCK3	O
is	O
also	O
involved	O
in	O
CoQ	O
(	O
10	O
)	O
biosynthesis	O
.	O

The	O
deleterious	O
nature	O
of	O
the	O
three	O
identified	O
missense	O
changes	O
was	O
confirmed	O
by	O
the	O
introduction	O
of	O
them	O
at	O
the	O
corresponding	O
positions	O
of	O
the	O
yeast	O
COQ8	O
gene	O
.	O

Interpretation	O
and	O
applicability	O
of	O
microRNA	O
data	O
to	O
the	O
context	O
of	O
Alzheimer	O
's	O
and	O
age	O
-	O
related	O
diseases	O
.	O

Generated	O
by	O
the	O
ribonuclease	O
III	O
Dicer	O
,	O
microRNAs	O
(	O
miRNAs	O
)	O
are	O
predicted	O
to	O
regulate	O
up	O
to	O
90	O
%	O
of	O
the	O
genes	O
in	O
humans	B
,	O
suggesting	O
that	O
they	O
may	O
control	O
every	O
cellular	O
processes	O
in	O
all	O
cells	O
and	O
tissues	O
of	O
the	O
human	B
body	O
!	O

Likely	O
to	O
play	O
a	O
central	O
role	O
in	O
health	O
and	O
disease	O
,	O
a	O
dysfunctional	O
miRNA	O
-	O
based	O
regulation	O
of	O
gene	O
expression	O
may	O
represent	O
the	O
main	O
etiologic	O
factor	O
underlying	O
age	O
-	O
related	O
diseases	O
affecting	O
major	O
organs	O
,	O
such	O
as	O
the	O
brain	O
.	O

Here	O
,	O
we	O
discuss	O
some	O
of	O
the	O
limitations	O
associated	O
to	O
the	O
interpretation	O
and	O
applicability	O
of	O
miRNA	O
data	O
,	O
based	O
on	O
our	O
recent	O
study	O
on	O
the	O
etiology	O
of	O
Alzheimer	O
's	O
disease	O
(	O
AD	O
)	O
.	O

Using	O
transiently	O
transfected	O
murine	B
neuronal	O
N2a	O
cells	O
in	O
culture	O
,	O
in	O
parallel	O
to	O
a	O
mouse	B
model	O
of	O
AD	O
,	O
we	O
were	O
able	O
to	O
demonstrate	O
a	O
role	O
for	O
two	O
miRNAs	O
(	O
miR-298	O
and	O
miR-328	O
)	O
in	O
the	O
regulation	O
of	O
beta	O
-	O
amyloid	O
(	O
Abeta	O
)	O
precursor	O
protein	O
(	O
APP	O
)	O
-converting	O
enzyme	O
(	O
BACE	O
)	O
messenger	O
RNA	O
(	O
mRNA	O
)	O
translation	O
,	O
thereby	O
providing	O
key	O
insights	O
into	O
the	O
molecular	O
basis	O
underlying	O
BACE	O
deregulation	O
in	O
AD	O
.	O

However	O
,	O
whether	O
miRNA	O
data	O
can	O
be	O
extrapolated	O
and	O
transposed	O
to	O
the	O
human	B
context	O
of	O
age	O
-	O
related	O
diseases	O
,	O
such	O
as	O
AD	O
,	O
not	O
only	O
requires	O
caution	O
,	O
but	O
also	O
warrants	O
several	O
considerations	O
.	O

Levels	O
of	O
protein	O
expression	O
of	O
endothelial	O
NO	O
synthase	O
(	O
eNOS	O
)	O
,	O
caveolin-1	O
,	O
and	O
calmodulin	O
were	O
assessed	O
in	O
carotid	O
arteries	O
using	O
Western	O
analysis	O
.	O

Plasma	O
NO	O
levels	O
were	O
doubled	O
by	O
daidzein	O
or	O
17beta	O
-	O
estradiol	O
.	O

NO	O
production	O
and	O
endothelium	O
-	O
dependent	O
contraction	O
in	O
response	O
to	O
the	O
NOS	O
inhibitor	O
NG	O
-	O
nitro	O
-	O
L	O
-	O
arginine	O
(	O
L	O
-	O
NNA	O
;	O
100	O
microM	O
)	O
was	O
enhanced	O
by	O
50	O
to	O
100	O
%	O
in	O
carotid	O
arteries	O
from	O
rats	B
treated	O
with	O
daidzein	O
or	O
17beta	O
-	O
estradiol	O
.	O

Acetylcholine	O
-	O
induced	O
relaxation	O
was	O
selectively	O
enhanced	O
in	O
carotid	O
arteries	O
from	O
rats	B
treated	O
with	O
daidzein	O
.	O

The	O
use	O
of	O
estrogen	O
for	O
protection	O
against	O
vascular	O
dysfunction	O
is	O
limited	O
due	O
to	O
its	O
effects	O
on	O
the	O
reproductive	O
system	O
,	O
particularly	O
in	O
males	O
.	O

We	O
postulated	O
that	O
daidzein	O
,	O
an	O
isoflavone	O
with	O
estrogen	O
-	O
like	O
effects	O
on	O
the	O
systemic	O
vasculature	O
but	O
not	O
the	O
reproductive	O
system	O
,	O
might	O
enhance	O
nitric	O
oxide	O
(	O
NO	O
)	O
-mediated	O
cerebral	O
vasodilatation	O
.	O

Male	O
rats	B
were	O
administered	O
vehicle	O
,	O
17beta	O
-	O
estradiol	O
(	O
0.1	O
mg	O
/	O
kg	O
s.c	O
.	O
)	O
,	O
or	O
daidzein	O
(	O
0.2	O
mg	O
/	O
kg	O
s.c	O
.	O
)	O
daily	O
for	O
7	O
days	O
.	O

Basal	O
and	O
acetylcholine	O
-	O
stimulated	O
NO	O
release	O
was	O
assessed	O
in	O
vitro	O
via	O
carotid	O
arterial	O
rings	O
or	O
in	O
vivo	O
by	O
measuring	O
changes	O
in	O
basilar	O
artery	O
diameter	O
.	O

Similarly	O
,	O
constrictor	O
responses	O
of	O
the	O
basilar	O
artery	O
to	O
L	O
-	O
NNA	O
in	O
vivo	O
were	O
selectively	O
augmented	O
by	O
approximately	O
100	O
%	O
by	O
17beta	O
-	O
estradiol	O
treatment	O
and	O
tended	O
to	O
be	O
approximately	O
50	O
%	O
greater	O
in	O
daidzein	O
-	O
treated	O
rats	B
.	O

Effect	O
of	O
short	O
-	O
term	O
phytoestrogen	O
treatment	O
in	O
male	O
rats	B
on	O
nitric	O
oxide	O
-	O
mediated	O
responses	O
of	O
carotid	O
and	O
cerebral	O
arteries	O
:	O
comparison	O
with	O
17beta	O
-	O
estradiol	O
.	O

These	O
data	O
suggest	O
that	O
short	O
-	O
term	O
administration	O
of	O
daidzein	O
or	O
17beta	O
-	O
estradiol	O
modulates	O
cerebral	O
artery	O
reactivity	O
in	O
males	O
by	O
enhancing	O
synthesis	O
and	O
release	O
of	O
endothelium	O
-	O
derived	O
NO	O
.	O
Isoflavone	O
therapy	O
may	O
therefore	O
be	O
a	O
feasible	O
approach	O
to	O
protect	O
against	O
cerebrovascular	O
disease	O
and	O
stroke	O
.	O

Expression	O
of	O
caveolin-1	O
was	O
decreased	O
,	O
and	O
calmodulin	O
was	O
increased	O
,	O
in	O
vessels	O
from	O
daidzein-	O
or	O
17beta	O
-	O
estradiol	O
-	O
treated	O
rats	B
.	O

eNOS	O
expression	O
was	O
unaffected	O
by	O
the	O
treatments	O
.	O

However	O
,	O
we	O
report	O
the	O
experience	O
of	O
a	O
patient	B
who	O
inadvertently	O
received	O
live	O
polio	O
vaccine	O
whilst	O
receiving	O
anti	O
-	O
TNF	O
therapy	O
.	O

International	O
guidelines	O
state	O
that	O
live	O
vaccines	O
are	O
contraindicated	O
in	O
patients	B
on	O
anti	O
-	O
TNF	O
therapy	O
.	O

Live	O
polio	O
vaccine	O
exposure	O
while	O
receiving	O
anti	O
-	O
TNF	O
therapy	O
for	O
reactive	O
arthritis	O
.	O

Patients	B
should	O
be	O
counseled	O
regarding	O
the	O
risks	O
of	O
live	O
vaccines	O
prior	O
to	O
treatment	O
with	O
anti	O
-	O
TNF	O
therapy	O
.	O

However	O
,	O
if	O
we	O
consider	O
adult	O
patients	B
with	O
rheumatic	O
diseases	O
to	O
have	O
altered	O
immunocompetence	O
,	O
it	O
is	O
recommended	O
that	O
they	O
receive	O
the	O
usual	O
inactivated	O
vaccines	O
according	O
to	O
standard	O
schedules	O
,	O
and	O
live	O
vaccines	O
should	O
be	O
avoided	O
in	O
those	O
who	O
are	O
treated	O
with	O
more	O
potent	O
forms	O
of	O
immune	O
suppression	O
.	O

No	O
clear	O
guidelines	O
are	O
available	O
for	O
all	O
vaccines	O
in	O
patients	B
with	O
specific	O
rheumatic	O
diseases	O
.	O

Patient	B
did	O
not	O
suffer	O
from	O
any	O
infectious	O
sequel	O
as	O
a	O
result	O
.	O

Autosomal	O
-	O
recessive	O
cerebellar	O
ataxias	O
comprise	O
a	O
clinically	O
and	O
genetically	O
heterogeneous	O
group	O
of	O
neurodegenerative	O
disorders	O
.	O

In	O
contrast	O
to	O
their	O
dominant	O
counterparts	O
,	O
unraveling	O
the	O
molecular	O
background	O
of	O
these	O
ataxias	O
has	O
proven	O
to	O
be	O
more	O
complicated	O
and	O
the	O
currently	O
known	O
mutations	O
provide	O
incomplete	O
coverage	O
for	O
genotyping	O
of	O
patients	B
.	O

By	O
combining	O
SNP	O
array	O
-	O
based	O
linkage	O
analysis	O
and	O
targeted	O
resequencing	O
of	O
relevant	O
sequences	O
in	O
the	O
linkage	O
interval	O
with	O
the	O
use	O
of	O
next	O
-	O
generation	O
sequencing	O
technology	O
,	O
we	O
identified	O
a	O
mutation	O
in	O
a	O
gene	O
and	O
have	O
shown	O
its	O
association	O
with	O
autosomal	O
-	O
recessive	O
cerebellar	O
ataxia	O
.	O

In	O
a	O
Dutch	O
consanguineous	O
family	O
with	O
three	O
affected	O
siblings	O
a	O
homozygous	O
12.5	O
Mb	O
region	O
on	O
chromosome	O
3	O
was	O
targeted	O
by	O
array	O
-	O
based	O
sequence	O
capture	O
.	O

Targeted	O
next	O
-	O
generation	O
sequencing	O
of	O
a	O
12.5	O
Mb	O
homozygous	O
region	O
reveals	O
ANO10	O
mutations	O
in	O
patients	B
with	O
autosomal	O
-	O
recessive	O
cerebellar	O
ataxia	O
.	O

The	O
analysis	O
of	O
ANO10	O
by	O
Sanger	O
sequencing	O
revealed	O
three	O
additional	O
mutations	O
:	O
a	O
homozygous	O
mutation	O
(	O
c.1150_1151del	O
[	O
p	O
.	O
Leu384fs	O
]	O
)	O
in	O
a	O
Serbian	O
family	O
and	O
a	O
compound	O
-	O
heterozygous	O
splice	O
-	O
site	O
mutation	O
(	O
c.1476	O
+	O
1G	O
>	O
T	O
)	O
and	O
a	O
frameshift	O
mutation	O
(	O
c.1604del	O
[	O
p	O
.	O
Leu535X	O
]	O
)	O
in	O
a	O
French	O
family	O
.	O

This	O
illustrates	O
the	O
power	O
of	O
using	O
initial	O
homozygosity	O
mapping	O
with	O
next	O
-	O
generation	O
sequencing	O
technology	O
to	O
identify	O
genes	O
involved	O
in	O
autosomal	O
-	O
recessive	O
diseases	O
.	O

Prioritization	O
of	O
all	O
detected	O
sequence	O
variants	O
led	O
to	O
four	O
candidate	O
genes	O
,	O
one	O
of	O
which	O
contained	O
a	O
variant	O
with	O
a	O
high	O
base	O
pair	O
conservation	O
score	O
(	O
phyloP	O
score	O
:	O
5.26	O
)	O
.	O

This	O
variant	O
was	O
a	O
leucine	O
-	O
to	O
-	O
arginine	O
substitution	O
in	O
the	O
DUF	O
590	O
domain	O
of	O
a	O
16	O
K	O
transmembrane	O
protein	O
,	O
a	O
putative	O
calcium	O
-	O
activated	O
chloride	O
channel	O
encoded	O
by	O
anoctamin	O
10	O
(	O
ANO10	O
)	O
.	O

Moreover	O
,	O
identifying	O
a	O
putative	O
calcium	O
-	O
dependent	O
chloride	O
channel	O
involved	O
in	O
cerebellar	O
ataxia	O
adds	O
another	O
pathway	O
to	O
the	O
list	O
of	O
pathophysiological	O
mechanisms	O
that	O
may	O
cause	O
cerebellar	O
ataxia	O
.	O

These	O
findings	O
further	O
support	O
the	O
idea	O
that	O
iron-	O
and	O
aluminum	O
-	O
sulfates	O
induce	O
genotoxicity	O
via	O
a	O
ROS	O
-	O
mediated	O
up	O
-	O
regulation	O
of	O
specific	O
regulatory	O
elements	O
and	O
pathogenic	O
genes	O
that	O
redirect	O
brain	O
cell	O
fate	O
towards	O
progressive	O
dysfunction	O
and	O
apoptotic	O
cell	O
death	O
.	O

Notably	O
,	O
these	O
same	O
miRNAs	O
are	O
up	O
-	O
regulated	O
in	O
AD	O
brain	O
.	O

The	O
main	O
finding	O
was	O
that	O
these	O
ROS	O
-	O
generating	O
neurotoxic	O
metal	O
sulfates	O
also	O
up	O
-	O
regulate	O
a	O
specific	O
set	O
of	O
miRNAs	O
that	O
includes	O
miR-9	O
,	O
miR-125b	O
and	O
miR-128	O
.	O

In	O
this	O
study	O
we	O
have	O
extended	O
our	O
investigations	O
to	O
analyze	O
the	O
expression	O
of	O
micro	O
RNA	O
(	O
miRNA	O
)	O
populations	O
in	O
iron-	O
and	O
aluminum	O
-	O
sulfate	O
treated	O
human	B
neural	O
cells	O
in	O
primary	O
culture	O
.	O

Notably	O
,	O
iron-	O
and	O
aluminum	O
-	O
sulfate	O
induce	O
genes	O
in	O
cultured	O
human	B
brain	O
cells	O
that	O
exhibit	O
expression	O
patterns	O
similar	O
to	O
those	O
observed	O
to	O
be	O
up	O
-	O
regulated	O
in	O
moderate-	O
to	O
late	O
-	O
stage	O
Alzheimer	O
's	O
disease	O
(	O
AD	O
)	O
.	O

Previous	O
studies	O
have	O
shown	O
that	O
following	O
ROS	O
induction	O
,	O
a	O
family	O
of	O
pathogenic	O
brain	O
genes	O
that	O
promote	O
inflammatory	O
signalling	O
,	O
cellular	O
apoptosis	O
and	O
brain	O
cell	O
death	O
is	O
significantly	O
over	O
-	O
expressed	O
.	O

Iron-	O
and	O
aluminum	O
-	O
sulfate	O
together	O
,	O
at	O
nanomolar	O
concentrations	O
,	O
trigger	O
the	O
production	O
of	O
reactive	O
oxygen	O
species	O
(	O
ROS	O
)	O
in	O
cultures	O
of	O
human	B
brain	O
cells	O
.	O

Induction	O
of	O
specific	O
micro	O
RNA	O
(	O
miRNA	O
)	O
species	O
by	O
ROS	O
-	O
generating	O
metal	O
sulfates	O
in	O
primary	O
human	B
brain	O
cells	O
.	O

The	O
rapid	O
and	O
exciting	O
pace	O
of	O
advances	O
in	O
glioblastoma	O
genetics	O
has	O
prompted	O
this	O
up	O
-	O
to	O
-	O
date	O
review	O
.	O

The	O
likely	O
impact	O
on	O
care	O
delivery	O
in	O
the	O
clinic	O
may	O
only	O
be	O
a	O
few	O
years	O
away	O
.	O

Within	O
the	O
last	O
few	O
years	O
,	O
high	O
-	O
throughput	O
efforts	O
such	O
as	O
The	O
Cancer	O
Genome	O
Atlas	O
and	O
a	O
massive	O
sequencing	O
project	O
have	O
yielded	O
novel	O
insights	O
and	O
classifications	O
of	O
this	O
dreaded	O
cancer	O
.	O

It	O
has	O
been	O
hoped	O
that	O
dissection	O
of	O
the	O
genetics	O
of	O
this	O
cancer	O
would	O
lead	O
to	O
more	O
targeted	O
and	O
effective	O
treatments	O
,	O
and	O
new	O
advances	O
may	O
finally	O
be	O
bringing	O
this	O
closer	O
to	O
fruition	O
.	O

Glioblastoma	O
genetics	O
:	O
in	O
rapid	O
flux	O
.	O

Glioblastoma	O
is	O
the	O
most	O
common	O
and	O
most	O
lethal	O
primary	O
brain	O
tumor	O
.	O

While	O
small	O
progress	O
has	O
been	O
made	O
in	O
treating	O
this	O
cancer	O
in	O
recent	O
years	O
,	O
glioblastoma	O
remains	O
largely	O
resistant	O
to	O
all	O
existing	O
therapies	O
.	O

Novel	O
animal	O
models	O
for	O
studying	O
complex	O
brain	O
disorders	O
:	O
BAC	O
-	O
driven	O
miRNA	O
-	O
mediated	O
in	O
vivo	O
silencing	O
of	O
gene	O
expression	O
.	O

In	O
schizophrenia	O
,	O
glutamic	O
acid	O
decarboxylase	O
1	O
(	O
GAD1	O
)	O
disturbances	O
are	O
robust	O
,	O
consistently	O
observed	O
,	O
cell	O
-	O
type	O
specific	O
and	O
represent	O
a	O
core	O
feature	O
of	O
the	O
disease	O
.	O

In	O
addition	O
,	O
neuropeptide	O
Y	O
(	O
NPY	O
)	O
,	O
which	O
is	O
a	O
phenotypic	O
marker	O
of	O
a	O
sub	O
-	O
population	O
of	O
GAD1-containing	O
interneurons	O
,	O
has	O
shown	O
reduced	O
expression	O
in	O
the	O
prefrontal	O
cortex	O
in	O
subjects	O
with	O
schizophrenia	O
,	O
suggesting	O
that	O
dysfunction	O
of	O
the	O
NPY+	O
cortical	O
interneuronal	O
sub	O
-	O
population	O
might	O
be	O
a	O
core	O
feature	O
of	O
this	O
devastating	O
disorder	O
.	O

However	O
,	O
modeling	O
gene	O
expression	O
disturbances	O
in	O
schizophrenia	O
in	O
a	O
cell	O
type	O
-	O
specific	O
manner	O
has	O
been	O
extremely	O
challenging	O
.	O

To	O
more	O
closely	O
mimic	O
these	O
molecular	O
and	O
cellular	O
human	B
post	O
-	O
mortem	O
findings	O
,	O
we	O
generated	O
a	O
transgenic	B
mouse	I
in	O
which	O
we	O
downregulated	O
GAD1	O
mRNA	O
expression	O
specifically	O
in	O
NPY+	O
neurons	O
.	O

This	O
novel	O
,	O
cell	O
type	O
-	O
specific	O
in	O
vivo	O
system	O
for	O
reducing	O
gene	O
expression	O
uses	O
a	O
bacterial	O
artificial	O
chromosome	O
(	O
BAC	O
)	O
containing	O
the	O
NPY	O
promoter	O
-	O
enhancer	O
elements	O
,	O
the	O
reporter	O
molecule	O
(	O
eGFP	O
)	O
and	O
a	O
modified	O
intron	O
containing	O
a	O
synthetic	O
microRNA	O
(	O
miRNA	O
)	O
targeted	O
to	O
GAD1	O
.	O

The	O
animals	O
of	O
isogenic	O
strains	O
are	O
generated	O
rapidly	O
,	O
providing	O
a	O
new	O
tool	O
for	O
better	O
understanding	O
the	O
molecular	O
disturbances	O
in	O
the	O
GABAergic	O
system	O
observed	O
in	O
complex	O
neuropsychiatric	O
disorders	O
such	O
as	O
schizophrenia	O
.	O

In	O
the	O
future	O
,	O
because	O
of	O
the	O
small	O
size	O
of	O
the	O
silencing	O
miRNAs	O
combined	O
with	O
our	O
BAC	O
strategy	O
,	O
this	O
method	O
may	O
be	O
modified	O
to	O
allow	O
generation	O
of	O
mice	B
with	O
simultaneous	O
silencing	O
of	O
multiple	O
genes	O
in	O
the	O
same	O
cells	O
with	O
a	O
single	O
construct	O
,	O
and	O
production	O
of	O
splice	O
-	O
variant	O
-	O
specific	O
knockdown	O
animals	O
.	O

Biomarkers	O
associated	O
with	O
metastasis	O
of	O
lung	O
cancer	O
to	O
brain	O
predict	O
patient	B
survival	O
.	O

This	O
research	O
involves	O
comprehensive	O
miRNA	O
expression	O
profiling	O
,	O
evaluation	O
of	O
normalisation	O
techniques	O
and	O
combination	O
of	O
miRNA	O
with	O
imaging	O
features	O
FDG	O
-	O
PET	O
/	O
CT	O
and	O
CT	O
Scan	O
.	O

We	O
combine	O
validated	O
miRNA	O
expression	O
values	O
with	O
imaging	O
features	O
to	O
classify	O
NSCLC	O
brain	O
mets	O
from	O
non	O
-	O
brain	O
mets	O
and	O
identify	O
possible	O
biomarkers	O
of	O
brain	O
mets	O
.	O

Generally	O
,	O
one	O
miRNA	O
is	O
predicted	O
to	O
regulate	O
several	O
hundred	O
genes	O
,	O
and	O
as	O
a	O
result	O
,	O
miRNAs	O
could	O
serve	O
as	O
a	O
better	O
classifier	O
than	O
gene	O
expression	O
.	O

MicroRNAs	O
influence	O
cell	O
physiology	O
;	O
alteration	O
in	O
miRNA	O
regulation	O
can	O
be	O
implicated	O
in	O
carcinogenesis	O
and	O
disease	O
progression	O
.	O

The	O
biomarkers	O
were	O
validated	O
on	O
an	O
independent	O
data	O
set	O
to	O
predict	O
potential	O
brain	O
mets	O
.	O

Through	O
various	O
experimental	O
approaches	O
,	O
we	O
validated	O
computational	O
predictions	O
and	O
demonstrated	O
that	O
miR-298	O
and	O
miR-328	O
recognize	O
specific	O
binding	O
sites	O
in	O
the	O
3'-UTR	O
of	O
BACE1	O
mRNA	O
and	O
exert	O
regulatory	O
effects	O
on	O
BACE1	O
protein	O
expression	O
in	O
cultured	O
neuronal	O
cells	O
.	O

Here	O
we	O
also	O
observed	O
a	O
loss	O
of	O
correlation	O
between	O
BACE1	O
mRNA	O
and	O
protein	O
levels	O
in	O
the	O
hippocampus	O
of	O
a	O
mouse	B
model	O
of	O
AD	O
.	O
Consistent	O
with	O
an	O
impairment	O
of	O
miRNA	O
-	O
mediated	O
regulation	O
of	O
BACE1	O
expression	O
,	O
these	O
findings	O
prompted	O
us	O
to	O
investigate	O
the	O
regulatory	O
role	O
of	O
the	O
BACE1	O
3'-UTR	O
element	O
and	O
the	O
possible	O
involvement	O
of	O
specific	O
miRNAs	O
in	O
cultured	O
neuronal	O
(	O
N2a	O
)	O
and	O
fibroblastic	O
(	O
NIH	O
3T3	O
)	O
cells	O
.	O

Our	O
results	O
may	O
provide	O
the	O
molecular	O
basis	O
underlying	O
BACE1	O
deregulation	O
in	O
AD	O
and	O
offer	O
new	O
perspectives	O
on	O
the	O
etiology	O
of	O
this	O
neurological	O
disorder	O
.	O

MicroRNAs	O
(	O
miRNAs	O
)	O
are	O
key	O
regulatory	O
RNAs	O
known	O
to	O
repress	O
mRNA	O
translation	O
through	O
recognition	O
of	O
specific	O
binding	O
sites	O
located	O
mainly	O
in	O
their	O
3'-untranslated	O
region	O
(	O
UTR	O
)	O
.	O

MicroRNA-298	O
and	O
microRNA-328	O
regulate	O
expression	O
of	O
mouse	B
beta	O
-	O
amyloid	O
precursor	O
protein	O
-	O
converting	O
enzyme	O
1	O
.	O

Intriguingly	O
,	O
previous	O
post	O
-	O
mortem	O
analyses	O
showed	O
higher	O
beta	O
-	O
amyloid	O
precursor	O
protein	O
-	O
converting	O
enzyme	O
(	O
BACE	O
)	O
protein	O
,	O
but	O
not	O
mRNA	O
,	O
levels	O
in	O
the	O
brain	O
of	O
patients	B
that	O
suffered	O
from	O
Alzheimer	O
disease	O
(	O
AD	O
)	O
.	O

Loss	O
of	O
specific	O
miRNA	O
control	O
of	O
gene	O
expression	O
is	O
thus	O
expected	O
to	O
underlie	O
serious	O
genetic	O
diseases	O
.	O

These	O
findings	O
reveal	O
a	O
significant	O
additional	O
mechanism	O
by	O
which	O
alpha	O
-	O
synuclein	O
is	O
regulated	O
and	O
point	O
toward	O
new	O
therapeutic	O
regimes	O
for	O
lowering	O
endogenous	O
alpha	O
-	O
synuclein	O
levels	O
in	O
patients	B
with	O
familial	O
or	O
sporadic	O
Parkinson	O
disease	O
.	O

Overexpression	O
of	O
mir-7	O
and	O
mir-153	O
significantly	O
reduces	O
endogenous	O
alpha	O
-	O
synuclein	O
levels	O
,	O
whereas	O
inhibition	O
of	O
mir-7	O
and	O
mir-153	O
enhances	O
translation	O
of	O
a	O
luciferase	O
construct	O
bearing	O
the	O
alpha	O
-	O
synuclein	O
3'-untranslated	O
region	O
in	O
primary	O
neurons	O
.	O

They	O
are	O
expressed	O
predominantly	O
in	O
the	O
brain	O
with	O
a	O
pattern	O
that	O
mirrors	O
synuclein	O
expression	O
in	O
different	O
tissues	O
as	O
well	O
as	O
during	O
neuronal	O
development	O
,	O
indicating	O
that	O
they	O
play	O
a	O
tuning	O
role	O
in	O
the	O
amount	O
of	O
alpha	O
-	O
synuclein	O
produced	O
.	O

These	O
microRNAs	O
bind	O
specifically	O
to	O
the	O
3'-untranslated	O
region	O
of	O
alpha	O
-	O
synuclein	O
and	O
down	O
-	O
regulate	O
its	O
mRNA	O
and	O
protein	O
levels	O
,	O
with	O
their	O
effect	O
being	O
additive	O
.	O

Here	O
,	O
two	O
microRNAs	O
,	O
namely	O
mir-7	O
and	O
mir-153	O
,	O
have	O
been	O
identified	O
to	O
regulate	O
alpha	O
-	O
synuclein	O
levels	O
post	O
-	O
transcriptionally	O
.	O

Genetic	O
and	O
biochemical	O
studies	O
have	O
established	O
a	O
central	O
role	O
for	O
alpha	O
-	O
synuclein	O
accumulation	O
in	O
the	O
pathogenesis	O
of	O
Parkinson	O
disease	O
.	O

Post	O
-	O
transcriptional	O
regulation	O
of	O
alpha	O
-	O
synuclein	O
expression	O
by	O
mir-7	O
and	O
mir-153	O
.	O

Learning	O
,	O
retention	O
and	O
generalization	O
of	O
a	O
mirror	O
tracing	O
skill	O
in	O
Alzheimer	O
's	O
disease	O
.	O

The	O
present	O
study	O
examined	O
the	O
ability	O
of	O
12	O
patients	B
with	O
probable	O
Alzheimer	O
's	O
disease	O
(	O
AD	O
)	O
and	O
12	O
age-	O
and	O
education	O
-	O
matched	O
normal	O
control	O
(	O
NC	O
)	O
subjects	O
to	O
learn	O
and	O
retain	O
the	O
visuomotor	O
skills	O
necessary	O
to	O
efficiently	O
trace	O
a	O
pattern	O
(	O
e.g.	O
,	O
a	O
4-	O
or	O
6-pointed	O
star	O
)	O
seen	O
only	O
in	O
mirror	O
-	O
reversed	O
view	O
.	O

Those	O
AD	O
(	O
N=6	O
)	O
and	O
NC	O
(	O
N=7	O
)	O
subjects	O
who	O
were	O
able	O
to	O
initially	O
perform	O
the	O
basic	O
mirror	O
tracing	O
task	O
did	O
not	O
differ	O
significantly	O
in	O
initial	O
level	O
of	O
performance	O
,	O
learning	O
over	O
trials	O
,	O
retention	O
of	O
the	O
skill	O
over	O
a	O
30-min	O
delay	O
interval	O
,	O
and	O
generalization	O
of	O
the	O
skill	O
to	O
a	O
new	O
figure	O
or	O
to	O
the	O
opposite	O
direction	O
of	O
tracing	O
.	O

The	O
AD	O
patients	B
who	O
were	O
unable	O
to	O
initially	O
perform	O
the	O
mirror	O
tracing	O
task	O
were	O
significantly	O
worse	O
than	O
those	O
who	O
could	O
perform	O
the	O
task	O
on	O
several	O
neuropsychological	O
measures	O
sensitive	O
to	O
deficits	O
in	O
problem	O
solving	O
and	O
executive	O
functions	O
,	O
but	O
not	O
on	O
tests	O
of	O
global	O
cognitive	O
decline	O
,	O
memory	O
,	O
language	O
,	O
or	O
visuoperceptual	O
functioning	O
.	O

These	O
results	O
indicate	O
that	O
acquisition	O
and	O
retention	O
of	O
a	O
complex	O
visuomotor	O
skill	O
can	O
proceed	O
normally	O
in	O
the	O
early	O
stages	O
of	O
AD	O
in	O
those	O
individuals	O
who	O
can	O
initially	O
perform	O
the	O
basic	O
task	O
,	O
and	O
that	O
inability	O
to	O
perform	O
the	O
basic	O
task	O
may	O
be	O
related	O
to	O
the	O
frontal	O
lobe	O
dysfunction	O
that	O
is	O
often	O
prominent	O
in	O
the	O
disorder	O
.	O

Thus	O
,	O
miR-206	O
slows	O
ALS	O
progression	O
by	O
sensing	O
motor	O
neuron	O
injury	O
and	O
promoting	O
the	O
compensatory	O
regeneration	O
of	O
neuromuscular	O
synapses	O
.	O

Here	O
,	O
we	O
show	O
that	O
a	O
key	O
regulator	O
of	O
this	O
signaling	O
is	O
miR-206	O
,	O
a	O
skeletal	O
muscle	O
-	O
specific	O
microRNA	O
that	O
is	O
dramatically	O
induced	O
in	O
a	O
mouse	B
model	O
of	O
ALS	O
.	O

Mice	B
that	O
are	O
genetically	O
deficient	O
in	O
miR-206	O
form	O
normal	O
neuromuscular	O
synapses	O
during	O
development	O
,	O
but	O
deficiency	O
of	O
miR-206	O
in	O
the	O
ALS	O
mouse	B
model	O
accelerates	O
disease	O
progression	O
.	O

miR-206	O
is	O
required	O
for	O
efficient	O
regeneration	O
of	O
neuromuscular	O
synapses	O
after	O
acute	O
nerve	O
injury	O
,	O
which	O
probably	O
accounts	O
for	O
its	O
salutary	O
effects	O
in	O
ALS	O
.	O

miR-206	O
mediates	O
these	O
effects	O
at	O
least	O
in	O
part	O
through	O
histone	O
deacetylase	O
4	O
and	O
fibroblast	O
growth	O
factor	O
signaling	O
pathways	O
.	O

MicroRNA-206	O
delays	O
ALS	O
progression	O
and	O
promotes	O
regeneration	O
of	O
neuromuscular	O
synapses	O
in	O
mice	B
.	O

Amyotrophic	O
lateral	O
sclerosis	O
(	O
ALS	O
)	O
is	O
a	O
neurodegenerative	O
disease	O
characterized	O
by	O
loss	O
of	O
motor	O
neurons	O
,	O
denervation	O
of	O
target	O
muscles	O
,	O
muscle	O
atrophy	O
,	O
and	O
paralysis	O
.	O

Understanding	O
ALS	O
pathogenesis	O
may	O
require	O
a	O
fuller	O
understanding	O
of	O
the	O
bidirectional	O
signaling	O
between	O
motor	O
neurons	O
and	O
skeletal	O
muscle	O
fibers	O
at	O
neuromuscular	O
synapses	O
.	O

[	O
A	O
study	O
on	O
miRNA	O
alternation	O
after	O
H2O2-induced	O
PC12	O
cell	O
apoptosis	O
using	O
microarray	O
technique	O
]	O
.	O

METHODS	O
:	O
PC12	O
cells	O
were	O
treated	O
with	O
different	O
concentrations	O
of	O
H2O2	O
for	O
12	O
hours	O
,	O
and	O
then	O
the	O
cell	O
viabilities	O
were	O
evaluated	O
by	O
MTT	O
assay	O
and	O
cell	O
apoptosis	O
rates	O
were	O
assessed	O
by	O
flow	O
cytometry	O
(	O
FCM	O
)	O
.	O

OBJECTIVE	O
:	O
To	O
screen	O
the	O
differentially	O
expressed	O
microRNAs	O
(	O
miRNA	O
)	O
between	O
H2O2-induced	O
PC12	O
cell	O
apoptosis	O
and	O
normal	O
PC12	O
cells	O
with	O
microarray	O
chips	O
.	O

Of	O
the	O
46	O
miRNAs	O
in	O
the	O
H2O2	O
treated	O
groups	O
,	O
39	O
were	O
similar	O
to	O
that	O
of	O
the	O
control	O
group	O
and	O
6	O
were	O
significantly	O
down	O
-	O
regulated	O
.	O

CONCLUSION	O
:	O
Our	O
preliminary	O
data	O
may	O
provide	O
a	O
new	O
potential	O
foundation	O
for	O
further	O
study	O
of	O
pathogenesis	O
and	O
its	O
treatment	O
of	O
nerve	O
cell	O
apoptosis	O
caused	O
by	O
cerebral	O
ischemia	O
reperfusion	O
.	O

The	O
apoptosis	O
rates	O
for	O
them	O
were	O
2.6	O
%	O
,	O
5.2	O
%	O
,	O
7.2	O
%	O
,	O
10.4	O
%	O
,	O
16.6	O
%	O
,	O
and	O
72.2	O
%	O
accordingly	O
.	O

Expression	O
of	O
68	O
miRNAs	O
and	O
46	O
miRNAs	O
were	O
detected	O
in	O
both	O
control	O
group	O
and	O
the	O
H2O2	O
treated	O
groups	O
.	O

miRNAs	O
were	O
isolated	O
from	O
control	O
(	O
0	O
nmol	O
/	O
L	O
H2O2	O
)	O
and	O
H2O2	O
treated	O
(	O
at	O
concentrations	O
of	O
50	O
,	O
100	O
,	O
200	O
,	O
and	O
400	O
nmol	O
/	O
L	O
H2O2	O
,	O
respectively	O
)	O
groups	O
of	O
the	O
PC12	O
cells	O
,	O
respectively	O
,	O
and	O
were	O
then	O
detected	O
and	O
analyzed	O
by	O
microarray	O
chips	O
.	O

RESULTS	O
:	O
The	O
P12	O
cell	O
viabilities	O
in	O
control	O
and	O
H2O2	O
treated	O
group	O
were	O
(	O
92	O
+	O
/-	O
9.8	O
)	O
%	O
,	O
(	O
90	O
+	O
/-	O
14.70	O
)	O
%	O
,	O
(	O
80	O
+	O
/-	O
13.85	O
)	O
%	O
,	O
(	O
54	O
+	O
/-	O
12.23	O
)	O
%	O
,	O
and	O
(	O
22	O
+	O
/-	O
7.35	O
)	O
%	O
,	O
respectively	O
.	O

In	O
particular	O
,	O
SNP	O
rs12720208	O
in	O
the	O
3	O
'	O
untranslated	O
region	O
(	O
3	O
'	O
UTR	O
)	O
was	O
linked	O
to	O
PD	O
-	O
risk	O
through	O
a	O
mechanism	O
that	O
would	O
implicate	O
a	O
differential	O
binding	O
to	O
microRNA-433	O
(	O
miR-433	O
)	O
.	O

The	O
reduction	O
of	O
the	O
affinity	O
of	O
miR-433	O
to	O
the	O
3	O
'	O
UTR	O
would	O
result	O
in	O
increased	O
FGF20	O
expression	O
and	O
upregulation	O
of	O
alpha	O
-	O
synuclein	O
,	O
which	O
could	O
in	O
turn	O
promote	O
dopaminergic	O
neurons	O
degeneration	O
.	O

FGF20	O
rs12720208	O
SNP	O
and	O
microRNA-433	O
variation	O
:	O
no	O
association	O
with	O
Parkinson	O
's	O
disease	O
in	O
Spanish	O
patients	B
.	O

DNA	O
variation	O
at	O
the	O
FGF20	O
gene	O
has	O
been	O
associated	O
with	O
Parkinson	O
's	O
disease	O
(	O
PD	O
)	O
.	O

In	O
conclusion	O
,	O
our	O
work	O
did	O
not	O
confirm	O
the	O
association	O
between	O
rs12720208	O
and	O
PD	O
,	O
or	O
an	O
effect	O
of	O
miR-433	O
variants	O
on	O
this	O
disease	O
.	O

None	O
of	O
the	O
patients	B
had	O
miR-433	O
variants	O
.	O

We	O
did	O
not	O
find	O
significant	O
differences	O
in	O
allele	O
and	O
genotype	O
frequencies	O
between	O
patients	B
and	O
controls	O
.	O

We	O
genotyped	O
the	O
rs12720208	O
SNP	O
in	O
a	O
total	O
of	O
512	O
PD	O
patients	B
and	O
258	O
healthy	O
controls	O
from	O
Spain	O
,	O
and	O
searched	O
for	O
miR-433	O
variants	O
in	O
the	O
patients	B
.	O

The	O
results	O
suggest	O
(	O
a	O
)	O
that	O
unless	O
specifically	O
stabilized	O
,	O
certain	O
brain	O
-	O
enriched	O
miRNAs	O
represent	O
a	O
rapidly	O
executed	O
signaling	O
system	O
employing	O
highly	O
transient	O
effectors	O
of	O
CNS	O
gene	O
expression	O
,	O
and	O
(	O
b	O
)	O
that	O
in	O
AD	O
temporal	O
lobe	O
neocortex	O
specific	O
brain	O
miRNAs	O
are	O
significantly	O
up	O
-	O
regulated	O
in	O
abundance	O
and	O
strongly	O
correlate	O
with	O
the	O
presence	O
of	O
AD	O
-	O
type	O
neuropatholgical	O
change	O
.	O

In	O
short	O
PMI	O
Alzheimer	O
's	O
disease	O
(	O
AD	O
)	O
-affected	O
temporal	O
lobe	O
neocortex	O
,	O
miRNA-9	O
,	O
miRNA-125b	O
and	O
miRNA-146a	O
were	O
found	O
to	O
be	O
significantly	O
up	O
-	O
regulated	O
,	O
an	O
effect	O
that	O
was	O
not	O
seen	O
in	O
several	O
related	O
neurological	O
disorders	O
.	O

In	O
these	O
studies	O
,	O
miRNA	O
array	O
and	O
Northern	O
blot	O
based	O
tracking	O
of	O
specific	O
miRNA	O
abundances	O
and	O
decay	O
kinetics	O
in	O
human	B
neural	O
(	O
HN	O
)	O
cells	O
in	O
primary	O
culture	O
and	O
in	O
short	O
post	O
-	O
mortem	O
interval	O
(	O
PMI	O
,	O
approximately	O
1h	O
)	O
human	B
brain	O
tissues	O
showed	O
a	O
limited	O
stability	O
and	O
relatively	O
short	O
half	O
-	O
life	O
(	O
approximately	O
1	O
-	O
3.5h	O
)	O
for	O
specific	O
brain	O
-	O
enriched	O
miRNAs	O
.	O

Micro	O
-	O
RNA	O
(	O
miRNA	O
)	O
mediated	O
regulation	O
of	O
messenger	O
RNA	O
(	O
mRNA	O
)	O
complexity	O
in	O
the	O
central	O
nervous	O
system	O
(	O
CNS	O
)	O
is	O
emerging	O
as	O
a	O
critical	O
factor	O
in	O
the	O
control	O
of	O
CNS	O
-	O
specific	O
gene	O
expression	O
during	O
development	O
,	O
plasticity	O
,	O
aging	O
and	O
disease	O
.	O

Micro	O
-	O
RNA	O
abundance	O
and	O
stability	O
in	O
human	B
brain	O
:	O
specific	O
alterations	O
in	O
Alzheimer	O
's	O
disease	O
temporal	O
lobe	O
neocortex	O
.	O

Keystone	O
symposium	O
,	O
Neurodegenerative	O
Diseases	O
:	O
New	O
Molecular	O
Mechanisms	O
17	O
-	O
22	O
February	O
2009	O
.	O

Glioma	O
angiogenesis	O
:	O
Towards	O
novel	O
RNA	O
therapeutics	O
.	O

Brain	O
tumors	O
exhibit	O
marked	O
and	O
aberrant	O
blood	O
vessel	O
formation	O
indicating	O
angiogenic	O
endothelial	O
cells	O
as	O
a	O
potential	O
target	O
for	O
brain	O
tumor	O
treatment	O
.	O

The	O
brain	O
tumor	O
blood	O
vessels	O
are	O
used	O
for	O
nutrient	O
delivery	O
,	O
and	O
possibly	O
for	O
cancer	O
cell	O
migration	O
.	O

The	O
process	O
of	O
angiogenesis	O
is	O
complex	O
and	O
involves	O
multiple	O
players	O
.	O

The	O
current	O
angiogenesis	O
inhibitors	O
used	O
in	O
clinical	O
trials	O
mostly	O
target	O
single	O
angiogenic	O
proteins	O
and	O
so	O
far	O
show	O
limited	O
effects	O
on	O
tumor	O
growth	O
.	O

Besides	O
the	O
conventional	O
angiogenesis	O
inhibitors	O
,	O
RNA	O
-	O
based	O
inhibitors	O
such	O
as	O
small	O
-	O
interfering	O
RNAs	O
(	O
siRNAs	O
)	O
are	O
being	O
analyzed	O
for	O
their	O
capacity	O
to	O
silence	O
the	O
message	O
of	O
proteins	O
involved	O
in	O
neovascularization	O
.	O

More	O
recently	O
,	O
a	O
new	O
family	O
of	O
non	O
-	O
coding	O
RNAs	O
,	O
named	O
angiomirs	O
[	O
microRNAs	O
(	O
miRNAs	O
)	O
involved	O
in	O
angiogenesis	O
]	O
has	O
emerged	O
.	O

These	O
small	O
RNAs	O
have	O
the	O
advantage	O
over	O
siRNAs	O
in	O
that	O
they	O
have	O
the	O
potential	O
of	O
silencing	O
multiple	O
messages	O
at	O
the	O
same	O
time	O
and	O
therefore	O
they	O
might	O
become	O
therapeutically	O
relevant	O
in	O
a	O
""""	O
one	O
-	O
hit	O
multiple	O
-	O
target	O
""""	O
context	O
against	O
brain	O
tumor	O
angiogenesis	O
.	O

In	O
this	O
review	O
we	O
will	O
discuss	O
the	O
emerging	O
technologies	O
in	O
anti	O
-	O
angiogenesis	O
emphasizing	O
on	O
RNA	O
-	O
based	O
therapeutics	O
.	O

Diseases	O
potentially	O
mediated	O
by	O
alterations	O
in	O
RNA	O
processes	O
include	O
tauopathies	O
,	O
myotonic	O
dystrophy	O
,	O
Alzheimer	O
disease	O
,	O
brain	O
cancer	O
,	O
and	O
many	O
others	O
.	O

Some	O
noncoding	O
RNAs	O
have	O
been	O
shown	O
to	O
be	O
involved	O
in	O
human	B
brain	O
diseases	O
.	O

Furthermore	O
,	O
there	O
is	O
poor	O
correlation	O
between	O
mRNA	O
levels	O
and	O
protein	O
levels	O
in	O
mammalian	O
cells	O
,	O
due	O
partly	O
to	O
complicated	O
post	O
-	O
transcriptional	O
regulation	O
by	O
hitherto	O
unknown	O
noncoding	O
RNAs	O
.	O

For	O
example	O
,	O
neurologic	O
illnesses	O
may	O
arise	O
because	O
of	O
perturbations	O
in	O
distinct	O
but	O
interrelated	O
tiers	O
of	O
RNA	O
-	O
based	O
genetic	O
regulation	O
:	O
pre	O
-	O
mRNA	O
splicing	O
;	O
nonsplicing	O
RNA	O
modifications	O
;	O
and	O
mRNA	O
translational	O
regulation	O
.	O

A	O
variety	O
of	O
unforeseen	O
complexities	O
have	O
been	O
identified	O
,	O
many	O
with	O
relevance	O
to	O
human	B
brain	O
disease	O
.	O

RNA	O
research	O
has	O
made	O
great	O
progress	O
in	O
recent	O
years	O
.	O

RNA	O
in	O
brain	O
disease	O
:	O
no	O
longer	O
just	O
""""	O
the	O
messenger	O
in	O
the	O
middle	O
""""	O
.	O

Here	O
we	O
present	O
an	O
overview	O
of	O
new	O
research	O
highlighting	O
functions	O
for	O
RNA	O
that	O
far	O
surpass	O
the	O
""""	O
messenger	O
in	O
the	O
middle	O
""""	O
role	O
and	O
that	O
identify	O
RNA	O
molecules	O
as	O
important	O
agents	O
in	O
the	O
human	B
brain	O
in	O
health	O
and	O
in	O
disease	O
states	O
.	O

RNA	O
editing	O
by	O
adenosine	O
deamination	O
is	O
a	O
posttranscriptional	O
mechanism	O
for	O
the	O
regulation	O
of	O
gene	O
expression	O
and	O
is	O
particularly	O
widespread	O
in	O
mammals	O
.	O

Gene	O
regulation	O
through	O
RNA	O
editing	O
.	O

Here	O
,	O
I	O
am	O
reviewing	O
main	O
features	O
of	O
this	O
epigenetic	O
phenomenon	O
,	O
its	O
relevance	O
for	O
health	O
and	O
disease	O
,	O
as	O
well	O
as	O
potential	O
prospects	O
for	O
using	O
RNA	O
editing	O
as	O
a	O
therapeutic	O
tool	O
.	O

Widespread	O
A	O
-	O
to	O
-	O
I	O
modification	O
of	O
repeat	O
sequences	O
in	O
the	O
human	B
transcriptome	O
suggests	O
additional	O
roles	O
for	O
RNA	O
editing	O
and	O
links	O
it	O
to	O
other	O
processes	O
of	O
gene	O
regulation	O
,	O
such	O
as	O
RNA	O
splicing	O
as	O
well	O
as	O
siRNA	O
mediated	O
gene	O
silencing	O
and	O
miRNA	O
function	O
.	O

The	O
deficiency	O
or	O
misregulation	O
of	O
editing	O
has	O
been	O
implicated	O
in	O
the	O
etiology	O
of	O
neurological	O
diseases	O
,	O
such	O
as	O
epilepsy	O
,	O
amyotrophic	O
lateral	O
sclerosis	O
(	O
ALS	O
)	O
,	O
depression	O
and	O
tumor	O
progression	O
.	O

Also	O
,	O
it	O
regulates	O
important	O
functional	O
properties	O
of	O
neurotransmitter	O
receptor	O
genes	O
in	O
the	O
central	O
nervous	O
system	O
by	O
changing	O
single	O
codons	O
in	O
pre	O
-	O
mRNA	O
.	O

A	O
-	O
to	O
-	O
I	O
RNA	O
editing	O
generates	O
transcriptome	O
and	O
proteome	O
diversity	O
allowing	O
organisms	O
to	O
produce	O
many	O
more	O
gene	O
products	O
and	O
functions	O
than	O
predicted	O
based	O
on	O
the	O
number	O
of	O
genes	O
within	O
their	O
genome	O
.	O

Gliomas	O
display	O
a	O
microRNA	O
expression	O
profile	O
reminiscent	O
of	O
neural	O
precursor	O
cells	O
.	O

Gliomas	O
express	O
many	O
genes	O
that	O
play	O
a	O
role	O
in	O
neural	O
precursor	O
cells	O
(	O
NPCs	O
)	O
,	O
but	O
no	O
direct	O
comparison	O
between	O
glioma	O
and	O
stem	O
cell	O
(	O
SC	O
)	O
gene	O
expression	O
profiles	O
has	O
been	O
performed	O
.	O

To	O
investigate	O
the	O
similarities	O
and	O
differences	O
between	O
gliomas	O
and	O
SCs	O
,	O
we	O
compared	O
the	O
microRNA	O
(	O
miRNA	O
)	O
expression	O
signatures	O
of	O
glial	O
tumors	O
,	O
embryonic	O
SCs	O
(	O
ESCs	O
)	O
,	O
NPCs	O
,	O
and	O
normal	O
adult	O
brains	O
from	O
both	O
human	B
and	O
mouse	B
tissues	O
.	O

We	O
demonstrated	O
that	O
both	O
human	B
gliomas	O
(	O
regardless	O
of	O
their	O
grade	O
)	O
and	O
methylcholanthrene	O
-	O
induced	O
mouse	B
glioma	O
shared	O
an	O
miRNA	O
expression	O
profile	O
that	O
is	O
reminiscent	O
of	O
NPCs	O
.	O

About	O
half	O
of	O
the	O
miRNAs	O
expressed	O
in	O
the	O
shared	O
profile	O
clustered	O
in	O
seven	O
genomic	O
regions	O
susceptible	O
to	O
genetic	O
/	O
epigenetic	O
alterations	O
in	O
various	O
cancers	O
.	O

These	O
clusters	O
comprised	O
the	O
miR17	O
family	O
,	O
mir183	O
-	O
182	O
,	O
and	O
the	O
SC	O
-	O
specific	O
clusters	O
mir367	O
-	O
302	O
and	O
mir371	O
-	O
373	O
,	O
which	O
are	O
upregulated	O
in	O
gliomas	O
,	O
ESCs	O
,	O
and	O
NPCs	O
.	O

The	O
bipartite	O
cluster	O
of	O
7	O
+	O
46	O
miRNAs	O
on	O
chromosome	O
14q32.31	O
,	O

which	O
might	O
represent	O
the	O
largest	O
tumor	O
suppressor	O
miRNA	O
cluster	O
,	O
was	O
downregulated	O
in	O
the	O
shared	O
expression	O
profile	O
.	O

This	O
study	O
provides	O
the	O
first	O
evidence	O
for	O
association	O
between	O
these	O
clusters	O
and	O
gliomas	O
.	O

Despite	O
the	O
broad	O
similarity	O
in	O
the	O
miRNA	O
expression	O
profiles	O
,	O
15	O
miRNAs	O
showed	O
disparate	O
expression	O
between	O
SC	O
and	O
gliomas	O
.	O

Ten	O
miRNAs	O
belong	O
to	O
the	O
2	O
SC	O
-	O
specific	O
clusters	O
and	O
the	O
remaining	O
(	O
mir135b	O
,	O
mir141	O
,	O
mir205	O
,	O
mir200C	O
,	O
and	O
mir301a	O
)	O
have	O
been	O
previously	O
shown	O
to	O
associate	O
with	O
malignancies	O
.	O

Our	O
finding	O
showed	O
that	O
all	O
gliomas	O
displayed	O
NPC	O
-	O
like	O
miRNA	O
signatures	O
,	O
which	O
may	O
have	O
implications	O
for	O
studies	O
of	O
glioma	O
origins	O
.	O

Furthermore	O
,	O
careful	O
study	O
of	O
the	O
15	O
miRNAs	O
that	O
differ	O
in	O
expression	O
between	O
SCs	O
and	O
gliomas	O
,	O
particularly	O
those	O
5	O
that	O
are	O
not	O
SC	O
-	O
specific	O
,	O
may	O
enhance	O
our	O
understanding	O
of	O
gliomagenesis	O
.	O

New	O
insights	O
into	O
the	O
roles	O
of	O
microRNAs	O
in	O
drug	O
addiction	O
and	O
neuroplasticity	O
.	O

In	O
this	O
review	O
,	O
the	O
aim	O
is	O
to	O
provide	O
an	O
overview	O
of	O
the	O
emerging	O
role	O
of	O
miRNAs	O
in	O
addiction	O
.	O

miRNAs	O
are	O
small	O
non	O
-	O
coding	O
RNAs	O
,	O
particularly	O
abundant	O
in	O
the	O
nervous	O
system	O
,	O
that	O
play	O
key	O
roles	O
as	O
regulatory	O
molecules	O
in	O
processes	O
such	O
as	O
neurogenesis	O
,	O
synapse	O
development	O
and	O
plasticity	O
in	O
the	O
brain	O
.	O

They	O
also	O
act	O
as	O
key	O
spatiotemporal	O
regulators	O
during	O
dendritic	O
morphogenesis	O
,	O
controlling	O
the	O
expression	O
of	O
hundreds	O
of	O
genes	O
involved	O
in	O
neuroplasticity	O
and	O
in	O
the	O
function	O
of	O
synapses	O
.	O

Recent	O
studies	O
have	O
identified	O
changes	O
of	O
several	O
specific	O
miRNA	O
expression	O
profiles	O
and	O
polymorphisms	O
affecting	O
the	O
interactions	O
between	O
miRNAs	O
and	O
their	O
targets	O
in	O
various	O
brain	O
disorders	O
,	O
including	O
addiction	O
:	O
miR-16	O
causes	O
adaptive	O
changes	O
in	O
production	O
of	O
the	O
serotonin	O
transporter	O
;	O
miR-133b	O
is	O
specifically	O
expressed	O
in	O
midbrain	O
dopaminergic	O
neurons	O
,	O
and	O
regulates	O
the	O
production	O
of	O
tyrosine	O
hydroxylase	O
and	O
the	O
dopamine	O
transporter	O
;	O
miR-212	O
affects	O
production	O
of	O
striatal	O
brain	O
-	O
derived	O
neurotrophic	O
factor	O
and	O
synaptic	O
plasticity	O
upon	O
cocaine	O
.	O

Clearly	O
,	O
specific	O
miRNAs	O
have	O
emerged	O
as	O
key	O
regulators	O
leading	O
to	O
addiction	O
,	O
and	O
could	O
serve	O
as	O
valuable	O
targets	O
for	O
more	O
efficient	O
therapies	O
.	O

ABSTRACT	O
:	O
Drug	O
addiction	O
is	O
a	O
major	O
public	O
health	O
issue	O
.	O

It	O
is	O
typically	O
a	O
multigenetic	O
brain	O
disorder	O
,	O
implying	O
combined	O
changes	O
of	O
expression	O
of	O
several	O
hundred	O
genes	O
.	O

Psychostimulants	O
(	O
such	O
as	O
cocaine	O
,	O
heroin	O
and	O
amphetamines	O
)	O
induce	O
strong	O
and	O
persistent	O
neuroadaptive	O
changes	O
through	O
a	O
surfeit	O
of	O
gene	O
regulatory	O
mechanisms	O
leading	O
to	O
addiction	O
.	O

Activity	O
-	O
dependent	O
synaptic	O
plasticity	O
of	O
the	O
mesolimbic	O
dopaminergic	O
system	O
,	O
known	O
as	O
the	O
'	O
reward	O
pathway	O
'	O
,	O
plays	O
a	O
crucial	O
role	O
in	O
the	O
development	O
of	O
drug	O
dependence	O
.	O

